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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about selenium and the effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities.  Selenium has been found in at least 508 of the 1,623 current 
or former NPL sites.  However, the total number of NPL sites evaluated for selenium is not 
known. As more sites are evaluated, the sites at which selenium is found may increase.  This 
information is important because exposure to selenium at high levels may harm you and because 
these sites may be sources of exposure. A minimum dietary level of selenium is required for 
good health. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it.  You may be 
exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to selenium, many factors determine whether you'll be harmed.  These factors 
include the dose (how much), the duration (how long), and how you come in contact with 
it/them.  You must also consider the other chemicals you're exposed to and your age, sex, diet, 
family traits, lifestyle, and state of health. 
1.1 WHAT IS SELENIUM? 
Selenium is a naturally occurring, solid substance that is widely but unevenly distributed in the 
earth's crust.  It is also commonly found in rocks and soil.  Selenium, in its pure form of metallic 
gray to black crystals, is often referred to as elemental selenium or selenium dust.  Elemental 
selenium is commercially produced, primarily as a by-product of copper refining.  Selenium is 
not often found in the environment in its elemental form, but is usually combined with other 
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substances. Much of the selenium in rocks is combined with sulfide minerals or with silver, 
copper, lead, and nickel minerals.  Selenium also combines with oxygen to form several 
substances that are white or colorless crystals.  Some selenium compounds are gases.  Selenium 
and its compounds are used in some photographic devices, gun bluing (a liquid solution used to 
clean the metal parts of a gun), plastics, paints, anti-dandruff shampoos, vitamin and mineral 
supplements, fungicides, and certain types of glass.  For example, selenium sulfide is used in 
anti-dandruff shampoos by the common trade name Selsun Blue.  Selenium is also used to 
prepare drugs and as a nutritional feed supplement for poultry and livestock.  More information 
on the chemical and physical properties, production, and uses of selenium are found in 
Chapters 4 and 5. 
1.2 WHAT HAPPENS TO SELENIUM WHEN IT ENTERS THE ENVIRONMENT? 
Selenium occurs naturally in the environment.  As an element, selenium cannot be created or 
destroyed, although selenium can change forms in the environment.  Weathering of rocks and 
soils may result in low levels of selenium in water, which may be taken up by plants.  
Weathering also releases selenium into the air on fine dust-like particles.  Volcanic eruptions 
may release selenium in air.  Selenium commonly enters the air from burning coal or oil.  
Selenium that may be present in fossil fuels combines with oxygen when burned, which may 
then react with water to form soluble selenium compounds.  Airborne particles of selenium, such 
as in ash, can settle on soil or surface water. Disposal of selenium in commercial products and 
waste could also increase the amount of selenium in soil.  The forms and fate of selenium in soil 
depend largely on the acidity of the surroundings and its interaction with oxygen.  In the absence 
of oxygen when the soil is acidic, the amount of selenium that can enter plants and organisms 
should be low. Elemental selenium that cannot dissolve in water and other insoluble forms of 
selenium are less mobile and will usually remain in the soil, posing smaller risk of exposure.  
Selenium compounds that can dissolve in water are sometimes very mobile.  Thus, there is an 
increased chance of exposure to these compounds.  Selenium may enter surface water in 
irrigation drainage waters. Some evidence indicates that selenium can be taken up in tissues of 
aquatic organisms and possibly increase in concentration as the selenium is passed up through 
the food chain. Selenium concentrations in aquatic organisms have been a problem as a result of 
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irrigation runoff in some dry areas of the United States.  Chapter 6 contains more information on 
what happens to selenium in the environment. 
1.3 HOW MIGHT I BE EXPOSED TO SELENIUM? 
People are exposed to low levels of selenium daily through food, water, and air.  Selenium is also 
an essential nutrient for humans and animals.  However, selenium can be harmful when regularly 
taken in amounts higher than those needed for good health.  People receive the majority of their 
daily intake of selenium from eating food, and to a lesser extent, from water intake.  Estimates of 
the average intake of selenium from food for the U.S. population range from 71 to 152 millionths 
of a gram of selenium per person per day.  Low levels of selenium can also be found in drinking 
water. Selenium levels are less than 10 parts of selenium in a billion parts of water (10 ppb) in 
99.5% of drinking water sources tested.  People may be exposed to higher-than-normal levels of 
selenium at hazardous waste sites by swallowing soil or water, or by breathing dust.  In some 
parts of the United States, especially in the western states, some soils naturally have higher levels 
of selenium compounds.  Some plants can build up selenium to levels that harm livestock 
feeding on them.  In these areas, people could be exposed to too much selenium if they eat a lot 
of locally grown grains and vegetables or animal products that have built up high levels of 
selenium.  People may also be exposed to selenium from industrial sources.  Humans are 
normally not exposed to large amounts of selenium in the air, unless selenium dust or volatile 
selenium compounds are formed in their workplace.  Occupations in which humans may be 
exposed to selenium in the air are the metal industries, selenium-recovery processes, paint 
manufacturing, and special trades.  Chapter 6 contains more information on how people can be 
exposed to selenium. 
1.4 HOW CAN SELENIUM ENTER AND LEAVE MY BODY? 
Selenium from the environment mainly enters the body when people eat food containing 
selenium.  The human body easily absorbs the organic selenium compounds (for example, 
selenoamino acids) when eaten, and makes them available where needed in the body.  The 
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selenium in drinking water is usually in the form of inorganic sodium selenate and sodium 
selenite; these forms of selenium are also easily absorbed from the digestive tract.  The human 
body can change these inorganic selenium compounds into forms that it can use.  Selenium in the 
air may also enter your body when you breathe it. 
Hazardous waste sites at which selenium is present could represent a major source of exposure.  
The way that selenium can enter the body from a particular site depends on such factors as 
whether vegetables are grown in soil in which selenium from the site has been deposited, 
whether water at the site contains selenium and is able to flow into drinking water supplies, and 
whether selenium dust blows into the air.  As mentioned earlier, specific conditions at a site can 
greatly influence which selenium compounds form and whether they can move in the 
environment to places where people might be exposed.  Therefore, it is important to know that 
the presence of selenium at a site does not necessarily mean that people are being exposed to it.  
Specific tests of locally grown food, drinking water, and air must be done to find out whether 
exposure is occurring. You should also be aware that selenium compounds, including those used 
in some medicated dandruff shampoos, are not easily absorbed through the skin. 
Most of the selenium that enters the body quickly leaves the body, usually within 24 hours.  
Beyond what the body needs, selenium leaves mainly in the urine, but also in feces and breath.  
Selenium in the urine increases as the amount of the exposure goes up.  Selenium can build up in 
the human body, however, if exposure levels are very high or if exposure occurs over a long 
time.  The amount that builds up in the body depends on the chemical form of the selenium.  It 
builds up mostly in the liver and kidneys but also in the blood, lungs, heart, and testes.  Selenium 
can build up in the nails and in hair, depending on time and amount of exposure.  Chapter 3 
contains more information on how selenium enters and leaves the human body. 
1.5 HOW CAN SELENIUM AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.   
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One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary.  Animal testing may 
also be used to identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method to get information needed to make wise decisions 
to protect public health. Scientists have the responsibility to treat research animals with care and 
compassion.  Laws today protect the welfare of research animals, and scientists must comply 
with strict animal care guidelines. 
The general public rarely breathes high levels of selenium, although some people may be 
exposed to selenium dust and selenium compounds in workplace air.  Dizziness, fatigue, and 
irritation of mucous membranes have been reported in people exposed to selenium in workplace 
air at concentrations higher than legal levels.  In extreme cases, collection of fluid in the lungs 
(pulmonary edema) and severe bronchitis have been reported.  The exact exposure levels at 
which these effects might occur are not known, but they become more likely with increasing 
amounts of selenium and with increasing frequency of exposure. 
The normal intake of selenium by eating food is enough to meet the Recommended Daily 
Allowance (RDA) for this essential nutrient.  However, as discussed in Chapters 2 and 3 of this 
profile, selenium compounds can be harmful at daily dietary levels that are higher than needed.  
The seriousness of the effects of excess selenium depends on how much selenium is eaten and 
how often. Intentional or accidental swallowing of a large amount of sodium selenate or sodium 
selenite (for example, a very large quantity of selenium supplement pills) could be life-
threatening without immediate medical treatment.  Even if mildly excessive amounts of selenium 
are eaten over long periods, brittle hair and deformed nails can develop.  In extreme cases, 
people may lose feeling and control in arms and legs.  These health effects, called selenosis, 
were seen in several villages in China where people were exposed to foods high in selenium for 
months to years. No human populations in the United States have been reported with long-term 
selenium poisoning, including populations in the western part of the country where selenium 
levels are naturally high in the soil.  Because most people in the United States eat foods produced 
in many different areas, overexposure to selenium in food is unlikely to occur. 
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In some regions of China where soil levels of selenium are very low, not eating enough selenium 
has resulted in health effects.  Selenium is used by the body in antioxidant enzymes that protect 
against damage to tissues done by oxygen, and in an enzyme that affects growth and metabolism.  
Not eating enough selenium can cause heart problems and muscle pain.  Muscle pain has also 
been noted in people fed intravenously for a long time with solutions that did not contain 
selenium.  Babies born early may be more sensitive to not having enough selenium, and this may 
contribute to lung effects. In the United States, selenium in food is sufficient to meet the RDA 
and prevent harmful effects from not enough selenium. 
Upon contact with human skin, industrial selenium compounds have been reported to cause 
rashes, redness, heat, swelling, and pain.  Brief, acute exposure of the eyes to selenium dioxide 
as a dust or fume in workplace air may result in burning, irritation, and tearing.  However, only 
people who work in industries that process or use selenium or selenium compounds are likely to 
come into contact with levels high enough to cause eye irritation. 
Studies of laboratory animals and people show that most selenium compounds probably do not 
cause cancer. In fact, some studies of cancer in humans suggest that lower-than-normal selenium 
levels in the diet might increase the risk of cancer.  Other studies suggest that dietary levels of 
selenium that are higher than normal might reduce the risk of cancer in humans.  However, 
taking selenium so that your daily amount is greater than that required might just increase your 
risk of selenium poisoning. 
Based on studies done until 1987, the International Agency for Research on Cancer (IARC) 
determined that selenium and selenium compounds could not be classified as to their ability to 
cause cancer in humans.  However, since then, the EPA has determined that one specific form of 
selenium, called selenium sulfide, is a probable human carcinogen.  Selenium sulfide is the only 
selenium compound shown to cause cancer in animals.  Rats and mice that were fed selenium 
sulfide daily at very high levels developed cancer.  Selenium sulfide is not present in foods, and 
it is a very different chemical from the organic and inorganic selenium compounds found in 
foods and in the environment.  Also, if introduced into the environment, selenium sulfide does 
not dissolve readily in water and would probably bind tightly to the soil, further reducing any 
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chance of exposure. Because selenium sulfide is not absorbed through the skin, the use of anti­
dandruff shampoos containing selenium sulfide is generally considered safe. 
Very high amounts of selenium have caused decreased sperm counts, increased abnormal sperm, 
changes in the female reproductive cycle in rats, and changes in the menstrual cycle in monkeys.  
The relevance of the reproductive effects of selenium exposure in animals studied to potential 
reproductive effects in humans is not known.  Selenium compounds have not been shown to 
cause birth defects in humans or in other mammals. 
Chapter 3 contains more information on the health effects of selenium and selenium compounds 
in humans and animals. 
1.6 HOW CAN SELENIUM AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans. 
Children living near selenium waste sites or coal burning plants are likely to be exposed to 
higher environmental levels of selenium through breathing, touching soil, and eating 
contaminated soil.  Children living in areas of China with high selenium in the soil had higher 
levels of selenium in the blood than adults from that area.  Very few studies have looked at how 
selenium can affect the health of children.  Children need small amounts of selenium for normal 
growth and development.  Children will probably show the same sort of health effects from 
selenium exposure as adults, but some studies suggest that they may be less susceptible to health 
effects of selenium than adults. 
We do not know if exposure to selenium could result in birth defects in people.  Selenium 
compounds have not been shown to cause birth defects in humans or in other mammals.  We 
have no information to suggest that there are any differences between children and adults in 
where selenium is found in the body or in how fast it enters or leaves the body.  Studies in 
laboratory animals have shown that selenium crosses the placenta and enters the fetus.  Studies in 
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humans show that infants are supplied with selenium through breast milk, and therefore, women 
who were exposed to selenium by living near a waste site might transfer selenium to their babies.  
However, babies in areas of China with high selenium in the soil did not show any signs of 
health effects due to selenium, even though some of their parents did. 
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO SELENIUM? 
If your doctor finds that you have been exposed to significant amounts of selenium, ask whether 
your children might also be exposed.  Your doctor might need to ask your state health 
department to investigate. 
Since selenium occurs naturally in the environment, we cannot avoid exposure to it.  Certain 
dietary supplements and anti-dandruff shampoos contain selenium in high levels.  You should 
not exceed the recommended dosages when using these products. 
Children living near selenium waste sites or coal burning plants are likely to be exposed to 
higher environmental levels of selenium through breathing, touching soil, and eating 
contaminated soil.  Some children eat a lot of dirt.  You should discourage your children from 
eating dirt. Make sure they wash their hands frequently and before eating.  Discourage your 
children from putting their hands in their mouths or from other hand-to-mouth activity. 
The primary route of human exposure to selenium is through eating food.  People who irrigate 
their home gardens with groundwater containing high levels of selenium may grow and eat 
plants that contain high levels of selenium because this element is taken up in some plants.  
Fishermen and hunters of waterfowl who regularly eat fish and game from waterways with high 
selenium content may also consume above average levels of selenium.  To reduce your family’s 
exposure to selenium, obey any wildlife advisories issued by your state.  Information on fish and 
wildlife advisories in your state is available from your state public health or natural resources 
department. 
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1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO SELENIUM? 
Selenium can be measured in the blood, urine, and fingernails or toenails of exposed individuals.  
However, since selenium is an essential nutrient normally present in foods, low levels of 
selenium are normally found in body tissues and urine.  Tests for selenium are most useful for 
people who have recently been exposed to high levels.  Samples of blood, urine, or nails can be 
properly collected in a physician's office and sent to a laboratory that has the special equipment 
needed to measure selenium.  Urine can be used to determine short-term exposure.  Because red 
blood cells last about 120 days before they are replaced by newly made red blood cells, the 
presence of selenium in red blood cells can show whether a person was exposed to selenium 
during the 120 days before testing, but not if exposed more than 120 days before testing.  Toenail 
clippings can be used to determine longer-term exposure. 
Many methods are available to measure selenium levels in human tissue and the environment.  
However, none of the methods that are routinely available can measure or detect each selenium 
compound in one test, and better tests that measure lower levels of different selenium 
compounds are needed.  Also, these tests cannot determine the exact levels of selenium you may 
have been exposed to or predict whether health effects will occur, even though very high 
amounts of selenium in blood are clearly related to selenosis.  Some human as well as animal 
studies suggest that when people are exposed over a long period to higher-than-normal amounts 
of selenium, their bodies adjust to the higher amounts.  Chapter 3 contains more information on 
studies that have measured selenium in blood and other human tissues. 
The length of time that selenium stays in the body after exposure stops depends on the form of 
selenium to which the person was exposed.  Thus, it is difficult to predict how useful a test will 
be if some time has gone by since exposure stopped.  Chapter 7 contains more information on the 
methods available to measure selenium in human tissues and in the environment. 
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1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA).  
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals; then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for selenium include the following: 
The EPA Office of Drinking Water regulates the amount of selenium allowed in drinking water.  
Public water supplies are not allowed to exceed 50 ppb total selenium. 
The FDA regulations allow a level of 50 ppb of selenium in bottled water.  OSHA is responsible 
for setting regulations on selenium levels allowable in the workplace.  The exposure limit for 
selenium compounds in the air for an 8-hour period is 0.2 mg selenium/m3. Chapter 8 contains 
other regulations and guidelines for selenium. 
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1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 
may request a copy of the ATSDR ToxProfiles CD-ROM by calling the information and 
technical assistance toll-free number at 1-888-42ATSDR (1-888-422-8737), by email at 
atsdric@cdc.gov, or by writing at: 
Agency for Toxic Substances and Disease Registry 

Division of Toxicology 









For-profit organizations may request a copy of final profiles from the following: 
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/ 
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2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO SELENIUM IN THE 
UNITED STATES 
Selenium is an essential micronutrient for humans and animals that is found ubiquitously in the 
environment, being released from both natural and anthropogenic sources.  The principal release of 
selenium into the environment from anthropogenic sources is from coal combustion.  Natural sources of 
selenium include the weathering of selenium-containing rocks and soils, and volcanic eruptions.  
Selenium is found in most rocks and soils, and naturally occurs at low concentrations in surface waters 
and groundwaters of the United States.  Accumulation of selenium in agricultural drainage waters has 
been documented in basins in the western United States, particularly in California.  Ambient background 
concentrations of selenium in the air are very low, generally in the nanogram per cubic meter (ng/m3) 
range. 
Exposure of the general population to selenium is primarily by ingestion of its organic and inorganic 
forms, both of which occur naturally in the diet.  The greatest portion of dietary intake occurs from 
organic forms of selenium, mainly the amino acids selenomethionine and selencysteine, in grains, cereals, 
and forage crops. The main inorganic sources of selenium in the diet are selenate and selenite, which are 
less absorbed than the organic forms.  Other exposure pathways for selenium, which are of lesser 
importance, are water and air.  Various estimates of the selenium intake for Americans have ranged from 
0.071 to 0.152 mg selenium/day (approximately 1–2 µg/kg/day in adults).  Some people living in areas 
with high soil concentrations of selenium (as in areas of the western United States) might have higher 
exposure because of the natural selenium levels found locally, particularly if they consume crops 
primarily grown in that area.  Metal industry workers, health service professionals, mechanics, and 
painters may be exposed to higher levels of selenium than the general population or workers employed in 
other trades. 
2.2 SUMMARY OF HEALTH EFFECTS 
As an essential trace element in humans and animals, selenium is a biologically active part of a number of 
important proteins, particularly enzymes involved in antioxidant defense mechanisms (e.g., glutathione 
peroxidases), thyroid hormone metabolism (e.g., deiodinase enzymes), and redox control of intracellular 
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reactions (e.g., thioredoxin reductase).  Depending upon the level of intake, selenium can have nutritional 
or possibly toxic effects.  Most people in the United States are unlikely to suffer from selenium 
deficiency.  Although excessive intake of selenium can cause adverse health effects, these are generally 
observed at doses more than 5 times greater than the Recommended Dietary Allowance (RDA). 
The current RDA for selenium, established by the Food and Nutrition Board of the National Research 
Council (National Academy of Sciences), is 55 µg/day for male and female adults (approximately 
0.8 µg/kg/day).  This recommendation represents a decrease from the previous RDA of 70 µg/day for 
males; 55 µg/day was already the RDA for females.  The current NAS Tolerable Upper Intake Level (UL) 
for selenium is 400 µg/day for adults (approximately 5.7 µg/kg/day).  At the time that the RDA was in the 
process of being reevaluated (i.e., late 1990s), selenium was found to have entered the environment from 
old mining operations in some northwestern U.S. locations.  This resulted in public concern about the 
potential effects of selenium on livestock grazing in the vicinity, and ultimately possible effects in 
humans consuming food products from plants and animals raised in those areas.  The combination of the 
increased concern regarding selenium toxicity and the reduction in the selenium RDA indicated to 
ATSDR that an Agency reevaluation of selenium from a toxicological perspective is warranted; the 
previous version of the ATSDR Toxicological Profile for Selenium was published in 1996. 
Although selenium deficiency is not a health issue in the United States, it has been associated with two 
endemic diseases found in selenium-poor regions of China:  a cardiovascular condition known as Keshan 
Disease and an osteoarthropathy called Kashin-Beck Disease.  Keshan Disease is a cardiomyopathy 
characterized by cardiac enlargement, abnormal ECG patterns, cardiogenic shock, and congestive heart 
failure, with multifocal necrosis of the myocardium.  The disease is reported to occur primarily in 
children and women of child-bearing age and has been successfully treated by selenium supplementation; 
however, a low incidence of cases persisting after selenium supplementation suggests that there may be 
other contributing factors.  The evidence for the involvement of selenium in Kashin-Beck disease is less 
clear than for its involvement in Keshan disease.  Kashin-Beck Disease is characterized by atrophy, 
degeneration, and necrosis of cartilage tissue, and occurs primarily in children between the ages of 5 and 
13 years; it also has been successfully treated with selenium supplements.  Chronically ill people and 
older people have been shown to have lower organ concentrations of selenium than healthy individuals, 
but it is not clear if this is a cause or consequence of aging or illness. 
Relatively little information is available on health effects of elevated inhalation levels of selenium.  The 
primary target organ in humans and laboratory animals in cases of acute, high-level inhalation exposure to 
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selenium dusts or fumes is the lung, with cardiovascular, hepatic, nervous, and renal involvement as well.  
Lesser effects are observed in other organs/organ systems.  Workers acutely exposed to high 
concentrations of elemental selenium dust have reported stomach pain and headaches, whereas workers 
briefly exposed to high levels of selenium dioxide dust experienced respiratory symptoms such as 
pulmonary edema, bronchial spasms, symptoms of asphyxiation and persistent bronchitis, elevated pulse 
rates, lowered blood pressure, vomiting, nausea, and irritability.  No information is available on health 
effects in humans or laboratory animals from intermediate-duration (up to 1 year) inhalation exposure to 
selenium or selenium compounds.  Regarding chronic inhalation exposure, several occupational studies 
describe respiratory effects such as irritation of the nose, respiratory tract, and lungs, bronchial spasms, 
and coughing following exposure to selenium dioxide or elemental selenium as dust.  Respiratory 
symptoms similar to those reported for occupationally-exposed humans have been seen in animals 
inhaling high doses of elemental selenium fumes or dust, and studies of animals with acute inhalation 
exposure to hydrogen selenide or elemental selenium fumes or dust have reported hepatocellular 
degeneration and atrophy of the liver. 
Acute oral exposure to extremely high levels of selenium (e.g., several thousand times more than normal 
daily intake) produces nausea, vomiting, and diarrhea in both humans and laboratory animals. Acute oral 
exposure of humans to selenium has occasionally caused cardiovascular symptoms, such as tachycardia, 
but no electrocardiographic abnormalities were found in individuals from a human population chronically 
exposed to selenium.  In laboratory animals, acute- and intermediate-duration oral exposure to very large 
amounts of selenium (approximately 100 times normal human intake) has produced myocardial 
degeneration in laboratory animals.  
Chronic oral intake of very high levels of selenium (10–20 times more than normal) can produce selenosis 
in humans, the major effects of which are dermal and neurological.  As shown by affected populations in 
China, chronic dietary exposure to these excess levels of selenium has caused diseased nails and skin and 
hair loss, as well neurological problems, including unsteady gait and paralysis.  Additional information on 
selenosis is summarized in the following subsection of this chapter.  In contrast, studies of people living 
in areas of naturally occurring high selenium concentrations in the United States have not revealed 
adverse health effects in those populations.  This difference may result from a lower (~2-fold) selenium 
exposure in the U.S. population compared to the Chinese population, as well as a better balanced, higher 
protein diet in the United States, which could lead to reduced toxicity of selenium through interactions 
with dietary components. 
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Intermediate and chronic oral exposure of livestock to high levels of dietary selenium compounds also 
produces dermal and neurological effects.  Studies in rats and other laboratory animals with high selenium 
tissue concentrations demonstrate that many organ systems retain selenium and are affected.  The primary 
adverse effects in laboratory animals exposed to inorganic selenium salts or to selenium-containing amino 
acids are cardiovascular, gastrointestinal, hematological, hepatic, dermal, immunological, neurological, 
and reproductive, although doses causing these effects are generally at least 5 times higher than normal 
daily selenium intake.  A condition (syndrome) referred to as “blind staggers” has been repeatedly 
observed in cattle feeding off vegetation in areas with high selenium content in the soil.  However, the 
neurological effects have not been replicated in experimentally-exposed cattle receiving doses of 
selenium sufficient to induce hoof lesions, and thus, the neurological signs associated with “blind 
staggers” may be due to other compounds found within this vegetation. 
Some evidence for effects on the endocrine system has also been found following long-term oral exposure 
to elevated levels of dietary selenium in humans and rats.  In humans, blood levels of thyroid T3 hormone 
(triiodothyronine) decreased in response to increased dietary selenium for durations of 3 months and 
longer at intakes several times higher than normal intake, although the hormone levels remained within 
the normal range.  In rats, type-I-deiodinase activity decreased in response to increased exposure to 
selenium for several months, but the levels of thyroid hormones in these animals did not show a 
consistent pattern. 
Studies of Chinese populations and laboratory animals exposed to high levels of organic and/or inorganic 
selenium compounds have not found evidence of selective teratogenic effects in mammals. 
There is no evidence to support a causal association between selenium compounds and cancer in humans.  
In fact, some epidemiological and experimental evidence suggests that selenium exposure under certain 
conditions may contribute to a reduction in cancer risk.  The chemopreventive potential of supplemental 
selenium is currently under research.  Selenium sulfide and ethyl selenac are the only selenium 
compounds that have been shown to be carcinogenic upon oral administration in rodents; however, 
significant exposure of humans to these chemical forms of selenium is extremely unlikely. 
Additional information on main health effects of selenium in humans and animals is summarized below 
and detailed in Chapter 3. 
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Selenosis. Following chronic oral exposure to excessive amounts of the organic selenium compounds 
in food, the two principal clinical conditions observed in humans are dermal and neurological effects, as 
described most completely in the epidemiological study of endemic selenosis in the People's Republic of 
China. The dermal manifestations of selenosis include loss of hair, deformation and loss of nails, and 
discoloration and excessive decay of teeth, while neurological effects include numbness, paralysis, and 
occasional hemiplegia.  The average dietary intake of selenium associated with selenosis in these people 
has been estimated to be 1,270 µg/day (~0.02 mg/kg/day, or 10–20 times higher than normal daily 
intake). 
Loss of hair and malformation of hooves in pigs, horses, and cattle, and poliomyelomalacia in pigs have 
been reported to occur following long-term exposure to excessive amounts (more than 30 times the 
normal dietary amount of selenium) of the organic selenium compounds found in seleniferous plants.  
Histologically, swine with selenium-induced neurological signs exhibit bilateral macroscopic lesions of 
the ventral horn of the spinal cord. The selenium in the selenium-accumulating plant Astragalus 
bisulcatus appears to be a more potent neurotoxicant than D,L-selenomethionine or selenate.  The form of 
selenium in A. bisulcatus is unknown, although it is apparently nonprotein.  Myocardial degeneration has 
been experimentally produced in cattle, sheep, and swine (as well as in laboratory mammals) by acute and 
longer-term exposures to inorganic salts of selenium, but it is unclear whether seleniferous grains or 
forages, or other natural sources of selenium, cause the same cardiomyopathy. 
The neurological signs and histopathology observed in livestock following oral exposure to excess 
selenium compounds have not been recorded in laboratory animals. This suggests that (1) small 
laboratory mammals might not be appropriate models for selenium toxicity in humans due to 
toxicokinetic differences (e.g., laboratory animals absorb selenium compounds to a lesser extent, or 
metabolize and/or excrete selenium compounds more quickly), (2) some as yet unidentified organic form 
of selenium contributes to the neurological manifestations of chronic selenosis in humans and in 
livestock, (3) unrecognized confounding factors, such as other plant toxins, have contributed to the 
neurological syndrome associated with chronic selenosis in field studies of humans and livestock, and/or 
(4) species differences in interactions between selenium and other nutrients or xenobiotics, such as 
vitamin E and methionine, which have been found to be antagonistic to selenium toxicity 
Endocrine Effects. Selenium is a component of all three members of the deiodinase enzyme family, 
the enzymes responsible for deiodination of the thyroid hormones, and has a physiological role in the 
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control of thyroid hormone levels.  Significant decreases in serum T3 hormone levels have been observed 
in humans that were environmentally or experimentally exposed to elevated dietary levels of selenium 
(several times higher than normal).  However, the T3 hormone levels observed in these studies were still 
within the normal human range, so the biological impact of this change is unclear.  The effect of increased 
dietary selenium on other thyroid hormones is also uncertain.  Intermediate-duration studies in rats show a 
decrease in type-I-deiodinase activity in response to elevated selenium; however, the levels of thyroid 
hormones in these animals did not show any consistent changes. 
Reduced growth rate of young animals and weight loss in older animals are two of the most common 
effects in experimental animals following long-term oral intake of excessive levels of inorganic and 
organic compounds of selenium.  It is quite possible that selenium-induced reduction in growth has a 
thyroid or other endocrine component.  For example, selenite treatment of young rats decreased 
somatomedin C levels, although somatomedin C was not a sensitive index of elevated selenium exposure 
in humans from a high-selenium area of South Dakota, and growth hormone secretion in response to the 
growth hormone releasing factor was also reduced in selenium-treated rats.  The primary endocrine target 
of selenium leading to decreased growth has yet to be elucidated.  Pancreatic toxicity has been observed 
following excess selenium exposure.  Cytoplasmic flocculation was observed in lambs treated with a 
single oral dose of selenite, and pancreatic damage, which was not further described, was noted in rats 
following chronic oral treatment with selenate or selenite.  Pancreatic toxicity associated with excessive 
selenium exposure is likely related to the unique ability of that organ to accumulate the element. 
Reproductive Effects. In humans, no correlation has been found between selenium levels in seminal 
fluid and sperm count or mobility.  No significant increase in spontaneous abortions was reported among 
women chronically exposed to drinking water containing increased selenium, but the concentration was 
not considered to be unusually high.  In animals, oral exposure to high doses of sodium selenate or 
selenite (at least 8 times greater than those normally supplied by an adequate diet) caused increased 
numbers of abnormal sperm, as well as testicular hypertrophy, degeneration, and atrophy in male rats, and 
affected the estrous cycle in female rats and mice.  The animals that showed these effects were not mated, 
so it is not clear if fertility was affected.  Oral treatment with L-selenomethionine similarly caused 
disturbances in the menstrual cycle (anovulation, short luteal and follicular phases) in monkeys.  
Selenium deficiency has also been reported to cause decreased sperm production and motility in rats.  The 
relevance of the reproductive effects of high and low levels of selenium in laboratory animals to potential 
reproductive effects in humans is not known. 
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Hepatic Effects. Liver effects have not been reported for humans exposed to excessive amounts of 
selenium.  No significant abnormalities were found in blood levels of liver enzymes in people living in 
high selenium areas, or in liver morphology (ultrasonographic examination) of individuals suffering from 
severe symptoms of selenosis.  In experimental animals and livestock, however, the liver has been shown 
to be affected following inhalation or oral exposure to different kinds of selenium compounds.  
Hepatocellular degeneration occurred in guinea pigs following short-term inhalation exposure to 
excessive levels (hundreds of times higher than normal) of elemental selenium dust (8 mg/m3) or 
hydrogen selenide (33 mg/m3). Cirrhosis, hepatocellular degeneration, and changes in liver enzyme 
levels in serum have been reported for rats, pigs, and mice orally exposed to selenite, selenate, or organic 
selenium.  The oral doses of selenium producing the various adverse liver effects were approximately 
10 times the amount normally found in an adequate diet.  Excessive dietary exposure to selenium sulfide 
(several thousands of times higher than normal selenium intake) produced frank hepatotoxicity in rats, but 
not in mice.  Although the liver appears to be the primary target organ for the oral toxicity of selenium in 
experimental animals following intermediate and chronic exposure, liver cirrhosis or dysfunction has not 
been a notable component of the clinical manifestations of chronic selenosis in humans.  The lack of 
evidence of liver damage in humans due to selenosis, despite all of the animal data to the contrary, 
suggests a problem with the animal models of the disease. 
Renal Effects. No reports of renal effects in humans were located.  In animals, mild kidney effects 
have been observed following oral exposure to seleniumat levels several hundred times higher than 
normal human intake.  These effects include hydropic degeneration in sheep following a single dose of 
5 mg Se/kg/day as sodium selenite.  Rats appear to be more sensitive than mice to renal effects of 
repeated oral exposures to selenium compounds.  A dose-related increase in renal papilla degeneration, 
described as mild to minimal, was observed in rats at very high levels of selenate or selenite (0.5 mg 
Se/kg/day, several hundreds of times higher than normal human intake) in the drinking water for 
13 weeks, although increased kidney weight was the only renal effect in similarly exposed mice.  Mice 
that were given excessive daily doses of selenium sulfide by gavage (464 mg Se/kg/day for 13 weeks), 
however, developed interstitial nephritis. 
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2.3 MINIMAL RISK LEVELS (MRLs) 
Inhalation MRLs 
No MRLs were derived for inhalation exposure to selenium because of insufficient quantitative data 
concerning both human and animal exposures.  Data on the health effects of inhaled selenium in humans 
are available from studies of occupationally exposed workers (Clinton 1947; Glover 1970; Holness et al. 
1989; Kinnigkeit 1962; Wilson 1962).  These studies suggest that the respiratory system is the most 
sensitive end point for inhaled selenium dust, but they do not provide quantitative measurements of 
exposure levels and are frequently confounded by concurrent exposures to other chemicals.  Laboratory 
animal studies support the respiratory system as the main target of selenium inhalation toxicity (Dudley 
and Miller 1941; Hall et al. 1951), but the available data are for acute exposures to high concentrations of 
selenium that also produced serious health effects, including death. 
Oral MRLs 
No MRLs were derived for acute or intermediate oral exposure to selenium because of insufficient 
information regarding adverse health effect levels in humans and experimental animals.  For acute 
exposure, no quantitative data are available from studies of humans.  Some acute oral animal studies 
identify lowest-observed-adverse-effect levels (LOAELs) for organ weight changes, behavioral changes, 
and reduced body weight, but these occur at doses similar to those producing serious LOAELs for 
paralysis and developmental effects in other mammalian studies. 
Information on health effects of intermediate-duration (15–365 days) oral exposure to selenium in 
humans is mainly available from a 120-day experimental study of men who were exposed to a controlled 
diet of foods naturally low or naturally high in selenium (Hawkes and Turek 2001; Hawkes et al. 2001).  
Eleven subjects were fed diets providing selenium intake levels of 0.6 µg/kg/day for 21 days (baseline 
period), followed by 0.2 µg/kg/day (6 subjects) or 4 µg/kg/day (5 subjects) for the subsequent 99 days. 
This was more a nutritional study than a toxicological study, as indicated by selenium intake levels that 
bracketed the current RDA (~0.8 µg Se/kg/day) and were well below the tolerable upper limit (~5.7 µg 
Se/kg/day) recommended by the Food and Nutrition Board (NAS 2000).  Comprehensive evaluations 
were performed that included serum levels of thyroid hormones (T3 and TSH) and reproductive hormones 
(testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone), 
sperm quality indices (number and concentration, motility, forward progression and velocity, and 
morphology), and immunological end points (including serum immunoglobulin levels, lymphocyte counts 
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and phenotypes, natural-killer cell activity, proliferative response of lymphocytes to mitogenic 
stimulation, delayed-type hypersensitivity skin responses to recall antigens, and antibody responses to 
diptheria-tetanus and influenza vaccines).  Effects were essentially limited to subclinical changes in 
thyroid hormones and sperm motility, which are not considered to be toxicologically meaningful.  Serum 
T3 concentrations decreased in the high selenium group and increased in the low selenium group, but all 
values apparently remained within the normal human range.  Serum TSH concentrations increased in the 
high-selenium group with no change in the low-selenium group, but values also remained in the normal 
range. Sperm motility was slightly lower than the baseline value in the high selenium group at study 
termination.  The decrease in sperm motility cannot be clearly attributed to selenium because the effect 
was not consistent over the duration of exposure, and is unlikely to be adverse because it is at the low end 
of the normal range and was not accompanied by any changes in other indices of sperm movement 
(progression or forward velocity) or sperm numbers or morphology. 
Effects in intermediate-duration studies in experimental animals include reductions in liver enzyme 
activities, changes in liver and body weights, and histological changes in the liver and kidney, but the 
relevance of these effects to selenium toxicity in humans is questionable.  For example, humans with 
selenosis did not display any changes in serum levels of liver enzymes or morphological damage to the 
liver, as shown by ultrasonographic examination (Yang et al. 1989a).  Further, the liver and kidney effects 
in animal studies occurred at doses (≥0.2 mg/kg/day) that were considerably higher than the 4 µg/kg/day 
intake level that caused the subclinical thyroid hormone and sperm motility alterations in humans 
(Hawkes and Turek 2001; Hawkes et al. 2001).  Although the human experimental study identifies a no-
observed-adverse-effect level (NOAEL) of 4 µg/kg/day for sensitive endocrine and male reproductive end 
points, it is an inappropriate basis for derivation of an intermediate oral MRL.  In particular, because this 
is a free-standing NOAEL, proximity to the LOAEL region is not known, and the use of the NOAEL to 
derive an MRL would yield a value that is in the range of the selenium RDA (approximately 
0.8 µg/kg/day) (NAS 2000) and below the chronic oral MRL derived below. 
•	 An MRL of 0.005 mg/kg/day (5 µg/kg/day) has been derived for chronic oral exposure (>365 days) 
to selenium. 
This MRL is based upon a study by Yang and Zhou (1994), who examined of a group of five individuals 
who were recovering from selenosis, and who were drawn from a larger population from an area of China 
where selenosis occurred (Yang et al. 1989a, 1989b). The study collected data on selenium levels in the 
diet, blood, nails, hair, urine, and milk of residents at three sites with low, medium, and high selenium, 
and compared the incidence of clinical symptoms of selenosis (morphological changes in fingernails) 
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with dietary intake of selenium and selenium levels in blood.  The average adult body weight was 55 kg 
(Yang et al., 1989b).  It was found that selenium levels in blood corresponded to the dietary intake of 
selenium, and that symptoms of selenosis occurred at or above a selenium intake level of 910 µg/day 
(0.016 mg/kg/day) (Yang et al. 1989a).  In 1992, Yang and Zhou (1994) reexamined five individuals from 
the high selenium site who had been suffering from symptoms of selenosis (loss of fingernails and hair), 
but were recovering (nails were regrowing).  Since their earlier report, the living conditions of the 
population had improved; they had been cautioned against consuming high selenium foods, and part of 
their diet from locally produced corn had been replaced with rice or cereals.  Yang and Zhou (1994) 
found that the concentration of selenium in the blood of these individuals had fallen from 1,346 µg/L 
(measured in 1986) to 968 µg/L (measured in 1992). Using a regression equation derived from the data in 
an earlier report (Yang et al. 1989b), it was calculated that the dietary intake of selenium associated with 
selenosis in these individuals was 1,270 µg/day, while an intake of 819 µg Se/day (was associated with 
recovery (Yang and Zhou 1994). 
The chronic oral MRL is based on a NOAEL of 819 µg/day (0.015 mg/kg/day) for disappearance of 
symptoms of selenosis in recovering individuals (Yang and Zhou 1994) and uses an uncertainty factor of 
3 for human variability.  An uncertainty factor of 3 was considered appropriate because the individuals in 
this study were sensitive individuals drawn from a larger population and because of supporting studies, as 
discussed in Appendix A.  The NOAEL used to derive the MRL is consistent with NOAELs observed for 
other human populations (Longnecker et al. 1991).  The MRL is about 2.5–5 times higher than normal 
selenium intake levels of 71–152 µg/day (approximately 0.001–0.002 mg/kg/day) (DHHS 2002; FDA 
1982a; Levander 1987; Pennington et al. 1989; Schrauzer and White 1978; Schubert et al. 1987; Welsh et 
al. 1981), and approximately 6 times greater than the RDA for selenium of 55 µg/day 
(~0.0008 mg/kg/day) (NAS 2000).  The MRL does not represent a threshold for toxicity, but a daily 
intake that ATSDR considers to be safe for all populations.  The exact point above the MRL at which 
effects might occur in sensitive individuals is uncertain. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of selenium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
Selenium is a naturally occurring element that is widely distributed in rocks and soils.  Although selenium 
has been reported at hazardous waste sites where it can occur in many forms, analysis of specific forms 
present at these sites has not been performed, and it is unclear how much selenium is present in some of 
the sites. Selenium has multiple oxidation states (valence states) including -2, 0, +4, and +6. The type of 
selenium found is a result of its oxidation state, which may vary according to ambient conditions, such as 
pH and microbial activity. 
Elemental selenium (selenium[0]) is rarely found naturally, but it is stable in soils.  Selenates 
(selenium[+6]) and selenites (selenium[+4]) are water soluble and can be found in water.  Sodium 
selenate is among the most mobile forms of selenium because of its high solubility and inability to adsorb 
to soil particles. More insoluble forms, such as elemental selenium, are less mobile; therefore, there is 
less risk for exposure. Because of greater bioavailability, water-soluble selenium compounds are 
probably more toxic than elemental selenium by any route.  Selenium is found in nature complexed with 
multiple compounds, and although various forms are discussed in the profile, many others exist.  Some 
plants, such as alfalfa, yeasts, white grain, and cruciferous species (e.g., mustard, cabbage, broccoli, and 
cauliflower), are efficient accumulators of selenium. Plants can contain organic selenium primarily in the 
form of the amino acids, selenomethionine and selenocysteine, along with the dimethyl selenides.  
Elemental selenium can be oxidized to form selenium dioxide.  While the products of oxidation might be 
expected at the soil surface, elemental selenium would be the expected predominant form in soils or 
sediments where anaerobic conditions exist.  Selenium sulfides, used in some anti-dandruff shampoos, are 
not very water soluble and, therefore, like elemental selenium, are relatively immobile in the 
environment. 
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Much of the selenium released to the environment comes from the burning of coal and other fossil fuels, 
and from other industrial processes such as the production of rubber.  For more information on the 
physical and chemical properties of selenium, see Chapter 4.  For more information on the potential for 
human exposure, see Chapter 6. 
In humans and animals, selenium is an essential nutrient that plays a role in protecting tissues from 
oxidative damage as a component of glutathione peroxidase.  It is also found in the deiodinases, including 
type I and II iodothyronine 5'-deiodinase, which convert thyroxine to triiodothyronine and in thioredoxin 
reductase, which catalyses the NADPH-dependent reduction of the redox protein thioredoxin.  The 
biologically active form of selenium in these enzymes is the modified amino acid, selenocysteine.  
Humans and animals can be exposed to increased amounts of selenium through the use of dietary 
supplements containing selenium.  The nutritional role of selenium is further discussed in Section 3.4.  
Although selenium is an essential nutrient, exposure to high levels via inhalation or ingestion may cause 
adverse health effects.  The mechanism by which selenium exerts toxic effects is unknown, but existing 
theories are discussed in Section 3.5.  Most of the studies available on health effects involve exposure to 
selenite, selenate, and a form found in foods (selenomethionine). 
Several factors should be considered when evaluating the toxicity of selenium compounds.  The purity 
and grade of the particular test substance used in the testing are important factors.  For example, in studies 
of selenium sulfide compounds, the amounts of mono- and disulfides are often not specified by the study 
authors. The solubility and the particle size of selenium compounds can also influence their toxicity. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in Tables 3-1, 3-2, and 3-3 and 
illustrated in Figures 3-1, 3-2, and 3-3.  The points in the figures showing no-observed-adverse-effect 
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levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of 
exposure) used in the studies.  The oral doses presented in these tables and figures, as well as those 
included in the text of this chapter, are expressed on a per kg of body weight basis.  LOAELs have been 
classified into "less serious" or "serious" effects.  "Serious" effects are those that evoke failure in a 
biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death).  "Less 
serious" effects are those that are not expected to cause significant dysfunction or death, or those whose 
significance to the organism is not entirely clear.  ATSDR acknowledges that a considerable amount of 
judgment may be required in establishing whether an end point should be classified as a NOAEL, "less 
serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be insufficient data to decide 
whether the effect is indicative of significant dysfunction.  However, the Agency has established 
guidelines and policies that are used to classify these end points.  ATSDR believes that there is sufficient 
merit in this approach to warrant an attempt at distinguishing between "less serious" and "serious" effects.  
The distinction between "less serious" effects and "serious" effects is considered to be important because 
it helps the users of the profiles to identify levels of exposure at which major health effects start to appear.  
LOAELs or NOAELs should also help in determining whether or not the effects vary with dose and/or 
duration, and place into perspective the possible significance of these effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables 
(Tables 3-1, 3-2, and 3-3) and figures (Figures 3-1, 3-2, and 3-3) may differ depending on the user's 
perspective. Public health officials and others concerned with appropriate actions to take at hazardous 
waste sites may want information on levels of exposure associated with more subtle effects in humans or 
animals (LOAELs) or exposure levels below which no adverse effects (NOAELs) have been observed.  
Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may be of interest to 
health professionals and citizens alike. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for selenium.  An MRL is defined as an estimate of daily human exposure to a substance that is 
likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of 
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of 
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure. 
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Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990b), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, chronic 
bronchitis, or multiple chemical exposure.  As these kinds of health effects data become available and 
methods to assess levels of significant human exposure improve, these MRLs will be revised. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
Table 3-1 and Figure 3-1 describe the health effects observed in experimental animals that inhaled 
elemental selenium dust or hydrogen selenide.  Studies of other forms of selenium are not presented in the 
LSE tables and figures (Table 3-1 and Figure 3-1) because either the reporting of the studies was 
incomplete or no studies on other forms were located.  All doses are expressed in terms of total selenium. 
3.2.1.1 Death 
No studies were located regarding death in humans after inhalation of elemental selenium or selenium 
compounds. 
In animals, the acute lethality of hydrogen selenide and elemental selenium dust when inhaled has been 
investigated. In guinea pigs exposed to hydrogen selenide for 2, 4, or 8 hours, 5/16 died within 10 days 
of exposure at 12 mg selenium/m3, 3/16 died at 6 mg selenium/m3, and 8/16 died at 6 mg selenium/m3, 
respectively (Dudley and Miller 1941). 
No deaths were observed among rabbits or guinea pigs exposed to elemental selenium dust at levels of 
31 mg selenium/m3 for 4 hours every other day for 8 exposure days (Hall et al. 1951).  Higher levels were 
not tested. 
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All LOAEL values from each reliable study for death in each species and duration category are recorded 
in Table 3-1 and plotted in Figure 3-1. 
3.2.1.2 Systemic Effects 
The selenium compounds that are most likely to be encountered in air in occupational settings are dusts of 
elemental selenium, hydrogen selenide, and selenium dioxide.  Other volatile selenium compounds (e.g., 
dimethyl selenide, dimethyl diselenide) might be encountered in some naturally occurring situations.  
Because selenium is converted from one form to another, as in plant biosynthesis of selenoamino acids, it 
is not clear which specific forms may be encountered at hazardous waste sites.  If a hazardous waste site 
specifically contains deposits of compounds of selenium, those compounds could be released off-site in 
dust or air. Toxicity data for exposures via inhalation are available for elemental selenium, selenium 
dioxide, selenium oxychloride, hydrogen selenide, and dimethyl selenide.  Because there are few studies 
of inhalation of selenium of any single form, all available studies of inhalation exposures to selenium 
compounds will be included in this discussion. 
In studies of human occupational exposures, it appears that the respiratory tract is the primary site of 
injury after inhalation of selenium dust or selenium compounds, but gastrointestinal (possibly due to 
swallowed selenium) and cardiovascular effects, as well as irritation of the skin and eyes, also occur.  
Little of the available information for humans, however, relates health effects exclusively to measured 
concentrations of the selenium dust or compounds because of the possibility of concurrent exposures to 
multiple substances in the workplace.  In animals, the respiratory tract is also the primary site of injury 
following inhalation exposure to selenium dust and hydrogen selenide.  Hematological and hepatic effects 
have also been noted in animals.  Inhalation data from laboratory animal studies are available only for 
acute exposures. 
No information was located regarding hematological, musculoskeletal, dermal, or ocular effects in 
humans or laboratory animals after inhalation exposure to selenium or selenium compounds.  The 
systemic effects that have been observed after inhalation exposure are discussed below.  The highest 
NOAEL values and all LOAEL values for each reliable study for systemic effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
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Respiratory Effects. In humans, the respiratory system is the primary site of injury after inhalation 
of elemental selenium or selenium compounds.  The largest number of reported human exposures 
occurred in occupational settings, especially in industries that extract, mine, treat, or process selenium-
bearing minerals and in industries that use selenium or selenium compounds in manufacturing.  The 
reports of occupational exposure do not link observed symptoms to specific air concentrations of 
elemental selenium or selenium compounds.  Several reports, however, have noted common effects 
associated with inhalation exposure in occupational settings. 
Selenium dioxide is formed when selenium is heated in air.  Direct exposure to selenium dioxide is, 
therefore, primarily an occupational hazard and not likely to be a risk at hazardous waste sites.  Selenium 
dioxide forms selenious acid on contact with water, including perspiration, and can cause severe irritation.  
Acute inhalation of large quantities of selenium dioxide powder can produce pulmonary edema as a result 
of the local irritant effect on alveoli (Glover 1970).  Bronchial spasms, symptoms of asphyxiation, and 
persistent bronchitis have been noted in workers briefly exposed to high concentrations of selenium 
dioxide (Wilson 1962).  Kinnigkeit (1962) reported that selenium dioxide concentrations of 0.007– 
0.05 mg selenium/m3 in a selenium rectifier plant produced slight tracheobronchitis in 9 of 62 exposed 
workers. 
Hydrogen selenide, a highly poisonous selenium compound, is a gas at room temperature, with a density 
much higher than air.  Selenium oxychloride, also highly toxic, is more irritating and corrosive to the 
human respiratory tract than are other forms of selenium because the compound hydrolyzes to hydrogen 
chloride (HCl), which can then form hydrochloric acid in humid air and in the respiratory tract (Dudley 
1938). Hydrogen selenide and selenium oxychloride are occupational exposure hazards that are not 
expected to be much of a concern at hazardous waste sites. 
Acute inhalation exposure to elemental selenium dust, possibly including some selenium dioxide, in 
occupational settings has been shown to irritate mucous membranes in the nose and throat and produce 
coughing, nosebleed, loss of olfaction, and in heavily exposed workers, dyspnea, bronchial spasms, 
bronchitis, and chemical pneumonia (Clinton 1947; Hamilton 1949).  Chronic exposure of 40 workers at a 
copper refinery produced increased nose irritation and sputum (Holness et al. 1989).  The exact 
concentration of selenium was not given, but the concentration was reported to exceed 0.2 mg 
selenium/m3. Confounding variables in this study include concurrent exposure to several other metals 
including copper, nickel, silver, lead, arsenic, and tellurium. 
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In experimental animals, the respiratory tract is the primary site of injury following acute inhalation 
exposure to elemental selenium and selenium compounds.  Rats exposed to selenium fumes (selenium 
concentration and particle size were not reported) for 2–16 minutes experienced moderate to severe 
respiratory effects, including hemorrhage and edema of the lungs (Hall et al. 1951).  Rats exposed to 
selenium dust (average particle diameter, 1.2 µm) at levels of 33 mg selenium/m3 for 8 hours experienced 
severe respiratory effects, including hemorrhage and edema of the lungs, and several animals died (Hall et 
al. 1951).  Histopathological examinations of surviving animals revealed chronic interstitial pneumonitis.  
Acute exposure of rabbits and guinea pigs to selenium dust (average particle diameter, 1.2 µm) at a 
concentration of 33 mg selenium/m3 resulted in mild interstitial pneumonitis or congestion, and slight 
emphysema in both species (Hall et al. 1951).  Other histological findings included vascular lymphocytic 
infiltration and intra-alveolar foci of large macrophages. 
Acute inhalation exposure of guinea pigs to 8 mg selenium/m3 as hydrogen selenide for 4 hours produced 
diffuse bronchopneumonia and pneumonitis (Dudley and Miller 1941).  The investigators do not indicate 
if any of these guinea pigs died as a result of the exposure.  Histologic examination of animals that died 
following exposure to higher concentrations revealed thickening of the alveolar walls and congestion of 
alveolar capillaries (Dudley and Miller 1937).  In contrast, 1-hour exposure of rats to 25,958 mg 
selenium/m3 as dimethyl selenide produced only minor effects (increased weight of lung and liver) 1 day 
postexposure. These changes disappeared by 7 days postexposure (Al-Bayati et al. 1992).  Enzymatic 
methylation of selenium compounds is the primary route of detoxification and may explain the low 
toxicity of dimethyl selenide (Al-Bayati et al. 1992). Although this form of selenium is environmentally 
relevant since it is formed in soil, plants, and microorganisms, dimethyl selenide appears to be relatively 
nontoxic in comparison to occupational exposure to hydrogen selenide. 
The effects of intratracheal instillation of selenium on pulmonary function may be dependent on the form 
in which it is supplied (Nonavinakere et al. 1999).  Instillation of 0.06 mg selenium/100 g body weight as 
selenium dioxide produced a significant decrease in respiratory rate and a significant increase in lung 
resistance compared with controls.  Instillation with 0.06 mg selenium/110 g body weight as seleno-L­
methionine also produced a decrease in respiratory rate and an increase in lung resistance, but the values 
were not significantly different from controls. 
Intratracheal instillation of 0.3 mg selenium as sodium selenite in male Hartley-guinea pigs decreased 
dynamic-lung-compliance and increased pulmonary resistance compared with control animals instilled 
with saline (Bell et al. 1997). Analysis of bronchoalveolar-lavage fluid showed increased activities of 
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lactate dehydrogenase, β-glucuronidase, alkaline phosphatase, and protein, suggesting damage to lung 
tissue. 
Histological analysis of guinea pigs that received single intratracheal instillations of 0.3 mg selenium as 
sodium selenite found mild acute inflammation in approximately one-third of the lung tissue and a 
noticeable amount of sloughed epithelium and mucus within the bronchi (Bell et al. 2000).  Lungs of 
animals treated with 0.06 mg selenium showed neutrophils aggregated in the alveoli and some dilation of 
the alveoli suggestive of emphysema.  Relative lung weights and the ratio of wet/dry lung weight were 
increased in the selenium-treated animals compared with controls; the increase was only significant for 
those receiving the higher dose of selenium.  Leukocyte counts in bronchoalveolar-lavage fluid were 
decreased for selenium-treated animals compared with controls, and the difference was significant for the 
animals receiving 0.3 mg selenium, but not the 0.06 mg dosage. 
No studies were located regarding respiratory effects in animals after intermediate or chronic inhalation of 
selenium or selenium compounds. 
Cardiovascular Effects. Several workers experienced symptoms of shock, including lower blood 
pressure and elevated pulse rates, following an acute exposure (at most 20 minutes) to selenium dioxide 
fumes resulting from a fire (Wilson 1962).  The subjects were treated with oxygen and inhalation of 
ammonia vapor, and pulse rates were normalized within 3 hours. 
Cardiovascular effects were not observed in guinea pigs exposed to hydrogen selenide at 8 mg 
selenium/m3 for 4 hours (Dudley and Miller 1941), or in guinea pigs and rabbits exposed to elemental 
selenium dust (average particle diameter, 1.2 µm) every other day at 33 mg selenium/m3 for eight 4-hour 
exposure periods (Hall et al. 1951). 
Gastrointestinal Effects. Vomiting and nausea were reported in workers exposed to high 
concentrations of selenium dioxide for a maximum of 20 minutes during a fire (Wilson 1962).  Stomach 
pain was frequently reported by workers exposed to elemental selenium and selenium dioxide at a 
selenium rectifier plant (Glover 1967), and by copper refinery workers exposed to an unspecified form of 
selenium (Holness et al. 1989).  Exposure concentrations were not reported for the rectifier plant, but 
were >0.2 mg selenium/m3 at the copper refinery. 
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No studies were located regarding gastrointestinal effects in animals after inhalation of selenium or 
selenium compounds. 
Hepatic Effects. No studies were located regarding hepatic effects in humans after inhalation of 
selenium or selenium compounds. 
Hepatoxicity has been observed in experimental animals following inhalation exposure to elemental 
selenium dust and to hydrogen selenide.  One month after an 8-hour exposure to elemental selenium dust 
at a level of 33 mg selenium/m3, most rats exhibited slight liver congestion and a few exhibited mild 
centrilobular atrophy (Hall et al. 1951).  In contrast, 1 week after exposure to 25,958 mg selenium/m3 as 
dimethyl selenide for 1 hour, rats showed no observable changes in the liver (Al-Bayati et al. 1992).  
Three weeks following acute exposure to elemental selenium dust at a level of 33 mg selenium/m3 for 
4 hours every other day for 8 days, 4/10 guinea pigs exhibited slight hepatic congestion with mild central 
atrophy and 2/10 showed some fatty hepatocellular degeneration (Dudley and Miller 1941).  In contrast, 
exposure of guinea pigs to lower concentrations of selenium (8 mg/m3), as hydrogen selenide, for a single 
4-hour period produced mild fatty hepatocellular metamorphosis (Dudley and Miller 1941). 
Renal Effects. No studies were located regarding renal effects in humans after inhalation of selenium 
or selenium compounds. 
The kidneys do not appear to be affected in guinea pigs (Dudley and Miller 1941; Hall et al. 1951) after 
acute inhalation exposure to 33 mg selenium/m3 as hydrogen selenide for 8 hours or to 8 mg selenium/m3 
as elemental selenium dust for 4 hours.  Likewise, the kidneys were not affected in rabbits following 
acute inhalation exposure to 33 mg selenium/m3 as hydrogen selenide for 8 hours (Hall et al. 1951) or in 
rats following acute inhalation exposure to 25,958 mg selenium/m3 as dimethyl selenide for 1 hour or to 
33 mg selenium/m3 as hydrogen selenide for 8 hours (Al-Bayati et al. 1992; Hall et al. 1951). 
Endocrine Effects. No studies were located regarding endocrine effects in humans after inhalation of 
selenium or selenium compounds. 
No histopathological changes in the adrenal gland were observed in guinea pigs exposed to hydrogen 
selenide at 8 mg selenium/m3 for 4 hours (Dudley and Miller 1941) or in rats exposed to elemental 
selenium at 33 mg selenium/m3 for 8 hours (Hall et al. 1951). 
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Body Weight Effects. No studies were located regarding effects on body weight in humans 
following inhalation of selenium or selenium compounds. 
No effects on body weight were observed in guinea pigs following a single 8-hour exposure to elemental 
selenium at 33 mg selenium/m3 or in guinea pigs and rabbits exposed to elemental selenium dust at 33 mg 
selenium/m3 every other day for 4 hours for a total of eight exposures (Hall et al. 1951). 
3.2.1.3 Immunological and Lymphoreticular Effects  
No studies were located regarding immunological or lymphoreticular effects in humans after inhalation 
exposure to selenium or selenium compounds. 
Lymphoid hyperplasia was noted in the spleen of guinea pigs following a single 4-hour exposure at 8 mg 
selenium/m3 as hydrogen selenide (Dudley and Miller 1941). Histopathological changes in the spleen 
were not observed in guinea pigs exposed to elemental selenium dust (average particle diameter, 1.2 µm) 
at 33 mg selenium/m3 for 8 hours (Hall et al. 1951). Injury to the spleen was observed in guinea pigs 
following exposure for 4 hours, every other day, for 8 days to elemental selenium dust at a level of 33 mg 
selenium/m3 (Hall et al. 1951). Specific effects included congestion of the spleen, fissuring red pulp, and 
increased polymorphonuclear leukocytes (Hall et al. 1951). 
3.2.1.4 Neurological Effects 
Information concerning possible neurological effects caused by inhalation of selenium or selenium 
compounds is limited.  Severe frontal headaches were reported by workers exposed during an accident to 
high concentrations of selenium fumes (compound not stated) for approximately 2 minutes (Clinton 
1947).  Workers at a selenium rectifier plant reported symptoms of malaise and irritability when working 
with selenium (exposure was probably to selenium dioxide and elemental selenium, but the form was not 
stated) (Glover 1967).  The symptoms resolved whenever the workers were moved to other work.  
Urinary concentrations of selenium were about 0.08 mg/L, compared to 0.024–0.034 mg/L in unexposed 
workers. 
No studies were located regarding neurological effects in animals after inhalation of selenium or selenium 
compounds. 
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No studies were located regarding the following health effects in humans or animals after inhalation 
exposure to selenium or selenium compounds: 
3.2.1.5 Reproductive Effects 
3.2.1.6 Developmental Effects 
3.2.1.7 Cancer 
There are no epidemiologic data that support a causal association between the inhalation of elemental 
selenium dusts or selenium compounds and the induction of cancer in humans (Gerhardsson et al. 1986; 
Wester et al. 1981).  In one study, postmortem samples were collected from copper smelter workers who 
were exposed to several different airborne compounds, including selenium compounds.  Samples from 
lung cancer cases had lower concentrations of selenium in lung tissue than samples from controls or from 
workers who had died from other causes (Gerhardsson et al. 1986).  In another autopsy study of smelter 
workers, Wester et al. (1981) found that the selenium concentrations in kidney tissues from workers who 
had died of malignancies were lower than the selenium concentrations in kidney tissues from workers 
who died of other causes.  Further discussions regarding the cancer protective effects of selenium can be 
found in Section 3.2.2.7. 
No studies were located regarding carcinogenic effects in laboratory animals after inhalation exposure to 
selenium or selenium compounds. 
3.2.2 Oral Exposure 
Table 3-2 and Figure 3-2 describe the health effects observed in humans and experimental animals 
associated with dose and duration of oral exposure to selenium and selenium compounds (i.e., elemental 
selenium dust, selenium dioxide dissolved in water [selenious acid], sodium selenate, sodium selenite, 
potassium selenate, and dietary selenium compounds, which include selenoamino acids).  All doses for 
these compounds are expressed in terms of total selenium.  Table 3-3 and Figure 3-3 describe health 
effects observed in laboratory animals following oral exposure to selenium sulfides (SeS2 and SeS) at 
varying doses and exposure durations.  All doses for selenium sulfide compounds are expressed in terms  

























6700 M (LD50) 
Reference 
Chemical Form 








7 M (LD50) 








































35.9 M (LD50) 







16 M (LD50) 







2.3 F (LD50) 
Pletnikova 1970 
selenite 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
10 Rabbit	 once Pletnikova 19701 F (LD50)

(NS) (G) selenite 
 
Systemic 
11 Rat 14 d NTP 1996 
Bd Wt 0.251 F	 0.418 F (significant (36%) reduction inad lib(Sprague- body weight) sodium selenate
 Dawley) (W)
 
12 Mouse	 14 d Johnson et al. 2000 
ad lib Hemato 0.38 M 0.82 M (significant increase in red blood(BALB/c) cell count)	 Selenite (W) 
Hepatic 0.38 M 0.82 M (significant decrease in relative 
liver weight) 
Renal 0.17 M 0.38 M (significant increase in relative 
kidney weight) 
Bd Wt 0.38 M 0.82	 (significant decrease in body 
weight gain) 
13 Mouse	 14 d Johnson et al. 2000 
ad lib Hemato 1.36 M
 (BALB/c) selenomethionine 
 (W) 
Hepatic 1.36 M 
Renal 1.36 M 
Bd Wt 1.36 M 




















Pig 5 d 
Resp 1.25 













ad lib 0.38 M 0.82 (increased proliferation of 
splenic lymphocytes and 
LPS-induced production of TNF 
alpha and IL-1beta) 
M 







ad lib 1.36 M 








1.6 (decreased activity, muscle 
tone, touch response, 
respiration; hypothermia) 







ad lib 0.24 M 0.58 (significant increase in the 
levels of striatal 
dihydroxyphenylacetic acid and 
homovanillic acid) 
M 
Tsunoda et al. 2000 
Selenite 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
19 Mouse	 14 d Tsunoda et al. 2000 
ad lib 1.96 M
(BALB/c) Organic selenium 

(W) 
20 Pig	 10 d Wilson et al. 19891.3 (hypoactivity, focal symmetrical1x/d(NS)	 poliomalacia, histopathological selenite 
(C) lesions in brain and spinal cord) 
Developmental 
21 Hamster once Ferm et al. 1990 
7.1 	 7.9 (encephalocele; decreasedGd 8(Syrian LKV) crown-rump length) selenite
 (GW) 
 
22 Hamster	 once Ferm et al. 19907.1 (encephalocele)Gd 8(Syrian LKV) selenate 
 (GW)
 
23 Hamster once Ferm et al. 1990 




24 Rat 6 wk Halverson et al. 19660.48 M (1/8 died)ad lib(Sprague- selenite
 Dawley) (F)
 




26 Rat	 13 wk NTP 19942.54 (20/20 died)























(Fischer- 344) (W) 
13 wkRat 









ad lib 0.84 M (4/6 died) 








ad lib 0.84 M (2/6 died) 









1.05 M (1/3 died) 
1.05 F (3/5 died) 








Schroeder and Mitchener 1971a 
selenite 
(50% males died at 58 days 













14.2 M (15/15 died) 
Sayato et al. 1993 
D,L-selenocystine 




Endocr 0.0039 M 
























Hemato 0.004 M 












0.15 F (vomiting) 
0.15 F (increased weight loss) 











0.105 (significant reduction in type I 
deiodinase activity) 
M 







ad lib Endocr 
Bd Wt 
0.118 (significant reduction in type I 
deiodinase activity) 
M 
0.118 (significant reduction in body 
weight (15%)) 
M 












0.2 (nodular regenerative 
hyperplasia, increased relative 
liver weight) 
M 
Bioulac-Sage et al. 1992 
selenite 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
40 Rat 8 wk Chen et al. 1993 
Resp 0.45 M 
(Sprague- (F)	 selenite 
Dawley) 
Cardio 0.45 M 
Gastro 0.45 M 
Hepatic 0.45 M (diffuse panlobular vacuolar 
accumulation of glycogen and 
lipid) 
Renal 0.45 M 
Bd Wt 0.25 M (final body weights about 14% 0.35 M (final body weights about 29% 
lower than controls) lower than controls) 
41 Rat	 40 d Eder et al. 1995 
ad lib Hemato 0.27 M
 (Sprague- sodium selenite 
 Dawley) (F)
 
Endocr 0.026 M 0.055 M (significant reduction in serum 
tri-iodothyronine levels) 
Bd Wt 0.27 M 
42 Rat	 6 wk Halverson et al. 1966 
ad lib Hemato 0.24 M 0.32 M (23% decrease in hemoglobin) 0.56 M (79% decrease in hemoglobin)(Sprague- 	 organic
Dawley) (F) 
Hepatic	 0.4 M (6-fold increase in bilirubin) 
Endocr 0.32 M 0.4 M (pancreas weight 1.4 times 
greater than diet restricted 
controls) 
Bd Wt 0.32 0.4 M (body weight gain 36% lower 
than controls) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
43 Rat 6 wk Hotz et al. 1997 
ad lib Endocr 0.09 M (significant increase in serum
(Sprague- TSH (~30%)) sodium selenate
 Dawley) (F)
 
Bd Wt 0.09 M 
Metab 0.09 M (significant increase in GSH-Px 
in kidney (~30%) and 
erythrocytes (~100%)) 
44 Rat 3 mo Kolodziejczyk et al. 2000 
1x/d Hepatic 0.002 M (sporadic infiltrations of 0.005 M (distict swelling of Kupffer cells 
(Wistar) mononuclear cells in portal in dilated sinusoidal vessels andsodium selenite 
 (F) canals and weak activation of necrotic areas comprising single 
Kupffer cells) groups of hepatocytes) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
45 Rat 13 wk NTP 1994 
Resp 1.57 M 
(Fischer- 344) (W)	 selenate 
Cardio 1.57 M 
Gastro 1.57 M 
Hemato 0.92 M 1.57 M (increased hematocrit and 
hemoglobin associated with 
decreased water intake) 
Musc/skel 1.57 M 
Hepatic 0.92 M 1.57 M (increased bile acids indicating 
cholestasis) 
Renal 0.31 F 0.47 F	 (minimal papilla degeneration of 
the kidneys) 
Endocr 1.57 M 
Ocular 1.57 M 
Bd Wt 0.47 F 0.88 F (body weights 10% less than 1.35 F (body weights 29% less than 
controls) controls, associated with 
decreased water intake) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
46 Rat 13 wk NTP 1994 
Resp 1.67 F 
(Fischer- 344) (W)	 selenite 
Cardio 1.67 F 
Gastro 1.67 F 
Hemato 0.86 F 1.67 F	 (increased hematocrit 
associated with decreased 
water intake) 
Musc/skel 1.67 F 
Hepatic 1.67 F 
Renal 0.28 F 0.5 F 	 (mild papilla degeneration) 
Endocr 1.67 F 
Ocular 1.67 F 
Bd Wt 0.98 M 1.59 M (body weights 34% less than 
controls; associated with 
decreased water intake) 
47 Rat	 23-29 d b b  b  NTP 1996 
ad lib Bd Wt 0.167 M 0.293 M (significant (11%) reduction in 0.418 (significant (20% male, 39%(Sprague- body weight) female) reduction in body sodium selenate
 Dawley) (W)
 0.209 F	 weight)0.334 F 
48 Rat 	 4-6 wk Palmer and Olson 1974 
ad lib Hepatic 0.84 M (cirrhosis)
(Sprague- selenate 
 Dawley) (W) 
Bd Wt 0.42 M (body weight gain 10% lower 
than controls) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
49 Rat	 6 wk Salbe and Levander 1990a 
ad lib Bd Wt 0.125 M (Sprague- selenate
 Dawley) (F)
 
50 Rat	 6 wk Salbe and Levander 1990a 
ad lib Bd Wt 0.125 M
 (Sprague- selenomethionine 
 Dawley) (F)
 
51 Rat	 3-6 wks Thorlacius-Ussing 1990 
ad lib Endocr 0.64 F (decreased somatomedin C)(Wistar)	 selenite 
(W) 
Bd Wt 0.64 F	 (body weight gain 30% lower 
than controls) 




Hepatic 0.324	 (degeneration of liver tissue with 
dilation of sinusoidal capillaries) 
Bd Wt 0.324	 (significant decrease in body 
weight (17%)) 
53 Mouse 90 d Hasegawa et al. 1994
Hepatic 2.4 M 4.7 M (increased serum aspartate
(ICR) (G) aminotransferase and alanine D,L-selenocystine 
aminotransferase) 
Bd Wt 2.4 M 4.7 M (body weights 16% lower than 7.1 M (body weights 22% lower than 
controls) controls) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
54 Mouse 13 wk NTP 1994 
Resp 3.83 F 
(B6C3F1) (W) selenite 
Cardio 3.83 F 
Gastro 3.83 F 
Hemato 3.83 F 
Musc/skel 3.83 F 
Hepatic 3.83 F 
Renal 0.91 M 1.61 M (increased relative kidney 
weight; decreased water intake) 
Endocr 3.83 F 
Ocular 3.83 F 
Bd Wt 1.61 M 3.31 M (body weights 20% lower than 
controls; decreased water 
intake) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
55 Mouse 13 wk NTP 1994 
Resp 7.17 F 
(B6C3F1) (W)	 selenate 
Cardio 7.17 F 
Gastro 7.17 F 
Hemato 7.17 F 
Musc/skel 7.17 F 
Hepatic 7.17 F 
Renal 1.07 M 1.87 M (increased kidney weight 
associated with decreased 
water intake) 
Endocr 7.17 F 
Ocular 7.17 F 
Bd Wt 1.87 2.95 M (body weights 13% lower than 5.45 M (body weights 24% lower than 
controls; decreased water controls; decreased water 
intake) intake) 
56 Mouse	 30 d Sayato et al. 1993 
6d/wk Hepatic 4.7 M 9.4 M (significant 2-3-fold increases in(ICR) aspartate aminotransferase and 	 D,L-selenocystine(G) alanine aminotransferase) 
Renal 9.4 M 
Bd Wt 9.4 M (final body weight about 13% 18.9 M (final body weight about 29% 
lower than controls) lower than controls) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
figure (Strain) (Specific Route) System Chemical Form(mg/kg/day) (mg/kg/day)	 (mg/kg/day) 
57 Mouse 12 wk Skowerski et al. 1997a 
ad lib Hepatic 0.2 M (vacuolization of hepatocytes)Balby sodium selenite 
(F) 
58 Mouse	 12 wk Skowerski et al. 1997b 
ad lib Cardio 0.2 M (cardiocytes have numerousBalby damaged mitochondria, large 	 sodium selenite (F) number of lipid droplets and 
numerous lysosomes) 
Bd Wt 0.2 M 
59 Rabbit 	 3 mo Turan et al. 1999b Cardio	 0.137 (disruption of myofibrils,ad lib(New irregular sarcomeres, and sodium selenite
 Zealand) (F)
 diosrganization of bands in 
sarcomeres) 
Hemato 0.137 
Bd Wt 0.137 
60 Pig	 8 wk Baker et al. 1989 
ad lib Hepatic 1.1 (vacuolar degeneration, portal(mixed breed) fibrosis) 	 selenate (F) 
Dermal	 1.1 (cracked hoof walls) 
Bd Wt 1.1 	 (body weight gain 83% lower 
than controls, accompanied by 
decreased food intake) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
61 Pig 35 d Mahan and Magee 1991 
ad lib Dermal 0.014 0.25 (hoof cracking)(NS) selenite 
(F) 
Bd Wt 0.25 0.47	 (body weight gain 78% lower 
than controls, accompanied by 
decreased food intake) 
62 Pig 8 wk	 Mihailovic et al. 1992 Hepatic 0.33 0.59	 (atrophic cirrhosis)ad lib(crossbred L 	 selenite 
x Y) (F) 
Dermal 0.33 0.59	 (hoof cracking, alopecia, 
redness of skin, petechiae) 





Dermal 1.25	 (symmetrical hair loss, dry 
scaling skin, cracked overgrown 
hooves 3/5 pigs) 
Bd Wt 1.25 	 (body weight gain 15% less 
than controls) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 






Dermal 1.25	 (symmetrical hair loss, dry 
scaling skin, cracked overgrown 
hooves 1/5 pigs) 
Bd Wt 1.25 	 (body weight gain 22% less 
than controls) 
65 Pig	 34 d Stowe et al. 1992 Cardio	 0.46 (vacuolation, pyknosis of nuclei)ad lib(NS) 	 NS 
(F) 
Musc/skel 0.46	 (hyperplasia of sarcolemma 
nuclei; disintegration of 
myofibrils) 
66 Pig 	 NS Wahlstrom and Olson 1959b 
ad lib Dermal 0.4 F (2/10 alopecia; 1/10 hoof(Duroc) separation) 	 selenite (F) 
Bd Wt 0.4 F 




















Cattle 120 d 
1x/d Resp 0.808 M 
O’Toole and Raisbeck 1995 
selenomethionine 
(F) 
Cardio 0.808 M 
Gastro 0.808 M 
Musc/skel 0.808 M 
Hepatic 0.808 M 
Renal 0.808 M 
Endocr 0.808 M 
Dermal 0.158 M 0.288 M (mild parakeratosis of hoof) 0.808 (severe parakeratosis and 
epithelial hyperplasia of hoof) 
M 





























O’Toole and Raisbeck 1995 
sodium selenite 

















0.808 M (mild parakeratosis of hoof) 



















ad lib 0.173 (reduced B-cell function and 
OVA-specific antibody 
concentration) 
Raisbeck et al. 1998 
selenocystine 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
72 Mouse	 47 d Raisbeck et al. 1998 
ad lib 0.173 (reduced B-cell function and(BALB/c) OVA-specific antibody	 selenomethionine (W) concentration) 
73 Mouse 47 d Raisbeck et al. 1998 
ad lib 0.173 (reduced OVA-specific antibody(BALB/c) concentration) sodium selenite 
(W) 
74 Cattle	 120 d O’Toole and Raisbeck 1995 
1x/d 0.808 M Hereford selenomethionine 
(F) 
75 Cattle	 120 d O’Toole and Raisbeck 1995 
1x/d 0.808 M Hereford sodium selenite 
(F) 
Neurological 
76 Human 120 d Hawkes and Hornbostel 1996 
0.0048 M 
(F) selenomethionine 
77 Monkey	 30 d Cukierski et al. 1989 




78 Pig	 7 wk Baker et al. 19891.3 (tetraplegia, poliomyelomalacia)ad lib(mixed breed)	 organic
(F) 
79 Pig	 8 wk Mihailovic et al. 1992 0.33	 0.59 (hind limb paresis, hind limbad lib(crossbred L x ataxia, symmetric selenite 
Y) (F) poliomylomalacia of the ventral 
horn of the spinal cord) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
80 Pig	 20-42d Wilson et al. 1983 1	 2.1 (poliomylelomalacia, paralysis,ad lib(NS)	 difuse gliosis of the spinal cord) selenite 
(F) 
81 Cattle	 120 d O’Toole and Raisbeck 1995 
1x/d 0.808 M Hereford selenomethionine 
(F) 
82 Cattle	 120 d O’Toole and Raisbeck 1995 
1x/d 0.808 M Hereford sodium selenite 
(F) 
Reproductive 
83 Human 102d Hawkes and Turek 2001 
0.0039 M 
(F)	 dietary 
84 Monkey 	 30 d Cukierski et al. 1989 




85 Rat	 5 wk Kaur and Parshad 1994 0.1 M (3.9% abnormal sperm; 0.2 M (24.6% abnormal sperm;






86 Rat	 13 wk b  NTP 1994 0.29 M (15% decreased sperm counts)
(Fischer- 344) (W) 	 selenate 
0.31 F (more time in diestrus and less 
time in proestrus, estrus, and 





















(Fischer- 344) (W) 
13 wkRat 
0.5 F 0.17 
b  
(11% decrease epididymal 
sperm counts) 
M 
0.86 (more time in diestrus and less 






Rat 12-14 wk 
ad lib 0.324 (testicular hypertrophy) 







ad lib 0.17 F 0.34 (proportion of mice with longer 
estrus cycles increased by 
11.8%) 
F 






























1x/wk 0.001 (significant reduction in serum 
testosterone (49%)) 
M 







ad lib 0.4 (decreased fertility, 
maternal toxicity) 
Wahlstrom and Olson 1959b 
selenite 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
Developmental 
94 Rat	 8 wks Thorlacius-Ussing 1990 
ad lib 0.64 (decrease weight gain of pups(Wistar) exposed during lactation)	 selenite (W) 
95 Mouse	 pre-Gd:30 d Nobunaga et al. 1979 
Gd 0-18 0.17 0.34 (decreased fetal body weight,(IVCS) ad lib	 delayed vertebral ossification) selenite 
(W) 
96 Pig	 NS Wahlstrom and Olson 1959b0.4 (increased number of deathsad lib(Duroc)	 between birth and weaning; selenite 
(F) reduced birth weight and 
reduced body weight at 
weaning) 
97 Cattle 	 3 mo Yaeger et al. 1998 





98 Rat 2 yr Harr et al. 1967; Tinsley et al. 19670.5 (reduced longevity from aboutad lib(Wistar) 500 days to about 60-100 days)selenate, selenite
(F) 
Systemic 
99 Human >3 yr Bratter and Negretti De Bratter 1996







































0.023 (selenosis: sloughing of nails 
and brittle hair) 


























0.2 (soft bones) 
0.1 (hyperplastic lesions) 
0.1 (nephritis) 
Harr et al. 1967; Tinsley et al. 1967 
selenite, selenate 
























ad lib Resp 0.5 F 
Nelson et al. 1943 
organic 
Gastro 0.5 F 
Musc/skel 0.5 F 
Hepatic 0.25 F (slight to moderate cirrhosis) 
Endocr 0.5 F 






ad lib Resp 0.57 (amyloidosis) 
Schroeder and Mitchener 1972 
selenate 
Cardio 0.57 (amyloidosis) 
Hepatic 0.57 (amyloidosis) 
Renal 0.57 (amyloidosis) 
Endocr 0.57 (amyloidosis of adrenal gland) 
Dermal 0.57 (poor coat) 
Bd Wt 0.57 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
106 Mouse lifetime Schroeder and Mitchener 1972 
Resp 0.57 (amyloidosis)ad lib(Swiss) selenite 
(W) 
Cardio 0.57 (amyloidosis) 
Hepatic 0.57 (amyloidosis) 
Renal 0.57 (amyloidosis) 
Endocr 0.57 (amyloidosis of adrenal gland) 
Dermal 0.57 (poor coat) 
Bd Wt 0.57 
Neurological 
107 Human yr Yang et al. 1983
0.027 0.058 (tendon hyperflexia, peripheral
(F) anesthesia, pain in extremities, organic 
polyneuritis) 
Reproductive 
108 Rat 1 yr Rosenfeld and Beath 1954 
daily 0.21 0.35 (50% reduction in number of 1.05 (decreased fertility, pup survival,
(Wistar) ad lib pups reared in second maternal toxicity; second selenate 
 
generation) generation failed to reproduce) 

(W) 
109 Mouse 3 gen Schroeder and Mitchener 1971b0.57 (failure to breed in the thirdad lib(CD) generation) selenate 
(W) 

























0.57 (increased number of runts; 
postnatal lethality) 
Schroeder and Mitchener 1971b 
selenate 
a The number corresponds to entries in Figure 3-2. 
b Differences in levels of health effects and cancer effects between males and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
c Used to derive a chronic oral minimal risk level (MRL) of 0.005 mg/kg-day; The NOAEL is divided by an uncertainty factor of 3 (for human variability). 
ad lib = ab libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = female; (G) = gavage; gastro = 
gastrointestinal; gd = gestation day; GHS-Px = selenium-dependent glutathione peroxidase; (GW) = gavage in water; Hemato = hematological; (IN) = ingestion; LD50 = lethal dose, 
50% kill; LOAEL = lowest-observed-adverse-effect level; LPS = lipopolysaccharide; M = male; metab = metabolic; mg/kg/day = milligram per kilogram per day;  mo = month(s); 
Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; (NS) = not specified; Resp = respiratory; TNF = tumor necrosis factor; TSH = thyroid-stimulating hormone; 














Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
ACUTE EXPOSURE 
Death 
1 Rat once Cummins and Kimura 1971138 M (LD50)





2 Rat once Moore et al. 1996b75 M (3/6 died) 

(Wistar) (GO) SeS 
 
3 Rat once Moore et al. 1996b50 (3/15 died)

(Wistar) (GO) SeS 
 
4 Mouse once Henschler and Kirschner 19693700 (LD50)

(NMRI) (G) SeS 
 
Systemic 
5 Rat once Moore et al. 1996b 
Hepatic 75 M (widespread hepatic necrosis) 





6 Rat 17 d NTP 1980c112 M (LD50)1x/d(Fischer- 344) b  SeS, SeS2(G) 56 F (LD50) 







































Bd Wt 31.6 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
9 Mouse 13 wk NTP 1980c 





















10 Rat 103 wk NTP 1980c15 (hepatocellular carcinomas7d/wk(Fischer- 344)	 14/49 males, 21/50 females) SeS, SeS21x/d 
(G) 
 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
11 Mouse 103 wk NTP 1980c100 F (hepatocellular7d/wk(B6C3F1) carcinomas/adenomas 25/49, SeS, SeS21x/d 
alveolar/bronchiolar
(G) carcinoma/adenomas 12/49) 
a The number corresponds to entries in Figure 3-3. 
b Differences in levels of health effects and cancer effects between males and females are not indicated in Figure 3-3. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
ad lib = ab libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr - endocrine; F = female; gastro =  gastrointestinal; (G) = gavage; gd 
= gestation day; Hemato = hematological; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = metabolic; Musc/skel = musculoskeletal; NOAEL = 





3.   HEALTH EFFECTS 
of the compound, because selenium sulfide preparations often exist as a variable mixture of the mono- 
and disulfide forms, precluding accurate expression of the dose in terms of total selenium. 
Most of the available toxicity information for oral exposures to selenium compounds comes from 
domestic or experimental animal exposures to selenite, selenate, selenium sulfides (mixed), and organic 
selenium compounds (selenocystine, selenomethionine).  Some of the earliest recognized effects of 
selenium were observed in livestock (cattle, sheep, and horses) that grazed on plants in areas of South 
Dakota, where soil selenium concentrations are naturally high.  Selenium-associated effects observed in 
livestock include “blind staggers” and alkali disease.  “Blind staggers” is an acute syndrome in which 
there is usually a slight impairment of vision, which can result in the animal straying from the herd.  As 
the disease progresses, the blindness becomes more pronounced, and the animal may wander in circles.  
In the last stage, there are various degrees of paralysis and evidence of abdominal pain; death results from 
respiratory failure.  However, because the effects have not been replicated in experimentally exposed 
cattle receiving doses of selenium sufficient to induce hoof lesions, the neurological signs associated with 
“blind staggers” may be due to compounds other than selenium in the vegetation.  Alkali disease is a 
chronic disease in which the animals become emaciated, stiff, and lame; lose long hair from the mane and 
the tail; and the hooves become deformed.  Alkali disease is also associated with atrophy of the heart and 
liver, while congestion and focal necrosis of the liver are more prominent in “blind staggers”. 
Some epidemiological studies report data from populations exposed to selenium in the food chain in areas 
with high selenium levels in soil.  It is likely that selenite, selenate, and the selenium found in food and in 
dietary supplements comprise the majority of selenium compounds to which oral, off-site selenium 
exposures will occur at or near hazardous waste sites.  Aside from the variation in effective dose, the 
health effects from exposure to selenate, selenite, and dietary selenium are not expected to differ greatly.  
However, oral exposures to many other compounds of selenium could occur (primarily through soil or 
edible plant ingestion) if those compounds were deposited at the site, or if local environmental conditions 
greatly favor transformation to those forms.  Heavy metal selenides, aluminum selenide, tungsten 
diselenides, and cadmium selenide are used in industry and may end up in waste sites.  Mobilization of 
selenium, typically as selenate in water run-off, has the potential to impact nearby plants and animals, 
thus potentially exposing people through eating game meat, local plants, and agricultural or livestock food 
products from the area.  
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3.2.2.1 Death 
Accidental selenium poisonings in humans have occurred, but few fatalities have been reported.  The 
selenium doses associated with the reported deaths are unknown (Carter 1966; Koppel et al. 1986).  One 
3-year-old boy died 1.5 hours after ingestion of an unknown quantity of selenious acid contained in a gun-
bluing preparation (Carter 1966). Clinical signs included excessive salivation, garlic odor on the breath, 
and shallow breathing. A 15-year-old female survived ingestion of a solution of sodium selenate 
estimated to have provided 22 mg selenium/kg body weight, probably because she was forced to vomit 
soon after exposure (Civil and McDonald 1978).  Clinical signs included garlic odor of the breath and 
diarrhea. 
No cases of human death in the United States have been attributed to intermediate or chronic oral 
exposures to selenium or selenium compounds.  In the Hubei Province of China, in an area of endemic 
selenosis, a woman who died was suffering from hemiplegia thought to have been caused by chronic 
selenosis induced by eating locally grown foods that contained high levels of organic selenium 
compounds (Yang et al. 1983).  However, an autopsy was not performed and no clinical history of 
previous illness was available. 
In nonhuman animals, the most acutely toxic selenium compounds by ingestion appear to be sodium 
selenite and sodium selenate (Olson 1986).  Oral LD50 values for sodium selenite, expressed as mg 
selenium/kg body weight, were reported as 4.8–7.0 in rats, 1.0 in rabbits, 3.2 in mice, and 2.3 in guinea 
pigs (Cummins and Kimura 1971; Pletnikova 1970). Minimum lethal doses of sodium selenite, expressed 
as mg selenium/kg body weight, reported for larger animals were 13–18 for pigs and 9.9–11.0 for cows 
(Miller and Williams 1940); however, these values were estimated on the basis of a small number of 
animals.  Two of four 12-week-old lambs died within 16 hours of administration of 5 mg selenium/kg as 
sodium selenite (Smyth et al. 1990).  Selenium dioxide is reported to have LD50 values of 16 mg 
selenium/kg for mice and 48 mg selenium/kg body weight for rats, but these values are also based on a 
small number of animals (Singh and Junnarkar 1991).  An oral LD50 of 35.9 mg selenium/kg has been 
reported for L-selenocystine given to mice (Sayato et al. 1993).  Elemental selenium is less toxic than 
most selenium compounds, because of its extremely low solubility; an LD50 of 6,700 mg selenium/kg 
body weight has been reported for oral administration of elemental selenium as a suspension (particle size 
1–30 µm) in 0.5% methylcellulose to rats (Cummins and Kumura 1971). 
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Lower doses of selenium can cause signs of toxicity if administered over extended periods of time.  Eight 
weaned 5-week-old pigs receiving 1.3 mg selenium/kg/day as sodium selenite in gelatin capsules daily for 
10 days died during one study; only one dose level was tested (Wilson et al. 1989).  Two long-tailed 
macaques administered 0.60 mg selenium/kg/day as selenomethionine by nasogastric intubation died of 
either anorexia or aspirated vomitus secondary to emesis and gastritis after 10 or 15 days of treatment 
(Cukerski et al. 1989).  Seven of 12 female rats receiving diets containing 0.418 mg selenium/kg/day as 
sodium selenate for 14 days died before the end of the experiment (NTP 1996). Exposure to selenium in 
drinking water at a level of 0.84 mg selenium/kg/day as selenite or selenate for 4–6 weeks resulted in the 
death of four of six or two of six male rats, respectively (Palmer and Olson 1974).  Feeding male rats diets 
containing 0.48 mg selenium/kg/day as sodium selenite or 0.4 mg selenium/kg/day as seleniferous wheat 
for 6 weeks resulted in the death of one of eight rats in each group (Halverson et al. 1966).  
Administration of sodium selenite in drinking water at a level of 0.28 mg selenium/kg/day for 58 days 
resulted in the death of 25 of 50 male rats (Schroeder and Mitchener 1971a). Mortality was observed in 
rats, but not in mice, receiving either 1.67 mg selenium/kg/day as sodium selenite or 2.54 mg 
selenium/kg/day as sodium selenate in drinking water for 13 weeks (NTP 1994).  Gavage treatment of 
male mice with selenocystine 6 days per week for 30 days at a dose of 14.2 mg selenium/kg killed all 
15 treated animals, while no deaths were noted at 9.4 mg selenium/kg (Sayato et al. 1993).  The longevity 
of hamsters was not affected by dietary administration of sodium selenite at a dose of 0.42 mg 
selenium/kg/day for 124–144 weeks (Birt et al. 1986). 
Sodium selenate and sodium selenite exhibit similar toxicity in female rats, but male rats appear more 
susceptible to the toxicity of sodium selenite than selenate (Palmer and Olson 1974; Schroeder and 
Mitchener 1971a). Sodium selenate in drinking water at 0.28 selenium mg/kg/day for 1 year did not 
increase mortality of male or female rats compared with control rats (Schroeder and Mitchener 1971a).  
Ingestion of 0.28 mg selenium/kg/day of sodium selenite in drinking water for 1 year did not increase 
mortality in female rats, whereas 50% of the males died by day 58 of administration (Schroeder and 
Mitchener 1971a). 
The relative acute toxicities of sodium selenite, potassium selenite, sodium selenate, and potassium 
selenate in aqueous solution have been examined in mice (Pletnikova 1970).  No significant differences 
among the toxicities of the potassium and sodium salts of selenium were apparent in this study.  In 
another study, rats tolerated a dose of 1.05 mg selenium/kg/day administered in drinking water as 
potassium selenate for over 8 months with no deaths, but three of five females and one of three males died 
by the end of 1 year (Rosenfeld and Beath 1954).  Decreased survival was reported in rats fed sodium 
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selenate or selenite at 0.5 mg selenium/kg/day in a 2-year cancer study (Harr et al. 1967; Tinsley et al. 
1967).  No mortality was observed in hamsters fed 0.42 mg selenium/kg/day as sodium selenite in the diet 
for 82–142 weeks (Birt et al. 1986). 
Selenium sulfide (i.e., selenium monosulfide) and selenium disulfide are less water soluble and are of 
lower acute toxicity than sodium selenate or sodium selenite.  There are no reported human deaths due to 
ingestion of selenium sulfide.  The LD50 value for the gavage administration of 1–20% selenium disulfide 
in aqueous 0.5% methylcellulose to rats was 138 mg selenium disulfide/kg (Cummins and Kimura 1971).  
When 1% selenium disulfide shampoo was administered by gavage, the LD50 value was lower (78 mg 
selenium disulfide/kg) (Cummins and Kimura 1971).  The compound administered may have been a 
mixture of selenium sulfide and selenium disulfide; analysis of the compound was not reported. 
Henschler and Kirschner (1969) reported an LD50 of 3,700 mg selenium sulfide/kg for mice administered 
by gavage in aqueous 0.5% carboxymethylcellulose.  Administration of single gavage doses of selenium 
monosulfide to rats produced death in 3/15 animals dosed with 50 mg/kg, 3/6 animals dosed with 
75 mg/kg, 1/2 animals dosed with 100 mg/kg, and 2/2 animals dosed with 125 mg/kg (Moore et al. 
1996b). 
In the case of selenium sulfide, mice are more tolerant than rats, and males of both species appear to be 
more tolerant than females (NTP 1980c).  The daily doses producing 50% mortality for a 17-day gavage 
administration of a mixture of selenium mono- and disulfides were 112 mg selenium sulfides/kg for male 
rats, 56 mg selenium sulfides/kg for female rats, and 805 mg selenium sulfides/kg for male mice (NTP 
1980c). A 13-week gavage study using the same mixture of selenium mono- and disulfides reported 
survival as 10/10, 10/10, 10/10, 9/9, 8/9, and 6/10 in female mice and 10/10, 10/10, 10/10, 10/10, 10/10, 
and 9/10 in male mice receiving 0, 21.6, 46.4, 100, 216, and 464 mg selenium sulfides/kg/day, 
respectively (NTP 1980c).  Although the researchers intended to administer selenium monosulfide to the 
animals, elemental analysis, melting point, and x-ray diffraction revealed that the compound administered 
included some selenium disulfide.  No other chemical or physical analyses of the selenium compound 
administered were reported. 
The LD50 and lethal LOAEL values from each reliable study following oral exposure to elemental 
selenium dust, selenium dioxide dissolved in water (selenious acid), sodium selenate, sodium selenite, 
potassium selenate, and dietary selenium for each species and exposure duration are recorded in Table 3-2 
and plotted in Figure 3-2. The LOAEL values for death in rats and mice following acute and intermediate 
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oral exposures to selenium sulfide or selenium disulfide are recorded in Table 3-3 and plotted in 
Figure 3-3. 
3.2.2.2 Systemic Effects 
The highest NOAEL value and all LOAEL values for each reliable study for systemic effects in each 
species and duration category are recorded in Tables 3-2 and 3-3 and plotted in Figures 3-2 and 3-3. 
Respiratory Effects. Pulmonary edema and lesions of the lung have been noted in case reports of 
humans (Carter 1966; Koppel et al. 1986) and animals (Glenn et al. 1964a; Rosenfeld and Beath 1947) 
after ingestion of lethal doses of selenium compounds.  Rabbits orally administered sodium selenite 
(subroute not specified) at levels approximating the LD50 (1–5 mg selenium/kg body weight) developed 
pulmonary congestion, hemorrhages, and edema; dyspnea; general muscular weakness; and asphyxial 
convulsions (Smith and Westfall 1937).  Pulmonary edema and hemorrhages were observed in four sheep 
treated orally (subroute not specified) with a single dose of sodium selenite of 5 mg selenium/kg (Smyth 
et al. 1990). The lungs may be a target of acute exposure to excess selenium because the metabolite, 
dimethyl selenide, is exhaled. 
The effects of intermediate or chronic exposures to selenium compounds are less clear.  Although Harr et 
al. (1967) stated that absolute lung weights decreased with increasing doses of selenite or selenate 
chronically administered to rats in the diet in a 2-year cancer study, they did not report lung weights at 
specific dose levels.  Selenium administration also might have contributed to pneumonic lesions, but 
again, the authors did not statistically analyze their results or relate the severity of the effect to the doses 
of selenium administered.  Respiratory effects were not observed in rats treated with selenite in the diet 
for 8 weeks at a dose of 0.45 mg selenium/kg/day (Chen et al. 1993).  Effects on the lungs were not 
observed in pigs fed 1.25 mg selenium/kg as organic selenium found in the plant Astragalus bisulcatus 
for up to 5 days, or D,L-selenomethionine or selenate in the diet for up to 6 weeks (Panter et al. 1996). 
Treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day 
for 120 days did not produce any signs of respiratory distress or changes in lung weight or histology 
(O’Toole and Raisbeck 1995).  Ingestion of selenium in drinking water for 13 weeks at doses up to 
1.67 and 7.17 mg selenium/kg as selenate in rats and mice, respectively, and 1.57 and 3.83 mg 
selenium/kg as selenite in rats and mice, respectively, did not cause any respiratory effects (NTP 1994).  
Nelson et al. (1943) reported that no effects on the lungs were apparent in rats administered 0.50 mg 
selenium/kg/day as seleniferous corn for 2 years. 
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An increased incidence of amyloidosis of the major organs, including the lungs, was observed in mice 
following lifetime exposure to sodium selenate or sodium selenite in drinking water at a level of 0.57 mg 
selenium/kg/day (Schroeder and Mitchener 1972).  This effect was noted in 30% of control mice and 58% 
(p<0.001) of selenium-treated mice.  Data for individual organs were not provided. 
Administration of lethal doses of selenium sulfide particles in carboxymethylcellulose by gavage has been 
reported to cause irregular breathing in mice (Henschler and Kerschner 1969), but not in rats (Cummins 
and Kimura 1971).  No respiratory effects were seen in mice administered 464 mg selenium 
sulfides/kg/day or in rats administered 31.6 mg selenium sulfides/kg/day by gavage once daily for 
13 weeks (NTP 1980c). 
Cardiovascular Effects. Tachycardia has occasionally been reported as a result of a lethal, acute 
oral exposure to selenium compounds in humans (Carter 1966); however, the dose was not reported in 
this lethal exposure to a gun-bluing solution containing selenious acid.  Although myocardial disorders 
(cardiogenic shock, congestive heart failure, arrhythmia, multifocal necrosis of the myocardium) have 
been associated with selenium deficiencies (Yang et al. 1988), none has been reported to be associated 
with chronic dietary selenosis in humans observed at doses of ≥0.016 mg/kg/day (Yang et al. 1989a).  A 
preliminary study completed in China suggests that selenium supplementation (100 µg/day, form not 
stated) during pregnancy may reduce the incidence of pregnancy-induced hypertension (Li and Shi-mei 
1994). 
In contrast, postmortem studies of sheep that died from acute oral exposure to sodium selenite or sodium 
selenate have revealed petechial hemorrhages of the endocardium (Glenn et al. 1964a; Smyth et al. 1990).  
The sheep were treated with a time-weighted average dose of 0.65 or 0.9 mg selenium/kg/day as selenate 
over a 171-day period (Glenn et al. 1964a, 1964b), or a single dose of selenite at 5 mg selenium/kg 
(Smyth et al. 1990).  Vacuolation and pyknosis of nuclei were observed in the hearts of pigs fed an 
unspecified form of selenium at a dose of 0.46 mg selenium/kg/day for 34 days (Stowe et al. 1992).  In a 
2-year cancer study, Harr et al. (1967) reported the occurrence of myocardial hyperemia, hemorrhage, and 
degeneration, as well as pericardial edema, in young rats administered sodium selenite or sodium selenate 
in the feed at doses of 0.5 mg selenium/kg/day, although the authors did not specify the duration of 
exposure required to produce the effects. 
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Exposure of pigs to feed containing 54 mg/kg selenium for 1–7 days resulted in severe toxicity and death 
of several of the animals (Penrith and Robinson 1996).  Histological examination of heart tissue from pigs 
that died revealed myocardial lesions consisting of widespread hypertrophy, atrophy, and disorganization 
of fibers, occasional fibrosis, and marked medial hypertrophy of the arterioles. 
Wistar rats administered 0.324 mg selenium/kg/day as sodium selenite in food for 12–14 weeks showed 
severe diffuse degenerative changes, including edema in the sub-endocardial connective tissue and the 
interfibers of prevascular regions, and myofibril swelling with profuse intercellular edema (Turan et al. 
1999a). Myocyte borders were irregular, and there was a loss of striations and a degeneration of the 
sarcolemma and myofibril structure and order.  Examination of the mechanical function of the heart in 
vitro using either Langendorff perfusion or papillary muscle recordings showed increased coronary 
perfusion pressure, increased resting force, and increased heart rate with irregular beating.  No difference 
in contractile force was observed. Chronic heart failure did not occur in any of the animals in the study. 
Cardiac damage was also observed in mice exposed to 0.2 mg selenium/kg/day as sodium selenite in food 
for 12 weeks (Skowerski et al. 1997b). Ultrastructural examination revealed cardiomyocytes that had 
numerous damaged mitochondria, a large number of lipid droplets, and numerous lysosomes. 
Hearts of New Zealand white rabbits administered 0.137 mg selenium/kg/day as sodium selenite in food 
for 3 months showed distinct, degenerative changes indicating disintegration of the internal structure of 
the myocytes (Turan et al. 1999b).  Muscle fibers were fragmented and separated.  Disruption and loss of 
myofibrils was observed, sarcomeres were irregular, and the I, Z, and H bands were disorganized and 
discontinuous.  Mitochondria were fewer and more variable in size and shape, with disoriented cristae and 
a loss of matrix substance.  Hearts of control animals (0.007 mg selenium/kg/day) had normal histology.   
Treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day 
for 120 days did not produce any changes in heart weight or histology (O’Toole and Raisbeck 1995).  
Histopathological changes in the heart were not observed in pigs fed selenium at 1.25 mg selenium/kg as 
organic selenium found in the plant A. bisulcatus for up to 5 days, or D,L-selenomethionine or selenate 
for up to 6 weeks (Panter et al. 1996). Histopathological changes were not observed in the hearts of rats 
treated with selenite in the diet for 8 weeks at a dose of 0.45 mg selenium/kg/day (Chen et al. 1993). 
Selenium administered to rats and mice in drinking water for 13 weeks at doses up to 1.57 and 7.17 mg 
selenium/kg/day as selenate, respectively, and up to 1.67 and 3.83 mg selenium/kg/day as selenite, 
respectively, did not cause any histopathological changes in the heart tissue (NTP 1994).  No 
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histopathological changes were noted in mice administered 464 mg selenium sulfides/kg/day or in rats 
administered 31.6 mg selenium sulfides/kg/day by gavage once daily for 13 weeks (NTP 1980c). 
An increased incidence of amyloidosis of the major organs, including the heart, was observed in mice 
following lifetime exposure to sodium selenate or sodium selenite in drinking water at a level of 0.57 mg 
selenium/kg/day (Schroeder and Mitchener 1972).  This effect was noted in 30% of control mice and 58% 
(p<0.001) of selenium-treated mice.  Data for individual organs were not provided. 
Although myocardial degeneration and necrosis have been experimentally induced in laboratory animals 
and livestock including cattle, sheep, and swine by acute and longer-term exposures to inorganic salts of 
selenium, it is unclear whether seleniferous grains or forages, or other natural sources of selenium, can 
also cause cardiomyopathy (Raisbeck 2000). 
Gastrointestinal Effects. In humans, gastrointestinal distress, including nausea, vomiting, diarrhea, 
and abdominal pain, has been reported following ingestion of aqueous sodium selenate (Civil and 
McDonald 1978; Gasmi et al. 1997; Helzlsouer et al. 1985; Koppel et al. 1986; Sioris et al. 1980).  Two 
studies provided an estimate of dose.  In a case report by Civil and McDonald (1978), diarrhea was 
observed in a 15-year-old girl about 45 minutes after she swallowed sheep drench containing selenate at a 
dose of about 22 mg selenium/kg.  This effect was observed despite the induction of vomiting shortly 
after the exposure. In a second case report of a suicide attempt, a 56-year-old man reported that vomiting, 
diarrhea, and abdominal pain occurred 1 hour after he ingested approximately 11 mg/kg selenium as 
sodium selenite (Gasmi et al. 1997).  Postmortem examinations following two deaths from selenium 
ingestion revealed dilation of the stomach and small intestine (Carter 1966) and erosive changes of the 
gastrointestinal tract (Koppel et al. 1986).  High (unspecified) levels of dietary selenium compounds have 
been implicated as causing gastrointestinal disturbances in chronically exposed humans (Smith et al. 
1936), but such symptoms are not specific to selenium intoxication. 
Exposure of pigs to feed containing 54 mg/kg selenium for 1–7 days resulted in severe toxicity and death 
of several animals. Clinical signs included anorexia and vomiting, and histological examination  
(70–79 days after exposure) of three of the exposed animals that died found lesions ranging from small 
erosions (1–2 mm diameter) to extensive mucosal necrosis (up to 100 mm diameter) near the cardia of the 
stomach (Penrith and Robinson 1996). 
Gross necropsy of steers that died after ingestion of sodium selenite revealed severe gastrointestinal 
irritation (Baker et al. 1989; Maag et al. 1960). In addition, cattle and other livestock exhibiting alkali 
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disease, perhaps as a result of long-term consumption of range plants high in selenium, ate and drank less 
and suffered from ulcers in the upper intestinal tract (Shamberger 1986).  A single oral dose of 5 mg 
selenium/kg as selenite caused edema and congestion of abdominal viscera in lambs (Smyth et al. 1990).  
However, treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg 
selenium/kg/day for 120 days did not produce any changes in histology of the gastrointestinal tissues 
(O’Toole and Raisbeck 1995). 
Gastrointestinal effects were not observed in rats treated with selenite in the diet for 8 weeks at a dose of 
0.45 mg selenium/kg/day (Chen et al. 1993).  Selenium treatment in drinking water for 13 weeks at doses 
up to 1.57 and 7.17 mg selenium/kg/day as selenate in rats and mice, respectively, and 1.67 and 3.83 mg 
selenium/kg/day as selenite in rats and mice, respectively, did not cause any gastrointestinal effects (NTP 
1994).  Gastrointestinal effects were not observed in rats fed organic selenium (seleniferous corn or 
wheat) at 0.5 mg selenium/kg/day for 24 months (Nelson et al. 1943).  Vomiting and anorexia were 
reported in monkeys receiving 0.15 mg/kg/day selenium as L-selenomethionine by oral intubation during 
gestation days 20–50 (Tarantal et al. 1991). 
Selenium sulfide administration by gavage at lethal levels has been reported to cause diarrhea and 
anorexia in rats (Cummins and Kimura 1971).  No gastrointestinal effects were seen in mice administered 
464 mg selenium sulfide/kg/day or in rats administered 31.6 mg selenium sulfide/kg/day by gavage once 
daily for 13 weeks (NTP 1980c). 
Hematological Effects. Hematological changes were evaluated in a 120-day double blind study of 
healthy men who consumed a controlled diet of foods naturally low or high in selenium (Hawkes et al. 
2001). Eleven subjects were fed 0.0006 mg selenium/kg/day in the diet for 21 days (baseline period), 
followed by 0.0002 mg/kg/day (6 subjects) or 0.004 mg/kg/day (5 subjects) for the following 99 days.  
Complete blood counts (white blood cells, lymphocytes, granulocytes, platelets, erythrocytes, hematocrit) 
and hemoglobin concentration measurements showed no adverse effects of selenium supplemenation.   
Mean within-subject changes from baseline in white blood cell counts were significantly different in the 
low- and high-selenium groups at last two time points in the study (days 70 and 99).  At the end of the 
study, the white blood cell counts were decreased by 5% in the high-selenium group and increased by 
10% in the low-selenium group, due mainly to changes in numbers of granulocytes.  Lymphocyte counts 
were significantly increased in the high-selenium group on day 45, but not at the end of the study.  There 
were no clear effects of selenium on numbers of activated or cytotoxic T-cells, lymphocyte phenotypes, 
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serum immunoglobulins, or complement fractions, as summarized in Section 3.2.2.3 (Immunological 
Effects). 
Increased prothrombin time was reported for individuals chronically exposed to estimated dietary doses 
of 0.016 mg selenium/kg/day in a high-selenium region of China (Yang et al. 1989a).  However, no 
increase in prothrombin time was found in another study of individuals consuming diets that supplied up 
to 0.0098 mg/kg/day selenium (Longnecker et al. 1991).  A study that compared children from 
seleniferous and nonseleniferous areas of Venezuela found slightly reduced (no statistical analysis was 
performed) hemoglobin levels and hematocrit values for the children from the seleniferous area (Jaffe et 
al. 1972).  However, the children from the seleniferous zone had a poorer diet, consumed less milk and 
meat, and had a greater incidence of intestinal parasites, which may account for the differences observed. 
Red blood cell counts were significantly increased in mice that received drinking water containing 9 ppm 
(0.82 mg selenium/kg/day) selenium as sodium selenite for 14 days (Johnson et al. 2000).  However, 
these mice also had a severe reduction in water consumption (43%) and this may have led to a decrease in 
blood volume.  No significant increase in red blood cell count (or decrease in water consumption) was 
observed for mice receiving 3 ppm (0.38 mg selenium/kg/day) selenium as sodium selenite, or up to 
9 ppm (1.36 mg selenium/kg/day) selenium as selenomethionine for 14 days (Johnson et al. 2000). 
No hematological changes (hemoglobin concentration, hematocrit, erythrocyte count, and cell volume) 
were reported for male Sprague-Dawley rats fed diets providing up to 0.27 mg selenium/kg/day as sodium 
selenite for 40 days (Eder et al. 1995). Increased hematocrit was observed in rats treated with selenate 
(1.56 mg selenium/kg/day) or selenite (1.67 mg selenium/kg/day) in the drinking water for 13 weeks, but 
only at concentrations that decreased water intake (NTP 1994).  No effects on hematology end points 
were observed in mice treated with selenate or selenite in drinking water for 13 weeks at 7.17 mg 
selenium/kg for selenate and 3.83 mg selenium/kg/day for selenite (NTP 1994). 
No differences in blood cell counts or hematological parameters were found in rabbits administered 
0.137 mg selenium/kg/day as sodium selenite in the diet for 3 months, compared with control animals 
receiving a normal laboratory diet (Turan et al. 1999b). 
A dose-related decrease in hematocrit was observed in rats fed seleniferous wheat (Halverson et al. 1966).  
Compared to controls, hemoglobin was decreased 23 and 79% at 0.32 and 0.56 mg selenium/kg/day, 
respectively.  Hemoglobin reductions were most evident in the animals that had died during the 
experiments.  In a 2-year cancer study, Harr et al. (1967) reported that the hemoglobin concentration 
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decreased by 0.5 g/100 mL with each 2-fold increase of sodium selenate in the diet, but did not specify 
the lowest dose at which hemoglobin concentrations were significantly reduced compared to the controls 
(the range of selenium doses used was 0.025–0.40 mg selenium/kg/day).  Hematocrit was increased in 
rats given selenite and selenate in drinking water for 13 weeks at concentrations that also resulted in 
decreased water intake (NTP 1994).  No hematological effects were noted in rats or mice treated with 
selenate at 0.92 and 7.17 mg selenium/kg/day, respectively, or selenite at 0.86 and 3.83 mg 
selenium/kg/day, respectively (NTP 1994). 
No studies were located regarding hematological effects in humans or other animals after oral exposure to 
selenium sulfide or selenium disulfide. 
Musculoskeletal Effects. No adverse musculoskeletal effects were reported following chronic oral 
exposure of humans to dietary levels of selenium of up to 0.0098 mg selenium/kg/day (Longnecker et al. 
1991). 
A single oral (subroute not specified) dose of sodium selenite (5 mg selenium/kg/day) caused edema in 
skeletal muscles of the diaphragm in sheep (Smyth et al. 1990).  Exposure of pigs to feed containing 
54 mg/kg selenium for 1–7 days resulted in severe toxicity and death of several animals (Penrith and 
Robinson 1996).  Histological examination of skeletal muscle from animals that died found damage with 
interstitial oedema and diffuse swelling of fibers.  Livestock suffering from chronic alkali disease, a 
disease once common in the southwestern United States where selenium levels are high, showed lameness 
due to joint erosion and hoof deformation (Shamberger 1986).  However, treatment of steers with 
selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day for 120 days did not 
produce any changes in muscle or bone histology (O’Toole and Raisbeck 1995).  Hyperplasia of the 
sarcolemma nuclei and disintegration of myofibrils were observed in the skeletal muscles of pigs fed an 
unspecified form of selenium for 34 days (Stowe et al. 1992).  In a 2-year cancer study, Harr et al. (1967) 
fed graded doses of selenium in the form of sodium selenate or selenite to rats and reported frank 
osteotoxicity at doses as low as 0.2 mg selenium/kg/day given for several months (duration specified as 
less than 100 days).  Selenium administered in drinking water for 13 weeks at doses up to 1.57 and 
7.17 mg selenium/kg/day as selenate in rats and mice, respectively, and 1.67 and 3.83 mg selenium/kg as 
selenite in rats and mice, respectively, failed to cause adverse musculoskeletal effects (NTP 1994).  
Musculoskeletal effects were not observed in rats fed seleniferous corn or wheat at 0.5 mg 
selenium/kg/day for 24 months (Nelson et al. 1943).  No musculoskeletal effects were seen in mice 
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administered 464 mg selenium sulfide/kg/day or in rats administered 31.6 mg selenium sulfide/kg/day by 
gavage once daily for 13 weeks (NTP 1980c). 
Hepatic Effects. Limited data suggest that hepatotoxicity can occur in humans following acute oral 
exposure to sodium selenate, but no definitive studies were located regarding hepatic effects in humans 
after intermediate or chronic oral exposure to selenium compounds.  Tests following an acute poisoning 
of a 15-year-old girl with sodium selenate revealed abnormally elevated serum bilirubin and alkaline 
phosphatase (Civil and McDonald 1978).  Hepatic effects, such as changes in serum liver enzymes or 
liver morphology (identified by ultrasonography ), have not been observed in humans at chronic dietary 
intakes of 0.0098 mg selenium/kg/day (Longnecker et al. 1991) or 0.025 mg selenium/kg/day (Yang et al. 
1989a). Selenium-induced hepatoxicity is documented in animals as summarized below.  The lack of 
evidence of liver damage in humans due to selenosis, despite the animal data to the contrary, suggests a 
problem with the animal models of the disease.   
Congestion and/or edema and hemorrhage in the liver have been reported in sheep following the acute 
oral (subroute not specified) administration of lethal levels of sodium selenate (Hopper et al. 1985) or 
sodium selenite (Smyth et al. 1990) and in mules and pigs following administration of lethal levels of 
sodium selenite (Miller and Williams 1940).  A significant decrease in relative liver weight was reported 
for mice exposed to 9 ppm (0.82 mg selenium/kg/day) selenium as sodium selenite in drinking water for 
14 days, but not to 3 ppm (0.38 mg selenium/kg/day) (Johnson et al. 2000).  No effect on liver weight was 
observed for mice receiving up to 9 ppm (1.36 mg selenium/kg/day) selenium as selenomethionine in 
drinking water for 14 days (Johnson et al. 2000).   
Administration of single gavage doses of selenium monosulfide to rats produced death and widespread 
hepatic necrosis in 3/6 animals dosed with 75 mg/kg, 1/2 animals dosed with 100 mg/kg, and 2/2 animals 
dosed with 125 mg/kg (Moore et al. 1996b). 
Hepatic effects have also been reported following intermediate-duration exposure in pigs, but not in 
cattle. Pigs exposed for 7 weeks to either dietary organic selenium in dried plants (either A. pruelongus or 
A. bisulcatus) or sodium selenate (at 1.1 or 1.3 mg selenium/kg/day) exhibited diffuse swelling and 
vacuolar degeneration of hepatocytes (Baker et al. 1989).  The doses used in this study reduced mean 
survival to only 44 days.  Pigs exposed to sodium selenite in feed for 35 days at doses less than half as 
high as those tested by Baker et al. (1989) (0.47 versus 1.1 or 1.3 mg selenium/kg/day) exhibited no liver 
damage (Mahan and Magee 1991).  A study of pigs treated with 0.08, 0.33, 0.59, or 1.07 mg 
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selenium/kg/day as sodium selenite in the feed for 8 weeks found hepatic nodules/granules in two pigs 
treated with 0.59 or 1.07 mg selenium/kg/day (Mihailovic et al. (1992).  The lesions were diagnosed as 
postdystrophic atrophic cirrhosis.  However, only these two severely affected pigs (one from each of the 
highest dose groups of 40 animals each) were selected for histopathological examination.  Hepatic effects 
were not observed in pigs fed selenium at 1.25 mg selenium/kg as organic selenium of the type(s) found 
in the plant A. bisulcatus for up to 5 days, or D,L-selenomethionine or selenate for up to 6 weeks (Panter 
et al. 1996). Treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg 
selenium/kg/day for 120 days did not produce any changes in liver weight or histology (O’Toole and 
Raisbeck 1995). 
Alterations or cirrhosis of the liver in experimental animals following intermediate or chronic oral 
exposure to selenium compounds have been reported by Bioulac-Sage et al. (1992), Fitzhugh et al. 
(1944), Halverson et al. (1970), Harr et al. (1967), Kolodziejczyk et al. (2000), Nelson et al. (1943), and 
Schroeder and Mitchener (1972).  Halverson et al. (1966) reported reduced liver-to-body-weight ratios 
and increased bilirubin in rats administered 0.44 mg selenium/kg/day for 6 weeks as naturally occurring 
selenium in wheat.  At this level, five of eight rats died. At a dose of 0.84 mg selenium/kg/day 
administered as sodium selenate in drinking water for 4–6 weeks, rats developed cirrhosis of the liver 
(Palmer and Olson 1974).  At this level, two of six rats died. 
Hepatic damage was observed in mice exposed to 0.2 mg selenium/kg/day as sodium selenite in food for 
12 weeks (Skowerski et al. 1997a), and ultrastructural examination showed that the cytoplasm of the 
hepatocytes contained extremely large and irregularly-shaped vacuoles.  Wistar rats administered 
0.324 mg selenium/kg/day as sodium selenite in food for 12–14 weeks showed degenerative changes to 
the liver (not fully described in text) (Turan et al. 1999a).  Livers of rats fed 0.002 or 0.005 mg 
selenium/kg/day as sodium selenite for 3 months showed damage that increased with dose (Kolodziejczyk 
et al. 2000). Rats from the 0.002 mg selenium/kg/day group had a distinct swelling of Küpffer cells in 
dilated sinusoidal vessels, mainly in the proximity of portal fields, and occasional necrotic areas 
comprising groups of hepatocytes, while livers from rats receiving 0.005 mg selenium/kg/day showed 
activation and swelling of the Küpffer cells in widened sinusoidal vessels, relatively abundant infiltrations 
of mononuclear cells into portal canals, and sporadic areas of necrosis within individual lobules.   
Young rats treated with sodium selenite in the feed for 2 months had nodular hyperplasia at a dose of 
0.2 mg selenium/kg/day. However, clinical tests of liver function (bilirubin, alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase activities) showed no 
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significant changes (Bioulac-Sage et al. 1992).  Diffuse panlobular vacuolar changes were reported in rats 
fed sodium selenite in the diet for 8 weeks at 0.45 mg/kg/day (Chen et al. 1993).  
In a 2-year cancer study, acute toxic hepatitis was common among rats fed sodium selenite or sodium 
selenate at 0.25 mg selenium/kg/day or higher (Harr et al. 1967; Tinsley et al. 1967).  Liver surfaces were 
mottled, and parenchymatous degeneration was present.  Hepatic lesions occurred at a dose as low as 
0.10 mg selenium/kg/day.  Absolute liver weights decreased with increasing levels of sodium selenate or 
sodium selenite in the diet.  The average liver weight of animals administered selenate (14.5 g) was twice 
the average liver weight of animals administered selenite (7.2 g); however, the average liver weight of 
control animals was not reported, and possible dose-related hepatic effects were not discussed by these 
authors. 
Increased serum bile acids, suggesting cholestasis, were observed in rats treated with 1.57 mg 
selenium/kg/day as sodium selenate in drinking water for 13 weeks, but no effects were noted at 
0.92 mg/kg/day (NTP 1994).  In a 13-week drinking water study, hepatic effects were not observed in 
mice treated with sodium selenate at 7.17 mg selenium/kg/day, in mice treated with sodium selenite at 
doses up to 3.83 mg selenium/kg/day, or in rats treated with sodium selenite at doses up to 1.67 mg 
selenium/kg/day (NTP 1994).  Increased serum aspartate aminotransferase and alanine aminotransferase 
activities were observed in mice treated by gavage with selenocystine at doses of 9.4 mg selenium/kg/day 
for 30 days (Sayato et al. 1993) or 4.7 mg selenium/kg/day for 90 days (Hasegawa et al. 1994).  No 
effects on liver enzymes were observed in mice treated with selenocystine at 4.7 mg selenium/kg/day for 
30 days (Sayato et al. 1993) or at 2.5 mg selenium/kg/day for 90 days (Hasegawa et al. 1994).  Chronic 
dietary administration of selenium as seleniferous corn or wheat at doses ranging from 0.25 to 
0.50 mg/kg/day for 24 months produced cirrhosis of the liver in rats (Nelson et al. 1943). 
An increased incidence of amyloidosis of the major organs, including the liver, was observed in mice 
following lifetime exposure to sodium selenate or sodium selenite in drinking water at a level of 0.57 mg 
selenium/kg/day (Schroeder and Mitchener 1972).  This effect was noted in 30% of control mice and 58% 
(p<0.001) of selenium-treated mice.  Data for individual organs were not provided. 
Selenium sulfide administered to rats daily by gavage for 13 weeks produced focal coagulation necrosis 
in the liver with infiltration by inflammatory cells.  These changes developed at a dose of 31.6 mg 
selenium sulfide/kg/day, but not at a dose of 17.8 mg selenium sulfide/kg/day (NTP 1980c).  In mice, on 
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the other hand, oral intubation of selenium sulfide at 464 mg selenium sulfide/kg/day did not produce 
hepatic effects (NTP 1980c). 
Renal Effects. No studies were located regarding renal effects in humans after oral exposure to 
selenium or selenium compounds. 
In domestic and experimental animals, renal effects have been observed following both acute and chronic 
oral exposures to selenium compounds.  Administration of a single oral (subroute not specified) dose of 
sodium selenite at 5 mg selenium/kg/day produced hydropic degeneration of the kidney in sheep (Smyth 
et al. 1990). In a study of the toxicity of L-selenomethionine to long-tailed macaques by nasogastric 
intubation, two animals administered 0.24 mg selenium/kg/day aspirated vomitus secondary to emesis, 
developed obvious gastritis, and died of anorexia, one after 10 days and the other after 15 days of 
administration (Cukierski et al. 1989).  Histopathologic examination of the kidneys of these animals 
revealed glomerulonephritis and proximal convoluted tubule nephropathy.  The study authors indicated 
that these changes were consistent with macaque fatal fasting syndrome and may not have resulted from 
the direct effects of L-selenomethionine.  Following long-term ingestion of plants high in selenium, 
livestock suffering from alkali disease exhibited nephritis (Shamberger 1986).  However, treatment of 
steers with selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day for 120 days did 
not produce any changes in kidney weight or histology (O’Toole and Raisbeck 1995). 
A dose-related increase in degeneration of the renal papilla (described as mild to minimal) was observed 
in rats treated with selenate or selenite in the drinking water at about 0.5 mg selenium/kg/day for 
13 weeks (NTP 1994).  No evidence of renal toxicity was observed in rats given 0.3 mg selenium/kg/day 
in this study.  In contrast to rats, the only kidney effect noted in mice treated with sodium selenate or 
selenite in the drinking water was increased relative kidney weight (NTP 1994). This effect, which 
occurred at  1.87 mg selenium/kg/day as selenate and 1.61 mg selenium/kg/day as selenite, was only noted 
at doses at which drinking water intake was decreased, leading the investigators to suggest that the effect 
may have been a result of dehydration. A similar increase in relative kidney weight associated with 
decreased water consumption was observed in mice consuming approximately 0.38 mg selenium/kg/day 
as selenite in drinking water, but no effect on kidney weight or water consumption was observed in mice 
consuming up to 1.36 mg selenium/kg/day as selenomethionine (Johnson et al. 2000).  No renal effects 
were observed in pigs fed selenium at 1.25 mg selenium/kg as organic selenium found in the plant A. 
bisulcatus for up to 5 days, or D,L-selenomethionine or selenate for up to 6 weeks (Panter et al. 1996).  
No effects on the kidneys were observed in rats treated with selenite in the diet for 8 weeks at a dose of 
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0.45 mg selenium/kg/day (Chen et al. 1993).  Gavage treatment of mice with selenocystine for 30 days at 
a dose of 9.4 mg selenium/kg/day had no adverse effect on the kidneys (Sayato et al. 1993). 
Rats chronically fed selenite in the diet were reported to exhibit more frequent and more severe nephritis 
than those given equivalent amounts of selenate (Harr et al. 1967); however, the study authors did not 
quantify these observations or statistically compare data from the two groups. An increased incidence of 
amyloidosis of the major organs, including the kidneys, was observed in mice following lifetime exposure 
to sodium selenate or sodium selenite in drinking water at a level of 0.57 mg selenium/kg/day (Schroeder 
and Mitchener 1972).  This effect was noted in 30% of control mice and 58% (p<0.001) of selenium-
treated mice.  Data for individual organs were not provided. 
A mixture of selenium sulfide and selenium disulfide administered to mice daily by gavage for 13 weeks 
at a dose of 464 mg selenium sulfides/kg/day produced an increase in the incidence and severity of 
interstitial nephritis compared with the controls, whereas a daily dose of 216 mg selenium sulfides/kg did 
not elicit renal toxicity (NTP 1980c).  In rats, selenium sulfide by oral intubation at 31.6 mg selenium 
sulfides/kg/day for 13 weeks did not produce renal effects (NTP 1980c). 
Endocrine Effects. A balance in selenium and iodine levels is needed for normal thyroid hormone 
metabolism. Selenium is an essential component of the iodothyronine 5'-deiodinase enzymes, which 
convert the prohormone thyroxine (T4) to the active form, triiodothyronine (T3) (Delange 2000; Köhrle 
1994; St Germain and Galton 1997).  Selenium is also a component of glutathione peroxidase (GPX), the 
main enzyme responsible for protecting thyroid cells against oxidative damage.  Selenium deficiency 
causes decreases in metabolic clearance of iodothyronines, extrathyroidal production of T3, and thyroid 
iodine concentrations in experimental animals (Arthur and Beckett 1989, 1994; Behne and Kyriakopolous 
1993). Deficiency in both selenium and iodine has been associated with goiter and cretinism in humans 
and causes thyroid gland necrosis and fibrosis in rats (Delange 2000; Goyens et al. 1987; Vanderpas et al. 
1990). Additional information on thyroid effects of selenium and iodine deficiency is discussed in 
Section 3.9. Thyroid hormone levels in humans and animals can also be affected by selenium 
supplementation; these effects include decreases in serum T3 and T4 levels and increases in serum TSH 
levels, suggesting suppression of thyroid hormone production, as discussed below. 
A limited amount of information is available regarding endocrine effects in humans following oral 
exposure to selenium.  Serum levels of thyroid and reproductive hormones were evaluated in a double 
blind 120-day study of healthy men (20–45 years old) who consumed a controlled diet of foods naturally 
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high or low in selenium (Hawkes and Turek 2001).  Eleven subjects were fed 0.0006 mg/kg/day of 
selenium in the diet for the first 21 days of the study, followed by 0.0002 µg selenium/kg/day (6 subjects) 
or 0.004 mg selenium/kg/day (5 subjects) for 99 days.  Blood samples were analyzed for serum levels of 
selenium, thyroid hormones (T3 and TSH), and reproductive hormones (testosterone, follicle-stimulating 
hormone, luteinizing hormone, prolactin, estradiol, and progesterone) during week 3 (baseline), week 
17 (ending value), and at several interim time points. 
Selenium levels in blood plasma began to change within 3 days of starting the low- and high-selenium 
diets and progressively continued throughout the study (Hawkes and Turek 2001).  By week 17, mean 
plasma selenium concentrations had increased by 109% in the high-selenium group and decreased by 
38.5% in the low-selenium group.  Group mean serum T3 concentrations (averages of within-subject 
changes from baseline) were significantly different in the low-selenium subjects and high-selenium 
subjects at all time points, but the changes are insufficient to be considered adverse as discussed below.  
In the low-selenium group, serum T3 levels increased an average of 14 and 8% from baseline at weeks 
8 and 17, respectively.  In the high-selenium group, serum T3 levels decreased an average of 23 and 11% 
from baseline at weeks 8 and 17, respectively.  Analysis of variance (ANOVA) showed a significant main 
effect of dietary selenium on serum T3 concentrations, as well as a significant selenium x time interaction, 
indicating that the changes in T3 levels decreased over time.  Although the decreases in serum T3 in the 
high-selenium group and increases in serum T3 in the low-selenium group lessened in magnitude during 
the study, all group mean values appear to have remained within the normal range.  The baseline and 
week 17 serum total T3 values (mean±SD) were 1.82±0.36 and 1.57±0.07 nmol/L in the high-selenium 
group, and 1.57±0.25 and 1.64±0.16 nmol/L in the low-selenium group, compared to the normal human 
range of 1.1–2.7 nM/L (Stockigt 2000), indicating that the changes in serum T3 were subclinical and not 
toxicologically significant.  Serum TSH concentrations increased significantly by 32% over its baseline 
concentration in the high-selenium group, but did not change significantly in the low-selenium group.  
Baseline and ending mean TSH values in the high-selenium group were 2.25±0.81 and 2.96±1.05 mU/L, 
respectively, both of which are in the normal range of 0.3–4.0 mU/L (Stockigt 2000).  The lack of 
clinically significant changes in serum T3 and TSH values is not surprising because the study was 
designed as a nutritional study and not as a toxicological study; the selenium intakes bracketed the current 
recommended dietary allowance (RDA) (~0.8 µg Se/kg/day) and were well below the tolerable upper 
limit level (~5.7 µg Se/kg/day) recommended by the Food and Nutrition Board (NAS 2000).  There were 
no significant changes in serum levels of free or total testosterone, follicle-stimulating hormone, 
luteinizing hormone, prolactin, estradiol, or progesterone.  This study also found no adverse immunologic 
or male reproductive changes as summarized in Sections 3.2.2.3 and 3.2.2.5. 
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An examination of thyroid hormone levels in lactating women residing in areas of Venezuela with high 
levels of selenium in the soil (selenium intake ranged from 250 to 980 µg per day as estimated from 
selenium content of breast milk) revealed a significant decrease in serum T3 levels, as compared with 
women having normal selenium intakes (90–350 µg/day), but these hormone levels remained within the 
normal range (Brätter and Negretti De Brätter 1996).  Additionally, a significant inverse correlation for 
selenium and serum T3 concentration was found using the Spearman Rank test.  The study authors noted 
that the effect of selenium on T3 levels became significant at dietary intake levels of 350–450 µg/day.  No 
significant alterations in serum T4 or TSH levels or correlations with selenium intake were found. 
Twenty weeks of selenium supplementation (10, 20, 30, or 40 µg/day) of New Zealanders who normally 
consume a diet low in selenium (unsupplemented intake of 28–29 µg/day), but show no signs of 
deficiency, produced a reduction in T4 concentration in all groups (Duffield et al. 1999).  However, only 
the differences between the 10 µg-group and controls and the combined supplemented individuals and 
controls were significant. T3 and TSH levels were not measured.  Thyroglobulin concentration did not 
change significantly with supplementation. 
In a study of 68 male Latvian fish consumers (Hagmar et al. 1998), a significant inverse correlation was 
found between serum levels of selenium and TSH.  No correlation was found between serum selenium 
concentration and the serum concentrations of T3 or T4. No measurements were made of dietary selenium 
intake. 
Selenium supplementation has been shown to affect type-I-deiodinase activity in male rats (Behne et al. 
1992; Eder et al. 1995; Hotz et al. 1997).  Exposure to 0.055 or 0.27 mg selenium/kg/day as sodium 
selenite in food for 40 days produced a significant decrease (approximately 50%) in serum levels of T3 
and a nonsignificant reduction in type-I-deiodinase activity compared with rats receiving 0.009 or 
0.026 mg selenium/kg/day (Eder et al. 1995).  Exposure to 0.27 mg selenium/kg/day did not produce any 
other adverse signs, such as weight loss or decreased food consumption, and serum T4 levels were similar 
in all groups. 
Exposure of weanling male Sprague-Dawley rats to 0.09 mg selenium/kg/day as sodium selenate in food 
for 6 weeks produced a significant (~30%) increase in TSH, compared with controls receiving 0.009 mg 
selenium/kg/day (Hotz et al. 1997).  Serum T3 and T4 levels and thyroid glutathione peroxidase levels 
were unaffected by dietary selenium.  Kidney type-I-deiodinase levels were decreased (~10%) in high 
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selenium animals compared with controls, but the differences were not significant, and liver type-I­
deiodinase levels were unaffected by dietary selenium.  Iodine-deficient diets produced greater thyroid 
glutathione peroxidase activity at each dietary level of selenium, and the greatest activity was in rats with 
high selenium. 
No significant changes in thyroid levels of T3 or T4 were found in male Wistar rats fed diets containing 
high selenium (0.105 mg selenium/kg/day as sodium selenite or 0.118 mg selenium/kg/day as 
L-selenomethionine) for 3 months, compared with controls receiving adequate selenium (0.0015 mg 
selenium/kg/day as sodium selenite) (Behne et al. 1992).  However, rats eating the high selenium diet 
showed a significant reduction in hepatic type I deiodinase activity, compared with controls, with a 29% 
reduction in the production rate of T3 from T4 and a 45% reduction in the production rate of 
3,3’-diiodothyronine from T4. 
Many studies have documented reduced body weight gain in young animals treated with selenium 
compounds, and abnormal weight loss in older animals (Grønbaek et al. 1995; Halverson et al. 1966; Harr 
et al. 1967; Jacobs and Forst 1981a; Johnson et al. 2000; Nelson et al. 1943; NTP 1994; Palmer and Olson 
1974; Panter et al. 1996; Schroeder 1967; Tarantal et al. 1991; Tsunoda et al. 2000).  There is evidence to 
suggest that these effects may be due in part to the interactions of selenium or selenium compounds with 
hormones that regulate normal growth and body weight.  In a 14-day study suggesting that selenium may 
inhibit pituitary function, Thorlacius-Ussing (1990) treated nursing rats with sodium selenite in drinking 
water (0.64 or 0.96 mg/kg/day).  The resulting decrease in the body weight gain of the pups observed at 
both doses may be associated with a reduction in somatomedin C levels (no other hormone levels were 
tested), and the weight deficiency could be reversed by administration of a growth hormone.  
Postweanling female Wistar rats treated with sodium selenite (0.64 mg selenium/kg/day) in drinking 
water for 3 or 6 weeks exhibited decreased weight gain and decreased somatomedin C serum 
concentrations. When the selenium supplement was removed after 3 weeks, body weight gain returned to 
normal, but the serum somatomedin C concentrations did not return to control levels.  Growth hormone 
secretion in response to growth hormone releasing factor was also reduced in the selenium-exposed group 
(Thorlacius-Ussing et al. 1988).  Serum somatomedin C levels were not significantly different among 
three exposure categories (<200, 201–240, and >240 ng selenium/mL) in 44 long-term residents of 
seleniferous areas in South Dakota, despite >50% differences in serum, whole blood, and toenail selenium 
levels among the groups (Salbe et al. 1993).  A 10% reduction in body weight and a reduction in tibia 
lengths, compared to pair-fed controls, were found in rats provided with sodium selenite in the drinking 
water at 0.46 mg selenium/kg/day for 35 days (Grønbaek et al. 1995).  A significant reduction in insulin­
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like growth factor-binding protein-3 was also noted.  The investigators concluded that the reduction in 
growth caused by excess selenium is not due to reduced caloric intake. 
Selenium administered in drinking water for 13 weeks at doses up to 1.57 and 7.17 mg selenium/kg/day 
as selenate in rats and mice, respectively, and 1.67 and 3.83 mg selenium/kg as selenite in rats and mice, 
respectively, failed to cause changes in the weights or histology of the thyroid, adrenal glands, 
parathyroid, or pancreas (NTP 1994). 
Lambs given a single oral (subroute not specified) dose of 5 mg selenium/kg as sodium selenite exhibited 
cytoplasmic flocculation of the pancreas (Smyth et al. 1990).  Increased pancreas weights were observed 
in rats fed organic selenium (seleniferous wheat) at a dose of 0.4 mg selenium/kg/day for 6 weeks 
(Halverson et al. 1966).  Chronic exposure of rats fed sodium selenite or sodium selenate in their diet for 
a lifetime was associated with pancreatic damage.  Although Harr et al. (1967) reported a dose-related 
increase in the incidence and severity of pancreatic lesions in treated rats, they did not specify the lowest 
dose at which pancreatic lesions were observed. 
Treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day 
for 120 days did not produce any changes in weight or histology of the pancreas, adrenal glands, thyroid, 
or pituitary gland (O’Toole and Raisbeck 1995).  
An increased incidence of amyloidosis of the major organs, including the adrenal gland, was observed in 
mice following lifetime exposure to sodium selenate or sodium selenite in drinking water at a level of 
0.57 mg selenium/kg/day (Schroeder and Mitchener 1972).  This effect was noted in 30% of control mice 
and 58% (p<0.001) of selenium-treated mice.  Data for individual organs were not provided. 
Dermal Effects. Jensen et al. (1984) described both marked alopecia and the deformity and loss of 
fingernails in a woman who had consumed a selenium supplement containing 31 mg total selenium (in 
the form of sodium selenite and elemental selenium) per tablet for 77 days.  The woman consumed one 
tablet each day in addition to vitamin supplements (vitamins C, A, D, E, B complex) and a mineral 
supplement "labeled as containing all 72 trace elements in undefined quantities."  In epidemiological 
studies of populations chronically exposed to high levels of selenium in food and water, investigators 
have reported discoloration of skin, pathological deformity and loss of nails, loss of hair, and excessive 
tooth decay and discoloration (Smith et al. 1936; Yang et al. 1983, 1989a, 1989b).  The 1989 studies by 
Yang et al. follow up their original 1983 study of Chinese populations living in areas classified as having 
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low-, medium-, and high-selenium exposure based on local soils and food supplies.  The average and 
standard error of selenium intakes in the low-, medium-, and high-intake regions were 0.0012±0.00009, 
0.0037±0.0004, and 0.025±0.001 mg/kg/day, respectively.  The whole blood (average ± standard error) 
concentrations of selenium in the low-, medium-, and high-intake regions were 0.16±0.00, 0.35±0.02, and 
1.51±0.05 mg/L, respectively.  The estimated daily dietary selenium intake required to produce these 
symptoms in an area of China characterized by endemic selenosis was at least 0.016 mg selenium/kg/day 
(Yang et al. 1989a). This corresponds to a blood concentration of 1.054 mg/L and an estimated daily 
intake of 0.91 mg/day, assuming a 55-kg Chinese man or woman and using the regression analysis 
provided by Yang et al. (1989b).  The NOAEL from the highest intake population not affected by nail 
disease is 0.015 mg selenium/kg/day, which corresponds to a blood concentration of 0.97 mg/L.  Foods 
that contributed the greatest levels of selenium were smoked pork, coal-dried corn, chestnuts, pumpkin 
seeds, dried fruits, and garlic. It has been noted that the selenosis problem in China began when coal with 
high levels of selenium was burned as the main source of fuel (Whanger 1989).  Food was cooked and 
dried over the open flame, adding selenium to the food.  In addition, the people breathed large amounts of 
smoke, but the contribution of volatilized selenium to the total dose of selenium has not been adequately 
characterized (Whanger 1989).  Coal was also burned on the fields as a fertilizer source.  Environmental 
selenium concentrations in the low-, medium-, and high-intake regions were 0.37–0.48, 0.73–5.66, and 
7.06–12.08 mg/kg in soil, and 370, 1,720, and 12,270 µg/L in water, respectively (Yang et al. 1989b). 
No evidence of nail disease was observed in a population living on selenium-rich ranches in the western 
United States (Longnecker et al. 1991).  Doses of selenium were calculated to be between 0.001 and 
0.01 mg/kg/day, corresponding to a maximum intake of 0.724 mg/day.  Whole blood selenium 
concentrations were 0.18–0.67 mg/kg.  Although these values for the United States are consistent with 
studies of the Chinese population, only one or a few individuals ingested the highest doses. 
The highest selenium intake for villagers in a high-selenium area of China in which endemic selenosis did 
not occur was estimated at 1.51 mg selenium/person/day (0.027 mg selenium/kg/day), with the average 
dietary selenium intake in this area of selenosis occurrence estimated to be 3.2 mg selenium/person/day 
(0.058 mg selenium/kg/day) (Yang et al. 1983).  The lowest daily dietary selenium intake associated with 
dermal effects, 0.91 mg selenium/day, was converted to equivalent daily doses from food 
(0.016 mg/kg/day) for presentation in Table 3-2.   
Five individuals from the high selenium region of China described by Yang et al. (1989a) who had been 
diagnosed with overt signs of selenosis (hair loss and nail sloughing) in 1986 were reexamined in 1992 
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(Yang and Zhou 1994).  The results of this examination showed that these individuals had recovered from 
selenosis (overt symptoms of nail sloughing were absent) and that the average selenium concentrations in 
their blood had fallen from 1,346 to 968 µg/L.  The corresponding dietary intakes of selenium were 
1,270 and 819 µg/day.  This study has been used to establish a LOAEL of 0.023 mg selenium/kg/day and 
a NOAEL of 0.015 mg selenium/kg/day.  Based on the occurrence of these dermal effects, a chronic oral 
MRL of 0.005 mg selenium/kg/day has been derived from the NOAEL, as described in the footnote in 
Table 3-2 and detailed in Appendix A.  This MRL is approximately 6 times greater than the NAS (2000) 
RDA for selenium of 55 µg/day (~0.0008 mg/kg/day). 
In a 30-day study of oral administration of L-selenomethionine to long-tailed macaques, skin lesions 
appeared on the forearm of one of two macaques given 0.01 mg selenium/kg/day.  However, the limited 
number of animals precludes identifying the dose as a LOAEL for dermal effects (Cukierski et al. 1989).  
Pigs receiving dietary administration of the same doses of selenium for 35 days exhibited hoof cracking 
(Mahan and Magee 1991).  Symmetrical hair loss, dry scaling skin, and cracked overgrown hooves were 
observed in one of five pigs and three of five pigs fed sodium selenate or D,L-selenomethionine at a dose 
of 1.25 mg selenium/kg/day for up to 6 weeks, respectively (Panter et al. 1996).  In an experiment limited 
to a duration of 5 days because of severe paralysis, similar dermal effects were not observed in pigs fed 
1.25 mg selenium/kg/day as selenium contained in the plant A. bisulcatus. The form of selenium in 
A. bisulcatus is unknown, although Panter et al. (1996) indicate that it is nonprotein. 
Exposure of pigs to feed containing 54 mg/kg selenium for 1–7 days resulted in severe toxicity and death 
of several animals; however, none of the pigs developed coronitis or hoof separation (Penrith and 
Robinson 1996).  Skin from four pigs with alopecia was examined about a month after exposure and was 
found to have epidermal thickening due to acanthosis and hyperkeratosis, vacuolar degeneration of the 
basal cells and acanthocytes, necrosis of individual keratinocytes, and serocellular crusts.  
In the late 19th and the early 20th century, livestock grazing on plants growing on seleniferous soils in 
areas of the Great Plains of the United States suffered from alkali disease attributed to the high selenium 
content of some plants. Alkali disease in horses, cattle, and swine is characterized by alopecia, inflam­
mation at the coronary band, followed by cracked or malformed hooves and rough hair coat (Draize and 
Beath 1935).  Daily selenium intakes associated with these effects were not quantified.  However, 
treatment of steers with selenomethionine in food at doses of 0.288 mg selenium/kg body weight/day or 
selenite at doses of 0.808 mg selenium/kg/day for 120 days produced hoof lesions (O’Toole and Raisbeck 
1995).  In intermediate-duration studies, cracked hoof walls have been observed in pigs fed selenate, 
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selenite, or an unspecified form of selenium at doses of 0.25 mg selenium/kg/day and greater (Baker et al. 
1989; Mahan and Magee 1991; Mihailovic et al. 1992; Wahlstrom and Olson 1959b).  Poor quality of the 
hair coat has also been reported in mice administered sodium selenite or selenate in the diet at 0.57 mg 
selenium/kg/day (Schroeder and Mitchener 1972).  Exposure of female BALB/c mice to 0.21 mg 
selenium/kg/day for 6 months from diets containing selenium as sodium selenite resulted in alopecia 
around the nose (Boylan et al. 1990). 
No studies were located regarding dermal effects in humans or other animals after oral exposure to 
selenium sulfide or selenium disulfide. 
Ocular Effects. A case-control study using a hospital discharge register indicated that there was no 
correlation between low serum selenium concentrations and cataract occurrence in humans (Knekt et al. 
1992). Since this is a case-control study, it does not provide information on the potential dietary factors, 
exposure to specific selenium compounds, or duration of exposure.   
Treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day 
for 120 days did not produce any changes in the histology of the eyes (O’Toole and Raisbeck 1995). 
Selenium given to rats and mice in drinking water for 13 weeks at up to 1.6 and 7.2 mg selenium/kg as 
selenate, respectively, or 1.7 and 3.8 mg selenium/kg as selenite, respectively, did not cause any ocular 
effects (NTP 1994). 
Body Weight Effects. Two studies reported body weight effects in humans after oral exposure to 
selenium.  Selenium intake was found to affect body weight in a study of 11 men (20–45 years old) who 
were fed 0.0006 mg/kg/day of selenium in the diet for the first 21 days of the study, followed by diets 
naturally low (0.0002 µg selenium/kg/day, 6 subjects) or high (0.004 mg selenium/kg/day, 5 subjects) for 
99 days at 2,800 kcal/day (Hawkes and Keim 1995).  Despite minor adjustments of intake to maintain 
body weight, by the 6th week, the high selenium group started to gain weight relative to the low selenium 
group, and the difference between the two groups became significant after the 10th week.  A similar 
increase in lean body mass was observed in both groups.  The study was designed as a nutritional study 
and not as a toxicological study, as the selenium intake levels were well below the tolerable upper limit 
level (~5.7 µg Se/kg/day) recommended by the Food and Nutrition Board (NAS 2000).  The weight gain 
observed in this study therefore has nothing to do with weight loss due to selenosis. 
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A study that compared children from seleniferous and nonseleniferous areas of Venezuela found slightly 
reduced height and weight (no statistical analysis was performed) for the children from the seleniferous 
area (Jaffe et al. 1972).  However, the children from the seleniferous zone had a poorer diet, consumed 
less milk and meat, and had a greater incidence of intestinal parasites, which may account for the 
differences observed. 
In contrast, reduced growth rates of young animals and reduced body weight in older animals are 
common observations associated with oral administration of excess sodium selenate, sodium selenite, or 
organic selenium compounds to experimental animals (Boylan et al. 1990; Cukierski et al. 1989; 
Donaldson and McGowan 1989; Grønbaek et al. 1995; Halverson et al. 1966; Harr et al. 1967; Hasegawa 
et al. 1994; Johnson et al. 2000; Nelson et al. 1943; NTP 1994, 1996; Palmer and Olson 1974; Panter et 
al. 1996; Penrith and Robinson 1996; Raisbeck et al. 1996; Sayato et al. 1993; Schroeder 1967; Tarantal 
et al. 1991; Thorlacius-Ussing 1990, Tsunoda et al. 2000; Turan et al. 1999a).  This reduction in growth is 
often accompanied by reduced food and water consumption, and in dietary or drinking water studies, may 
be an effect of poor palatability of selenium compounds.  However, reduced growth has also been 
observed in gavage studies (Cukierski et al. 1989; Hasegawa et al. 1994; Sayato et al. 1993) and, as 
discussed under endocrine and neurological effects, the growth retardation may have an endocrine or 
neurotransmitter component.  Selenium effects on the levels of thyroid hormones (Behne and 
Kyriakopoulos 1993; Behne et al. 1992; Eder et al. 1995; Hotz et al. 1997), dopamine metabolites 
(Tsunoda et al. 2000), insulin-like growth factor–binding protein-3 (Grønbaek et al. 1995), and 
somatomedin C (Thorlacius-Ussing 1990) have been observed in selenium-treated animals, although 
somatomedin C was not a sensitive end point in humans from a high selenium area of South Dakota 
(Salbe et al. 1993). 
Other Systemic Effects. Urinary excretion of selenium was about twice as great in children with a 
high incidence of dental caries than in children with a low incidence of caries (Hadjimarkos 1969b). 
Possible confounding factors (e.g., fluoride status and socioeconomic status) were not considered, 
however. In Yang et al. (1989a), the incidence of mottled teeth in the medium- and high-selenium groups 
was increased, but the effect was attributed to interactions between selenium and fluoride. 
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3.2.2.3 Immunological and Lymphoreticular Effects  
No studies were located regarding adverse immunologic or lymphoreticular effects in humans after oral 
exposure to selenium or selenium compounds.  Immune system effects were evaluated in a 120-day 
double blind study of healthy men who ingested a controlled diet of foods naturally low or high in 
selenium (Hawkes et al. 2001).  Eleven subjects were fed 0.0006 mg selenium/kg/day in the diet for 
21 days (baseline period), followed by 0.0002 mg/kg/day (6 subjects) or 0.004 mg/kg/day (5 subjects) for 
the following 99 days.  The results show that the high-selenium diet was not immunotoxic and had some 
mild and transient immune-enhancing properties.  There is an indication that selenium supplementation 
increased the secondary immune response to diphtheria vaccine when rechallenged at the end of the 
study.  The mean within-subject ratio of diphtheria antibody titers 14 days after reinoculation (day 116) to 
titers 14 days after the initial challenge at baseline (day 19) was significantly greater in the high-selenium 
group than in the low-selenium group (2.7±1.8-fold vs. 0.9±0.6-fold, p=0.03).  Lymphocyte counts were 
significantly increased in the high-selenium group on day 45, but not at the end of the study, and there 
were no clear effects of selenium on numbers of activated or cytotoxic T-cells.  The proliferative response 
of peripheral lymphocytes to stimulation with pokeweed mitogen (a B-cell mitogen) was significantly 
higher in the high-selenium group than in the low-selenium group on days 45 and 72, although not at the 
end of the study.  There was no selenium-induced lymphocyte proliferation in response to T-cell mitogens 
(phytohemagglutinin or concanavalin A), or changes in lymphocyte phenotypes, serum immunoglobulins 
(IgA, IgG, IgM), complement fractions, natural-killer cell activity, delayed-type hypersensitivity skin 
responses to seven recall antigens (tuberculin purified-protein derivative, mumps, tetanus toxoid, candida, 
trichophyton, streptokinase strepase, and coccidioidin), or antibody responses to diptheria-tetanus and 
influenza vaccines. This study was designed as a nutritional study and not as a toxicological study, as the 
selenium intake levels were well below the tolerable upper limit level (~5.7 µg Se/kg/day) recommended 
by the Food and Nutrition Board (NAS 2000). 
Other human studies also indicate that selenium contributes to enhancing immune function (Baum et al. 
1997; Kiremidjian-Schumacher et al. 1994; Peretz et al. 1991).  Lymphocyte response was enhanced by 
dietary selenium, as measured by the T-lymphocyte proliferative response to pokeweed mitogen in elderly 
people taking a selenium-enriched yeast supplement (0.0014 mg/kg/day for 6 months) (Peretz et al. 
1991).  This finding is similar to results of the Hawkes et al. (2001) study summarized above, although it 
was noted that the elderly as a group generally tend to have both lower blood selenium concentrations and 
lower lymphocyte proliferation than the general population.  Dietary supplementation with approximately 
0.001 mg selenium/kg/day (as sodium selenate) for 8 weeks caused increased proliferation of active T 
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cells in a group of 11 volunteer subjects (Kiremidjian-Schumacher et al. 1994). The lymphocytes in the 
exposed subjects had an increased response to stimulation with alloantigen and developed into cytotoxic 
lymphocytes capable of destroying tumor cells.  There was a 118% increase in cytotoxic lymphocyte-
mediated tumor cytotoxicity, as well as an 82.3% increase in natural killer cell activity, compared to 
baseline values. The selenium supplementation regimen used in this study did not cause significant 
increases in selenium levels in the plasma or red blood cells. 
Immune function was evaluated in 40 volunteers from a Finnish population with low blood selenium 
concentrations that were supplemented with selenium or placebo for 11 weeks (Arvilommi et al. 1983).  
At the end of the supplementation period, plasma selenium levels were 74 µg/L in the placebo group and 
169 µg/L in the supplemental group.  Intracellular killing of Staphylococcus aureus by granulocytes was 
slightly lower in the placebo group than in the selenium group (77.2% compared to 85.2%, p<0.05). No 
significant changes were observed in phagocytosis, chemotactic factor generation, antibody or leukocyte 
migration inhibitory factor production by lymphocytes, or proliferative responses to the T-cell mitogens 
phytohemagglutinin or concanavalin A.  
There is evidence that selenium has a role in protecting patients with HIV virus. Immune parameters and 
nutrients known to affect immune function were evaluated at 6-month intervals in 125 HIV-1-seropositive 
drug-using men and women (Baum et al. 1997).  When all factors that could affect survival were 
considered jointly, only reduced number of CD4 helper T cells over time and selenium deficiency were 
significantly associated with mortality.  Low plasma selenium (<85 µg/L) represented a significantly 
greater risk factor for mortality than low helper T cell counts, and conferred a more significant risk than 
any other nutrient studied, indicating that selenium-deficient HIV patients were more likely to die from 
HIV infection than those with adequate levels of selenium. 
Studies of mice, rats, and cattle suggest that exposure to high doses of sodium selenite, but not 
selenomethionine, may reduce immunological responses (Johnson et al. 2000; Koller et al. 1986; 
Raisbeck et al. 1998; Yaeger et al. 1998).  BALB/c mice (five males/group) were exposed to drinking 
water containing 0, 1, 3, and 9 ppm selenium as sodium selenite (0.024, 0.17, 0.38, and 0.82 mg 
selenium/kg/day) or seleno-L-methionine (0.024, 0.17, 0.47, and 1.36 mg selenium/kg/day) for 14 days 
(Johnson et al. 2000).  The mice exposed to sodium selenite showed significant decreases in the relative 
spleen weight at 9 ppm and the relative thymus weight at 3 and 9 ppm.  The number of splenocytes in the 
spleens of the 9 ppm group was reduced by 62%.  Single-cell splenocyte cultures were made from the 
spleens of treated animals and used to determine the effects of selenium treatment on mitogen-induced 
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lymphocyte blastogenesis and cytokine production.  Cultured splenic lymphocytes from mice exposed to 
9 ppm selenium as sodium selenite showed a significant (260%) increase in the basal rate of proliferation 
and a nonsignificant increase in mitogen-induced proliferation.  Exposure to 9 ppm selenium as sodium 
selenite also produced a significant increase in the amount of tumor necrosis factor α (TNFα) and 
interleukin-1β (IL-1β) produced by lipopolysaccharide (LPS)-stimulated splenic macrophages.  However, 
the results of this experiment must be interpreted with caution as treatment with 9 ppm selenium as 
sodium selenite also produced a large and statistically significant decrease in food (21%) and water (43%) 
consumption, so that some of the effects observed (e.g., changes in organ weights) may reflect effects of 
dehydration rather than selenium toxicity.  In contrast, the similar groups of mice treated with up to 9 ppm 
selenium as seleno-L-methionine (up to 1.36 mg selenium/kg/day)showed no significant changes in body 
weight gain, organ weights, water consumption, or food consumption compared with controls.  There 
were no changes in the basal or mitogen-stimulated lymphocyte proliferation following treatment with 
seleno-L-methionine, and no alteration in the production of TNFα or IL-1β from splenic macrophages 
was observed. 
Another study in BALB/c mice examined the effects of consumption for 47 days of drinking water 
containing 7 ppm selenium as selenocystine, selenomethionine, or sodium selenite on immune function 
(Raisbeck et al. 1998).  On the 14th day of the experiment, the mice received a subcutaneous injection of 
ovalbumin (OVA).  Examination of mitogen-stimulated blastogenesis, B-cell function, and IgG 
concentrations at the end of the experimental period showed a significant decrease in B-cell function for 
mice treated with the two organic forms of selenium and a significant reduction in the concentration of 
OVA-specific antibodies for animals treated with any of the three forms of selenium.  Total IgG 
concentration and OVA-stimulated blastogenesis did not vary between groups. 
Rats given sodium selenite in drinking water at 0.7 mg selenium/kg/day for 10 weeks exhibited reduced 
humoral antibody (IgG) production in response to an administered antigen, and reduced prostaglandin 
synthesis, but there was no effect on natural killer cell (NKC) cytotoxicity (Koller et al. 1986).  At lower 
doses (0.07 or 0.28 mg selenium/kg/day), NKC cytotoxicity was significantly increased, enhancing the 
immune response to antigenic stimulation, although the delayed-type hypersensitivity (DTH) and 
prostaglandin E2 synthesis were significantly reduced.  Selenium administration did not affect the ability 
of resident peritoneal cells to produce interleukin IL-1.  Given the enhanced NKC activity at 0.07 and 
0.28 mg selenium/kg/day, but not at 0.7 mg selenium/kg/day, and given the reduced antibody and 
prostaglandin synthesis at 0.7 mg selenium/kg/day, the dose of 0.7 mg selenium/kg/day is identified as 
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the lowest LOAEL. A NOAEL cannot be identified because of the conflict between enhanced NKC 
activity and reduced DTH and prostaglandin E2 synthesis occurring at the same dose levels in this study. 
Antibody responses to ovalbumin were significantly lower in five male antelope (Antilocapra americana) 
fed a diet containing 15 ppm selenium (a mixture of alfalfa and hay naturally high in selenium) for 
164 days than in controls fed a similar diet containing only 0.3 ppm selenium, but there was no difference 
in total globulin concentration between groups (Raisbeck et al. 1996).  No clinical signs of selenosis or 
treatment-associated lesions were observed in these animals. 
Treatment of steers with selenomethionine or selenite in food at doses up to 0.808 mg selenium/kg/day 
for 120 days produced symptoms of selenosis (hoof lesions), but did not produce any changes in the 
weight or histology of the spleen or thymus or in the histology of the lymph nodes (O’Toole and Raisbeck 
1995). 
Leukocyte function was significantly reduced in pregnant cows supplemented with 0.135 mg/kg/day 
selenium for 3 months from diets that contained 0.25 (control), 6, or 12 ppm selenium as sodium selenite.  
Treated animals showed a significant decrease in forced antibody production and a depression in 
mitogenic response compared with controls (0.005 mg selenium/kg/day) (Yaeger et al. 1998). No clinical 
signs of selenium toxicosis were observed in any of the cows during the experiment. 
As selenium can enhance some immune system functions, selenium may have a normal physiological 
function in the immune system.  This is supported by an 8-week study in which treatment of mice with 
selenium as sodium selenite (0.33 mg selenium/kg/day, dietary) resulted in enhanced ability of cytotoxic 
T-lymphocytes to destroy tumor cells (Kiremidjian-Schumacher et al. 1992). 
Selenium appeared to play a protective role against viral infection in rats (Beck et al. 1995).  When 
selenium-deficient rats were inoculated with a benign strain of Coxsackie’s virus (CVB3/0), six separate 
point mutations were identified with the progression of virulence, causing myocarditis.  Cocksackie’s 
virus appears to act as a cofactor in the development of the myocardits; this was shown when the virus 
was isolated from blood and tissue of people with Keshan disease (a cardiomyopathy particularly 
prevalent in selenium-deficient growing children and women of child-bearing age).   
No studies were located concerning immunological or lymphoreticular effects in humans or experimental 
animals following oral exposure to selenium sulfide or selenium disulfide. 
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The highest NOAEL values and all LOAEL values from each reliable study for immunological effects 
following oral exposure to selenium or selenium compounds for each species and duration category are 
recorded in Table 3-2 and plotted in Figure 3-2. 
3.2.2.4 Neurological Effects 
Following acute oral exposure to selenium compounds in humans, aches and pains and irritability (Civil 
and McDonald 1978), as well as chills and tremors (Sioris et al. 1980) have been reported.  The dizziness 
associated with selenium inhalation exposure has not been documented after selenium ingestion. 
In a 1964 study, Rosenfeld and Beath reported listlessness, a general lack of mental alertness, and other 
symptoms of selenosis in a family exposed for approximately 3 months to well water containing 9 mg 
selenium/L (0.26 mg selenium/kg/day from drinking water).  All of the symptoms resolved after use of 
the seleniferous water was discontinued.  Because Rosenfeld and Beath (1964) did not estimate the 
family's exposure to dietary selenium, it is not possible to identify the total daily selenium dose associated 
with the symptoms of selenosis in this family. 
In a dietary study of 11 men in a metabolic unit, selenium intake (80 µg/day for the first 21 days, then 
either 13 [n=6] or 356 [n=5] µg/day for 14 weeks) was reported to have no significant effect on mood, as 
measured using the Bi-Polar form of the profile of mood states (POMS) (Hawkes and Hornbostel 1996). 
However, subjects with initially low selenium levels did show significantly greater decreases in mood 
scores during selenium depletion. 
In areas of the People's Republic of China where populations suffer from chronic selenosis, peripheral 
anesthesia and pain in the limbs were reported (Yang et al. 1983).  In extreme cases, exaggerated tendon 
reflexes, convulsions, and some paralysis and hemiplegia occurred (Yang et al. 1983).  These latter cases 
were associated with an estimated daily dietary intake of selenium of at least 3.22 mg selenium/person/ 
day, averaging 4.99 mg selenium/person/day (Yang et al. 1983).  Assuming a weight of 55 kg for Chinese 
men (Yang 1989b), these dietary levels represent 0.027 mg selenium/kg/day and 0.09 mg 
selenium/kg/day, respectively.  In another high selenium area, no neurological effects were observed in 
individuals who consumed up to 1.51 mg selenium/day (0.027 mg/kg/day) (Yang et al. 1983). Danish 
geriatric patients with a mean age of 75.3 years were given daily either a placebo or an antioxidant 
cocktail containing 0.004 mg/kg/day of selenium as L-selenomethionine along with zinc, vitamins C, A, 
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B6, and E, and gamma-linolenic acid. After 1 year, whole blood selenium concentrations increased in the 
treated group, and slight but significant improvements in psychological scores were observed (Clausen et 
al. 1989).  Because a mixture of nutrients was administered, the improvement in the patients cannot be 
attributed to selenium.  People living on ranches with high selenium soils where selenium toxicity in 
livestock had historically been observed were compared to randomly selected residents in Wyoming and 
South Dakota.  Daily selenium intake was measured by analysis of duplicate food portions.  Subjects 
received a complete physical exam with a symptom questionnaire and laboratory tests.  There were no 
biologically significant changes in clinical signs or blood chemistry.  Calculated doses ranged from 
0.001 to 0.01 mg selenium/kg/day in the diet (Longnecker et al. 1991). 
An increased incidence (4 observed cases, 0.97 expected, standardized incidence ratio=4.14, 95% 
confidence interval [CI]=1.13–10.60) of amyotrophic lateral sclerosis, a human motor neuron disease of 
unknown origin, was reported for a cohort of 5,182 residents of Reggio Emilia, Italy who had been 
exposed to drinking water containing increased selenium (7–9 µg/L)from 1972 to 1988, compared with 
the incidence among residents of the surrounding area who had received municipal water containing 
<1 µg/L selenium (Vinceti et al. 1996).  A subcohort of 2,065 of these individuals who had been exposed 
from 1974 (the earliest date for which a chemical analysis of the municipal tap water was available) was 
also examined and found to have an increased incidence ratio (4 observed cases, 0.47 expected, 
standardized incidence ratio=8.59, 95% CI=2.34–21.98).  However, the study is limited by a water level 
of selenium that is not generally considered to be high, a lack of individual measurements of selenium 
exposure, and insufficient information on confounding variables.  The lack of data on selenium status 
indicates that the study found a correlation but not causation.  
In a 30-day study of the administration of L-selenomethionine to long-tailed macaques, severe 
hypothermia was observed in two of five animals administered 0.12 mg selenium/kg/day, but not in any 
of the eight animals receiving 0.08 mg selenium/kg/day (Cukierski et al. 1989).  However, the increased 
incidence of hypothermia was not statistically significant.  Following 1 week of treatment, all animals 
administered L-selenomethionine, including the two macaques treated with 0.01 mg selenium/kg/day, 
exhibited increased drowsiness and lethargy (Cukierski et al. 1989). 
Symmetrical focal poliomyelomalacia and other forms of paralysis were seen in swine exposed to  
0.58–2.1 mg selenium/kg/day after both acute and intermediate exposures (Baker et al. 1989; Goehring et 
al. 1984; Harrison et al. 1983; Mihailovic et al. 1992; Panter et al. 1996; Penrith and Robinson 1996; 
Stowe et al. 1992; Wilson et al. 1983, 1988, 1989).  This lesion was noted in animals that showed ataxia, 
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inability to stand, and paralysis of the hind limbs.  Additionally, bilateral lesions were noted in the ventral 
horns of the cervical and lumbar/sacral intumescences of the spinal cord.  Necrosis and cavitation were 
evident in the larger lesions (Harrison et al. 1983).  Bilateral lesions were also observed in several nuclei 
of the brain stem and in the reticular formation (Wilson et al. 1983).  Wilson et al. (1983) reproduced the 
syndrome in growing pigs by feeding them sodium selenite at 50 mg selenium/kg in the diet for 20– 
40 days.  The study authors did not provide sufficient information to calculate doses on a mg selenium/kg 
body weight basis, but assuming that young swine consume approximately 4% of their body weight each 
day, this dose was approximately 2.1 mg/kg/day. 
In a study of weaned 5-week-old pigs, a dose of 1.3 mg selenium/kg/day given as sodium selenite in 
capsules killed all eight pigs within 10 days.  Histopathological lesions were found in the brain and spinal 
cord (Wilson et al. 1989). In a study in which pigs were fed 1.25 mg selenium/kg/day in the form of 
A. bisulcatus, D,L-selenomethionine, or selenate, the selenium in A. bisulcatus was the most potent 
neurotoxin, resulting in complete paralysis in four of five pigs after 5 days of treatment, and in the last pig 
after 3 weeks of treatment (Panter et al. 1996).  In pigs fed selenate, three of five developed complete 
paralysis, and one pig developed posterior paralysis after 4–21 days of treatment.  Although 
D,L-selenomethionine resulted in the greatest incidence of selenosis, it was the least potent neurotoxicant, 
resulting in posterior paralysis in two of five pigs after 9 and 24 days of treatment; the pigs that did not 
develop paralysis were fed D,L-selenomethionine for approximately 31 days.  The form of selenium in 
A. bisulcatus is unknown, although Panter et al. (1996) indicate that it is nonprotein. 
It has long been believed that the blind staggers syndrome in livestock results from consumption of plants 
high in selenium (100–10,000 mg selenium/kg plant) (Rosenfeld and Beath 1964).  These plants, which 
include A. bisulcatus, are known as selenium-indicator plants.  “Blind staggers” is characterized by 
impaired vision, aimless wandering behavior, reduced consumption of food and water, and finally 
paralysis and death (Rosenfeld and Beath 1964; Shamberger 1986).  Trembling of the skeletal muscles 
was observed in steers fed sodium selenite mixed in the feed at doses between 0.6 and 1.1 mg 
selenium/kg/day (Maag et al. 1960).  At necropsy, two of six steers exhibited neuronal degeneration of 
the cerebral and cerebellar cortices. However, more recent studies in which cattle were treated with 
known amounts of selenium have not replicated these effects, and it is likely that “blind staggers” is not 
solely the result of selenium toxicity, but may also be attributable to other unidentified causes.  For 
example, treatment of 20 steers with selenomethionine or selenite in food at doses up to 0.808 mg 
selenium/kg/day for 120 days produced symptoms of selenosis (hoof lesions), but did not produce any 
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neurological signs associated with “blind staggers” or any treatment-related changes in the histology of 
the central nervous system (O’Toole and Raisbeck 1995). 
Neurological effects have also been reported for mice after acute or intermediate exposures to selenium.  
A single oral dose of selenium dioxide dissolved in water given to mice at 1/10th the LD50 (1.7 mg/kg) 
caused moderate reductions in alertness, spontaneous activity, touch response, muscle tone, and 
respiration. Pentobarbital sleeping time was also significantly increased, and there was moderate 
hypothermia (Singh and Junnarkar 1991).  Brain tissue from male BALB/c mice administered sodium 
selenite or seleno-L-methionine in drinking water at 0, 1, 3, or 9 ppm selenium (sodium selenite: 0.03, 
0.24, 0.58, or 1.34 mg selenium/kg/day; seleno-L-methionine: 0.03, 0.26, 0.63, or 1.96 mg 
selenium/kg/day) for 14 days was examined for changes in the concentrations of norepinephrine (NE), 
dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT), and 
5-hydroxyindolacetic acid (5-HIAA) (Tsunoda et al. 2000).  Treatment with seleno-L-methionine 
produced no significant changes in the concentrations of any of the neurotransmitters or their metabolites.  
DOPAC, DA, and HVA were increased in the striatum of mice receiving 3 or 9 ppm selenium as selenite. 
The increase was significant at both concentrations for DOPAC and at 3 ppm (but not 9 ppm) for HVA, 
but was not significant at either concentration for DA.  No changes were observed for levels of NE, 5-HT, 
or 5-HIAA levels in any brain region of mice treated with sodium selenite.  
Exposure of female BALB/c mice to 0.21 mg selenium/kg/day for 6 months from diets containing 
selenium as sodium selenite resulted in significant changes in behavior during open field testing (Boylan 
et al. 1990). Open field testing measures the arousal level of small rodents and can differentiate between 
fear-related behavior and general arousal.  Mice receiving excessive selenium had reduced sniffing 
behavior and exhibited greater activity entering more squares, and more interior squares than mice 
receiving normal selenium diets.  These behaviors are indicative of a general state of arousal rather than 
fear-motivated activity.   
No studies were located concerning neurological effects in humans or experimental animals following 
oral exposure to selenium sulfide or disulfide. 
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects 
following oral exposure to selenium or selenium compounds for each species and duration category are 
recorded in Table 3-2 and plotted in Figure 3-2. 
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3.2.2.5 Reproductive Effects 
No studies were located regarding adverse effects on human reproduction following oral exposure to 
elemental selenium or to selenium compounds.  Associations between high seminal plasma selenium and 
impaired sperm count or motility have been inconsistently observed in humans (Bleau et al. 1984; Hansen 
and Deguchi 1996; Roy et al. 1990).  A 120-day double blind experimental study found no adverse 
changes in sperm indices or reproductive hormone in men (20–45 years old) who consumed a controlled 
diet of foods naturally high or low in selenium (Hawkes and Turek 2001).  Eleven subjects were fed a diet 
that provided 0.0006 mg selenium/kg/day for the first 21 days of the study, followed by diets providing 
0.0002 mg selenium/kg/day (6 subjects) or 0.004 mg selenium/kg/day (5 subjects) for 99 days.  Semen 
quality (sperm concentration, semen volume, sperm total number, fraction motile sperm, percent 
progressive sperm, mean forward velocity, and various sperm morphology parameters), reproductive 
hormone levels (serum testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, 
estradiol, and progesterone), and thyroid hormone levels (serum T3 and TSH) were evaluated during 
weeks 3 (baseline values), 8, and 17 (ending values). 
Selenium levels in blood plasma began to change within 3 days of starting the low- and high-selenium 
diets and progressively continued throughout the study (Hawkes and Turek 2001).  By week 17, mean 
plasma selenium concentrations had increased by 109% in the high-selenium group and decreased by 
38.5% in the low-selenium group.  A similar pattern of changes occurred in seminal plasma selenium, 
although selenium levels in sperm did not change significantly in either group.  Mean sperm motility was 
significantly different in the low-selenium subjects and high-selenium groups at week 13, but not at 
weeks 8 or 17. The fraction of motile sperm increased an average of 10% in the low-selenium group by 
week 13, and was essentially the same as the baseline value at week 17.  Sperm motility decreased an 
average of 32% in the high-selenium group at week 13, and ended 17% lower than baseline value at 
week 17. ANOVA showed a significant main effect of dietary selenium on sperm motility, as well as a 
significant selenium x time interaction, indicating that the group responses diverged over time.  Baseline 
and ending motile sperm fractions in the high-selenium group were 0.588±0.161 and 0.488±0.193, 
respectively; ≥50% motility is considered normal (FDA 1993).  The decrease in sperm motility in the 
high-selenium group cannot be clearly attributed to selenium because the effect was not consistent over 
the duration of exposure, is unlikely to be adverse because it is at the low end of the normal range, and is 
not accompanied by any significant changes in other indices of sperm movement (progression or forward 
velocity), or sperm numbers or morphology.  Additionally, there were no effects of selenium on serum 
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levels of reproductive hormones, and changes in thyroid hormones, which could affect sperm function, 
were not outside normal ranges (see Endocrine Effects in Section 3.2.2.2). 
A nonsignificant increase in spontaneous abortions (relative risk [RR]=1.73; 95% CI=0.62–4.80) was 
reported among births in the municipality of Reggio Emilia, Italy, where women had been exposed to 
drinking water containing 7–9 ug/L levels of selenium (as selenate, reported estimated intake 10– 
20 ug/day) between 1972 and 1988 (Vinceti et al. 2000a).  This study is limited by a level of selenium in 
water that is not considered high, lack of data on selenium status, and insufficient information on 
confounding variables.  Selenium deficiency has been implicated as a risk factor for recurrent miscarriage 
in humans (Al-Kunani et al. 2001; Barrington et al. 1996, 1997; Güvenc et al. 2002; Kumar et al. 2002). 
Data from animal studies suggest that exposure to excessive selenium has adverse effects on testosterone 
levels and sperm production and increases the percentage of abnormal sperm (El-Zarkouny et al. 1999; 
Kaur and Parshad 1994; NTP 1994).  A significant reduction (49%) in serum testosterone levels was 
reported for New Zealand white rabbits gavaged with 0.001 mg selenium/kg/day as sodium selenite once 
a week for 6 weeks (El-Zarkouny et al. 1999).  The percentage of spermatozoa without an acrosome was 
also increased in treated rabbits compared with controls, but the difference was not significant.  Sperm 
motility, ejaculate volume, sperm concentration, and total sperm output were all reduced by selenium 
treatment, but statistical analysis of these data was not presented. 
Exposure of Wistar rats to 0.234 mg selenium/kg/day as sodium selenite in water produced testicular 
hypertrophy (Turan et al. 1999a).  A dose-related increase in abnormal sperm and a decrease in live sperm 
were observed in wild-caught rats exposed to selenite in the diet at 0.1 and 0.2 mg selenium/kg/day (Kaur 
and Parshad 1994).  The percentage of abnormal sperm was 3.9% at 0.1 mg/kg/day and 24.6% at 
0.2 mg/kg/day.  The abnormalities observed were principally in the midpiece region of the sperm, the 
region that contains a selenoprotein (Sunde 1990).  Decreased sperm counts were observed in rats 
provided with selenate or selenite in drinking water for 13 weeks at a dose of 0.29 mg selenium/kg/day 
for selenate and a dose of 0.17 mg selenium/kg/day for selenite (NTP 1994).  Effects on sperm were not 
observed in mice treated with selenate or selenite in the drinking water at doses up to 5.45 mg 
selenium/kg/day for selenate or up to 3.31 mg selenium/kg/day for selenite (NTP 1994).  The 
administration of 1.05 mg selenium/kg/day as potassium selenate to rats in drinking water for 1 year did 
not affect male fertility (Rosenfeld and Beath 1954), and the administration of 0.57 mg selenium/kg/day 
as sodium selenate for three generations did not reduce male fertility in mice (Schroeder and Mitchener 
1971b).  A short-term reproductive study of the effects of sodium selenate in drinking water on rats at 
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doses (0.418 mg selenium/kg/day) that produced signs of systemic toxicity did not cause any increase in 
sperm abnormalities or lesions of the testis or epididymis (NTP 1996).  Selenium administered in the diet 
or in drinking water over short exposure periods (e.g., 1 month) does not appear to affect the fertility of 
female animals unless the intake is sufficiently high to cause general toxicity (Nobunaga et al. 1979).  
Despite a small increase in the number of abnormal length estrous cycles, Nobunaga et al. (1979) found 
no adverse effect on the fertility of female mice from administration of sodium selenite at doses of 
0.34 mg selenium/kg/day in drinking water for 30 days before mating and for 18 days during pregnancy. 
On the other hand, chronic exposure of mice and rats to otherwise nontoxic doses has been shown to 
reduce fertility and to reduce markedly the viability of the offspring of pairs that are able to conceive 
(Schroeder and Mitchener 1971b; Wahlstrom and Olson 1959b). 
A study of supplementation of female pigs with 0.1 or 0.3 ppm selenium (doses not available) 
administered as a selenium-enriched yeast or sodium selenite in the diet, from 60 days before breeding 
until weaning found no adverse effects on reproductive performance (measured by number of offspring) 
or growth (Mahan and Kim 1996).  In another study of the effect of selenium on fertility in pigs, females 
fed sodium selenite at 0.4 mg selenium/kg/day from 8 weeks of age exhibited reduced rates of conception 
and also produced offspring with significantly reduced birth weight and weaning weights in the first and 
second litters (Wahlstrom and Olson 1959b).  An altered menstrual cycle was reported in monkeys 
administered 0.08 mg selenium/kg/day as L-selenomethionine for 30 days (Cukierski et al. 1989). 
Vaginal cytology of female rats provided with drinking water containing selenate or selenite indicated 
that the rats spent more time in diestrus and less time in proestrus and estrus than the controls (NTP 
1994).  This effect occurred following treatment with 0.31 mg selenium/kg/day as selenate or 0.86 mg 
selenium/kg/day as selenite.  The animals in these studies were not mated, so it is not known if the effects 
on the estrous cycle had any effect on fertility.  Effects on the estrous cycle were not observed in mice 
treated with selenate or selenite in the drinking water at doses up to 7.17 mg selenium/kg/day for selenate, 
or at doses up to 3.83 selenium/kg/day for selenite (NTP 1994). 
In a three-generation reproduction study, selenium administered as sodium selenate (0.57 mg 
selenium/kg/day) in the drinking water of breeding mice produced adverse effects on reproduction 
(Schroeder and Mitchener 1971b).  The most notable observed effects included the failure of about half of 
the F3 generation pairs to breed successfully.  In a two-generation study using rats, selenium administered 
as potassium selenate had no effect on reproduction at a dose of 0.21 mg selenium/kg/day for 1 year; 
however, decreased fertility and pup survival were noted at 1.05 mg selenium/kg/day (Rosenfeld and 
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Beath 1954).  At 0.35 mg selenium/kg/day for 1 year, the number of young successfully reared by the 
females was reduced by 50%, and the body weight of the females was approximately 20% less than that 
of the control females (Rosenfeld and Beath 1954). 
A short-term reproductive study of the effects of sodium selenate in drinking water on rats reported some 
female reproductive toxicity (reduced corpora lutea, reduced implants per litter, shorter estrous cycle), but 
only at doses (0.418 mg selenium/kg/day) that produced signs of severe maternal toxicity, including a 
large reduction in water consumption (NTP 1996). 
In a review of selenium poisoning in domestic animals, Harr and Muth (1972) noted a decreased 
conception rate and an increased fetal resorption rate in cattle, sheep, and horses fed diets naturally 
containing organic selenium compounds at 25–50 mg selenium/kg diet.  Assuming that large animals 
consume an amount of food equal to about 2–3% of their body weight daily, the doses would have been 
approximately 0.5–1.5 mg selenium/kg/day.  These levels of selenium also produced other signs of 
toxicity, including hair loss, lameness, and degeneration and fibrosis of the heart, liver, and kidneys.  In a 
case control study of 136 Holstein cows from four herds, an association of cystic ovaries with blood 
selenium concentrations >108 ng/mL was found (Mohammed et al. 1991).  The concentration of 
progesterone in the milk was significantly higher in the controls than in the cows receiving selenium 
supplementation, but no information on the selenium dose was presented.  No change in estrus cycle 
length, estrus behavior, progesterone, or estrogen profiles or pregnancy rate was observed in a study of 
the reproductive response of ewes fed alfalfa pellets containing sodium selenate (24 ppm selenium) or 
A. bisculcatus (29 ppm selenium) as a selenium source for 88 days, from >52 days before pregnancy up to 
day 28 of gestation (Panter et al. 1995).  Doses could not be calculated as food consumption was not 
listed, and the paper states that the food supply was limited to match that of the group with the lowest 
intake. 
The highest NOAEL value for reproductive effects following intermediate oral exposure to sodium 
selenite and all reliable LOAEL values for reproductive effects following intermediate or chronic oral 
exposure to selenium compounds other than selenium sulfide are recorded in Table 3-2 and plotted in 
Figure 3-2. 
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3.2.2.6 Developmental Effects 
No studies have demonstrated that selenium or its compounds are teratogenic in humans.  Robertson 
(1970) reported on the outcome of pregnancies in a laboratory in which workers handled sodium selenite. 
Of the five pregnancies, four ended in spontaneous abortion and one resulted in an infant with bilateral 
clubfoot.  The urinary selenium levels in all subjects were similar to those in other individuals living in 
the same area.  The limited number of cases, possible exposure to other toxic agents, and other 
confounding factors leave the relationship between sodium selenite and developmental effects 
inconclusive. 
No significant increase in spontaneous abortions (RR=1.73; 95% CI=0.62–4.80) was reported among 
births in the municipality of Reggio Emilia, Italy, where women had been exposed to drinking water 
containing 7–9 µg selenium/L (as selenate) between 1972 and 1988 (Vinceti et al. 2000a).  Body weight 
and length at birth were similar in infants of exposed and unexposed women, and no significant increase 
in the prevalence of congenital abnormalities was found for 353 infants of exposed mothers compared 
with the 14,481 births among unexposed women.  This study is limited by a level of selenium in water 
that is not considered high, lack of data on selenium status, and insufficient information on confounding 
variables. 
Zierler et al. (1988) performed a case control study of 270 children born in Massachusetts with severe 
congenital heart disease and 665 controls randomly selected from birth certificates.  The study compared 
the selenium concentrations in the public drinking water supply used by the mothers close to the time of 
conception to the selenium concentrations in the water consumed by the controls. The results indicated 
that selenium exposure via drinking water was associated with beneficial effects, particularly a reduction 
in the risk of congenital heart defects (cono-truncal defects, venticular septal defects, coarctation of the 
aorta, and patent ductus arteriosis), but many variables are unknown, including other possible 
confounders (no adjustment for age, parity, tobacco, alcohol, drug use, or socioeconomic status), other 
sources of selenium in the mothers' diet and environment, the amount of drinking water consumed, and 
the selenium concentrations in the water during the first trimester.  
Excess selenium is a demonstrated teratogen in birds.  However, there is no clear evidence linking 
selenium exposures to teratogenic effects in mammals.  Several studies have documented the sensitivity 
of chick embryos to selenium poisoning.  Hatchability of eggs is reduced by dietary levels of organic 
selenium in grain that are too low to cause toxicity in other farm animals.  The eggs are fertile but often 
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produce grossly deformed embryos lacking eyes and beaks and having deformed wings and feet (Franke 
and Tully 1935; Franke et al. 1936; Gruenwald 1958; Palmer et al. 1973).  Deformed embryos have also 
been produced by injection of aqueous sodium selenite or sodium selenate into the air cell of the normal, 
fertile eggs of chickens (Franke et al. 1936; Khan and Gilani 1980).  The incidence of malformation 
among coot, duck, stilt, and grebe embryos from eggs of birds ingesting plant and other food from 
irrigation drainwater ponds in the San Joaquin Valley of California was much higher than expected (10– 
42%, depending on the species, versus <1% based on data from other areas) (Ohlendorf et al. 1986a, 
1988). Selenium concentrations in these ponds were >0.3 mg/L. 
The consumption of naturally high seleniferous diets by sheep (Rosenfeld and Beath 1964) and cattle 
(Dinkel et al. 1963) may interfere with normal fetal development and produce malformations.  
Malformations were associated with alkali disease and occurred at dietary levels that produced other toxic 
manifestations, but it is not clear if these reports took into account consumption of other toxic range 
plants. The specific selenium compound or compounds possibly associated with livestock developmental 
toxicity have not been identified.  No change in the outcome of pregnancy was observed in a study of the 
reproductive response of ewes fed alfalfa pellets containing sodium selenate (24 ppm selenium) or 
A. bisculcatus (29 ppm selenium) as a selenium source for 88 days, from >52 days before pregnancy up to 
day 28 of gestation (Panter et al. 1995).  All lambs appeared normal, and there was no significant 
difference in the number or weight of lambs born to treated and control ewes.  Doses could not be 
calculated, as food consumption was not listed, and the paper states that the food supply was limited to 
match that of the group with the lowest intake. 
In an intermediate-duration study, an increased number of deaths between birth and weaning, reduced 
birth weight, and reduced body weight at weaning were observed in offspring of pigs fed selenite at 
0.4 mg/kg/day for an unstated period of time (Wahlstrom and Olson 1959b).  Treatment of 15 pregnant 
cows with diets containing 0.25 (control), 6, or 12 ppm selenium (0.005, 0.135, or 0.265 mg Se/kg/day) as 
sodium selenite beginning at 80–110 days gestation and continuing for 3 months resulted in no 
abnormalities among the offspring apart from one calf in the 12 ppm group that was born weak and 
subsequently died (Yaeger et al. 1998).  This calf had myocardial lesions similar to those described for 
selenium toxicosis and had markedly elevated hepatic selenium levels, although selenium levels in blood 
and hair of this calf and its dam were lower than average for the 12 ppm group. 
In studies of laboratory mammals, the administration of inorganic selenium compounds at levels that are 
not maternally toxic has not produced terata (Bergman et al. 1990; Chiachun et al. 1991; Ferm et al. 1990; 
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NTP 1996; Poulsen et al. 1989; Rosenfeld and Beath 1954; Schroeder and Mitchener 1971b; Thorlacius-
Ussing 1990).  Ferm et al. (1990) administered a single dose of sodium selenate, sodium selenite, or 
L-selenomethionine (0, 1.8, 2.2, 2.7, 4.0, 5.0, or 5.9 mg selenium/kg/day) to pregnant Syrian hamsters on 
gestation day 8.  Pathological examination of the fetuses on day 13 showed that the percentage of 
abnormal litters was significantly increased at doses of ≥2.7 mg/kg.  Encephalocele was the major 
malformation noted, and incidences were as follows: 0/71 controls; 4/55 (7.3%) at 1.8 mg/kg; 1/49 (2%) 
at 2.2 mg/kg; 7/66 (10.6%) at 2.7 mg/kg; 15/70 (21.4%) at 4 mg/kg; 9/38 (23.7%) at 5 mg/kg; and 
6/16 (37.5%) at 5.9 mg/kg.  Nobunaga et al. (1979) found that administration of sodium selenite in 
drinking water at 0.34 mg selenium/kg/day for 30 days before mating and for 18 days during pregnancy 
slightly, but significantly, reduced fetal growth in mice.  However, there was no effect on fetal growth in 
the same study at a dose of 0.17 mg selenium/kg/day.  A short-term developmental study (from gestation 
day 6 until birth) of the effects of sodium selenate in drinking water on rats produced some developmental 
toxicity (decreased number of live births, reduced pup weight, increased gestation period), but only at 
doses (0.418 mg selenium/kg/day) that produced signs of severe maternal toxicity including a large 
reduction in water consumption (NTP 1996).  Selenium administered as potassium selenate in drinking 
water to male and female rats at a dose of 1.05 mg selenium/kg/day for 1–8 months for two successive 
generations did not cause congenital malformations (Rosenfeld and Beath 1954).  Similarly, 
administration of 0.57 mg selenium/kg/day as sodium selenate in the drinking water of breeding mice for 
three generations did not have teratogenic effects, although there was an increased incidence in fetal 
deaths, and a high proportion of the surviving offspring were runts (Schroeder and Mitchener 1971b). 
Poulsen et al. (1989) demonstrated that pigs exposed to 42.4 mg/day of selenium as sodium selenite in 
feed throughout pregnancy produced normal litters, with no adverse effect on piglet survival, litter size, or 
body weight at birth.  Body weights of the pigs during pregnancy were not provided, and therefore, 
mg/kg/day doses could not be calculated.  Body weight gains of pigs fed selenium as selenite at a dose of 
0.4 mg selenium/kg/day after weaning (duration not specified) were reduced (Wahlstrom and Olson 
1959a). The reduction in body weight gain was greater among pigs from dams not fed selenium during 
gestation and lactation compared to pigs fed selenium (0.4 mg/kg/day) during gestation and lactation.  
Without providing data, the study authors indicated that there was a greater loss of pigs at birth and 
during lactation from sows fed selenium, which may have eliminated susceptible pigs. 
In a teratology study of long-tailed macaques, no gross abnormalities or growth retardations were 
observed in fetuses from mothers administered L-selenomethionine at levels of 0.003, 0.025, 0.15, or 
SELENIUM 117 
3.   HEALTH EFFECTS 
0.30 mg selenium/kg/day on gestational days 20–50 (10 animals per group); the mid and high doses were 
maternally toxic (Tarantal et al. 1991). 
The highest NOAEL value and all reliable LOAEL values for developmental effects following 
intermediate or chronic oral exposure to selenium compounds are recorded in Table 3-2 and plotted in 
Figure 3-2. 
3.2.2.7 Cancer 
Early studies reporting that selenium was carcinogenic in mammals after being provided as seleniferous 
corn or wheat in the diet (Nelson et al. 1943), as sodium selenite or sodium selenate in drinking water 
(Schroeder and Mitchener 1971a), or as sodium selenate in the diet (Volgarev and Tscherkes 1967) were 
flawed. The majority of subsequent studies of humans and animals have revealed no association between 
selenium intake and the incidence of cancer (Azin et al. 1998; Beems 1986; Coates et al. 1988; Harr et al. 
1967; Ma et al. 1995; Menkes et al. 1986; Ratnasinghe et al. 2000; Thompson and Becci 1979; Vinceti et 
al. 1995; Virtamo et al. 1987) or a clear chemopreventive association (Birt et al. 1982; Clark et al. 1996a, 
1999; Finley et al. 2000; Ip 1981, 1983; Ganther and Lawrence 1997; Ip and Lisk 1995; Ip et al. 1996, 
1997, 1998, 2000a, 2000b; Jiang et al. 1999; Ma et al. 1995; Medina and Shepherd 1981; Moyad 2002; 
Overvad et al. 1985; Schrauzer et al. 1976, 1977; Shamberger et al. 1976; Soullier et al. 1981; Thompson 
and Becci 1980; Woutersen et al. 1999; Yoshizawa et al. 1998).  Some epidemiological and experimental 
evidence suggests that selenium exposure, under certain conditions, may contribute to a reduction in 
cancer risk (Clark et al. 1996a, 1999; El-Bayoumy 2001; Ganther 1999; Moyad 2002; Spallholz 2001; 
Yoshizawa et al. 1998), and the chemopreventive potential of supplemental selenium is currently under 
research (Clark et al. 1999; Duffield-Lillico et al. 2002; Reid et al. 2002).   
The only selenium compound that has been shown to be carcinogenic in animals is selenium sulfide (NTP 
1980c), although there is also some evidence for carcinogenicity due to ethyl selenac (selenium 
diethyldithiocarbamate) (Innes et al. 1969; NCI 1968).  These compounds are very different chemically 
from the organic and inorganic forms found in foods and the environment.  Human dietary studies 
generally do not identify the selenium form specifically; both organic (from grains and other plant and 
animal products) and inorganic (from drinking water) forms are ingested.  Animal bioassays in which 
selenium was administered as sodium selenate, sodium selenite, or organic forms of selenium have all 
shown similar negative results. 
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Excess incidence of melanoma was reported for a cohort of 2,065 individuals that were exposed to  
7–9 µg/L levels of selenium as selenate in the municipal water supply in Reggio Emilia, Italy from 1972 
until 1988 (Vinceti et al. 1998). Eight individuals among the exposed cohort developed melanoma 
compared with 128 in the remainder of the municipal population (total number of individuals not given).  
The standardized mortality ratios (SMRs) were 5.0 (95% CI=1.6–12.0) for males and 3.2 (95%  
CI=1.0–7.7) for females.  The authors estimate the general dietary intake of selenium in the area to be  
45–50 µg/day and the excess selenium supplied in the contaminated tap water to be 10–20 µg/day.  
However, the study is limited by the fact that no individual measurements of selenium exposure were 
made, and individuals were classed as exposed or unexposed depending on their place of residence.  The 
lack of data on selenium status indicates that the study found a correlation but not causation.  Other 
limitations include a water level of selenium that is not generally considered to be high and insufficient 
information on confounding variables. 
A study of the effects of nutritional supplementation with selenium found a significant reduction in 
overall cancer mortality and in the incidence of lung (RR=0.54, 95% CI=0.3–0.98, p=0.04), colorectal 
(RR=0.42, 95% CI=0.18–0.95, p=0.03), and prostate (RR=0.37, 95% CI=0.18–0.71, p=0.003) cancer 
(Clark et al. 1996a, 1999). The original intent of the study was to assess the effects of selenium 
supplementation on nonmelanoma skin cancer.  Patients with a history of skin carcinoma 
(1,312 individuals) were randomized into two groups; one group received a selenium supplement of 
200 µg/day, and the other received a placebo.  Groups were treated for an average of 4.5 years and 
followed for an average of 6.5 years.  Supplementation produced no difference in skin cancer incidence; 
however, secondary end point analyses of the data found a protective effect for selenium for the cancers 
described above. A reanalysis of the lung cancer data added eight cases to the selenium-treated group, 
four cases to the placebo group, and increased follow-up to 7 years (Duffield-Lillico et al. 2002; Reid et 
al. 2002).  Selenium supplementation did not reduce lung cancer incidence in the full population 
(RR=0.70, 95% CI=0.40–1.21, p=0.18; hazard ratio [HR]=0.74, 95% CI=0.44–1.24, p=0.26), although a 
nominally significant decrease was observed among subjects with baseline plasma selenium 
concentrations in the lowest tertile (HR=0.42, 95% CI=0.18–0.96, p=0.04).  The analysis for the middle 
and highest tertiles of baseline selenium level showed HRs of 0.91 and 1.25, suggesting that there was a 
trend toward a reduction in risk of lung cancer with selenium supplementation. 
Supporting evidence for an antiprostate cancer effect of selenium was obtained for a nested case-control 
design within the Health Professional Follow-up study (Yoshizawa et al. 1998), which found that higher 
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prediagnostic selenium levels were associated with reduced prostate cancer incidence.  This study 
included 33,737 male health professionals aged 40–75 years who provided toenail clippings in 1987.  The 
cohort was assessed by questionnaire for incidence of new cases of prostate cancer from 1989 to 1994.  
Higher levels of selenium in toenail clippings were significantly associated with a reduced risk of prostate 
cancer. After controlling for factors such as a family history of prostate cancer, body mass index, calcium 
intake, lycopene intake, saturated fat intake, vasectomy, and geographical region, the odds ratio (OR) was 
0.35 (95% CI=0.16–0.78, p for trend=0.03).  Studies of selenium supplementation have generally shown a 
reduction in prostate cancer risk only in individuals who had lower levels of baseline plasma selenium, 
whereas subjects with normal or higher levels did not benefit and may have an increased risk for prostate 
cancer (Moyad 2002). 
Epidemiological studies that focused on the selenium concentration of forage crops as an indicator of 
available dietary selenium indicated an inverse association between selenium levels and cancer 
occurrence, with few exceptions.  In the United States, male mortality due to cancer of the tongue, 
esophagus, stomach, intestine, rectum, liver, pancreas, larynx, lungs, kidneys, and bladder was 
significantly lower in states with high selenium levels in forage crops (concentrations in excess of 
0.10 mg selenium/kg) (Shamberger et al. 1976).  For females in states with high selenium levels, 
significantly lower cancer death rates were found for cancer of the esophagus, stomach, intestine, rectum, 
liver, pancreas, lungs, bladder, thyroid, breast, and uterus (Shamberger et al. 1976).  Only male and 
female mortality due to cancer of the skin and eye, male mortality due to cancer of the lip and aleukemic 
leukemia (a deficiency or absence of leukocytes in the blood due to leukemia), and female mortality due 
to dermal melanoma were associated with high selenium levels in forage crops.  Many of the high 
selenium areas are in the southwestern portion of the United States, and therefore, exposures to ultraviolet 
light may have contributed to the skin cancers observed in these areas (Shamberger et al. 1976).  In a 
comparison of selenium intake and cancer mortality rates in different countries, Schrauzer et al. (1977) 
detected a cancer chemopreventive association between the selenium content of the diet and age-corrected 
cancer mortality from leukemia and cancers of the intestine, rectum, breast, ovary, prostate, lung, 
pancreas, skin, and bladder. 
In a case control study of lung cancer patients, Menkes et al. (1986) found that the risk of lung cancer was 
not associated with serum selenium levels (0.113 and 0.110 mg selenium/L in cases and controls, 
respectively), but was significantly increased with decreasing serum levels of vitamins A and E.  The 
study authors suggested that high serum selenium levels were significantly associated with an increased 
incidence of squamous cell carcinoma as compared to other cellular tumor types, but the statistical 
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analysis used was flawed.  In a region of China with high rates of stomach cancer and low intake of 
several micronutrients (selenium not specifically stated), an intervention trial in 29,584 adults for 
5.25 years demonstrated a 21% decrease in stomach cancer in the randomly selected group receiving a 
nutritional supplement of beta carotene (15 mg/day), vitamin E (30 mg/day), and selenium (50 µg 
selenium/day as selenium yeast) (Blot et al. 1993).  However, because the three nutrients were given in 
combination to a nutritionally deficient population, it is not possible to determine what part of this effect 
(if any) was due to selenium. 
Low serum selenium levels have been associated with an increased incidence of cancer in some 
prospective epidemiological studies (Salonen et al. 1984, 1985; Willet et al. 1983).  In the United States, 
Willet et al. (1983) found that the risk of cancer for subjects in the lowest quintile (fifth) of serum 
selenium concentrations (<0.115 mg selenium/L) was twice that of subjects in the highest quintile 
(>0.154 mg selenium/L).  In Finland, Salonen et al. (1985) found the risk of fatal cancer for subjects in 
the lowest tertile (third) of serum selenium concentrations (<0.047 mg selenium/L) was 5.8 times higher 
than that of the remaining subjects.  Mean serum selenium levels in Americans (0.129 mg selenium/L 
cases; 0.136 mg selenium/L controls) (Willett et al. 1983) are more than twice the mean serum selenium 
levels in the Finns (0.0505 mg selenium/L for cases; 0.0543 mg selenium/L for controls) (Salonen et al. 
1984).  Although the age-specific risk of fatal cancers in the two populations cannot be calculated from 
the data reported, the overall incidence of cancer in the 4-year Finnish study was less than half that in the 
5-year U.S. study.  In addition, other prospective studies of Americans have found no correlation between 
fatal cancer and blood selenium concentrations (Coates et al. 1988).  Thus, one may not be able to predict 
relative cancer risks with serum selenium levels in one population based on data from another population. 
A 9-year prospective follow-up study was conducted by Virtamo et al. (1987) on a group of men in 
Finland. At the beginning of the study, blood samples were taken as part of a study of coronary heart 
disease and other atherosclerotic diseases.  Cancer data were collected from central registries for the years 
1976 through 1983. The results indicated no association between low serum selenium levels (<0.045 mg 
selenium/L) and an increased risk of cancer.  Evidence suggests that combined dietary deficiencies of 
vitamin E and selenium may be associated with increased cancer risk (Salonen et al. 1985). 
Epidemiological studies of breast cancer have found inverse correlations, positive correlations, and no 
correlations between tissue selenium concentrations and cancer incidence (recently reviewed by Garland 
et al. 1993). In a case control study of plasma selenium and breast cancer in which the controls had 
benign breast disease, a preventive effect of selenium was found only among individuals who had higher 
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plasma selenium and were not taking selenium supplementation (Hardell et al. 1993).  This effect was 
significant (odds ratio 0.38) at a serum selenium concentration range of 0.08–0.09 mg/L in women 
50 years old or more.  GPX activity in erythrocytes was not found to be a marker for the risk of breast 
cancer. A case control study of 162 cases of breast cancer in Dutch women did not find a significant 
difference in dietary, plasma, erythrocyte, or toenail selenium between cases and 529 controls when 
multivariate-adjusted odds ratios were calculated.  Dutch women have lower selenium intake than women 
in the United States and one of the highest incidences of breast cancer in Western Europe.  The authors of 
this study surmised that other studies reporting an inverse relationship between selenium levels and breast 
cancer may be seeing an effect of the cancer (e.g., decreased uptake of selenium or anorexia), rather than 
lower selenium level contributing to the development of cancer (van't Veer et al. 1990).  Similarly, a large 
prospective study of 434 cases in the United States found no correlation between selenium content in 
nails, established as a long-term marker of selenium (Hunter et al. 1990a), and breast cancer (Hunter et al. 
1990b). It is interesting to note that a more recent investigation of the same cancer cases found an inverse 
correlation between vitamin A (retinoids) in the diet and breast cancer (Hunter et al. 1993).  Retinoids are 
believed to have chemopreventive activity (Clausen et al. 1989; Hunter et al. 1993).  Although the data as 
a whole for breast cancer and tissue selenium concentrations do not support a clear chemopreventive 
effect for selenium, it is possible that very high selenium concentrations or very low selenium 
concentrations outside the ranges observed in these studies could play a role in human cancer risk 
(Garland et al. 1993). 
There were several inadequacies in the early studies that reported carcinogenic effects in animals 
following oral administration of selenium-containing compounds.  Nelson et al. (1943) (also reported as 
Fitzhugh et al. 1944) administered naturally seleniferous corn or wheat diets containing 5, 7, or 10 mg 
selenium/kg diet (0.25, 0.35, or 0.50 mg selenium/kg/day) to female rats for 2 years.  Selenium 
administration produced high mortality (69%) in all treatment groups by the end of the first 12 months, 
and the first tumors appeared after 18 months of treatment.  Tumors developed only in animals with 
cirrhotic livers, and the tumors were reported to be nonmalignant.  The possible contribution of overt 
hepatotoxicity to the development of liver tumors is not known.  The incidences of tumors in the 
surviving animals in the three dose groups were 6/25, 3/21, and 2/7, respectively.  The investigators had 
difficulty discerning malignant from nonmalignant tumors, and most animals had died of cirrhosis of the 
liver before the appearance of liver tumors. These difficulties cast doubt on the conclusion of the 
investigators that selenium induced tumor formation in these rats. 
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A statistically significant increase was reported in the incidence of all tumors and malignant tumors in rats 
administered 0.28–0.42 mg selenium/kg/day as sodium selenite or sodium selenate in drinking water for a 
lifetime (Schroeder and Mitchener 1971a).  Not all autopsied animals were examined histologically, 
however, and high mortality in all groups occurred as a result of a virulent pneumonia epidemic that 
occurred during the study.  In addition, the statistical analysis failed to account for the fact that the 
selenium-treated rats lived longer than did the control rats.  Analysis of the incidence of tumors among 
animals with equal longevities indicates that the incidence of tumors in the selenate-treated rats was not 
significantly different from that in the controls. 
A series of dietary studies assessed the effects of various dietary supplements on selenium tumor 
induction in male rats (Volgarev and Tscherkes 1967), but the conclusions that can be drawn from these 
experiments are limited since they did not include controls.  Tumors (primarily liver) were found in 
10/23 male rats administered sodium selenate in the diet at a dose of 0.34 mg selenium/kg/day for more 
than 18 months (Volgarev and Tscherkes 1967).  The first tumors appeared after 18 months of selenium 
administration, by which time, 43% of the animals had already died (group started with 40 animals).  
Tumors were also found in 3/16 male rats administered sodium selenate in the diet at an initial dose of 
0.34 mg selenium/kg/day for 6 months, followed by 0.68 mg/kg/day until the animals’ death (Volgarev 
and Tscherkes 1967).  In a third group of experiments, no tumors were found in 200 male rats 
administered sodium selenate in the diet (0.34 mg selenium/kg/day) for 26 months.  However, there was 
very high mortality among these rats, and survival time was 10 months shorter than among the similarly 
fed animals in the first experiment.  The authors noted that an additional 200 male rats were maintained in 
their laboratory during these experiments and fed stock rations.  The life spans of these animals exceeded 
those used in the experiments and no tumors were found at autopsy. 
More recent animal bioassays have failed to demonstrate any association between excessive selenium 
exposure and carcinogenesis.  Chen et al. (2000) reported a significant increase in rat esophageal 
adenocarcinogenesis in response to supplementation with 0.06 mg selenium/kg/day as sodium selenite for 
40 weeks. However, selenium supplementation has generally been shown to significantly inhibit tumors 
induced by chemicals, viruses, or ultraviolet light (Birt et al. 1982; Finley et al. 2000; Ip 1981, 1983; Ip 
and Lisk 1995; Ip et al. 1996, 1997,1998, 2000a, 2000b; Jabobs 1983; Jacobs et al. 1977a, 1977b, 1979, 
1981; Jiang et al. 1999; Medina and Shepherd 1981; Overvad et al. 1985; Schrauzer et al. 1976; Soullier 
et al. 1981; Thompson and Becci 1980; Woutersen et al. 1999).  Results following administration of 
selenium as sodium selenate, sodium selenite, and organic forms of selenium are similar.  Additional 
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research reviewed in El-Bayoumy (1991, 1995, 1997) indicates that synthetic organoselenium compounds 
may be more potent cancer preventive agents than selenate, selenite, or the selenoamino acids. 
Two sources reported the results of a study of rats administered sodium selenate or sodium selenite in the 
diet for a lifetime (Harr et al. 1967; Tinsley et al. 1967).  A vehicle control and two positive control 
groups (administered a known hepatocarcinogen, N-2-fluorenyl-acetamide [FAA]) were included. 
Mortality was high in the highest dose group (0.8 mg selenium/kg/day), and therefore, selenium 
administration was discontinued.  Longevity was reduced in animals fed 0.4 mg selenium/kg/day, but not 
in the animals administered lower doses.  Of the original 1,437 experimental animals, 1,126 were 
necropsied. Half of the 88 FAA-fed rats developed neoplasms, half of which were hepatic carcinomas, 
indicating that the strain of rat and dietary conditions were compatible with the development of hepatic 
carcinogenesis. The incidence of cancer of all types in the necropsied control rats (11 out of 482, or 
2.3%) was somewhat higher than the incidence of cancer in the selenium-treated animals that were 
necropsied (9 out of 553, or 1.6%).  A statistical analysis of the data from this study was not reported.  
Although the reduced longevity of animals administered 0.4 mg selenium/kg/day might have prevented 
the observation of some late-developing cancers, the large number of rats necropsied, the end points 
examined, and the doses administered provide credible evidence of the lack of carcinogenic potential of 
sodium selenate or selenite. 
Mice were fed tortula yeast diets containing up to 1.0 mg selenium/kg diet (equivalent to 0.13 mg 
selenium/kg body weight/day) as sodium selenite for 2 weeks prior to a single application of 0.125 mg 
7,12-dimethylbenz[a]anthracene (DMBA) to the skin or repeated daily applications of 0.25 mL of a 
0.03% solution of benzo[a]pyrene in acetone for 27 weeks (Shamberger 1970).  The highest dose of 
selenite used, 0.13 mg selenium/kg/day, significantly decreased the number of tumors induced by both 
aromatic compounds.  No significant increase was found in the incidence of spontaneous tumors in mice 
following administration of 3 mg selenium/L in drinking water as either sodium selenite or sodium 
selenate for a lifetime (Schroeder and Mitchener 1972).  This level corresponds to doses of 0.31–0.34 mg 
selenium/kg/day for the males and 0.42 mg selenium/kg/day for the females.  The single dose 
administered, however, might not have been the maximal dose that could be tolerated.  There were 7% 
more malignant tumors in the selenium-treated animals (13 out of 88 sectioned, or 15%) than in the 
controls (10 out of 119 sectioned, or 8%), but the difference was not statistically significant.  The forms 
of selenium administered did not influence the incidence of tumors.  In this study, only 88 out of 
211 selenium-treated animals and 109 out of 209 control animals were examined histologically. 
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The only selenium compound that has been shown to be carcinogenic in animals is selenium sulfide (NTP 
1980c), although there is some inconclusive evidence that ethyl selenac may also be carcinogenic (Innes 
et al. 1969; NCI 1968).  A statistically significant increase in hepatomas (0/16 controls; 12/16 treated) 
was observed in male mice of one strain (C57BL/6 x C3H/Anf)F1) receiving 2 mg selenium/kg as ethyl 
selenac, but not in male or female mice of another strain (C57BL/6 x AKR)F1) receiving the same dose 
(Innes et al. 1969; NCI 1968).  
Statistically significant increases in hepatocellular carcinomas and adenomas in rats and hepatic 
carcinomas and adenomas, as well as alveolar/bronchiolar carcinomas and adenomas, in female mice 
have been observed following chronic oral exposure to selenium sulfide (NTP 1980c).  The incidence of 
hepatocellular carcinomas in rats was 1/50, 0/50, and 15/49 in males and 0/50, 0/50, and 21/50 in females 
at 0, 3, and 15 mg selenium sulfide/kg/day, respectively.  In mice, the incidences of hepatocellular 
carcinomas and adenomas were 15/50, 14/50, and 23/50 in males, and 0/49, 2/50, and 25/49 in females at 
0, 20, and 100 mg selenium sulfide/kg/day, respectively.  Selenium sulfide is a pharmaceutical compound 
used in some antidandruff shampoos and is not administered orally.  Because selenium sulfide is not 
absorbed through the skin, use of shampoos containing this compound should be safe, unless one 
intentionally consumes the product or has open cuts or sores on the scalp or hands.  Chemically, selenium 
sulfide and ethyl selenac are very different from the organic and inorganic selenium compounds found in 
foods and in the environment. 
In 1975, the International Agency for Research on Cancer (IARC) evaluated the literature relating 
selenium to carcinogenesis in both humans and animals.  The Agency stated that the available data 
provided no suggestion that selenium is carcinogenic in humans (IARC 1975a), and IARC subsequently 
assigned selenium to Group 3: not classifiable as to its carcinogenicity to humans (IARC 1987).  The 
forms of selenium considered included sodium selenate, sodium selenite, and the organic forms of 
selenium contained in plant materials.  Separate evaluations of ethyl selenac and methyl selenac assigned 
them to Group 3, also (IARC 1975a, 1987).  According to EPA, selenium is not classifiable as to its 
carcinogenicity in humans and is rated as Group D (IRIS 2003).  The evidence for selenium sulfide, 
however, is sufficient to classify it as Group B2 (probable human carcinogen) (IRIS 2003). 
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3.2.3 Dermal Exposure 
3.2.3.1 Death 
No studies were located concerning death in humans after dermal exposure to selenium or selenium 
compounds.  In a range-finding study using mice dermally exposed to selenium sulfide for a maximum of 
17 applications, 8 out of 20 animals died at 714 mg selenium sulfide/kg (NTP 1980a).  However, the 
effects noted in this study were equivocal since there was no indication that the application sites were 
covered to prevent ingestion.  Further, severe skin damage developed, and this may have led to direct 
systemic absorption of the compound. 
3.2.3.2 Systemic Effects 
No studies were located concerning respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, or body weight effects in humans or other animals following 
dermal exposure to selenium or selenium compounds. 
Dermal Effects. Skin toxicity in humans, notably skin rashes, burns, and contact dermatitis, has been 
reported for both acute and chronic exposure to selenium fumes and acute exposures to selenium dioxide 
(Middleton 1947).  No effects were detected in a study of eight women exposed daily for 2 weeks to an 
experimental sunscreen lotion containing up to 0.003 mg/kg/day selenium as L-selenomethionine (Burke 
et al. 1992a).  A case report of a severe allergic skin response following intermediate exposure to sodium 
selenite (Senff et al. 1988) is discussed under immunological effects.  Single topical exposures to 
selenious acid resulted in purpura, inflammation around hair follicles, and a pustular rash with some 
ulceration in exposed workers (Pringle 1942).  However, these effects may have been due to the caustic 
effects of the acid.  A single case report of hyperpigmentation and hair loss after use of a shampoo 
containing 1% selenium sulfide was located (Gillum 1996), but a study of the efficacy of an antidandruff 
shampoo containing 1% selenium sulfide found no adverse effects after 6 weeks of use by 150 individuals 
(Neumann et al. 1996). 
Application of 100 µL of a lotion (oil-in-water emulsion) containing 0.02% selenium as selenomethionine 
3 times a week to the shaved backs of mice for 39 weeks did not result in significant dermal effects (Burk 
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et al. 1992b).  Dermal effects were also not observed in hairless mice treated in the same manner for 
49 weeks. 
In mice, topical application of selenium sulfide resulted in erythema and skin irritation at 29 mg/kg, 
acanthosis at 143 mg/kg, and severe skin damage at 714 mg/kg (NTP 1980a). 
Ocular Effects. No studies were located regarding ocular effects in humans after dermal exposure to 
selenium or selenium compounds.  However, older reports on eye contact with selenium or selenium 
compounds indicate that acute exposure to selenium dioxide caused ocular and conjunctival irritation, and 
caused severe pain, lacrimation, blurred vision, and dulled corneas upon contact (Middleton 1947).  Brief 
exposure to clouds of selenium fumes resulted in lacrimation, irritation, and redness of the eyes (Clinton 
1947). 
No studies were located regarding ocular effects in laboratory animals after dermal exposure to selenium 
or selenium compounds.  
3.2.3.3 Immunological and Lymphoreticular Effects  
A 1988 case report describes a female laboratory technician who developed severely pruritic vesicles 
between the fingers after 6 months of exposure to a medium containing selenium.  After 2 years, the 
severity of the symptoms increased to include eczema on the face and neck, watering eyes, and two 
asthma attacks within a 2-month period.  Sodium selenite or the medium containing selenium were the 
only positive patch tests (Senff et al. 1988). 
No studies were located regarding immunological and lymphoreticular effects in laboratory animals after 
dermal exposure to selenium or selenium compounds. 
No studies were located regarding the following health effects in humans or laboratory animals after 
dermal exposure to selenium or to selenium compounds: 
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3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects 
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
No studies were located regarding carcinogenic effects in humans after dermal exposure to selenium or 
selenium compounds. 
The results of most animal studies have not indicated that elemental selenium or selenium compounds are 
carcinogenic when topically applied to the skin of experimental animals (NTP 1980a, 1980b; Shamberger 
1970).  Several studies indicate that selenium compounds may protect against effects of known dermal 
carcinogens (polynuclear aromatic hydrocarbons [PAHs] and ultraviolet light).  Shamberger (1970) 
reported that topical application of a solution containing 0.0005% sodium selenide significantly reduced 
the number of dermal papillomas induced by painting DMBA on the shaved backs of mice.  More 
recently, Burke et al. (1992b) reported orally and topically administered l-selenomethionine decreased 
ultraviolet burns and skin cancer in albino (BALB:c) and hairless pigmented (Skh:2) female mice. 
Only one study was found in which tumor development was reported after topical administration of 
selenium ointment (Tsuzuki et al. 1960).  An unspecified number of mice were exposed to an unspecified 
amount of ointment containing 2.5, 5.0, 7.5, or 10% elemental selenium 6 days/week for an unspecified 
period of time by topical administration to hip skin. Tumors developed on the base of the necks of two 
female mice.  Ingestion of the compound was possible because the animals may have licked the ointment.  
No other details were reported.  The study is inconclusive because of the lack of controls, short duration, 
and inadequate description of the study protocol and results. 
The National Toxicology Program (NTP 1980a) conducted a dermal application study of selenium 
monosulfide.  The compound was applied to the skin of groups of 50 male and 50 female Swiss mice at 0, 
0.5, or 1.0 mg selenium sulfide/mouse, 3 days/week for 86 weeks.  The application sites were not 
covered; therefore, ingestion of the test compounds was possible.  The incidence of tumors in the treated 
groups did not differ significantly from that in the control group. 
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NTP (1980b) also tested Selsun, a prescription dandruff shampoo containing 2.5% selenium sulfide (also 
a mixture of the mono- and disulfides), for carcinogenic properties.  Groups of 50 male and 50 female 
Swiss mice were dermally exposed to a 0, 25, or 50% solution of Selsun in distilled water 3 days/week for 
86 weeks. These doses were equivalent to 0, 0.31, or 0.625 mg selenium sulfide/mouse/day.  The 
incidences of alveolar or bronchiolar adenomas or carcinomas in male mice were significantly increased 
over vehicle control values, but not over untreated control values.  There was no significant effect in 
female mice.  Some ingestion of the compound was possible, because the application sites were not 
covered. Also, the male mice may have been susceptible to another ingredient in the shampoo (the 
chemical composition of the shampoo was not reported), or the bioassay may have been too short due to 
decreased survival to detect a carcinogenic effect in females.  Male mice that received dermal application 
of slightly larger doses of selenium sulfide (NTP 1980a) did not develop significantly more cancers than 
the controls. 
3.2.4 Other Routes of Exposure 
Endocrine Effects. Intraperitoneal injection of diabetic rats with sodium selenate has been reported 
to have insulin-like effects, producing a decrease in plasma glucose concentrations (McNeill et al. 1991).  
However, it is not clear that this is due to an effect of selenium on insulin metabolism, since food and 
water consumption were also decreased, and this is likely to have produced the decreased glucose levels. 
Neurological Effects.    Intraperitoneal injection of selenium (3.0 mg Se/kg as sodium selenite) into 
male Sprague-Dawley rats produced a significant increase (70%) in dopamine overflow from the striatum 
(as measured by an implanted dialysis probe) with a concomitant significant reduction in HVA levels 
(Rasekh et al. 1997).  DOPAC levels were not changed.  Direct infusion of 10 mM selenium into the 
striatum also produced a significant increase in dopamine overflow accompanied by slight, but significant 
decreases in HVA and DOPAC.  Direct infusion of 10 mM selenium into the nucleus accumbens also 
produced a rapid and significant increase in dopamine overflow, but with no changes in DOPAC or HVA 
concentrations. The selenium induced changes in dopamine overflow were suppressed by the dopamine 
receptor agonist quinpirole. 
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3.3 GENOTOXICITY 
Inorganic selenium compounds have been observed to have both genotoxic and antigenotoxic effects.  
The antigenotoxic effects generally occur at lower selenium exposure levels than the frank genotoxicity. 
This discussion will focus on genotoxic effects only. In vitro studies of the genotoxicity of selenium 
compounds are summarized in Table 3-4, and in vivo studies of the genotoxicity of selenium compounds 
are summarized in Table 3-5. 
Selenium dioxide was found to be mutagenic in both the Ames and the VITO-TOX Salmonella 
typhimurium tests of genotoxicity (van der Lelie et al. 1997). 
In general, sodium selenite and sodium selenate have produced mixed results in bacterial mutagenicity 
test systems (Table 3-4).  Sodium selenite induced base-pair substitution mutations using S. typhimurium 
and was also positive in the transformation assay using Bacillus subtilis (Kramer and Ames 1988; 
Nakamuro et al. 1976; Noda et al. 1979).  However, negative results have also been reported for sodium 
selenite both in S. typhimurium and the rec assay using B. subtilis (Lofroth and Ames 1978; Noda et al. 
1979).  Sodium selenate, on the other hand, has tested positive in S. typhimurium (base-pair substitution) 
and in the rec assay using B. subtilis (Lofroth and Ames 1978; Noda et al. 1979), but has tested negative 
using the transformation assay in B. subtilis (Nakamuro et al. 1976). 
Results with mammalian cell systems are also mixed, although sodium selenite is more consistently 
genotoxic in these systems.  Sodium selenite has been observed to induce unscheduled deoxyribonucleic 
acid (DNA) synthesis (UDS), chromosomal aberrations, and sister chromatid exchange in cultured human 
fibroblasts (Lo et al. 1978; Ray et al. 1978; Whiting et al. 1980); UDS in Chinese hamster V79 cells 
(Sirianni and Huang 1983); and chromosomal aberrations in cultured Chinese hamster ovary cells 
(Whiting et al. 1980). However, sodium selenate induced chromosomal aberrations in Chinese hamster 
ovary cells (Whiting et al. 1980) and UDS in Chinese hamster V79 cells (Sirianni and Huang 1983), but 
did not induce chromosomal aberrations in human leukocytes or cultured human fibroblasts (Lo et al. 
1978; Nakamuro et al. 1976).  A comparison of cytotoxicity and induction of tetraploidy in Chinese 
hamster V79 cells induced by sodium selenite or its major excretory product trimethylselenonium found 
that sodium selenite was about 1,000 times more cytotoxic than trimethylselenonium, but that neither 
compound produced a significant change in mitotic index (Ueda et al. 1997). 
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Table 3-4. Genotoxicity of Selenium In Vitro 
Result 
With Without 
Species (test system) End point activation activation Reference 
Prokaryotic organisms: Mutation
 Salmonella typhimurim (Na2SeO3) – Lofrothand 
(Na2SeO4) NT + Ames 1978
 S. typhimurim (SeO2) NT + van der Lelie 
et al. 1997
 S. typhimurim TA100 (Na2SeO3) NT + Noda et al. 
 S. typhimurium TA98, TA1537 NT – 1979
 S. typhimurium TA100 (Na2SeO4) NT + 
 S. typhimurium TA98, TA1537 NT – 
 Bacillus subtilis rec assay (Na2SeO3) NT – Noda et al. 
1979 
 B. subtilis rec assay (Na2SeO4) NT + Kanematsu et 
(SeO2) NT + al. 1980
 B. subtilis transformation (SeO2) NT + Nakamuro et 
(Na2SeO3) NT + al. 1976 
(Na2SeO4) NT – 
Eukaryotic organisms:
 Mammalian cells Chromosomal aberrations 
Chinese hamster ovary (Na2SeO3) NT + Whiting et al. 
(Na2SeO4) NT + 1980
 Human leukocytes (SeO2) NT + Nakamuro et 
(Na2SeO3) NT + al. 1976
(Na2SeO4) NT – 
 Human lymphocytes (Na2SeO4) NT + Biswas 1997
 Human lymphocytes (Na2SeO3) NT + Biswas et al. 
(Na2SeO4) NT + 2000
 Human lymphocytes (Na2SeO3) NT + Khalil 1989 
(Selenomethionine) NT + 
Cultured human fibroblasts (Na2SeO3) + + Lo et al. 1978 
(Na2SeO4) – – 
Tetraploidy 
Chinese hamster V79 cells (Na2SeO3) NT + Ueda et al. 
(Trimethylselenonium) NT + 1997 
DNA strand breaks 
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Mouse mammary carcinoma 	 (Na2SeO3) NT + Lu et al. 
 cells	 (Na2SeO4) NT + 1995b 
(Methylselenocyanate) NT – 
(Se-methylseleno- NT – 
cysteine) 
Unscheduled DNA synthesis 
Cultured human fibroblasts	 (Na2Se) NT + Whiting et al. 
(Na2SeO3) NT + 1980 
(Na2SeO4) NT + 
Sister chromatid exchange 
Cultured human fibroblasts (Na2SeO3) NT + Ray et al. 
1978
 Human lymphocytes (Na2SeO3) NT + Khalil 1989 
(Selenomethionine) NT + 
(Selenocystine) NT + Khalil 1994 
– = negative result; + = positive result; DNA = deoxyribonucleic acid; NT = not tested; (Na2Se) = sodium selenide; 
(Na2SeO3) = sodium selenite; (Na2SeO4) = sodium selenate; (SeO2) = selenium dioxide 
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Table 3-5. Genotoxicity of Selenium In Vivo 
Species (test system) End point	 Results Reference 
Human lymphocytes Chromosomal aberrations, –	 Norppa et al. 
(Na2SeO3) sister chromatic exchanges 1980a
 
Monkey (Macaca fisciculari) Micronuclei + (adult toxic dose) Choy et al. 1989 





Mouse bone marrow Chromosome breaks and Biswas et al. 1997
 




Mouse bone marrow Chromosome breaks and Biswas et al. 1999a
 














Rat bone marrow (Na2SeO3) Chromosomal aberrations + Newton and Lilly 
1986 
Rat bone marrow (SeS) Chromosomal aberrations – Moore et al. 1996b 
Rat bone marrow (SeS) Micronucleus induction +	 Moore et al. 1996b 
Rat spleen (SeS) Chromosomal aberrations –	 Moore et al. 1996b 
Rat spleen  (SeS) Micronucleus induction –	 Moore et al. 1996b 
Rat lymphocytes (Na2SeO3) Chromosomal aberrations –	 Newton and Lilly 
1986 
+ = positive result; – = negative result 
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The addition of glutathione to test mixtures enhances the genotoxicity of sodium selenite, sodium 
selenate, and sodium selenide in bacterial test systems, indicating that production of a reactive species 
mutagenic for bacteria occurs via a reductive mechanism following concomitant exposure to these 
compounds (Whiting et al. 1980).  This finding is supported by results in mammalian test systems.  For 
example, in cultured human leukocytes, sodium selenite induces chromosome aberrations and sister 
chromatid exchanges (Nakamuro et al. 1976; Ray and Altenburg 1978; Ray et al. 1978).  Sister chromatid 
exchange was not observed at similar sodium selenite concentrations in a human lymphoblastoid cell line; 
however, exchanges were observed when these same cells were incubated with sodium selenite and red 
blood cell lysate (Ray and Altenburg 1978).  The observation that internal constituents of red blood cells 
may contribute to the genotoxicity of sodium selenite supports the suggestion that metabolism is involved 
in the production of an active species following exposure to sodium selenite in these test systems.  The 
active species responsible for the genotoxic effects is not known. 
At high concentrations, sodium selenite induces unscheduled DNA synthesis and chromosome 
aberrations in cultured human fibroblasts (Lo et al. 1978).  The addition of a metabolic activator 
(S9 fraction) or glutathione increased both the number of aberrations and the toxicity of sodium selenite 
(Whiting et al. 1980) and sodium selenate (Lo et al. 1978; Whiting et al. 1980). 
Sodium selenite, sodium selenide, methylselenocyanate, and Se-methylselenocysteine were all found to 
be cytotoxic to cells of a mouse mammary carcinoma line; however, only sodium selenite and sodium 
selenide induced DNA strand breaks (Lu et al. 1995b). 
Selenomethionine (Khalil 1989) and selenocystine (Khalil 1994) have tested positive for sister chromatid 
exchanges in cultured human lymphocytes.  Selenomethionine, sodium selenite, and sodium selenate 
tested positive for chromosomal aberrations in cultured human lymphocytes (Biswas 1997; Biswas et al. 
2000; Khalil 1989).  Sodium selenite was considerably more clastogenic than sodium selenate (Biswas et 
al. 2000). 
The genotoxicity of selenium monosulfide was assessed in an in vivo/in vitro micronucleus and 
chromosome aberration assay in rats (Moore et al. 1996b).  Male Wistar rats (4/dose) were administered 
25, 50, or 100 mg/kg selenium monosulfide in corn oil.  Negative control rats received corn oil by gavage 
and positive controls were injected intraperitoneally with 20 mg/kg cyclophosphamide.  Animals were 
sacrificed 24 hours after treatment and the femur marrow and spleen were removed and cultured.  Spleen 
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and marrow cultures were examined 24 or 48 hours after establishment, respectively.  No increase in 
chromosome aberrations or micronucleus formation in cells from treated rats was observed. 
Results of in vivo genotoxicity tests have been both negative and positive (Table 3-5).  Chromosomal 
aberrations and sister chromatid exchanges in lymphocytes were not increased in nine neuronal ceroid 
lipofuscinosis patients treated with intramuscular sodium selenite injections or tablets (0.005–0.05 mg 
selenium/kg/day) for 1–13.5 months, or in five healthy persons given selenite (0.025 mg/kg/day) for 
2 weeks (Norppa et al. 1980a).  Among the treated patients, there was no distinction between route of 
exposure. 
Compared to untreated controls, a significant increase in the number of micronuclei was observed in bone 
marrow cells of macaques treated by nasogastric intubation with L-selenomethionine at a dose of 0.24 mg 
selenium/kg/day for 15 days (Choy et al. 1989).  No effect on the number of micronuclei was observed in 
macaques treated with L-selenomethionine at a dose of 0.12 mg selenium/kg/day for 19 days.  A 
significant increase in the number of micronuclei in bone marrow cells was not observed in the offspring 
of macaques treated by nasogastric intubation with L-selenomethionine at a dose of 0.12 mg 
selenium/kg/day on gestation days 20–50 (Choy et al. 1993).  The doses of L-selenomethionine used in 
these studies produced obvious signs of toxicity (loss of body weight, poor appetite, constipation, 
depression, weakness) in the macaques. 
Chromosomal aberrations were not increased in the lymphocytes of rats given two intravenous doses of 
sodium selenite at 2.3–2.7 mg selenium/kg (Newton and Lilly 1986).  Chromosomal aberrations in bone 
marrow cells were significantly increased in these rats, but the total dose of selenium was near the 
intravenous LD50 for selenite, which has been reported as 5.7 mg selenium/kg in rats (Olson 1986). 
Bone marrow cells of male mice gavaged with sodium selenate or sodium selenite showed a significant 
increase in chromosome breaks and spindle disturbances compared with untreated controls (Biswas et al. 
1997, 1999a). The number of chromosomal aberrations increased with dose and was slightly greater with 
sodium selenite than with sodium selenate.  A significant increase in micronucleus formation was 
observed in bone marrow cells of male mice intraperitoneally injected with selenous acid and in female 
mice intramuscularly injected with sodium selenite, but not in male mice intraperitoneally injected with 
sodium selenate (Itoh and Shimada 1996; Rusov et al. 1996). 
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Selenium appears to affect the ability of liver enzymes to activate some chemical mutagens.  Studies in 
animals exposed orally to sodium selenite in the diet at doses between 0.05 and 0.125 mg 
selenium/kg/day indicate that selenium may inhibit the mutagenic effect of other chemical agents (Gairola 
and Chow 1982; Schillaci et al. 1982).  In these studies, S. typhimurium was used to assess the 
mutagenicity of DMBA, benzo[a]pyrene (BAP), and 2-aminoanthracene (2AA) in the presence of liver 
microsomal enzymes from rats fed either a basal diet (0.02–0.15 mg selenium/kg diet or 0.001–0.0075 mg 
selenium/kg/day) or a sodium selenate-supplemented diet (basal diet plus 1–5 mg selenium/kg/diet or 
0.05–0.25 mg selenium/kg/day) for 3–20 weeks.  DMBA and 2AA were found to be less mutagenic in the 
presence of liver microsomal enzymes taken from rats fed the selenium-supplemented diets than in the 
presence of microsomal enzymes taken from rats fed the basal diet; BAP mutagenicity was not changed. 
The genotoxicity of selenium monosulfide was assessed in in vivo micronucleus and chromosome 
aberration assays in rats (Moore et al. 1996b).  Male Wistar rats (5/dose/timepoint) were administered 
12.5, 25, or 50 mg/kg selenium monosulfide in corn oil.  Negative control rats received corn oil by gavage 
and positive controls were injected intraperitoneally with 20 mg/kg cyclophosphamide.  Animals were 
sacrificed 24, 36, or 48 hours after treatment and the femur marrow and spleen cells were examined.  A 
small, but significant increase in micronucleated bone marrow cells was observed 24 hours after treatment 
with 50 mg/kg selenium monosulfide and 48 hours after treatment with 12.5 mg/kg selenium 
monosulfide.  Selenium monosulfide was cytotoxic at the 50 mg/kg dose after 24 hours.  No increase in 
micronucleus formation was observed in the spleen.  No increase in chromosome aberrations was 
observed in the bone marrow or spleen. 
3.4 TOXICOKINETICS 
Occupational studies indicate that humans absorb elemental selenium dusts and other selenium 
compounds, but quantitative inhalation toxicokinetic studies in humans have not been done.  Studies in 
dogs and rats indicate that following inhalation exposure, the rate and extent of absorption vary with the 
chemical form of selenium.  Studies in humans and experimental animals indicate that, when ingested, 
several selenium compounds including selenite, selenate, and selenomethionine are readily absorbed, 
often to greater than 80% of the administered dose.  Although a study of humans did not detect evidence 
of dermal absorption of selenomethionine, one study of mice indicates selenomethionine can be absorbed 
dermally.  There is little or no information available on the absorption of selenium sulfides, but selenium 
disulfides are not believed to be absorbed through intact skin. 
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Selenium accumulates in many organ systems in the body; in general, the highest concentrations are 
found in the liver and kidney (Table 3-6).  Selenium concentrations in tissues do not seem to be correlated 
with effects. Tissue concentrations were highest in pigs fed D,L-selenomethionine, while a similar dose 
of selenium (form not stated) given as A. bisulcatus was a more potent neurotoxin.  Blood, hair, and nails 
also contain selenium, and selenium has been found in human milk (Table 3-7).  In addition, selenium is 
subject to placental transfer. 
As a component of glutathione peroxidase and the iodothyronine 5'-deiodinases, selenium is an essential 
micronutrient for humans.  Its role in the deiodinase enzymes may be one reason that growing children 
require more selenium than adults.  Selenium is also a component of the enzyme thioredoxin reductase, 
which catalyses the NADPH-dependent reduction of the redox protein thioredoxin.  Other selenium-
containing proteins of unknown functions, including selenoprotein P found in the plasma, have also been 
identified. Excess selenium administered as selenite and selenate can be metabolized to methylated 
compounds and excreted.  
Selenium is primarily eliminated in the urine and feces in both humans and laboratory animals. The 
distribution of selenium between the two routes seems to vary with the level of exposure and time after 
exposure. The form of selenium excreted is dependent on the form of selenium that was ingested.  In 
cases of acute exposure to toxic concentrations of selenium or selenium compounds, significant amounts 
of selenium can be eliminated in the breath, causing the characteristic "garlic breath." 
A number of metabolism and other toxicokinetic studies of selenium are nutritional studies designed to 
answer a nutritional question, not a toxicological question.  For example, the dose used may not be toxic, 
but may be meant to provide information on how a dose relevant to selenium deficiency or cancer 
chemoprevention might be handled in the body.  Since the metabolism of selenium is a function of the 
dose ingested, these studies may be of limited toxicological relevance. 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
Studies regarding the absorption of selenium in humans following inhalation exposure are limited to 
occupational studies.  Glover (1970) examined urinary selenium levels of workers employed in a 
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Range Country Reference 
Liver (µg selenium/g)








Hadjimarkos et al. 1959 
Baglan et al. 1974c 
0.070 0.017 New Zealand Thompson and Robinson 1980 
0.061 0.014 Scandinavia Korpela et al. 1984 
Erythrocytes (mg selenium/L)
 0.39 0.08 United States Rudolph and Wong 1978 
0.149 Scandinavia Haga and Lunde 1978 
0.104 0.026 New Zealand Thompson and Robinson 1980 
Plasma (mg selenium/L)
 0.13 0.03 United States Rudolph and Wong 1978 
0.033 0.008 New Zealand Thompson and Robinson 1980 
Serum (mg selenium/L)
 0.052 Scandanavia Haga and Lunde 1978 
Adult/Infant tissues 
Adrenal gland (µg selenium/g)
 0.46 
 0.21 (infant) 





Blotcky et al. 1979 
Dickson and Tomlinson 1967 
0.11 
 0.16 (infant) 







Larsen et al. 1979 
Oster et al. 1988c 
Dickson and Tomlinson 1967 
Ejima et al. 1996 
Fat (µg selenium/g)
 0.09 (infant) 
 0.12 (adult) 
Gonad (µg selenium/g)
Canada Dickson and Tomlinson 1967 
 0.46 (infant) 
 0.47 (adult) 
Canada Dickson and Tomlinson 1967 
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Table 3-6. Selenium Concentrations in Human Tissuesa,b 
Selenium concentration 
Mean SD Range Country Reference 
Heart (µg selenium/g)
 0.33 0.13 
0.170 0.032 




 0.31 (infant) 
0.22 (adult) 
Kidney (µg selenium/g)

























































Blotcky et al. 1979 
Oster et al. 1988c 
Dickson and Tomlinson 1967 
Dickson and Tomlinson 1967 
Blotcky et al. 1979 
Oster et al. 1988c 
Dickson and Tomlinson 1967 
Muramatsu and Parr 1988 
Blotcky et al. 1979 
Zeisler et al. 1984 
McConnell et al. 1975c 
Larsen et al. 1979 
Oster et al. 1988c 
Alfthan et al. 1991c 
Aaseth et al. 1990 
Damyanova 1983 
Muramatsu and Parr 1988 
Casey et al. 1983 
Dickson and Tomlinson 1967 
Blotcky et al. 1979 
Oster et al. 1988c 
Dickson and Tomlinson 1967 
Blotcky et al. 1979 
McConnell et al. 1975c 
Dickson and Tomlinson 1967 
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Table 3-6. Selenium Concentrations in Human Tissuesa,b 
Selenium concentration 
Mean SD Range Country Reference 
Prostate (µg selenium/g)
 0.26 0.02 
0.150 0.035 
Skeletal muscle (µg selenium/g)





 0.24 0.02 
Spleen (µg selenium/g)





 0.19 (infant) 
0.17 (adult) 
Testis (µg selenium/g)
 0.28 0.03 
0.274 0.048 
Thyroid (µg selenium/g)






Blotcky et al. 1979 




Blotcky et al. 1979 
Oster et al. 1988c 
Dickson and Tomlinson 1967 
0.13–0.21 Denmark Larsen et al. 1979 




Blotcky et al. 1979 
Oster et al. 1988c 
Dickson and Tomlinson 1967 
Canada Dickson and Tomlinson 1967 
United States 
Germany 
Blotcky et al. 1979 





Blotcky et al. 1979 
Aaseth et al. 1990 
Dickson and Tomlinson 1967 
aGeneral population measures unless otherwise noted 
bSelenium concentrations in adult blood and blood components, urine, hair, nails, milk, placenta, and semen are 
found in Table 3-7. 
cDry weight 
LV = left ventricle; RV = right ventricle; SD = standard deviation 
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Table 3-7. Biomarkers: Selenium Concentrations in Human Tissues and Fluidsa 
Selenium concentration 
Mean SD Range Country Reference 
Whole blood (mg selenium/L) 
0.132 0.029 0.08–0.13 













0.092 0.001 0.06–0.013 
















0.081 0.001 0.056–0.105 




































Corden et al. 1989 
Allaway et al. 1968 
Dworkin et al. 1986 
Shamberger 1983 
Dickson and Tomlinson 1967 
Zhu 1981 
Yang et al. 1983 
Bratakos et al. 1990
Minoia et al. 1990 
Jaakkola et al. 1983 
Kumpusalo et al. 1990b 
Kumpusalo et al. 1990c 
Thomson and Robinson 1980d 
Rea et al. 1979 
Oster et al. 1988b 
Meyer and Verreault 1987 
Dworkin et al. 1986 
Rudolph and Wong 1978d 
Oster et al. 1988b 
Watkinson 1981 
Rea et al. 1979 
Thomson and Robinson 1980 
Clark et al. 1984 
Dworkin et al. 1986 
Rudolph and Wong 1978d 
Coates et al. 1988 
Dickson and Tomlinson 1967 
Hojo 1987 
van’t Veer et al. 1990 
Minoia et al. 1990 
Sesana et al. 1992 
Rea et al. 1979 
Thomson and Robinson 1980d 
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Table 3-7. Biomarkers: Selenium Concentrations in Human Tissues and Fluidsa 
Selenium concentration 
Mean SD Range Country Reference 




















































































































Willett et al. 1983 

Menkes et al. 1986 

Coates et al. 1988 





Longnecker et al. 1991 

Lalonde et al. 1982f
 
Minoia et al. 1990 

Morisi et al. 1989 

Luoma et al. 1992 

Virtamo et al. 1987 

Heese et al. 1988d
 
Brätter et al. 1991a 







Yang et al. 1983 

Bratakos et al. 1990 

Minoia et al. 1990
 




Yang et al. 1983 

Bratakos et al. 1990 

Muramatsu and Parr 1988e
 
Imahori et al. 1979e 
Razagui and Haswell 1997
 
Bermejo Barrera et al. 2000
 
Longnecker et al. 1991 

Hunter et al. 1990a 

van’t Veer et al. 1990 

Bratakos et al. 1990 

Van Noord et al. 1992
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Table 3-7. Biomarkers: Selenium Concentrations in Human Tissues and Fluidsa 
Selenium concentration 
Mean SD Range Country Reference 
Milk (µg selenium/mL) 
Africa Funk et al. 1990b 
United States Shrearer and Hadjimarkos 1975 
United States Hadjimarkos 1963 
Smith et al. 1990 
United States Ellis et al. 1990 
Chile Cortez 1984 
Finland Kumpulainen 1983 
Austria Li et al. 1999 
Germany Michalke and Schramel 1998 
Venezuela Brätter et al. 1991a 
Venezuela Brätter and Negretti De Brätter 1996 
United States Baglan et al. 1974e 
United States Korpela et al. 1984 
United States Hadjimarkos et al. 1959 
Singapore 
Finland 
Roy et al. 1990 
























aGeneral population measures unless otherwise noted 
bRange of mean concentration 
cRange of mean concentrations for multivitamin users 
dOnly women were sampled. 
eDry weight 
fOnly men were sampled. 
gStandard error of the mean 
SD = standard deviation 
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selenium rectifier plant.  Workers exposed to higher levels of unspecified inorganic selenium compounds 
in the air excreted higher levels of selenium in their urine than workers in other areas of the plant with 
lower concentrations of selenium in the air.  Although the study indicates that selenium was absorbed 
from the lungs of the workers, the nonspecific exposure levels and lack of compound identification 
precluded an estimate of the extent and rate of absorption from the lungs.  Significantly increased serum 
selenium levels were reported for workers at a rubber tire repair shop in Toluca City, Mexico compared 
with a group of unexposed individuals from the same city (Sánchez-Ocampo et al. 1996).  The workers in 
this study were exposed to selenium (no levels reported) from vulcanized rubber, both as dust in the air 
and from handling the tires; thus, it is not possible to attribute absorption to a single route. 
Studies using dogs and rats indicate that absorption of selenium following inhalation exposure is 
extensive, although the rate of absorption depends on the chemical form of selenium.  In rats (Medinsky 
et al. 1981a) and dogs (Weissman et al. 1983), the absorption of selenium following inhalation exposure 
to selenious acid aerosol is approximately twice as rapid as the absorption of selenium following 
inhalation exposure to elemental selenium aerosol.  However, Medinsky et al. (1981a) found that with 
either form after 4 days most of the selenium was absorbed following inhalation exposure and that the 
distribution of selenium in the body tissues was identical, suggesting that selenium entered the same body 
pool following pulmonary uptake (Medinsky et al. 1981a). 
3.4.1.2 Oral Exposure 
Selenium compounds are generally readily absorbed from the human gastrointestinal tract.  The bioavail­
ability of ingested selenium can be affected by the physical state of the compound (e.g., solid or solution), 
the chemical form of selenium (e.g., organic, inorganic), and the dosing regimen.  However, in general, it 
appears that the degree of selenium absorption (i.e., percent of administered dose absorbed) in humans is 
independent of the exposure level, but that in some cases, absorption is greater when selenium deficiency 
exists. 
In humans, absorption of sodium selenite or selenomethionine can exceed 80% for both small and 
relatively large doses (Griffiths et al. 1976; Thomson 1974; Thomson and Stewart 1974; Thomson et al. 
1977).  A total of 90–95% of a small amount of sodium selenite (0.010 mg selenium/person) administered 
in aqueous solution was absorbed (Thomson 1974). Absorption of a large dose (1.0 mg/person) of either 
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sodium selenite or selenomethionine was 90–95 and 97% of the administered dose, respectively 
(Thomson et al. 1977).  These data indicate a lack of homeostatic control over the dose range tested.  
Martin et al. (1989a) found no clear evidence of increased gastrointestinal absorption of selenium as 
sodium selenite in aqueous solution by healthy male volunteers kept on a selenium-deficient diet.  
Griffiths et al. (1976) reported 96–97% absorption of a single dose of 0.002 mg selenium administered as 
selenomethionine in solution.  Similarly, Thomson et al. (1977) reported 97% absorption of a single large 
dose of 1.0 mg selenium administered as selenomethionine in solution to one subject.  The subjects in 
these studies were New Zealand women. 
Other studies have indicated that humans might absorb selenomethionine more efficiently than sodium 
selenite (Moser-Veillon et al. 1992; Swanson et al. 1991).  Young et al. (1982) studied human absorption 
of dietary selenium in young men in the United States.  The men ate either 75Se-labeled chicken alone 
(0.013 mg selenium/person) or the chicken plus supplemental labeled sodium selenite (0.071 mg 
selenium/person in a solution mixed with the meal).  Eighty percent of the selenium in the chicken meat 
was absorbed, but less than 30% of the selenium administered as sodium selenite was absorbed.  
Similarly, Robinson et al. (1978) found that 75% of selenomethionine, but only 46% of selenite, was 
absorbed during a 10–11-week administration of solutions providing 0.0013–0.0023 mg selenium/kg/day 
to New Zealand women.  It is not clear why the estimated absorption of sodium selenite varied between 
46 and 30% in these trials. 
Experimental animals also efficiently absorb selenium compounds from the gut independent of the level 
of selenium exposure.  Several studies have reported absorption of 80–100% in rats given dietary 
selenium administered as sodium selenite, sodium selenate, selenomethionine, or selenocystine (Furchner 
et al. 1975; Thomson and Stewart 1973).  Other animal species also readily absorb orally administered 
selenium compounds.  Furchner et al. (1975) estimated that over 90% of an oral dose of selenious acid 
was absorbed in mice and dogs, although monkeys absorbed less of the administered dose (amount 
unspecified). Using an in vivo perfusion method in which selenite was added directly to the duodenal end 
of the small intestine, the absorption of selenite was linearly related to concentration (slope=0.0386) in 
the range of 1–200 µM (Chen et al. 1993). 
In one study of rats, absorption of selenite or selenomethionine into the blood stream following oral 
exposure occurred primarily in the duodenum and, to a lesser extent, in the jejunum and ileum (Whanger 
et al. 1976). Compared to the small intestine, little selenium was absorbed from the stomach (Whanger et 
al. 1976), and it was not determined whether absorption occurred in the large intestine.  In an in vitro 
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study using everted intestinal sacs from hamsters, Spencer and Blau (1962) found that selenomethionine 
was transported against a concentration gradient with the same characteristics as methionine.  
Selenomethionine was not found to be degraded during transport.  This study suggests that in the 
intestines, methionine and selenomethionine share the same transport mechanism. 
A comparison of absorption of selenium by selenium-depleted rats after oral administration of sodium 
selenate, selenomethionine, or methyl selenocysteine (from high-selenium broccoli) found that gross 
absorption of selenium from methyl selenocysteine was significantly lower (85%) than from sodium 
selenate or selenomethionine (91%); further, true selenium absorption adjusted for urinary excretion was 
significantly different for methyl selenocysteine, sodium selenate, and selenomethionine, with the lowest 
absorption for methyl selenocysteine and the highest for selenomethionine (Finley 1998).  Absorption of 
selenium from selenomethionine was not significantly lower than from sodium selenate.  
In vivo experiments with ligated rat intestines have shown that there is significantly higher absorption and 
transfer to the body of selenium as selenocystine or selenodiglutathione than selenium as selenite from 
ligated loops of ileum, but that absorption of the three forms of selenium in the jejunum was 
approximately similar (Vendeland et al. 1992).  In vitro experiments with brush border membrane 
vesicles derived from rat intestines have shown dramatic differences in the uptake and binding of 
selenium depending on the form in which it is presented, with absorption of organic forms being much 
more efficient than absorption from selenite or selenate (Vendeland et al. 1992, 1994).  Selenium from 
selenocystine or selenodiglutathione was absorbed 10 times more quickly than selenium from sodium 
selenite (Vendeland et al. 1992).  Similarly, selenium was much more efficiently absorbed from 
selenomethionine than from selenite or selenate (Vendeland et al. 1994).  Binding also varied between 
selenomethionine, selenite, and selenate, with selenite binding exceeding that of selenate by 37-fold and 
selenomethionine exceeding selenite by 14-fold (Vendeland et al. 1994).  These studies indicate that 
absorption of selenium from the gastrointestinal tract of animals is pH-dependent and influenced by the 
presence of sulfhydral-containing compounds, and that the increased absorption of selenium with 
sulfhydral compounds is likely due to complex formation with these compounds.   
3.4.1.3 Dermal Exposure 
Dermal absorption was tested in eight women at a maximum dose of 0.0029 mg selenium/kg as 
selenomethionine (0.05% L-selenomethionine in a lotion).  No detectable increase in serum selenium 
concentrations was observed, but because the concentrations tested were so low, absorption cannot be 
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ruled out (Burke et al. 1992a).  Absorption of selenium disulfide was examined using a monthly 24-hour 
urine specimen in 16 persons who washed their hair weekly with a 1% selenium disulfide shampoo.  No 
differences were found from control urinary selenium levels over the 1-year exposure period (Cummins 
and Kimura 1971).  No absorption of selenium from selenium sulfide was seen in 15 persons who applied 
a 2.5% selenium sulfide suspension to their torsos and allowed it to remain on the body overnight 
(Kalivas 1993). 
Mice were treated with a maximum of 0.02% selenium as selenomethionine by topical application of a 
lotion 3 times per week for 39 weeks to the shaved back and ears (size of area not specified).  The applied 
dose was 0.29 mg/kg/day.  Controls received the lotion without selenium.  Dermal effects were not 
observed in the selenomethionine-treated mice.  However, treated animals had significantly higher 
concentrations of selenium than the controls in the liver and ventral skin away from the application site 
(Burke et al. 1992b).  These data suggest that mice can absorb topically applied selenomethionine, but 
since the areas were not occluded, some oral absorption during grooming is also possible. 
3.4.2 Distribution 
Most studies report similar distribution patterns for both organic and inorganic selenium compounds 
tested. In plasma, selenium mainly distributes into three plasma proteins, namely selenoprotein P, 
glutathione peroxidase, and albumin (Ducros et al. 2000).  Approximately 3% of total plasma selenium is 
bound to lipoproteins, mainly to the LDL fraction, and the selenium may be incorporated as 
selenomethionine in place of methionine during protein synthesis and/or bound to cysteine residues by 
selenium-sulfur bonds.  Selenoprotein P is an extracellular protein in the plasma.  It is suggested that 
selenoprotein P is involved in the transport of selenium and as an antioxidant, but its biochemical function 
has not yet been established (Burk and Hill 2000; Hill and Burk 1989; Yang et al. 1989b). 
Normal levels of selenium found in various human tissues are shown in Table 3-6.  Selenium 
concentrations in human fluids and tissues that are easily collected (e.g., placenta) are provided in 
Section 3.8.1, Biomarkers Used to Identify or Quantify Exposure to Selenium.  Selenium from sodium 
selenite and sodium selenate is found at the highest concentrations in the liver and kidney of humans and 
other animals following oral administration or intravenous or subcutaneous injection (Cavalieri et 
al. 1966; Heinrich and Kelsey 1955; Jereb et al. 1975; Thomson and Stewart 1973).  Similarly, monkeys 
receiving high doses of L-selenomethionine orally for up to 30 days accumulated the highest 
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concentrations of selenium in the liver and kidneys (Willhite et al. 1992).  Selenium from 
selenomethionine tends to be retained in tissues at higher concentrations (3–10-fold greater) and for 
longer periods of time than inorganic selenium compounds.  The increased selenium tissue concentrations 
are not due to the slightly greater absorbance of selenomethionine (Butler et al. 1990; Grønbaek and 
Thorlacius-Ussing 1992; Ip and Hayes 1989; Salbe and Levander 1990b), but rather to the slower 
elimination as a consequence of its incorporation into body proteins (Stadtman 1983, 1987, 1990). 
3.4.2.1 Inhalation Exposure 
No studies were located regarding the distribution of selenium in humans after inhalation of elemental 
selenium or selenium compounds. 
Weissman et al. (1983) reported that selenium concentrated in the liver, kidney, spleen, and lungs of dogs 
following inhalation exposure to selenious acid or elemental selenium aerosols. 
3.4.2.2 Oral Exposure  
A study of 100 paired samples of maternal and neonate hair found that the concentration in neonatal hair 
(0.63±0.52 µg/g) was lower than in maternal hair (1.02±1.04 µg/g), but the results were not analyzed 
statistically (Razagui and Haswell 1997).  Levels of selenium in 30 paired samples of the hair of a mother 
and her child found no correlation between the selenium concentration of the hair of the mother and her 
child (Bermejo Barrera et al. 2000).  The average level of selenium in the children’s hair (0.77±0.24 µg/g) 
was higher than that of their mothers (0.54±0.34 µg/g).  The higher concentration of selenium in the 
children’s hair could represent increased absorption or retention, but no information was provided in the 
study as to the age of the children or to possible differences in dietary intake of selenium between mother 
and child. 
A study in rats found that young (weanling) animals accumulated more selenium in their tissues than 
adults (Salbe and Levander 1989).  Selenium-deficient rats were fed diets supplemented with the same 
amounts of selenium, as sodium selenate or L-selenomethionine, for 4 weeks.  Hair and nail selenium 
levels in adults were 10–20% and ~50% lower, respectively, than the amounts found in weanlings.  
Skeletal muscle and red blood cell selenium levels were ~50 and ~35% lower, respectively, in adults than 
weanlings, whereas levels in the liver were generally similar between the two growth phases.  
SELENIUM 148 
3.   HEALTH EFFECTS 
Selenomethionine caused greater deposition of selenium in the tissues than sodium selenate in both adults 
and weanlings, although the percent increase was similar for the two compounds in both growth phases.  
In rats and dogs, the selenium arising from sodium selenite administered in drinking water or in the diet is 
widely distributed in the body, although concentrated primarily in the liver and kidney (Furchner et al. 
1975; Sohn et al. 1991; Thomson and Stewart 1973).  
In most studies, selenium from selenomethionine accumulates in tissues to a greater extent than equal 
administered doses of selenium from selenite or selenate.  Behne et al. (1991) reported higher liver and 
muscle selenium concentrations in rats receiving selenium orally as selenomethionine for 3 or 6 weeks 
than as selenite for the same length of time.  Ip and Hayes (1989) reported similar results for blood, liver, 
kidney, and skeletal muscle.  Salbe and Levander (1990b) compared distribution of dietary seleno­
methionine and selenate in rats and found higher selenium concentrations in plasma, erythrocytes, liver, 
muscle, hair, and nails in animals receiving selenomethionine. (Hair and nails have been used to gauge 
long-term human selenium exposure and were, therefore, included in this study.)  Monkeys receiving 
selenomethionine in drinking water for 11 months had selenium concentrations in plasma, erythrocytes, 
liver, muscle, and hair that were 3–10-fold greater than monkeys receiving selenite (Butler et al. 1990).  
The higher levels of selenium found after selenomethionine compared to selenite treatment are likely a 
result of a greater retention of selenium from selenomethionine, rather than a difference in absorption.  
Butler et al. (1990) indicate that dietary ascorbic acid can reduce selenite absorption, but not 
selenomethionine absorption.  Therefore, the differential effect of ascorbic acid on selenium absorption 
may have contributed to the difference in selenium content of tissues observed in monkeys treated with 
selenite, compared to monkeys treated with selenomethionine.  Studies of rats indicate that the central 
nervous system also concentrates more selenium when administered as selenomethionine than when 
administered as inorganic selenium compounds (Grønbaek and Thorlacius-Ussing 1989, 1992; Zi-Jian Jie 
1992). 
A comparison of distribution of selenium in selenium-depleted rats after oral administration of sodium 
selenite, sodium selenate, selenomethionine, or methyl selenocysteine (from high-selenium broccoli) 
revealed that the rate of restoration of selenium in the liver and muscle was significantly slower for 
methyl selenocysteine than other forms of selenium (Finley 1998).  The rate of repletion in muscle was 
significantly faster for selenomethionine than other groups, but kidney and plasma showed no significant 
difference in the rate of repletion for any form of selenium.  The rate of repletion of glutathione 
peroxidase activity in the tissues was similar to the rate of repletion of the tissue itself and was slowest 
when methyl selenocysteine was the administered form. 
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Another study of distribution of selenium in selenium-deficient rats fed either sodium selenite or 
selenomethionine found that the concentration of selenium in blood and hair increased with administered 
dose, but was higher for selenium administered as selenomethionine (Shiobara et al. 1998). 
A study of dietary supplementation of female pigs with 0.1 or 0.3 ppm selenium from a selenium-
enriched yeast or from sodium selenite (doses not given) from 60 days before breeding until weaning 
found that the concentration of selenium in milk, dam, and offspring tissues increased with the dose of 
selenium administered and was higher when the source of selenium was the selenium-enriched yeast 
(Mahan and Kim 1996). 
A study using pigs indicates that tissue levels of selenium do not correlate with effects.  Tissue 
concentrations of selenium were higher in pigs fed 1.25 mg selenium/kg/day as D,L-selenomethionine 
than in pigs fed the same dose of selenium as A. bisulcatus or selenate, although neurological effects were 
more severe and occurred after fewer days of treatment with A. bisulcatus (Panter et al. 1996).  The form 
of selenium in A. bisulcatus is unknown, although Panter et al. (1996) indicate that it is nonprotein.   
In poultry, selenium is concentrated in the pancreas to a greater extent following oral administration of 
selenomethionine than following oral administration of sodium selenite (Cantor et al. 1975). The 
differential ability of the two compounds to concentrate in the pancreas of birds may explain why 
selenium administered as selenomethionine is more effective than the same dose of selenium 
administered as sodium selenite in preventing pancreatic fibrosis in chicks, a condition indicative of 
selenium deficiency (Cantor et al. 1975). 
The distribution profiles of single oral or intravenous doses of selenium (2 mg selenium/kg as sodium 
selenite) administered to Wistar rats were dependent on the route of administration (Kaneko et al. 1999). 
Selenium concentration was highest in the kidney or liver, followed by the heart, lung, or spleen; then 
plasma and the brain.  Oral administration produced lower doses of selenium than injection in all organs 
except the kidney where levels produced by the two routes were comparable (this may reflect the 
importance of urine as a route of excretion). 
Following oral exposure, selenium is found in human milk (Brätter and Negretti De Brätter 1996; Brätter 
et al. 1991b; Li et al. 1999; Michalke and Schramel 1998; Moser-Veillon et al. 1992; Rodríguez 
Rodríguez et al. 1999; Viitak et al. 1995; Yang 1989b).  Selenium is also found in the milk of mice, rats, 
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dogs, pigs, cows, and monkeys (Abdelrahman and Kincaid 1995; Archimbaud et al. 1992; Baňuelos and 
Mayland 2000; Chhabra and Rao 1994; Hawkes et al. 1994; Mahan and Kim 1996; Parizek et al. 1971a).  
This supplies offspring with selenium during the time period in which they are fed exclusively on milk 
(about 6 months for humans).  Transplacental transfer of selenium has been demonstrated in humans, rats, 
hamsters, dogs, pigs, and monkeys (Archimbaud et al. 1992; Choy et al. 1993; Hawkes et al. 1994; 
Jandial et al. 1976; Mahan and Kim 1996; Parizek et al. 1971a; Willhite et al. 1990). 
3.4.2.3 Dermal Exposure 
Although unable to detect increased selenium in human females exposed to selenomethionine dermally, 
Burke and coworkers found elevated liver and skin selenium concentrations in mice treated with a topical 
lotion containing selenomethionine applied to the shaved back and ears (size of area not specified), 
although since the areas were not occluded, some oral absorption during grooming is also possible (Burke 
et al. 1992a, 1992b).  In rats, between 9 and 27% of dermally applied selenious acid was absorbed, as 
measured in 75Se radioisotope studies (Medinsky et al. 1981b). 
3.4.2.4 Other Routes of Exposure 
In humans, selenium has been found to be widely distributed to organs and tissues following injection of 
sodium selenite, sodium selenate, and selenomethionine, with the highest concentrations generally found 
in the liver and kidneys (Ben-Porath and Kaplan 1969; Cavalieri et al. 1966; Jereb et al. 1975; Lathrop et 
al. 1972).  In studies involving injection of radiolabelled selenium, the pancreas accumulated high 
concentrations of radiolabelled selenium immediately following injection, but within hours, the selenium 
rapidly disappeared from this organ (Lathrop et al. 1972).  Using an in vitro, dually perfused, human term 
placenta, selenite has also been shown to cross the human placenta (Eisenmann and Miller 1994).  
Further, following intravenous injection, 75Se from selenomethionine was found to cross the near-term 
human placenta (Jandial et al. 1976). 
There is a rapid decline in serum selenium levels 1 hour after intravenous administration of sodium 
selenite or sodium selenate to humans (Burk 1974; Nelp and Blumberg 1965).  Burk (1974) found that 
50% of the plasma selenium was protein-bound within the first 2 hours after administration; 85% was 
bound within 4–6 hours after administration; and 95% was bound after 24 hours.  Circulating alpha-2 
globulins have been reported to have the greatest affinity for selenium (Hirooka and Galambos 1966a).  
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Burk (1974) found that lipoproteins, primarily the very low density lipoprotein (VLDL) and the low-
density lipoprotein (LDL) fractions, were also involved in selenium binding. 
In vitro studies of human plasma and whole blood incubated with sodium selenite have indicated that 
selenite is accumulated in erythrocytes by an active transport mechanism (Lee et al. 1969).  Several 
studies indicate that the selenite is chemically altered in the erythrocyte and then transported back into the 
plasma, where the selenium metabolite binds to plasma proteins (Burk 1974; Hirooka and Galambos 
1966a; Lee et al. 1969). 
A high degree of protein binding of selenium in the plasma has also been demonstrated in experimental 
animals.  Sandholm (1973) found that selenite administered intravenously to mice can be metabolically 
altered by erythrocytes to a form that binds to plasma proteins.  In mice, rats, and dogs, selenite initially 
binds to albumin.  Later, selenite can be found bound to alpha and gamma globulins in rats and to alpha-2 
and beta-1 globulins in dogs (Imbach and Sternberg 1967; Sternberg and Imbach 1967). 
3.4.3 Metabolism 
The metabolic fate of selenium, an essential element, is outlined in Figure 3-4.  In summary, inorganic 
selenium is reduced stepwise to the assumed key intermediate hydrogen selenide, and it (or a closely 
related species) is either incorporated into selenoproteins after being transformed to selenophosphate and 
selenocysteinyl tRNA according to the UGA codon encoding selenocysteinyl residue, or excreted into 
urine after being transformed into methylated metabolites of selenide (Lobinski et al. 2000).  
Consequently, selenium is mainly present in the mammalian body in forms of covalent carbon-selenium 
bonds, particularly selenoprotein P (the principal selenoprotein in plasma), selenoenzymes such as 
glutathione peroxidases (enzymes that catalyze the reduction of peroxidases and thereby protect cells 
from oxidative damage), type 1-iodothyronine deiodinase (which catalyzes the deiodination of thyroxine 
to triiodothyronine), and thioredoxin reductase (which may trigger cell signaling in response to oxidative  
stress) (Holmgren and Kumar 1989; Lobinski et al. 2000).  Additional information regarding the 
metabolism of selenium is discussed below.   
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Figure 3-4.  Metabolic Pathways for Selenium* 
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Four classes of selenoproteins have been defined (Sunde 1990):  selenium-specific proteins, proteins 
incorporating selenocysteine at cysteine codons, proteins incorporating selenomethionine at methionine 
position in those proteins, and proteins that bind selenide nonspecifically.  The selenium-specific proteins, 
which include the enzymes glutathione peroxidase, thyroxine reductase, and iodothyronine 5'-deiodinase, 
constitute the most physiologically important class of selenoproteins.  These proteins contain 
selenocysteine that is incorporated cotranslationally using selenide and serine as the precursors.  This 
process is specified by a uracil-guanine-adenine (UGA) codon, which usually functions as a stop codon.  
A stem-loop structure in the 3' untranslated region is required for UGA to specify selenocysteine (Berry et 
al. 1991).  This cotranslational process is the only known pathway for the production of selenocysteine in 
humans.  In contrast to selenocysteine, selenomethionine cannot be biosynthesized by human tissues 
(Levander 1986). 
The second and third classes of selenoproteins form in a similar manner: selenomethionine bound to the 
transfer ribonucleic acid (tRNA) for methionine competes with methionine bound to the tRNA for 
methionine at methionine codons, and selenocysteine bound to the tRNA for cysteine competes with 
cysteine bound to the tRNA for cysteine at cysteine codons (Sunde 1990).  The amount of selenoamino 
acids incorporated into protein is dependent on the ratio of the selenoamino acid and the amino acid 
bound to the amino acid tRNA. 
The last class of selenoproteins contains the selenium binding proteins.  This is an operational class 
defined by Sunde (1990) as "selenoproteins with selenium bound tightly enough so that the selenium 
remains attached during standard protein purification procedures that produce discrete selenium labeled 
species." This class contains selenoproteins that have not been fully characterized. 
As indicated in Figure 3-4, selenide, which can nonspecifically bind to proteins, is a central selenium 
species in the pathways leading to the formation and degradation of selenium proteins.  Selenide is also 
formed from selenite by reduction via glutathione following uptake in red blood cells.  This reaction 
occurs in rat (Gasiewicz and Smith 1978) and human (Lee et al. 1969) red blood cells, as well as in 
human plasma containing added glutathione (Mas and Sarker 1989).  Selenide is then transported to the 
plasma, bound selectively to albumin and transferred to the liver, and methylated for excretion in the 
urine, or incorporated into proteins after being transformed into selenium-phosphate and selenocysteinyl 
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tRNA according to the UGA codon encoding selenocysteinyl residue (Ganther and Lawrence 1997).  
Unlike selenite, selenate appears to be either taken up directly by the liver or excreted in urine by rats 
(Suzuki and Ogra 2002). 
Selenocysteine can also be metabolized to selenide.  This reaction requires a specific enzyme, 
selenocysteine β-lyase, which catalyzes the decomposition of selenocysteine to alanine and hydrogen 
selenide. The enzyme requires pyridoxal 5-phosphate as a cofactor.  In humans, the highest levels of 
selenocysteine β-lyase activity are found in the liver, followed by the kidney, heart, adrenal gland, and 
muscle (Daher and Van Lente 1992).  In mice orally exposed to selenocysteine, an intermediate 
metabolite selenocysteine-glutathione selenyl sulfide is formed in the small intestine and transported to 
the liver via the blood plasma (Hasegawa et al. 1995, 1996b).  This compound can be nonenzymatically 
reduced by excess glutathione or enzymatically reduced by glutathione reductase in liver cytosol extracts 
to reform selenocysteine, which can be further metabolized. 
When not immediately metabolized, selenomethionine can be incorporated into tissues such as skeletal 
muscle, liver, pancreas, stomach, gastrointestinal mucosa, and erythrocytes (Schrauzer 2000).  
Selenomethionine metabolism to selenide and the incorporation into selenium-specific proteins may occur 
by two pathways: metabolism to methane selenol and selenide or via selenocysteine.  Evidence that the 
incorporation of selenium from selenomethionine into protein is by the transsulfuration pathway 
(methionine to cysteine) comes from studies of selenomethionine metabolism in lymphoblast cell lines 
deficient in cystathionine lyase and cystathionine synthetase, enzymes of the transsulfuration pathway 
(Beilstein and Whanger 1992). Deficiency in these enzymes greatly reduces the incorporation of 
selenomethionine into glutathione peroxidase.  
Similar to metals, elemental selenium, a non-metal, is transformed into methylated metabolites prior to 
being excreted into the urine and/or exhaled.  Methylation is a detoxification pathway for selenium, and 
the extent of methylation is dose-dependent (Kobayashi et al. 2002).  Monomethylated selenium is 
excreted as the major form in urine at deficient, normal, and low-toxic levels of selenium.  When 
monomethylated selenium reaches a plateau in the urine (i.e., in the toxic dose range of selenium), 
trimethylated selenium in the urine and dimethylated selenium in the expired air increase.  The major 
monomethylated form of selenium has been thought to be methyselenol, but Kobayashi et al. (2002) 
identified it as a selenosugar (1β-methylselenol-N-acetyl-D-galactosamine). 
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Humans accidentally exposed to high levels of selenium have been reported to have a noticeable garlic 
odor of the breath, probably as a result of excretion of dimethyl selenide in expired air (Bopp et al. 1982; 
Wilbur 1980).  Garlic odor of the breath has been noted in humans following ingestion of toxic levels of 
sodium selenate (Civil and McDonald 1978) and following inhalation of elemental selenium dust or 
selenium dioxide (Glover 1970). 
In human populations with sufficient levels of selenium, dietary selenium is apparently partitioned into a 
selenite-exchangeable storage pool and a selenite-nonexchangeable storage pool.  The selenite-
exchangeable pool shows saturation kinetics.  After this pool is filled, dietary selenium as seleno­
methionine may be the primary determinant of selenium bioavailability and serum selenium 
concentrations (Meltzer et al. 1990, 1992).  There is experimental support for the concept that selenium 
metabolism can be divided into non-specific and specific components (Burk et al. 2001).  
Selenomethionine is the non-specific component as it appears to be incorporated into plasma proteins, 
presumably as selenomethionine, in proportion to its presence in the methionine pool.  There is no 
indication that selenocysteine and inorganic selenium (selanate) were incorporated non-specifically into 
plasma protein, suggesting that these forms are metabolized by specific selenium metabolic processes.  
For example, selenocysteine seems to incorporate selenium into selenoproteins, but not into other proteins 
in place of cysteine (Burk et al. 2001). Selenate was either taken up directly by the liver or excreted in 
the urine, and selenite was taken up by red blood cells, reduced to selenide by glutathione, and then 
transported to the plasma and transferred to the liver (Suzuki and Ogra 2002).  Data from both humans 
and Rhesus monkeys indicate that the selenium concentration in glutathione peroxidase is independent of 
the form of selenium administered and suggest a metabolic saturation at average intake rates (Butler et al. 
1990; Meltzer et al. 1990). 
In macaques that were orally administered doses of 0.025–0.3 mg selenium/kg as L-selenomethionine for 
up to 30 days, both erythrocyte selenium and glutathione peroxidase–specific activity showed a delay 
before increasing in a dose-related manner (Hawkes et al. 1992).  At 0.15 and 0.3 mg selenium/kg, 
glutathione peroxidase-specific activity in erythrocytes continued to increase for 15 days after cessation 
of treatment and remained elevated through the end of the study (40 days after the end of treatment).  The 
investigators attributed this effect to an initial deposition of selenium into a nonspecific pool (such as 
substitution for methionine in serum proteins), followed by slow release into the erythrocyte.  Wistar rats 
also show incorporation of selenomethionine into proteins (Behne et al. 1991). 
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In rats, dimethyl selenide has been identified as the primary respiratory metabolite following injection of 
sodium selenite or sodium selenate (Hirooka and Galambos 1966b) and appears to be produced in the 
liver (Nakamuro et al. 1977).  In mice, dimethyl selenide and dimethyldiselenide have been detected in 
expired air following the addition of unspecified amounts of sodium selenite, D,L-selenomethionine, or 
D,L-selenocystine to their drinking water (Jiang et al. 1983).  A third unidentified volatile selenium 
compound was detected in expired air of the mice following D,L-selenomethionine injection (Jiang et al. 
1983). 
In rats, the trimethylselenonium ion has been identified as the predominant urinary metabolite following 
intraperitoneal administration of sodium selenite (Byard and Baumann 1967), sodium selenate, seleno­
methionine, selenocystine, or methylselenocysteine, or following ingestion of seleniferous wheat (Palmer 
et al. 1970). A total of 30.8% of the urinary selenium was in the form of trimethylselenonium after 
administration of 15 ppm selenium in wheat.  Another major selenium metabolite that appeared in the 
urine more slowly than the trimethylselenonium ion was identified chromatographically, but the chemical 
structure of that metabolite was not defined (Palmer et al. 1970). 
Similarly, the trimethylselenonium ion was the major urinary metabolite of selenium excreted by rats 
after intraperitoneal injection of either methylselenocysteine (4 mg/kg) or selenocysteine (3 mg/kg) 
(Palmer et al. 1970).  The amounts of trimethylselenonium ion excreted were 50.6 and 49.7% of the total 
urinary metabolites after methylselenocysteine and selenocysteine administration, respectively.  In both 
cases, urinary metabolism accounted for only 10–15% of the administered dose.  As selenium was not 
measured in feces or expired air, recovery of the dose was incomplete.  In a review of the metabolic 
pathways resulting in the production of dimethyl selenide from selenite in rodents, Ganther (1979) 
indicated that reduction of selenite or selenate to dimethyl selenide requires glutathione and the 
methylating agent S-adenosylmethionine.  NADPH, coenzyme A, ATP, and magnesium (II) salts are also 
required to provide optimal conditions for this reaction (Ganther 1979).  Ganther (1971) and Hsieh and 
Ganther (1975) found that selenite initially reacts nonenzymatically with glutathione to form a seleno­
trisulfide derivative. The selenotrisulfide is then reduced nonenzymatically in the presence of glutathione 
or enzymatically by glutathione reductase in the presence of NADPH to a selenopersulfide (GSSeH).  The 
selenopersulfide is unstable and decomposes to glutathione and selenium or is enzymatically reduced by 
glutathione reductase in the presence of NADPH to hydrogen selenide (Ganther 1971; Hsieh and Ganther 
1975).  Hydrogen selenide can be methylated by S-adenosylmethionine in the presence of selenium 
methyltransferase to form dimethyl selenide (Figure 3-5). 
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Figure 3-5.  Proposed Pathway for Formation of Dimethyl Selenide from 

Selenite in Animals* 
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Selenate apparently is not converted to dimethyl selenide as readily as is selenite.  Studies of selenate 
metabolism are limited in mammals, but studies using bacteria indicate that selenate must be activated 
prior to conversion to selenite (Bopp et al. 1982).  Dilworth and Bandurski (1977) demonstrated that in 
the presence of ATP, magnesium (II) salts, and ATP-sulfurylase, yeast could convert selenate to 
eventually yield selenite (Figure 3-6). Data regarding the metabolism of selenium sulfide after 
administration to humans or other animals were not located in the literature. 
3.4.4 Elimination and Excretion 
Excretion of selenium can occur in the urine, feces, and expired air (Griffiths et al. 1976; Hawkes et al. 
1992, 1994; Lathrop et al. 1972; McConnell and Roth 1966; Thomson and Stewart 1974).  Sweat is a 
minor pathway of selenium excretion in humans (Levander et al. 1987).  Moreover, the initial rate of 
excretion appears to be dose dependent (Lathrop et al. 1972; McConnell and Roth 1966; Thomson and 
Stewart 1974). Some researchers have found that urinary excretion and fecal excretion of selenium are 
similar, with each route contributing approximately 50% of the total output (Stewart et al. 1978).  
However, the proportion excreted via each route seems dependent on several factors, including the level 
of exposure, the time since exposure, and the level of exercise.  Lactating women and subjects depleted of 
selenium have decreased excretion of selenium in the urine and feces (Martin et al. 1989a, 1989b; Moser-
Veillon et al. 1992).  At high selenium exposure levels, excretion of selenium in expired air becomes 
more significant (McConnell and Roth 1966; Olson et al. 1963). 
3.4.4.1 Inhalation Exposure 
Following acute inhalation exposures to selenium compounds, humans excrete some of the absorbed dose 
in the expired air (Glover 1970), but no studies were located that actually quantified the rate of excretion 
or identified the selenium compounds in the expired air of humans. 
3.4.4.2 Oral Exposure 
Several human studies have indicated that the rate of urinary excretion is most rapid in the first 24 hours 













*Adapted from Dilworth and Bandurski 1977 
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Figure 3-6. Activation and Reduction of Selenate to Selenite in 

Yeast Saccharomyces cerevisiae* 
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Thomson and Stewart 1974).  Thomson and Stewart (1974) found that <6% of a trace dose (0.01 mg 
selenium) of orally administered sodium selenite was excreted in the urine within 24 hours of 
administration, whereas 64–73% of a 1-mg dose of selenium was excreted in the first 24 hours (Thomson 
1974).  Thomson et al. (1977) also found that a lower proportion of the selenium from an oral dose of 
0.1 mg selenium administered as selenomethionine was excreted in the 24-hour urine than from a larger 
dose (1.0 mg selenium).  Similarly, low selenium New Zealand residents excreted proportionally less 
selenium in their urine than North Americans of higher selenium status (Robinson et al. 1985), and there 
is limited evidence of such adaptation to selenium intake in some animal studies (Jaffe and Mondragon 
1969, 1975; WHO 1987).  Thus, when higher amounts of selenium are administered, a higher proportion 
of the selenium is excreted in the urine during the first 24 hours following exposure.   
Decreasing urinary or fecal excretion appears to be the homeostatic mechanism by which the body retains 
greater amounts of selenium.  Martin et al. (1989a) observed greater retention of selenium by individuals 
maintained on a selenium-deficient diet.  This increase in retention was correlated with a decrease in fecal 
elimination.  Similarly, the increased retention of selenium from selenomethionine compared to selenite 
was correlated with decreased elimination (Swanson et al. 1991).  Lactating women have a greater 
retention of selenium from selenomethionine compared to selenite and a decreased urinary elimination 
(Moser-Veillon et al. 1992).  Muscle activity seems to influence urinary excretion of selenium as 
demonstrated by the doubling of selenium concentration in the urine of women following vigorous 
exercise (Oster and Prellwitz 1990). 
Less information is available regarding the elimination of selenium in the feces of humans than in the 
urine of humans. However, levels of fecal excretion of selenium have been reported to be similar to 
levels of urinary selenium excretion when dietary levels of selenium are not excessive (Patterson et al. 
1989).  Over a 14-day period, Stewart et al. (1978) found urinary elimination of selenium to average 
0.013 mg selenium/day and fecal elimination of selenium to average 0.011 mg selenium/day in four New 
Zealand women exposed to 0.024 mg selenium/day in their normal diets.  Balance data on 27 healthy U.S. 
adults (12 men and 15 women) similarly indicated an approximately even split between urine and fecal 
selenium excretion (Levander and Morris 1985).  Determination of selenium balance at four time points 
(spring, summer, fall, and winter) showed respective average levels of selenium in the urine and feces of 
48±2 and 34±1 µg/day in the men, and 39±1 and 23±1 µg/day in the women.  Plasma selenium levels 
remained essentially constant during the year and were similar in the men and women, averaging 136±4 
and 133±4 ng/L, respectively.  Although the U.S. men consumed more selenium in the diet than the 
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women, their selenium balance (8±4) was less positive than the women (12±3) because they tended to 
excrete more in the feces (Levander and Morris 1985).  It has been suggested that some of the selenium 
content in feces can be attributed to biliary excretion (Levander and Baumann 1966a, 1966b). 
In humans, whole body retention studies following oral administration of sodium selenite have indicated 
that selenium elimination is triphasic (Thomson and Stewart 1974).  During the initial phase, which lasted 
about 1 week, elimination of selenium was rapid, with a half-life of approximately 1 day (Thomson and 
Stewart 1974). In the second phase, which also lasted approximately 1 week, selenium elimination was 
slower, with a half-life of 8–9 days.  In the third phase, selenium elimination was much slower, with a 
half-life estimated to be 115–116 days.  The first two elimination phases correspond to the fecal 
elimination of nonabsorbed selenium and the urinary excretion of absorbed but unutilized selenium 
(Thomson and Stewart 1974).  Selenomethionine elimination is also triphasic; however, its terminal half-
life is longer than that of sodium selenite.  The average half-lives of selenomethionine for the three phases 
were measured to be approximately 0.4–2, 5–19, and 207–290 days, respectively (Griffiths et al. 1976). 
An examination of elimination data from 44 pigs exposed to excess selenium as sodium selenite in feed 
was found to fit a one-compartment model of selenium elimination (Davidson-York et al. 1999).  Serum 
selenium levels were monitored over a period of 46 days beginning 1–14 days after termination of 
exposure to the feed containing excess selenium.  Data were not adequate to depict the initial distribution 
phase, but a geometric mean elimination half-life of 12 days was calculated.  It is likely that the period of 
elimination included in this study corresponds to the second phase described by Thomson and Stewart 
(1974). 
The chemical form of selenium may play a role in determining how rapidly selenium is excreted in the 
urine. In rats, the rate of urinary excretion of selenium has been found to be greater following oral 
administration of sodium selenite than of selenomethionine (Thomson and Stewart 1973).  A comparison 
of excretion of selenium by selenium-depleted rats after oral administration of sodium selenate, 
selenomethionine, or methyl selenocysteine (from high-selenium broccoli) found that excretion of 
selenium from methyl selenocysteine or selenomethionine was significantly lower than from sodium 
selenate; further, that there was no significant difference between secretion of selenium from methyl 
selenocysteine and selenomethionine (Finley 1998). This may contribute to the greater retention of 
selenium from selenomethionine, than from inorganic selenium (Martin et al. 1989a).  However, another 
study of excretion of selenium from rats fed selenium as either sodium selenite or selenomethionine found 
that excretion of selenium increased with administered dose, but was similar for both forms of selenium 
(Shiobara et al. 1998). 
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As exposure to oral L-selenomethionine increased in macaques, the amount of selenium eliminated in the 
urine/day increased, as did the maximum rate of urinary excretion.  However, the percentage of 
administered dose appearing in the urine decreased with an increase in dose (Hawkes et al. 1994). 
3.4.4.3 Dermal Exposure  
No studies were located regarding the excretion of selenium by humans or other animals after dermal 
exposure to elemental selenium or selenium compounds. 
3.4.4.4 Other Routes of Exposure 
Whole body retention studies in sheep following injection of selenium have indicated that selenium 
excretion in animals follows a triexponential profile (Blodgett and Bevill 1987b; Ewan et al. 1967).  In a 
2-week study, Blincoe (1960) estimated the half-life for 75Se in rats following intraperitoneal injection of 
75Se-labeled sodium selenite (0.93 mg selenium/kg).  Initially, the excretion of selenium was rapid, with a 
half-life of approximately 0.8 day; the second phase of excretion was slower, with a half-life of 13 days.  
These results parallel the initial phases of selenium excretion seen in humans.  The abbreviated duration 
of the Blincoe (1960) study did not permit the determination of a terminal elimination phase half-life.  In 
rats, Ewan et al. (1967) found the final phase of elimination of selenium following a single subcutaneous 
injection of sodium selenite to be dose independent (from 0.008 mg selenium/kg to 2 mg selenium/kg), 
with a half-life of 65–78 days.  Blodgett and Bevill (1987b) found the elimination rate of selenium in 
sheep during the second phase following a single intramuscular injection of sodium selenite to be dose 
dependent, with larger doses resulting in longer half-lives (i.e., doses of 0.4, 0.6, 0.7, or 0.8 mg 
selenium/kg resulting in half-lives for selenium elimination of 6.3, 8.8, 15.1, and 20.4 hours, 
respectively).  The reasons for the decreasing elimination rate with increasing dose during the second 
phase are not clear. 
Dietary levels of selenium and the individual's selenium nutritional status are the most important factors 
that influence the route and rate of selenium excretion.  Selenium excretion in expired air is only 
significant when exposures to selenium are high.  Rats injected subcutaneously with sodium selenite at 
doses of 2.2–5.4 mg selenium/kg excreted 41–62% of the administered selenium in exhaled air, whereas 
rats injected with sodium selenite at doses of 0.005–0.9 mg selenium/kg excreted only 0.2–11% of the 
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administered selenium in expired air (McConnell and Roth 1966; Olson et al. 1963).  As the amount of 
administered sodium selenite increased, the percent of the administered selenium excreted in the urine 
decreased (from approximately 22–33% of the administered selenium at doses of 0.005–0.9 mg 
selenium/kg to 3–14% of the administered selenium at doses of 3.1–5.4 mg selenium/kg) (McConnell and 
Roth 1966). Selenium in the feces was not measured in this study.  Burk et al. (1972) found that as the 
dietary level of sodium selenite was increased, a larger proportion of an injected tracer dose of selenium 
(as sodium selenite) was excreted.  At a dietary level of 0.005 mg selenium/kg, approximately 60% of the 
injected selenium had been excreted in the first 35 days following administration.  At a dietary level of 
0.05 mg selenium/kg, over 94% of the injected selenium had been excreted over the same period of time. 
In experimental animals, other factors that can cause an increase in selenium levels in expired air are 
higher dietary levels of selenium, protein, or methionine (Ganther et al. 1966).  Phenobarbital induction of 
microsomal enzymes has also led to increased exhalation of selenium following intravenous 
administration of sodium selenite (Sternberg et al. 1968). 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
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PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-7 shows a conceptualized representation of a PBPK model. 
Two models for selenium were located in the literature.  Patterson and coworkers (Patterson and Zech 
1992; Patterson et al. 1989, 1993) have developed compartmental models of the kinetics of selenium 
orally administered as selenite or selenomethionine in adult humans. 
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Figure 3-7.  Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance 

Source: adapted from Krishnan et al. 1994 
Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by 
inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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Patterson et al. (1989) Selenite Model 
Description of the model. Patterson and coworkers (Patterson and Zech 1992; Patterson et al. 
1989, 1993) developed a compartmental model of the kinetics of ingested selenite in adult humans based 
on data from human subjects who consumed a single oral dose of 200 µg 74Se as selenite.  The model 
assumes that 84% of the administered selenium is absorbed and that absorption is rapid.  Absorbed 
selenite is assumed to distribute to six compartments: gastrointestinal tract, plasma, hepatopancreatic/ 
lymphatic system, liver/pancreas, bile, and tissues (Figure 3-8).  Unabsorbed selenium is excreted in the 
feces. Absorption occurs from the gastrointestinal compartment (probably the small intestine, but also 
possibly the stomach) into a rapidly turning-over pool (the intestinal cells or enterocytes) from which it 
leaves by two pathways.  The central compartment is represented as four kinetically distinct plasma pools, 
P1 (the portal circulation), P2 (before passage through the liver), P3 (after passage through the liver), and 
P4 (after passage through the tissues).  In the first pathway, selenium enters P1.  The second pathway is to 
a liver/pancreatic compartment.  Transport into and out of P1 is very rapid (T1/2 approximately 
0.36 hours) and this may represent selenium in the portal circulation passing through the liver before 
appearing in P3, but not removed in the first pass.  The second pathway is via the hepatopancreatic/ 
lymphatic system compartment to a second plasma pool (P2).  Appearance of selenium in P2 is delayed 
(T1/2 approximately 0.55 hours), representing the time needed to move through the hepatopancreatic/ 
lymphatic system compartment.  From the two plasma pools (P1 and P2), selenium can be excreted in the 
urine (T1/2 approximately 3.94 and 1.96 hours, respectively) or it can move into the liver/pancreas 
compartment.  After a delay of 4–6 hours, the selenium leaves the liver/pancreas either to a bile 
compartment (T1/2 approximately 0.13 hours) and thence to the gut (G1) for excretion in feces or to a third 
plasma pool (P3) (T1/2 approximately 0.19 hours).  From P3, selenium can be excreted in the urine (T1/2 
approximately 4.15 hours) or can move into a large, slowly turning-over tissue compartment.  Finally, 
selenium is transferred very slowly (T1/2 approximately 1.27 hours) from the tissues (probably final 
metabolic products) to a fourth plasma pool (P4) and hence to the urine (T1/2 approximately 6.54 hours).  
Validation of the model. The extent to which this model has been validated is not described in 
Patterson and coworkers (Patterson and Zech 1992; Patterson et al. 1991, 1993). 
Risk assessment. The model was designed to simulate the pharmacokinetics of selenium orally 
administered as selenite to humans as a preparation for a larger anticancer supplementation study jointly 
undertaken by the National Cancer Institute (NCI) and the U.S. Department of Agriculture (USDA) 
(Patterson and Zech 1992; Patterson et al. 1991, 1993). 
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Figure 3-8. Selenite Model, a Kinetic Model for Selenite Metabolism 
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The arrow with an asterisk indicates the site of entry of the oral Se tracer. Arrows between compartments 
represent pathways of fractional transport. Compartments depicted as rectangles represent delays. 
Compartments G1, G2, G3, three-gut compartments, probably the small intestine; ENT, enterocytes 
(intestinal cells); HPL, compartment in hepato-pancreatic subsystem or lymphatic system; L/P, liver and 
pancreas; LI, large intestine; T1, T2, peripheral tissues, e.g., skeletal muscle, bone, kidney. Feces and 
urine compartments are drawn in the shape of test tubes to represent fractional (single) collections. The 
model includes absorption distributed along the gastrointestinal tract, enterohepatic recirculation, 
four-kinetically distinct plasma pools, P1–P4, a subsystem consisting of liver and pancreas, and a slowly 
turning-over tissue pool. 
Source: Patterson et al. 1993 
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Target tissues. The model is designed to simultaneously account for the appearance and 
disappearance of selenium in plasma, urine, and feces after administration of a single oral dose of 74Se as 
selenite (Patterson and Zech 1992; Patterson et al. 1991, 1993). 
Species extrapolation. The model is designed for applications to human dosimetry and cannot be 
applied to other species without modification. 
Interroute extrapolation. The model is designed to simulate oral exposures to selenite and cannot 
be applied to other routes of exposure without modification. 
Extrapolation to other forms of selenium. The model is designed to simulate oral exposures to 
selenite and cannot be applied to other forms of selenium without modification.    
Swanson et al. (1991) Selenomethionine Model 
Description of the model. Swanson and coworkers (Patterson et al. 1993; Swanson et al. 1991) 
produced a model for ingested selenomethionine in adult humans based on data from human subjects who 
consumed a single oral dose of 200 µg 74Se as selenomethionine and the model of the kinetics of ingested 
selenite described above. Four major changes (indicated by bold lines in Figure 3-9) were made to the 
selenite model to achieve an adequate fit to the selenomethionine data: (1) the amount of label absorbed 
into the enterocyte was increased (the absorption of 74Se was 98% for selenomethionine compared with 
84% for selenite), (2) the amount of label removed from the plasma in the first pass through the liver was 
increased, (3) a pathway from P4 back to the liver was added, providing for conservation and reutilization 
of amino acids (estimated 95% of material from P4 is recycled), and (4) a second tissue subgroup was 
added to the model and rate constants were adjusted so that the subgroups had different turnover times. 
The most important differences between the selenite and selenomethionine models lie in the turnover 
times. The estimated turnover times in the plasma, liver/pancreas, and tissues are shorter for seleno­
methionine than for selenite, but the estimated turnover time for the whole body is more than twice as 
long for selenomethionine as for selenite.  This is probably because selenite is not recirculated, whereas 
selenomethionine is extensively recycled, passing through the individual organs and tissues many times 
before being excreted. 
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The arrow with an asterisk indicates the site of the oral Se tracer.  Arrows between compartments 
represent pathways of fractional transport.  Compartments depicted as rectangles represent delays.  G1, 
G2, G3, three-gut compartments, probably small intestine; ENT, enterocytes (intestinal cells); HPL, 
compartment in hepatopancreatic subsystems or lymphatic system; L/P, liver and pancreas; LI, large 
intestine; T1, T2, T3, T4, peripheral tissues, e.g., skeletal muscle, bone, kidney.  Feces and urine along 
the gastrointestinal tract, enterohepatic recirculation, four-kinetically distinct plasma pools, P1–P4, a 
subsystem consisting of the liver and pancreas, two tissue subsystems that are slowly turning-over, and a 
pathway for reutilization of selenium metabolites from peripheral tissues.  The bold lines indicate the 
major modifications to the Selenite Model (Figure 3-8).  
Source: Patterson et al. 1993 
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Validation of the model. The extent to which this model has been validated is not described by the 
authors (Patterson et al. 1993; Swanson et al. 1991). 
Risk assessment. The model was designed to simulate the pharmacokinetics of selenium orally 
administered as selenomethionine to humans as a preparation for a larger anti-cancer supplementation 
study jointly undertaken by the NCI and the USDA (Patterson et al. 1993; Swanson et al. 1991). 
Target tissues. The model is designed to simultaneously account for the appearance and 
disappearance of selenium in plasma, urine, and feces after administration of a single oral dose of 74Se as 
selenomethionine (Patterson et al. 1993; Swanson et al. 1991). 
Species extrapolation. The model is designed for applications to human dosimetry and cannot be 
applied to other species without modification. 
Interroute extrapolation. The model is designed to simulate oral exposures to selenomethionine 
and cannot be applied to other routes of exposure without modification. 
Extrapolation to other forms of selenium. The model is designed to simulate oral exposures to 
selenomethionine and cannot be applied to other forms of selenium without modification. 
3.5 MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms 
As discussed in Section 3.4.1, selenium is readily absorbed by inhalation or ingestion when present in any 
of several compounds.  Inhalation and oral absorption are extensive, although the rate of absorption varies 
depending on the form of selenium (Medinsky et al. 1981a; Moser-Veillon et al. 1992; Swanson et al. 
1991; Weissman et al. 1983; Young et al. 1982).  Oral bioavailability is generally independent of the 
exposure level, but may be increased in some selenium-deficient individuals (Griffiths et al. 1976; Martin 
et al. 1989a; Thomson 1974; Thomson et al. 1977).  Selenate and selenomethionine appear to be absorbed 
by the intestine largely unchanged, while selenite and selenocysteine are metabolized during absorption 
(Hasegawa et al. 1995, 1996b; Spencer and Blau 1962; Whanger et al. 1976, 1996).  No evidence of 
significant dermal absorption of selenium by humans was located, although mice can absorb topically-
applied selenomethionine (Burke et al. 1992b).  An active transport mechanism for selenomethionine 
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absorption in the intestine has been described (Spencer and Blau 1962), but mechanisms of absorption 
and distribution for dermal and pulmonary uptake are unknown and subject to speculation.  
Absorbed selenium is carried throughout the body in the blood, eventually being distributed to all tissues.  
Injection studies in humans have shown that after selenium enters the blood, it rapidly becomes protein-
bound (Burk 1974; Hirooka and Galambos 1966a), while in vitro studies have shown that selenite is 
accumulated in erythrocytes via an active transport mechanism (Lee et al. 1969).  Selenium is an essential 
element and is incorporated into selenoproteins (e.g., glutathione peroxidase, iodothyronine deiodinases) 
as selenocysteine.  Most studies report similar distribution patterns for selenium, regardless of the form in 
which it was administered; however, the concentration reached is generally higher for doses delivered as 
an organic form of selenium, such as selenomethionine, than for the same dose delivered as an inorganic 
form (Behne et al. 1991; Butler et al. 1990; Grønbaek and Thorlacius-Ussing 1992; Ip and Hayes 1989; 
Salbe and Levander 1990b; Shiobara et al. 1998; Zi-Jian Jie 1992).  In humans, the highest levels of 
selenium are found in the liver and kidney (see Table 3-6 for normal levels of selenium in human tissues).  
Selenomethionine is not synthesized by humans, but can be incorporated into proteins in the place of 
methionine; because of this, selenomethionine is retained for a longer time within the body than inorganic 
forms, and it may therefore represent a storage form of the element.  Unlike selenomethionine, there is no 
evidence that selenocysteine and inorganic selenium (selanate) are incorporated non-specifically into 
plasma protein, suggesting that these forms are metabolized by specific selenium metabolic processes.  
For example, selenocysteine seems to incorporate selenium into selenoproteins, but not into other proteins 
in place of cysteine (Burk et al. 2001). 
Selenium and the glutathione (GSH) system have key functions in the body’s antioxidant defense (Arteel 
and Sies 2001; Brigelius-Flohe 1999).  GSH is involved in direct interception of pro-oxidants, as well as 
the reduction of other antioxidants from their oxidized forms (Arteel and Sies 2001).  GSH also has 
ancillary functions (e.g., metabolism, cell signaling, and protein interactions) that can mediate defense 
against antioxidants. The redox reactions of GSH involve glutathione peroxidase (GPX) and glutathione 
disulfide (GSSG) as catalysts, whereas the main class of enzymes involved in thioether formation are the 
GSH transferases.  Antioxidant protection by selenium in the mammalian cell is mediated by selenoamino 
acids, either as selenocysteine or selenomethionine.  Selenomethionine has GPX-like activity, and the 
active site of GPX contains selenocysteine residues.  GPX catalyzes the reduction of various kinds of 
hydroperoxides (e.g., simple hydroperoxides, lipid peroxides) by using GSH as the reducing substrate.  
Several isozymes of GPX have been identified, including plasma GPX, gastrointestinal GPX, and 
phospholipid hydroperoxide GPX (reduces lipid hydroperoxides found in biomembranes and sperm) 
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(Brigelius-Flohe 1999).  Other selenoproteins (e.g., selenoprotein P and thioredoxin reductase) also have 
been shown to have antioxidant properties, and can function in the defense against peroxynitrite, by 
reducing this oxidizing and nitrating species into nitrite (Arteel and Sies 2001; Holmgren and Kumar 
1989; Burke and Hill 2000; Ganther 1999).   
The antioxidant action of GPX towards hydroperoxides appears to involve an enzymatic catalysis reaction 
cycle (a ‘tert-uni ping-pong’ mechanism) (Arteel and Sies 2001).  The reaction cycle is thought to 
proceed in three main steps, involving the enzyme-bound selenocysteine, which is present as the selenol.  
In the first step of the reaction, the organic hydroperoxide reacts to yield selenenic acid and the 
corresponding alcohol.  The remaining steps consist of the sequential reduction by thiols (GSH), leading 
to regeneration of the selenol and glutathione disulfide.  GPX serves more as an ancillary reductant than 
as a direct antioxidant per se. 
Deiodination is an important mechanism for the deactivation of the thyroid hormones, T4 and T3 , as well 
as for the production of extrathyroidal thyroid T3. The deiodination reactions are catalyzed by selenium-
dependent deiodinase enzymes (selenodeiodinases).  Three selenodeiodinases have been described that 
differ in substrate preference, reaction products, response to inhibitors, and response to T3 (Larsen et al. 
1998). Full activity of each enzyme requires selenocysteine in the amino acid sequence of the active site, 
which is the basis for deiodination activity being responsive to nutritional selenium status (see 
Section 3.9). 
Excretion of selenium by humans occurs in the urine, feces, expired air, and sweat, but urine and feces are 
the major routes of elimination.  Some of the selenium in feces may be due to bilary excretion (Levander 
and Baumann 1966a, 1966b). Elimination is reduced in selenium-deficient individuals and may represent 
a mechanism by which selenium levels are regulated (Martin et al. 1989a; Swanson et al. 1991).  
Methylation is an important mechanism of detoxification for selenium; dimethyl selenide is exhaled, and 
the trimethylselenonium ion is the major urinary metabolite of selenium.  Experiments in mice suggest 
that the hepatic toxicity of selenium may be at least partly due to depression of selenium methylation in 
the liver, resulting in the accumulation of excess selenides (Nakamuro et al. 2000). 
3.5.2 Mechanisms of Toxicity 
Selenium in the body can be grouped in three main categories:  selenium in proteins, non-protein 
selenium species, and selenoamino acids (Lobinski et al. 2000).  The most prevalent selenium species 
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include selenocysteine, selenomethionine, and inorganic forms of selenium (selenite and selenate).  
Selenocysteine-containing proteins are particularly important because they are largely responsible for the 
antioxidant properties of selenium.  The main selenoproteins are glutathione peroxidase (GPX), 
thioredoxin reductase, and iodothyronine 5'-deiodinases, and the activity of these selenocysteine enzymes 
generally decreases and increases when selenium is depleted or repleted (Lobinski et al. 2000).  Selenium 
can also be incorporated directly into non-specific proteins in the place of methionine (i.e., as 
selenomethionine), which contributes to the pool of selenomethionine-rich proteins present in human and 
animal tissues, or become part of selenium-binding proteins in which selenium is not covalently bound to 
the molecules (Arteel and Sies 2001; Bansal et al., 1989, 1990; Gladyshev and Kryukov 2001; Lobinski et 
al. 2000; Sani et al., 1988). 
Little is known about the specific biochemical mechanism(s) by which selenium and selenium 
compounds exert their acute toxic effects.  Generally, water-soluble forms are more easily absorbed and 
are generally of greater acute toxicity.  Several mechanisms have been proposed to explain the various 
long-term toxic effects of excess selenium, such as alterations in the hair, skin, nails, liver, thyroid, and 
nervous system, as discussed below.  This includes information on mechanisms by which selenium exerts 
effects as a component of GPX, thioredoxin reductase, and the iodothyronine deiodinases, although the 
roles of other selenium-containing proteins in mammalian metabolism have not been clarified. Selenium 
also has strong interactions with other nutrients such as vitamin E, toxic metals such as mercury and 
cadmium, and various xenobiotics (see Section 3.9). 
Selenium readily substitutes for sulfur in biomolecules and in many biochemical reactions, especially 
when the concentration of selenium is high and the concentration of sulfur is low in the organism 
Stadtman 1983; Raisbeck 2000). Inactivation of the sulfhydryl enzymes necessary for oxidative reactions 
in cellular respiration, through effects on mitochondrial and microsomal electron transport, might 
contribute to acute selenium toxicity (Levander 1982; Lombeck et al. 1987; Mack 1990; Shamberger 
1981).  Selenium may have a role in hepatic heme metabolism that is related to GPX or lipid peroxidation 
(Levander 1982). Selenocysteine is specifically found in some proteins (e.g., glutathione peroxidase); 
selenomethionine appears to randomly substitute for methionine in protein synthesis.  This appears to be 
an additional mechanism for intermediate- or chronic-duration toxicity (Levander 1982; Stadtman 1983; 
Tarantal et al. 1991).  Skin, hair, and nail damage are significant indicators of chronic selenium 
overexposure. The mechanism causing these integumentary effects is unclear, but could be related to the 
high selenium concentrations in these tissues as a consequence of the substitution of selenium for sulfur 
in certain amino acids, including the disulfide bridges that provide tertiary structure and function to 
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proteins. For example, substitution of selenium for sulfur in keratin results in weakened physical protein 
structure and failure of keratinized tissues such as hair and hoof (Raisbeck 2000).  The nails and hair are 
considered to be routes for excretion of excess selenium (Yang et al. 1989b). 
Considerable evidence is available supporting oxidative stress as the key biochemical lesion of selenium 
intoxication (Raisbeck 2000; Spallholz et al. 1994).  Inorganic forms of selenium appear to react with 
tissue thiols by redox catalysis resulting in formation of reactive oxygen species (superoxide anion [O2-]). 
For example, selenite is a prooxidant catalyst that reacts with GSH endogenously in cells or 
extracellularly causes toxicity by the formation of superoxide and elemental selenium (Seko and Imura 
1997; Seko et al. 1989; Spallholz 1994).  Selenocystamine (a diselenide) catalyzes the formation of 
superoxide under aerobic conditions in the presence of thiol; this reaction could play a role in the toxicity 
of diselenides and alkylselenols (Chaudiere et al. 1992).  Selenium can have inhibitory effects on thiol 
proteins by modification via (1) formation of S-Se-S (selenotrisulfides) and S-Se (selenylsulfide) bonds, 
(2) catalysis of S-S (disulfide bonds) with no incorporation of selenium in the protein, and (3) formation 
of Se-Se diselenides (Ganther 1999).  Proteins that contain regulatory cysteines can similarly form 
selenium adducts with toxicity resulting from inactivation of essential thiol groups.   
Selenium can also play a role in the redox-regulating activities of GPXs with inflammatory superoxides 
and phospholipid hydroperoxides.  A selenoprotein P-supported plasma GPX could bind to endothelial 
cells and protect them against inflammatory hydroperoxides (Hill and Burke 1989, 1997).  Metabolites 
from reactions of GPX and phospholipid hydroperoxides could suppress cytokine or growth factor 
triggered gene activation (Flohe et al. 1997).  Selenium appears to be a key element that, through its 
modulation of GPX activity, can inhibit activation of the transcription factor NF-κB, which is involved in 
the regulation of the expression of numerous cellular genes, particularly those involved in immune, 
inflammatory, and stress responses (Kretz-Remy and Arrigo 2001). 
Apotosis induced by tumor necrosis factor might be inhibited by overexpression of cytosolic GPX or 
phospholipid hydroperoxide GPX because the apoptotic signaling cascade could be stimulated by 
hydroperoxides (Brigelius-Flohe 1999).  Selenium compounds that form the methylselenide anion 
(selenol) have been shown to induce cellular apotosis, and one selenium compound, selenium­
methylselenocysteine, induced apotosis in cancer cells through activation of capsases (a likely mechanism 
for other selenium compounds that also induce apotosis) (Ganther 1999; Spallholz 2001).  Hypotheses for 
the protective role of selenium against cancer development include the inhibition of carcinogen-induced 
covelant DNA adduct formation, retardation of oxidative damage to DNA, lipids, and proteins, and 
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modulation of cellular and molecular events that are critical in cell growth inhibition and in the multi-step 
carcinogenesis process (El-Baoumy 2001; Ganther 1999; Spallholz 2001). 
Intracellular redox function can also be affected by selenium deficiency.  In general, the toxicity of 
compounds that are metabolized to form free radicals increases in selenium-deficient animals, and many 
of the effects are prevented by supplements of selenium.  For example, the active role of selenium in 
thioredoxin reductase helps reduce nucleotides in DNA synthesis, and selenium in GPX reduces 
phospholipid hydroperoxides and hydrogen peroxide (Ganther 1999; Holmgren and Kumar 1989; 
Spallholz 2001).  Peroxidative degradation of polyunsaturated fatty acids in membranes causes formation 
of chemicals, such as free radicals, aldehydes, and epoxides, which can have cytotoxic, hepatotoxic, and 
genotoxic effects (Esterbauer et al. 1989).  The role of selenium in protecting against early pregnancy loss 
may be linked to reduced antioxidant protection of biological membranes and DNA by low concentrations 
of GPX. Levels of hemoglobin adducts from aldehydes and epoxides in selenium-deficient animals were 
enhanced due to loss of selenium-dependent GPX activity (Kautiainen et al. 2000).  Degenerative diseases 
such as skeletal and cardiac myopathies, which occur particularly in selenium-deficient cattle and sheep, 
appear to be due to loss of membrane phospholipid hydroperoxide GPX activity (Arthur and Beckett 
1994b).  
Selenium status can also influence thyroid hormone function via the deiodinase enzymes (Brätter and 
Negretti De Brätter 1996; Hawkes and Turek 2001).  Selenium is a critical component of the deiodinase 
enzymes, including iodothyronine 5'-deiodinases, which convert the prohormone thyroxine (T4) to the 
active circulating form, triiodothyronine (T3) (Delange 2000; Köhrle 1994; St Germain and Galton 1997). 
Selenium is also a component of GPX, the main enzyme responsible for protecting thyroid cells against 
oxidative damage.  GPX is involved in the detoxification of hydrogen peroxide, which is produced in the 
thyroid during the conversion of T4 to T3. 
3.5.3 Animal-to-Human Extrapolations 
No studies were located that specifically examined species-related differences in selenium 
pharmacokinetics. Similar patterns of absorption, distribution, and elimination have been reported for 
human and animal systems and the dermal, endocrine, and neurological effects of chronic exposure in 
humans are similar to those reported for animals exposed to very high doses of selenium.  However, 
species-specific differences in toxicity are present (e.g., the main effect of selenium toxicity in rodents is 
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damage to the liver, which is not observed in humans) and this may represent evidence of underlying 
differences in how selenium is metabolized. 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the 
Environmental Protection Agency (EPA) to develop a screening program for “...certain substances 
[which] may have an effect produced by a naturally occurring estrogen, or other such endocrine 
effect[s]...”.  To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and 
Testing Advisory Committee (EDSTAC), which in 1998 completed its deliberations and made 
recommendations to EPA concerning endocrine disruptors.  In 1999, the National Academy of Sciences 
released a report that referred to these same types of chemicals as hormonally active agents. The 
terminology endocrine modulators has also been used to convey the fact that effects caused by such 
chemicals may not necessarily be adverse.  Many scientists agree that chemicals with the ability to disrupt 
or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and 
wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, 
particularly in view of the fact that hormone mimics exist in the natural environment.  Examples of 
natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et 
al. 1992).  These chemicals are derived from plants and are similar in structure and action to endogenous 
estrogen. Although the public health significance and descriptive terminology of substances capable of 
affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the 
synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible 
for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997).  Stated differently, 
such compounds may cause toxicities that are mediated through the neuroendocrine axis.  As a result, 
these chemicals may play a role in altering, for example, metabolic, sexual, immune, and neurobehavioral 
function.  Such chemicals are also thought to be involved in inducing breast, testicular, and prostate 
cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
Selenium is a component of all three members of the deiodinase enzyme family, the enzymes responsible 
for deiodination of the thyroid hormones (Köhrle 1994; St. Germain and Galton 1997).  The deiodinases 
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contain a selenocysteine at the active site, which is required for catalytic activity.  There are three types of 
deiodinases and they differ in terms of tissue distribution, reaction kinetics, efficiency of substrate 
utilization, and sensitivity to inhibitors.  The first to be recognized as a selenoprotein was type I 
iodothyronine 5'-deiodinase, which converts the prohormone thyroxine (T4) to the active form, 
triiodothyronine (T3) and to date, studies of the effects of excess selenium have focused on this protein.  
Under normal circumstances, the human thyroid produces only 20–30% of its hormone as T3; the 
remainder is T4 (a minute amount of reverse T3 (rT3) is also produced), which is largely converted to 
active T3 by type I deiodinase located within the liver, euthyroid pituitary, kidney, thyroid, and brain.  
Type I deiodinase is a membrane bound protein and, thus, its activity has not been directly measured in 
studies of humans supplemented with selenium.  Human studies have instead measured serum levels of 
T3, rT3, T4, and TSH. 
Two human studies have demonstrated a decrease in T3 levels in response to increased dietary selenium 
although the hormone levels remained within the normal human range (Brätter and Negretti De Brätter 
1996; Hawkes and Turek 2001).  The effect of increased dietary selenium on other thyroid hormones is 
unclear. No significant correlation between selenium intake and serum T4 or TSH levels was found in the 
study of Brätter and Negretti De Brätter (1996), although Hawkes and Turek (2001) showed that TSH 
concentration increased (+37%) and was significantly different relative to baseline levels (p<0.06) in a 
high selenium group.  In a third study of the effects of selenium supplementation, New Zealanders with 
normally low selenium intake (unsupplemented intake of 28–29 µg/day) showed a reduction in T4 
concentration in all groups after 20 weeks (Duffield et al. 1999).  A significant inverse correlation was 
found between serum levels of selenium and TSH among fish consumers; however, it is not known if this 
population had a high selenium intake (Hagmar et al. 1998). 
Male rats receiving diets supplying 0.05mg selenium/kg/day for 6–12 weeks have been shown to have 
reductions in type-I-deiodinase activity (Behne et al. 1992; Eder et al. 1995; Hotz et al. 1997).  However, 
the levels of thyroid hormones in these animals have not shown a consistent pattern.  Exposure to 
0.055 mg selenium/kg/day as sodium selenite for 40 days produced a significant decrease in serum levels 
of T3 (Eder et al. 1995).  In another study, a dose of 0.09 mg selenium/kg/day as sodium selenate in food 
for 6 weeks produced a significant (~30%) increase in TSH (Hotz et al. 1997), and no significant changes 
in thyroid levels of T3 or T4 were found in rats receiving 0.105 mg selenium/kg/day as sodium selenite or 
0.118 mg selenium/kg/day as L-selenomethionine for 3 months (Behne et al. 1992). 
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Many studies have documented reduced body weight gain in young animals treated with selenium 
compounds and abnormal weight loss in older animals (Grønbaek et al. 1995; Halverson et al. 1966; Harr 
et al. 1967; Jacobs and Forst 1981a; Nelson et al. 1943; NTP 1994; Johnson et al. 2000; Palmer and Olson 
1974; Panter et al. 1996; Schroeder 1967; Tsunoda et al. 2000).  There is evidence to suggest that these 
effects may be due in part to the interactions of selenium or selenium compounds with hormones that 
regulate normal growth and body weight.  Reduced insulin-like growth factor-binding protein-3, growth 
hormone secretion in response to growth hormone releasing factor, and somatomedin C levels have been 
reported in rats exposed to sodium selenite in drinking water (Grønbaek et al. 1995; Thorlacius-Ussing et 
al. 1988), although somatomedin C was not a sensitive end point in humans from a high selenium area of 
South Dakota (Salbe et al. 1993). 
No studies were located regarding adverse effects on human reproduction following oral exposure to 
elemental selenium or to selenium compounds.  However, data from animal studies suggest that oral 
exposure to selenium may be associated with male infertility.  Adverse effects associated with selenium 
exposure include decreased sperm counts in rats and rabbits (El-Zarkouny et al. 1999; Kaur and Parshad 
1994; NTP 1994), sperm abnormalities in rats and rabbits (El-Zarkouny et al. 1999; Kaur and Parshad 
1994), testicular hypertrophy in rats (Turan et al. 1999a), and a significant reduction in serum testosterone 
in rabbits (El-Zarkouny et al. 1999).  However, it is not clear what effect, if any, this had on the ability of 
the animals to reproduce, as chronic administration of selenate did not affect male fertility in rats or mice 
(Rosenfeld and Beath 1954; Schroeder and Mitchener 1971b). 
Chronic exposure of mice and rats to otherwise nontoxic doses has been shown to reduce fertility and to 
markedly reduce the viability of the offspring of pairs that are able to conceive (Schroeder and Mitchener 
1971b; Wahlstrom and Olson 1959b).  Selenium exposure has been shown to alter the length of the 
estrous cycle in female mice (Nobunaga et al. 1979) and to alter the menstrual cycle in monkeys 
(Cukierski et al. 1989).  Vaginal cytology of female rats provided with drinking water containing selenate 
or selenite indicated that the rats spent more time in diestrus and less time in proestrus and estrus than the 
controls (NTP 1994). However, it is not clear what effect, if any, this had on the ability of the animals to 
reproduce. 
Fertility studies in mice, rats, and pigs have demonstrated reduced rates of conception after oral treatment 
with selenium as selenate or selenite (Rosenfeld and Beath 1954; Schroeder and Mitchener 1971b; 
Wahlstrom and Olson 1959b).  Decreased conception rates and increased resorption rates have been 
reported for cattle, sheep, and horses fed diets naturally containing organic selenium compounds and 
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exhibiting symptoms of selenosis (Harr and Muth 1972).  An increased concentration of progesterone in 
the milk and an association of cystic ovaries with elevated blood selenium concentrations was observed in 
cows receiving selenium supplementation (Mohammed et al. 1991). 
Other possible examples of endocrine disruption due to selenium exposure include pancreatic damage in 
sheep and rats fed selenium as sodium selenite, sodium selenate, or seliniferous wheat (Halverson et al. 
1966; Harr et al. 1967; Smyth et al. 1990) and decreased plasma glucose (an insulin-like effect) in rats 
injected with sodium selenate.  However, these are isolated reports and it is not clear what relevance they 
have for selenium toxicity in humans. 
3.7 CHILDREN’S SUSCEPTIBILITY 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
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proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
Selenium is known to be an essential micronutrient for humans and animals; therefore, inadequate as well 
as excessive selenium intake can cause adverse health effects.  The Food and Nutrition Board of the 
National Research Council has established adequate intakes (AI) of 15–20 µg/day for infants based on the 
selenium content of milk of well nourished, but unsupplemented, mothers (NAS 2000).  No data were 
available on which to base RDAs for children or adolescents; thus, the RDAs for children and adolescents 
are extrapolated from adult values.  Studies of selenium deficient populations suggest that children are 
more susceptible to the effects of selenium deficiency and have the highest need for selenium of any 
individuals in the population (Chen et al. 1980; Yang et al. 1988). Premature and full-term infants 
generally have significantly lower blood selenium levels than their mothers and/or normal adults 
(Gathwala and Yadav 2002).  Infants born prematurely have lower hepatic selenium stores than term 
infants at birth, indicating that premature infants are at particular risk for the development of a deficiency 
state if adequate selenium is not provided in the diet (Bayliss et al. 1985). 
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Limited information is available relevant to the toxicity of selenium in children. Observations from the 
early literature, particularly in livestock and chickens, suggest that young animals are less resistant to 
selenium than older ones (NAS 1976a; Rosenfeld and Beath 1964b), and a study in rats found that 
weanlings accumulated more selenium in their tissues than adults (Salbe and Levander 1989).  In contrast, 
the available information in humans suggests that children may be less susceptible to toxic effects of 
selenium than adults.  Most data come from children living in areas of chronic high dietary selenium 
intake (Yang et al. 1989a, 1989b).  Children (aged 3–12 years) in a seleniferous area of China were found 
to have a significantly higher intake of selenium than the adults in their community, but a corresponding 
increase in blood levels of selenium appeared only in the children aged 7–12.  When the incidence of 
selenosis in different age groups was examined, it was found that 97% of cases were older than 18 years, 
and no cases were observed in children below 12 years of age, even though selenium intakes per kg body 
weight and blood selenium levels in these age groups were found to be either higher than or equal to those 
of affected adults.  One study of children living in a seleniferous area of Venezuela found a significant 
increase in the percentage of children showing lower than normal height compared with controls from a 
nonseleniferous area (Brätter et al. 1991a).  However, these children also had very low intakes of zinc 
compared with controls (10–25% of controls), and it is likely that their reduced growth rate is due to 
inadequate intake of zinc.  Another study that compared children from seleniferous and non-seleniferous 
areas of Venezuela found slightly reduced height, weight, hemoglobin levels, and hematocrit values for 
the children from the seleniferous area (no statistical analysis was performed), although no clinical signs 
of selenosis were observed (Jaffe et al. 1972).  However, the children from the seleniferous zone had a 
poorer diet, consumed less milk and meat, and had a greater incidence of intestinal parasites, which may 
account for the differences observed. 
No adverse developmental effects of excess selenium have been reported for humans.  Excess selenium is 
a demonstrated teratogen in birds (Franke and Tully 1935; Franke et al. 1936; Gruenwald 1958; Khan and 
Gilani 1980; Palmer et al. 1973), but there is no clear evidence linking selenium exposures to develop­
mental effects in mammals.  Malformations have been reported for livestock that consumed naturally high 
seleniferous diets (Dinkel et al. 1963; Rosenfeld and Beath 1964), but it is not clear that these reports took 
into account consumption of other toxic range plants.  Other studies of developmental effects in livestock 
receiving controlled diets with known amounts of selenium have generally not observed abnormalities, 
reduced birth weights, or increased mortality (Panter et al. 1995; Yaeger et al. 1998).  Likewise, studies of 
laboratory animals have not observed developmental effects, except at levels of selenium administration 
that produce maternal toxicity (Bergman et al. 1990; Chiachun et al. 1991; Ferm et al. 1990; NTP 1996; 
Poulsen et al. 1989; Rosenfeld and Beath 1954; Schroeder and Mitchener 1971b; Thorlacius-Ussing 
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1990).  In a teratology study of long-tailed macaques, no gross abnormalities or growth retardations were 
observed in fetuses from mothers administered doses that produced maternal toxicity. 
No studies were located that compared pharmacokinetic properties of selenium in humans or animals of 
different ages. Selenium is transferred to fetuses via the placenta (Archimbaud et al. 1992; Choy et al. 
1993; Hawkes et al. 1994; Jandial et al. 1976; Mahan and Kim 1996) and to infants via breast milk 
(Brätter and Negretti De Brätter 1996; Brätter et al. 1991b; Li et al. 1999; Michalke and Schramel 1998; 
Moser-Veillon et al. 1992; Rodríguez Rodríguez et al. 1999; Viitak et al. 1995; Yang 1989b). Studies of 
lactating women have shown a clear relationship between levels of selenium in the mother’s diet and the 
concentration of selenium in her breast milk (Brätter et al. 1991b).  Colostrum contains more than twice 
the selenium concentration of mature human milk, but the selenium content of mature milk changes little 
with advancing stages of lactation (Gathwala and Yadav 2002; Higashi et al. 1983; Mannan and Picciano 
1987; Smith et al. 1982). No information was located regarding adverse effects in infants breast-fed by 
mothers in regions with high selenium diets. 
A series of conditions are associated with oxygen therapy in neonates, including bronchopulmonary 
dysplasia, retinopathy of prematurity, necrotizing enterocolitis, patent ductus arteriosus, and neuronal 
injury in hypoxic ischemic encephalopathy (Gathwala and Yadav 2002).  Because these effects might be 
caused at least in part by oxygen radicals, it has been suggested there is an “oxygen radical disease” in 
neonatology.  This indicates that antioxidants may form an important modality of treatment in neonates, 
and because selenium is part of the antioxidant enzyme glutathione peroxidase, good selenium nutrition is 
important for antioxidant defense (Gathwala and Yadav 2002).  
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
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readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to selenium are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by selenium are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10 “Populations That Are Unusually Susceptible”. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Selenium 
Biomarkers of exposure are available for high and low exposures to selenium.  Selenium can be detected 
in the blood, feces, urine, hair, and nails of exposed individuals.  Both selenium deficiency and excessive 
levels of selenium are associated with several disorders.  For purposes of comparison, reported mean 
selenium concentrations in whole blood, blood constituents, urine, hair, nails, and the placenta for healthy 
individuals living in the United States and several other countries are listed in Table 3-7.  Based on 
information collected from 1988 to 1994 in the third National Health and Nutrition Examination Survey 
(NHANES III), the serum concentration of selenium in the U.S. population has been estimated by sex and 
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age (DHHS 1997).  The mean selenium serum concentration for all ages and both sexes was estimated to 
be 0.125 mg/L.  Additional results from NHANES III are summarized in Chapter 6 (Section 6.5, 
Table 6-6). The analytical methods used to measure selenium (described in Chapter 7) have improved, 
and the more recent studies may be more reliable.  The values for the Chinese populations studied by 
Yang et al. (1983, 1989b) were those reported for individuals living in the selenium "adequate" regions 
included in the study.  "Normal" selenium concentrations in blood constituents and other tissues in people 
from some countries (e.g., New Zealand) are generally lower than those in people living in the United 
States. In general, urinary excretion rates of 20–200 µg selenium/day are not associated with either 
selenium deficiency or toxicity (Sanz Alaejos and Diaz Romero 1993). 
In the United States and other developed countries, hair selenium concentrations are not necessarily 
indicative of dietary exposure to environmental selenium.  Users of therapeutic dandruff shampoos 
containing selenium sulfide may have high levels of selenium in their hair because the externally 
deposited selenium adsorbs to hair (Alfthan 1985).  However, due to minimal levels of dermal absorption 
of selenium from shampoo, blood and urine levels are not significantly affected by selenium-containing 
shampoos (Howe 1979). Toenail samples have also been used as biomarkers of selenium exposure 
(Hunter et al. 1990a). Selenium levels in toenails were measured in volunteers who ate bread containing 
selenium for 1 year (Longnecker et al. 1993).  During this time period, selenium in the large toenail did 
not reach a steady state, while a steady state was reached in the other toenails.  After conclusion of the 
1-year exposure, levels of selenium continued to decline until they reached baseline levels in 2 years. 
Below plasma and whole blood selenium concentrations of 0.10 mg selenium/L, a positive correlation has 
been reported between blood selenium levels and both erythrocyte and whole blood GPX activity 
(Duffield et al. 1999; Perona et al. 1977; Thomson 1977; Valentine et al. 1988).  GPX is an enzyme that 
acts as a scavenger of peroxides and protects cells from oxidative damage.  However, whole blood 
selenium levels ≤0.10 mg selenium/L represent the lower end of the range of whole blood selenium 
concentrations reported by Allaway et al. (1968) for American males.  
A correlation between blood selenium levels and GPX activity was not observed when plasma and whole 
blood selenium levels were above 0.10 mg selenium/L.  Therefore, GPX activity is likely to be a 
biomarker for selenium deficiency but not for overexposure.  Neve et al. (1988), on the other hand, found 
no relationship between erythrocyte or plasma GPX activity levels and plasma selenium levels in a group 
of Belgian subjects with plasma selenium levels between 0.087 and 0.13 mg selenium/L.  However, 
platelet GPX activity levels did correlate with plasma selenium levels within this range (Neve et al. 1988).  
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Valentine et al. (1980) measured the level of selenium in whole blood, urine, and hair of 33 residents 
from a Mexican village who consumed drinking water contaminated with selenium (0.026–1.8 mg 
selenium/L) from a uranium mill tailing pond.  Blood levels ranging from 0.133 to 0.248 mg selenium/L, 
urine excretion rates ranging from 14.4 to 337.5 µg selenium/day, and hair selenium levels ranging from 
0.02 to 1.98 µg selenium/g were not correlated with GPX activity. In examining the relationship between 
selenium and GPX activity, selenium-dependent GPX activity must be distinguished from nonselenium­
dependent GPX activity (Edwards and Blackburn 1986). 
Selenoprotein P, which contains 10 selenocysteines, is the principal selenoprotein found in plasma (Sunde 
1990). Selenoprotein P in plasma also does not continue to increase with increasing selenium and has 
been suggested as an alternative to GPX as a biomarker for selenium status (Duffield et al. 1999; Huang 
et al. 1995). The function of selenoprotein P has still not been determined. 
Field studies have used primarily blood or urine levels to indicate the degree of selenium exposure.  
Valentine et al. (1978) found a significant correlation between selenium levels in well water used for 
drinking and urine selenium excretion measured for 35 residents in a New Mexico community.  However, 
no correlation was found between selenium levels in well water and the blood selenium levels of the 
35 residents (Valentine et al. 1978).  The correlation coefficients between the log of urine-selenium 
excretion (µg selenium/day) and the log of blood-selenium (mg selenium/L) with the log of the well water 
selenium concentration (mg selenium/L) were 0.57 (p<0.01) and 0.14 (p>0.05), respectively.  The 
correlation coefficient between the log of hair selenium concentration (µg selenium/g) and the log of the 
well water selenium levels (mg selenium/L) was 0.45 (p<0.01).  
Methylation is a detoxification pathway for selenium, and the extent of methylation is dose-dependent.  
Monomethylated selenium is excreted in the urine at deficient, normal, and low-toxic levels of selenium, 
and excretion of trimethylated selenium increases at toxic doses (Kobayashi et al. 2002).  The main 
monomethylated form of selenium has been identified as a selenosugar (1β-methylselenol-N-acetyl-D­
galactosamine). The dose-dependent nature of the metabolism indicates that urinary monomethylated 
(selenosugar) and trimethylated selenium could be used as indicators of selenium exposure that increase 
within the required to low-toxic range and with a distinct toxic dose, respectively (Kobayashi et al. 2002). 
Clinical symptoms have been associated with excessive blood, urine, and hair levels of selenium in 
exposed patients. Glover (1967) examined workers in a selenium rectifier factory and found that 
selenium levels in urine from workers exposed to selenium (annual averages from 1954 and 1958 range 
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from 0.076 to 0.109 mg selenium/L urine) were higher than the average urine selenium levels of 
preemployment applicants (average, 0.034 mg selenium/L urine; range, 0–0.15 mg selenium/L).  Garlic 
breath, skin rashes, indigestion, lassitude, and irritability were noted, but no increase in mortality among 
exposed workers was detected.  Smith and Westfall (1937) examined urine selenium levels in rural 
populations in Wyoming, South Dakota, and Nebraska and reported evidence of skin discoloration and 
lesions, tooth decay, diseased nails, gastrointestinal disturbances, and arthritis in individuals with urine 
selenium levels of 0.2–1.98 mg selenium/L; however, the authors did not find a significant correlation 
between clinical signs and the level of selenium in the urine.  Longnecker et al. (1991) examined ranchers 
in the same area of the United States where selenosis of livestock had been observed.  No clinical effects 
were observed with concentrations up to 2.2 mg/L in urine.  Yang et al. (1983, 1989a, 1989b) measured 
mean blood, urine, and hair selenium levels of 3.2 mg selenium/L, 2.68 mg selenium/L, and 32.2 µg 
selenium/g, respectively, in a high selenium area where chronic selenosis was common in China.  The 
clinical signs of selenium intoxication included loss of hair and nails, skin lesions, tooth decay, and 
nervous system disorders.  In another area of China with high environmental levels of selenium but no 
signs of chronic selenosis in the population, blood selenium levels averaged 0.44 mg selenium/L (with a 
range from 0.35 to 0.58 mg selenium/L). 
At blood levels of 0.06–0.20 mg selenium/L, Deguchi (1985) found selenium to be positively correlated 
with grasping power and blood pressure in normal men and women and with hematocrit and hemoglobin 
concentrations in normal women.  Similar correlations were not found in subjects with proteinuria or 
hypertension.  In addition, Gebre-Medhin et al. (1988) found that in healthy children, serum selenium 
levels of 0.055–0.082 mg selenium/L were positively correlated with serum cholesterol, serum 
triglycerides, low and very low density lipoproteins, and apolipoproteins.  Similar correlations were not 
found in diabetic children, who have slightly elevated serum selenium levels. 
Biomarkers of Deficiency. Two endemic diseases, Keshan disease and Kashin-Beck disease, have been 
reported in selenium-deficient populations in China in which mean hair, blood, and urine selenium levels 
are low (Yang et al. 1988).  Acute Keshan disease, manifested as nausea, vomiting of yellowish fluid, and 
necrosis of the myocardium, has been found in a population with an average whole blood selenium 
concentration of 0.018 mg selenium/L, an average urinary concentration of 0.007 mg selenium/L, and an 
average hair selenium concentration of 0.123 µg/g (Yang et al. 1988).  Kashin-Beck disease, which 
causes atrophy, degeneration, and necrosis of cartilage tissue, was observed in selenium-deficient areas in 
China, in which the average selenium concentration in hair ranged from 0.077 to 0.165 µg selenium/g and 
blood selenium concentrations averaged approximately 0.02 mg selenium/L.  In nonaffected areas in 
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China, the selenium content is >0.2 µg selenium/g in hair and >0.06 mg selenium/L in blood (Yang et al. 
1988). Although the association between selenium deficiency and Kashin-Beck disease is unclear, 
selenium-deficiency diseases are unlikely to occur in persons in the United States.  If selenium is not 
added to parenteral nutrition solutions, persons on long-term total parenteral nutrition are at risk for 
developing selenium deficiency symptoms which include cardiomyopathies, muscle pain, and weakness 
(Thomson 1991). 
There is also some evidence that low serum selenium levels are associated with increased cancer risk, but 
this is not conclusive (Hojo 1981a; Willett et al. 1983).  Salonen et al. (1984) concluded that an increased 
risk of cancer (a combination of gastrointestinal, respiratory, urogenital, hematologic, dermal, and skeletal 
cancers) in humans in Finland is associated with serum selenium levels of 0.045 mg selenium/L and 
below. Virtamo et al. (1987) found that cancer patients in Finland, including individuals with 
gastrointestinal, respiratory, skin, skeletal, urogenital, and hematological cancers, had slightly but not 
significantly lower serum selenium levels (mean and standard error of 0.0539±0.0015 mg selenium/L) 
compared with noncancer patients (0.0553±0.0005 mg selenium/L).  However, serum selenium is 
generally an indicator only of very recent selenium status.  As such, serum selenium may indicate an 
effect of cancer (malabsorption or anorexia) rather than a cause (Lockitch 1989; van't Veer et al. 1990). 
A deficiency of selenium is also associated with cardiomyopathy (Johnson et al. 1981; Oster et al. 1983).  
Salonen et al. (1982) noted a statistically significant association between serum selenium concentrations 
of less than 0.045 mg selenium/L and the adjusted relative risk of coronary death, cardiovascular death, 
and myocardial infarction.  Hojo (1981a) noted that patients with epilepsy had significantly lower urinary 
selenium levels than controls. 
3.8.2 Biomarkers Used to Characterize Effects Caused by Selenium 
Specific biomarkers were not found for effects of excess selenium, indicating that better markers of 
effects are needed at high levels of exposure.  Garlic breath is a marker of over-exposure to selenium 
compounds.  However, as other metals that are methylated (e.g., arsenic) also result in garlic odor of the 
breath, this effect is not a unique marker of selenium over-exposure.  Hair and nail effects may be the 
most frequent effects of overexposure to selenium. Hair becomes dry and brittle and breaks off at the 
scalp. Nails are also brittle and have white spots and longitudinal streaks, and break off easily (Lockitch 
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1989). Although these effects may not be specific to selenium, if they are observed, a determination of 
selenium status may be useful. 
Yang et al. (1989b) used increased prothrombin time (increased clotting time), a measure of hepatic 
damage, as a biomarker for selenium but their interpretation of their observations may be unwarranted.  
The difference they saw in affected humans was very small (1 second); prothrombin time has not been 
previously demonstrated to correlate with symptoms of selenosis nor used to detect selenosis; and since 
the test has not been widely used, the results reported for the small number of affected individuals may be 
within the range of normal values for the general population or a subpopulation (IRIS 2003). 
In humans and in animal studies, high concentrations of selenium have been demonstrated to cause 
neurological effects.  Biomarkers of effect for the neurological system have been reviewed by ATSDR 
(OTA 1990). 
3.9 INTERACTIONS WITH OTHER CHEMICALS 
A wide variety of interactions of selenium with essential and nonessential elements, vitamins, 
xenobiotics, and sulfur-containing amino acids have been demonstrated in numerous studies.  Selenium 
has been reported to reduce the toxicity of many metals including mercury, cadmium, lead, silver, and to 
some extent, copper (Frost 1972; Levander 1982).  Most forms of selenium and arsenic interact to reduce 
the toxicity of both elements (Levander 1977).  Because of selenium's role in the antioxidant glutathione 
peroxidase enzymes, selenium also reduces the toxicity of metals in vitamin E-deficient animals (Diplock 
et al. 1967). 
The interactions of selenium with other elements and compounds are complex and not well understood 
(Naganuma et al. 1983; NAS 1976a).  The degree to which selenium is toxic, is taken up by tissues, or is 
excreted can be influenced by these interactions.  Some of the major interactions of selenium compounds 
with other elements and compounds are described below. 
Arsenic.  In general, arsenic antagonizes selenium toxicity (Levander 1977).  This effect extends to 
selenium in sodium selenite and selenate, seleniferous wheat, selenocystine, and selenomethionine 
(Levander 1977).  However, a very pronounced synergistic toxicity exists between arsenic and two 
methylated selenium metabolites, trimethylselenonium ion and dimethyl selenide (Obermeyer et al. 
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1971).  One of the more striking demonstrations is the antagonism of arsenic-induced terata in rodents by 
concomitant selenium exposure (Holmberg and Ferm 1969), and pretreatment of mice with sodium 
selenite reduced the clastogenic effects of a subsequent dose of sodium arsenite (Biswas et al. 1999b).  
Moxon et al. (1945) found that arsenic could reduce selenium toxicity when compounds of both elements 
were injected subcutaneously, thereby indicating that arsenic did more than interfere with the 
gastrointestinal absorption of selenium.  Kamstra and Bonhorst (1953) found that arsenic reduced the 
excretion of volatile selenium compounds in expired air following the injection of compounds of both 
elements into rats at acutely toxic levels.  Levander and Baumann (1966a) found that the amount of 
selenium retained in the liver decreased and the amount of selenium appearing in the gastrointestinal tract 
increased as the dose of administered arsenic was increased.  Experiments with rats and guinea pigs with 
cannulated bile ducts confirmed that arsenic increased the biliary excretion of selenium and that selenium 
increased the biliary excretion of arsenic (Levander and Baumann 1966b).  It has recently been suggested 
that the mutual reduction in toxicity of arsenic and selenium administered together is due to the formation 
of an arsenic-selenium compound, seleno-bis(S-glutathionyl)arsinium (Gailer et al. 2000b).  This 
compound was isolated from the bile of rabbits injected with selenium and arsenic and identified by X-ray 
spectroscopy. 
Cadmium. Selenium can antagonize the nephrotoxic and hepatotoxic effects of cadmium in rats (Flora et 
al. 1982; Lindh et al. 1996; Nehru and Bansal 1996; Stajn et al. 1997), the inflammation, atrophy, and 
necrosis induced by cadmium in testes of rats (Jones et al. 1997; Mason and Young 1967; Ohta and 
Imamiya 1986; Wlodarczyk et al. 1995; Yiin et al. 1999), and the cardiotoxicity of cadmium in rats 
(Jamall et al. 1989).  The protective effects are thought to occur as a result of the formation of a selenium-
cadmium complex of high molecular weight (Chen et al. 1975; Jamall et al. 1989; Jamba et al. 1997; Ohta 
and Imamiya 1986). 
Fluoride. Fluoride ion may interact with selenium; however, the degree and types of interaction depend 
upon the chemical form of selenium (i.e., organic or inorganic) and the dose.  Moxon and DuBois (1939) 
reported that fluoride increased the toxicity of selenium in rats at 5 mg fluoride/L in the drinking water of 
young rats fed a diet containing 11 ppm selenium (0.55 mg selenium/kg/day) as seleniferous wheat.  
Selenium decreased growth and increased mortality in rats drinking fluoridated water compared to rats 
drinking deionized water. These results were disputed by Hadjimarkos (1969a) who administered 3 mg 
selenium/L as sodium selenite (0.15 mg selenium/kg/day) either with or without 50 mg fluoride/L as 
sodium fluoride in the drinking water of rats.  The growth and mortality data indicated that the combined 
administration of selenium and fluoride under the conditions used did not increase selenium toxicity.  
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However, the amount of administered fluoride was significantly higher and the amount of administered 
selenium was significantly lower in the Hadjimarkos (1969a) study than the amounts administered by 
Moxon and DuBois (1939).  No additional studies were located that reexamined the possible interaction 
between fluoride and selenium. 
Iodine. Selenium and iodine interact to affect thyroid function.  There are at least two aspects to this 
interaction. First, selenium is an important component of the deiodinase enzymes, including 
iodothyronine 5'-deiodinases, which convert the prohormone thyroxine (T4) to the active circulating form, 
triiodothyronine (T3) (Delange 2000; Köhrle 1994; St Germain and Galton 1997).  Second, selenium is 
also a component of GPX, the main enzyme responsible for protecting thyroid cells against oxidative 
damage.  Hydrogen peroxide (H2O2) is produced in the thyroid during the conversion of T4 to T3 and is 
detoxified by GPX.  An apparent consequence of interaction between iodine and selenium has been 
observed in human populations deficient in iodine.  In some iodine-deficient geographic regions, a 
reversible hypothyroidism with goiter formation (myxedematous cretinism) is observed (Goyens et al. 
1987; Vanderpas et al. 1990).  In other iodine-deficient areas, hypothyroidism is accompanied by thyroid 
cell necrosis.  The thyroid cell necrosis appears to result in populations that are deficient in both iodine 
and selenium (Contempré et al. 1991a, 1992, 1993, 1995; Köhrle 1994).  Selenium supplementation of 
individuals deficient in both iodine and selenium produces a further decrease in thyroid function, but if 
selenium supplementation is preceded by normalization of iodine levels, then normal thyroid function is 
restored (Contempré et al. 1991, 1992).  Selenium supplementation also affects thyroid hormone levels in 
humans with no iodine deficiency; these effects include decreases in serum T3 and T4 levels and increases 
in serum TSH levels, suggesting suppression of thyroid hormone production (Brätter and Negretti De 
Brätter 1996; Duffield et al. 1999; Hagmar et al. 1998; Hawkes and Turek 2001). The necrotizing effect 
of iodine on thyroid cells was greater in selenium-deficient rats than in selenium-supplemented rats 
(Contempré et al. 1993).  Other studies in rats showed that selenium deficiency causes decreased 
metabolic clearance of iodothyronines and decreased extrathyroidal production of T3, as a result of 
decreased iodothyronine deiodinase activity, which can be restored to normal by selenium repletion 
(Arthur and Beckett 1989, 1994; Behne and Kyriakopolous 1993). The effects observed in iodine and 
selenium deficient humans and animals is consistent with a proposed mechanism in which (1) iodine 
deficiency results in hyperstimulation of the thyroid by TSH and consequently in increased production of  
H2O2 within the cells, (2) selenium deficiency results in GPX deficit and consequently in accumulation of 
H2O2, and (3) induction of thyroid cell necrosis and fibrosis from the excess H2O2 that cannot be 
detoxified due the lack of GPX (Contempré et al. 1995; Delange 2000; Köhrle 1994).  The available data 
suggest that iodine supplements could cause adverse effects in selenium-deficient individuals. 
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Mercury.  Simultaneous administration of mercury and selenium in equimolar doses to animals resulted 
in decreased toxicity of both elements in acute and chronic studies with inorganic and organic mercury 
and with either inorganic or organic selenium compounds, although inorganic forms of selenium appear 
to be more effective than organic forms (Chang 1983; Rao et al. 1998; Skerfving 1978).  Selenium 
protects against the acute nephrotoxicity of the mercuric ion and methylmercuric ion in rats (Ganther et 
al. 1972; Hansen 1988; Magos et al. 1987; Parizek and Ostadalova 1967) and possibly against acute 
neurotoxicity of the methylmercuric ion in rats (Ohi et al. 1980).  The protective effect of selenium has 
been associated with a higher whole body retention of mercury rather than with increased mercury 
excretion (Hansen 1988; Magos et al. 1987).  Selenium has been shown to inhibit biliary excretion of 
methyl mercury in rats (Urano et al. 1997), while mercury exposure reduces urinary selenium excretion in 
humans (Ellingsen et al. 1995).  Although the mechanism of the interaction has not yet been elucidated, 
selenium and mercury appear to form a metabolically inert compound by reaction with GSH (Gailer et al. 
2000b).  Further support for the role of this compound comes from the observation that selenium-treated 
animals can remain unaffected despite an accumulation of mercury in tissues to levels that are otherwise 
associated with toxicity (Skerfving 1978).  Additional support comes from the 1:1 ratio of selenium and 
mercury found in the livers of marine mammals and in the bodies of experimental animals injected with 
mercury and selenium, regardless of the ratio of the administered doses (Hansen 1988). 
Although the fetotoxicity of methylmercuric chloride has been enhanced in selenium-deficient mice 
(Nishikido et al. 1987), additional selenium administration does not appear to protect against teratogenic 
effects (i.e., cleft palate) of methylmercuric chloride in mice (Lee et al. 1979).  High doses of selenium 
administered as selenite for 30 days prior to gestation and through gestation day 18 to mice fed a diet 
containing high doses of methylmercuric chloride increased the incidence of cleft palate (Nobunaga et 
al. 1979).  Concurrent treatment of pregnant or lactating mice receiving nontoxic doses of methyl mercury 
in drinking water with selenomethionine increased the deposition of mercury in the offspring (Nielsen and 
Andersen 1995). 
Methionine and Vitamin E. Combinations of methionine and vitamin E have been found to be 
antagonistic to selenium toxicity.  In one study, selenium concentrations in the liver and kidneys of rats 
fed selenium (sodium selenate)-containing diets with methionine and vitamin E were less than the 
concentrations found in the livers and kidneys of rats fed selenium with either methionine or vitamin E 
alone (Levander and Morris 1970).  The results are compatible with the hypothesis that methionine 
detoxifies selenium by forming methylated derivatives of selenium that are eliminated in the urine and in 
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expired air (see Section 3.4.4) (Stadtman 1977, 1980, 1983, 1987, 1990).  As discussed in Section 3.11, 
methionine administered as an antidote for acute selenium toxicity in rats was ineffective (Lombeck et al. 
1987). 
Silver. Selenium has been shown to be protective against the hepatotoxic effects of silver in vitamin E-
deficient rats.  A 0.15% solution of silver acetate in the drinking water of rats produced necrotic 
degeneration of the liver and high mortality.  Dietary selenium supplementation at 1 mg selenium/kg food 
resulted in a significant reduction in the toxic effects of silver (Diplock et al. 1967).  One report indicates 
a nontoxic dose of silver acetate in rats minimizes effects of acute selenium toxicity.  However, the body 
burden of selenium in several organs increased with treatment with silver acetate.  It is postulated that this 
antagonistic effect may be due to the formation and disposition of silver selenides, which are relatively 
insoluble and nontoxic (Eybl et al. 1992).  
Sulfate. Sulfate appears to reduce the growth inhibition that results from dietary exposure of rats to high 
levels of selenite or selenate (Halverson and Monty 1960).  Sulfate does not appear to be protective 
against selenium-induced liver damage (Halverson and Monty 1960). 
Antagonistic interactions with several additional metals including antimony, germanium, and bismuth 
have been reported (Paul et al. 1989).  Complex interactions of selenium with other metals, vitamins, and 
nutrients usually lead to a reduced toxicity of selenium and/or a reduced toxicity of the interacting 
substance. However, vitamin C (ascorbic acid) may increase the absorption and toxic effects of selenium 
in humans (HSDB 2001; Lombeck et al. 1987; Mack 1990; Martin et al. 1989a, 1989b).  The relevance of 
these interactions to selenium exposure of the general public is unknown.  Many review articles are 
available concerning the interactions of selenium and other chemicals, including those by Combs, Jr., and 
Combs (1987), Hansen (1988), Levander (1972), Magos and Webb (1980), Naganuma et al. (1983), and 
Whanger (1981). 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to selenium than will most persons 
exposed to the same level of selenium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of selenium, or compromised function of organs 
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affected by selenium.  Populations who are at greater risk due to their unusually high exposure to 
selenium are discussed in Section 6.7, Populations With Potentially High Exposures. 
Data concerning human subpopulations with unusual susceptibility to the toxic effects of selenium were 
not located. Epidemiologic studies have identified populations with very low or very high nutritional 
status, and these groups are expected to have very different responses to selenium exposures.  Pregnant 
and nursing women are believed to require more selenium than the general public (NRC 1989). 
It is possible that persons exposed to high fluoride levels in drinking water might be at greater risk of 
adverse health effects from exposure to excessive levels of selenium (Moxon and DuBois 1939; Yang et 
al. 1989a), but evidence on this point is equivocal (Hadjimarkos 1969a) and requires further study. 
Individuals with vitamin E-deficient diets might also be at greater risk of liver damage from exposure to 
excess selenium (Levander and Morris 1970).  Based on studies of chemically induced diabetes in rats, 
selenium may change insulin needs (McNeil et al. 1991).  Therefore, insulin-dependent diabetics may be 
more sensitive to adverse health effects due to selenium exposure than the general population. 
Cretins or other individuals with iodine or thyroid deficiencies may be more sensitive to adverse health 
effects from selenium exposure (Contempré et al. 1991b, 1992).  Iodine supplementation of these 
individuals without selenium supplementation may further exacerbate the effects.  The elderly may be 
less susceptible to the negative effects of selenium and more prone to selenium deficiencies.  A number of 
researchers have reported lower absorption of selenium and lower selenium tissue concentrations in the 
elderly compared to younger adults (Martin et al. 1991; Morisi et al. 1989). 
Populations living in the western United States in areas eating produce grown in highly seleniferous soils 
could be at greater risk of adverse health effects from additional environmental exposure to selenium if 
their selenium nutritional status is already high (see Section 6.6). 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to selenium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to selenium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
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for medical advice. The following texts provide specific information about treatment following exposures 
to selenium:  
Nadig RJ. 1994.  Cadmium and other metals and metalloids.  In:  Goldfrank LR, Weisman RS, 
Flomenbaum N, et al. eds.  Goldfrank’s toxicological emergencies. 6th ed. Norwalk, CT:  Appleton and 
Lange, 1342-1343. 
Mofenson HC, and Caraccio TR. 1998. Toxicity of household products.  In: Viccellio P, ed.  
Emergency toxicology.  2nd ed. Philadelphia, PA:  Lippincott-Raven, 519. 
3.11.1 Reducing Peak Absorption Following Exposure  
No specific recommendations have been reported for reducing absorption following acute high-dose 
exposure to selenium or selenium compounds via inhalation or dermal exposure (Gosselin et al. 1984; 
HSDB 2001). There have been very few reported cases of overexposure via inhalation in industrial 
settings but some have resulted in toxic effects (Lockitch 1989).  General procedures suggested for 
reducing absorption following accidental industrial exposure include moving the exposed person into 
fresh air, removing contaminated clothing and shoes, and flushing exposed skin or eyes with running 
water (HSDB 2001). 
Oral exposures to toxic quantities of selenious acid, sodium selenate, and selenium dioxide have been 
reported (Lockitch 1989).  In general, only supportive treatment has been recommended (HSDB 2001; 
Mack 1990).  In some cases, gastric lavage and induction of vomiting by use of emetics have been 
reported to be useful in reducing absorption, but because selenious acid (in gun bluing, pH 1) is caustic, 
both procedures could result in additional damage by this compound (Lombeck et al. 1987; Mack 1990). 
The possibility of a sudden onset of shock, seizures, severe hypotension, and cardiorespiratory arrest has 
been used to argue against emesis (Mack 1990).  It has also been suggested that oils and alcohol are to be 
avoided in treatment of ingested selenium sulfide because these agents may increase absorption (Gosselin 
et al. 1984). 
3.11.2 Reducing Body Burden  
In acute exposure situations, selenium compounds are rapidly absorbed and widely distributed throughout 
many organ systems following inhalation or ingestion (see Section 3.4.2).  Extensive parenteral fluid 
administration has been used to force the urinary excretion of selenium (Lombeck et al. 1987).  Chelating 
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agents have not been effective in experiments, and both calcium disodium ethylene diamine tetraacetate 
(EDTA) and dimercaprol (British Anti-Lewisite, BAL) may increase the toxic effects of selenium 
(Lombeck et al. 1987; Mack 1990; Paul et al. 1989).  Although vitamin C (ascorbic acid) is used to reduce 
the body burdens of other metals, it may also increase the absorption and toxic effects of selenium in 
humans (HSDB 2001; Lombeck et al. 1987; Mack 1990; Martin et al. 1989a, 1989b).  Bromobenzene has 
been reported to increase the urinary excretion of selenium, but because bromobenzene is also a hepatic 
toxin, its use is dangerous (Gosselin et al. 1984; HSDB 2001). 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
The exact molecular mechanism of toxic action by selenium and selenium compounds is not known.  One 
theory is that at a biochemical level, selenium inactivates sulfhydryl enzymes leading to depression of 
cellular oxidative processes (Lombeck et al. 1987; Mack 1990; Shamberger 1981).  No information was 
located on established therapies designed to interfere with this possible mechanism of action of selenium.  
Because selenomethionine is known to randomly insert into proteins, rats were treated with methionine 
after acute selenosis had developed, but no effect was observed (Lombeck et al. 1987).  However, 
pretreating rats with dietary methionine and vitamin E reduced the toxicity of dietary selenium as 
measured by decreased liver damage, reduced body weight gain, and decreased liver and kidney 
concentrations of selenium compared to those in rats that had not received supplements (Levander and 
Morris 1970).  Inorganic sulfate fed simultaneously with selenite or selenate in the diet protected rats 
from the toxicity of selenium as measured by body weight gain; however, sulfate did not protect against 
liver necrosis caused by selenium (Halverson et al. 1962).  It would, therefore, seem plausible that another 
nontoxic sulfur-containing chemical could be found to be effective against acute selenium toxicity.  
The search for an agent that both reduces the acute toxicity of selenium and increases the excretion of the 
selenium compound formed has proved difficult (Paul et al. 1989).  In some experimental cases, other 
metals have been shown to mitigate the toxicity of selenium, possibly by forming metal selenides with 
low solubility and toxicity (see Section 3.9).  Several metal-containing compounds were tested for 
efficacy in reducing toxic effects and increasing elimination of selenium from sodium selenate injected 
into rats. Germanium citrate is nontoxic and was found to be effective both at reducing toxic effects and 
increasing the rate of selenium elimination.  However, the germanium compound, bis-carboxyethyl 
germanium sesquioxide, had no positive effect on toxicity or distribution to organs but did increase the 
amount of selenium excreted in the urine (Paul et al. 1989).  In mice, pretreatment with a nontoxic dose of 
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silver acetate was shown to reduce the toxic effects of sodium selenite.  However, this treatment increased 
the whole body burden of selenium, and the concentrations in several organs were raised compared to 
those in the controls injected with sodium selenite only (Eybl et al. 1992).  Arsenic was proposed as a 
possible prophylactic against selenium poisoning in workers, based on counteraction of selenium toxicity 
in pigs exposed to sodium arsenate (Amor and Pringle 1945). 
3.12 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of selenium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of selenium. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Selenium 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
selenium are summarized in Figure 3-10.  The purpose of this figure is to illustrate the existing 
information concerning the health effects of selenium.  Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect.  The dot does not necessarily imply 
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
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Figure 3-10.  Existing Information on Health Effects of Selenium 
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As seen in Figure 3-10, very little quantitative information is available regarding the health effects in 
humans exposed to selenium compounds via inhalation.  The only quantitative inhalation studies in 
humans that relate selenium exposure levels or selenium body levels to health effects following inhalation 
exposure are epidemiological cancer studies.  Fatalities following inhalation exposure to selenium 
compounds have not been reported.  Despite the large number of cases of reported inhalation exposures in 
occupational settings, characterization of exposure concentrations and the selenium compounds present in 
the air are generally lacking.  It is therefore not possible to link the degree and types of symptoms 
reported in workers to selenium exposure levels.  There have been no reports of immunological, 
developmental, reproductive, or genetic effects in humans resulting from inhalation exposure to selenium 
compounds.  Complaints of dizziness and fatigue have accompanied occupational inhalation exposures, 
but characterization of the exposure levels required to produce neurological symptoms is lacking. 
Most of the information concerning the health effects in humans following exposure to selenium and 
selenium compounds is for the oral exposure route. However, exposure levels associated with the few 
documented fatalities resulting from accidental or suicidal poisoning with selenium compounds are 
lacking, as are exposure levels for other nonfatal poisonings by ingestion.  A series of epidemiological 
studies in China have provided the only data about chronic exposure levels to excess dietary selenium that 
resulted in adverse effects on skin, nails, and hair and in possible neurological effects. 
Older reports from the western United States described similar symptomology in the 1930s, but did not 
characterize daily selenium intake.  More recent reports show no clinical symptoms in the same area.  The 
possible inverse relationship between dietary selenium intake and the risk of various types of cancer has 
been examined in numerous epidemiological studies in the United States and other countries. 
Concern for the dermal route of exposure to selenium compounds as a cause of adverse health effects in 
humans is extremely low except for the acid forms, which owe their dermal effects to their acidity more 
than to their selenium content.  Selenium sulfide, an ingredient in some antidandruff shampoos, does not 
appear to be absorbed through the skin.  Ingestion of large amounts of the compound, however, would be 
of concern because selenium sulfide has been shown to be carcinogenic in rats and mice following oral 
exposure. 
Data are available for acute inhalation exposures for a few of the volatile selenium compounds that have 
resulted in the death of animals. These exposures also produced signs of central nervous system toxicity, 
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lung injury, and possible damage to heart and liver.  No studies were located concerning health effects in 
animals following intermediate or chronic inhalation exposures to volatile selenium compounds or 
selenium dust. 
In animals, the focus on the oral toxicity of selenium has taken two routes, one in laboratory animals and 
the other in studies of selenium toxicity to livestock.  In laboratory animals, attention has been directed 
toward the hepatotoxic properties of selenites, selenates, and selenium contained in grains following early 
reports that selenium produced hepatic carcinomas in rats.  An intermediate-duration study has also 
shown that selenate and selenite can cause kidney effects in rats while mice are less sensitive to this effect 
of selenium compounds.  In recent years, much of the research in laboratory animals using the oral route 
of administration of selenium compounds has been directed toward the anticarcinogenic properties of 
selenium compounds. 
In livestock, concern for selenium toxicity and deficiency is high. In areas of the country with selenium-
poor soils, dietary selenium supplementation for livestock has been necessary to prevent chronic selenium 
deficiency diseases.  Dietary supplementation programs have resulted in cases of accidental poisonings 
from misuse of the selenium supplements (Hopper et al. 1985). 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. The primary target organ in humans following acute exposure to high 
concentrations of selenium by inhalation or oral routes is the lung, with cardiovascular, hepatic, and renal 
systems all affected (lesser systemic effects were observed in all other organ systems except the 
musculoskeletal system) (Carter 1966; Civil and McDonald 1978; Clinton 1947; Koppel et al. 1986; 
Wilson 1962).  Two case reports of acute dermal exposure were also located; the results revealed effects 
on the skin and eyes (Middleton 1947; Pringle 1942).  Additional epidemiological or occupational studies 
would be useful to further characterize the effects of acute exposure via all routes and to confirm the 
target organ data. 
Studies regarding single inhalation or oral exposures of rats, guinea pigs, rabbits, and mice have provided 
information on lethal levels of exposure to selenium compounds (Cummins and Kimura 1971; Dudley 
and Miller 1941; Hall et al. 1951; Miller and Williams 1940; Olson 1986; Smyth et al. 1990). However, 
few levels at which sublethal effects first appear have been identified.  Clinical observations and gross 
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necropsies have been performed, but no single-dose exposure study has included internal examination of 
the animals to identify dose-response data for sublethal systemic toxic effects.  Such studies might 
provide information on the thresholds for systemic toxicity following single-dose exposure.  Repeated 
inhalation exposure studies in animals are limited to a few days of exposure (Hall et al. 1951).  Although 
the studies have demonstrated cumulative toxicity following repeated inhalation exposure to inorganic 
selenium compounds, effects other than lethality have been poorly characterized.  Single-dose exposure 
studies have been conducted with selenium monosulfide in mice (target systems: respiratory and 
neurological) and selenium disulfide in rats (target organ not specified); however, the results have varied 
and there is uncertainty about which or how much of each of the compounds was administered.  There 
were no effects in mice following acute dermal exposure.  Additional dermal exposure studies in animals 
would be useful to confirm the effects found in humans.  The data were insufficient for the derivation of 
acute oral and inhalation MRLs. 
Intermediate-Duration Exposure. No human studies of intermediate inhalation exposure to 
selenium were located.  Following oral exposure, one study in humans revealed endocrine effects in 
iodine-deficient individuals (Contempré et al. 1991a, 1992) and others revealed endocrine effects in 
individuals receiving sufficient levels of iodine (Duffield et al. 1999; Hawkes and Turek 2001).  Results 
from one study in humans revealed dermal effects following intermediate dermal exposure (Pringle 
1942).  There were insufficient data to derive intermediate MRLs.  Additional epidemiological or 
occupational studies would be useful in elucidating the potential target organs and effect levels. 
No intermediate inhalation studies were located in animals.  Intermediate-duration inhalation studies, in 
which selenium is administered as selenium dioxide, hydrogen selenide, or selenium dust, might help to 
identify air concentrations of these substances that produce sublethal effects not only on the respiratory 
system, but also on the hepatic, renal, hematological, and cardiovascular systems.  As exposure to the 
selenoamino acids is via ingestion, inhalation studies of these compounds would not be necessary. 
Intermediate-duration oral exposure studies have been performed with rats, pigs, mice, and monkeys at 
several dose levels using several selenium compounds (Baker et al. 1989; Behne et al. 1992; Bioulac-
Sage et al. 1992; Chen et al. 1993; Cukierski et al. 1989; Das et al. 1989b; Eder et al. 1995; Halverson et 
al. 1966; Hasgawa et al. 1994; Hotz et al. 1997; Mahan and Magee 1991; Mihailovic et al. 1992; NTP 
1980c, 1994; Palmer and Olson 1974; Panter et al. 1996).  The major effects were hepatic, dermal, 
endocrine, and neurological.  Additional studies are needed to confirm these data. No intermediate-
duration dermal administration studies have been conducted with the environmental forms of inorganic 
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selenium likely to be of concern (e.g., sodium selenate and sodium selenite), although it is unlikely that 
these forms would be dermally absorbed to a significant degree.  Dermal application of selenomethionine 
to the skin of mice did not result in any direct effects on the skin, or other signs of toxicity, although it 
was absorbed (Burke et al. 1992b).  The organic compounds of selenium are usually not free in the 
environment but, rather, are contained in plant and animal material.  Therefore, no further dermal studies 
would be useful. 
Chronic-Duration Exposure and Cancer. Several occupational studies of chronic inhalation 
exposure to inorganic selenium compounds were located (Glover 1967; Holness et al. 1989; Kinnigkeit 
1962). Effects reported in these studies were primarily respiratory, although cardiovascular, gastro­
intestinal, hematological, musculoskeletal, dermal, ocular, and neurological effects were also noted.  
Animal data are not available for inhalation exposures of chronic duration.  Data in this area would be 
helpful to establish an animal model for respiratory effects of inorganic selenium compounds, since most 
human exposure has been occupational and to a variety of compounds.  Neurological effects have been 
documented in animals after chronic oral exposure, but further study of neurological effects in animals 
after inhalation exposure is needed to provide a model for the effects observed after occupational 
exposure in humans.  Following chronic oral exposure, the primary effects in humans were dermal, 
neurological, and endocrine (Brätter and Negretti De Brätter 1996; Clausen et al. 1989; Longnecker et al. 
1991; Yang et al. 1983, 1989a, 1989b; Yang and Zhou 1994).  An MRL has been derived for chronic oral 
exposure to selenium based on a NOAEL for dermal effects.  One case report of chronic dermal exposure 
revealed dermal effects (Senff et al. 1988).  Additional epidemiological or retrospective studies of chronic 
exposure would be helpful for confirming the existing data.  Studies examining the role of nutrition in 
selenium toxicity would be especially useful. 
Although the lung does not appear to be a target organ in animals after chronic oral exposure to selenium 
compounds, data have not been adequately reported (Harr et al. 1967; Henschler and Kerschner 1969; 
Schroeder and Mitchener 1972), and further studies might be useful to fully rule out these effects.  Studies 
examining possible gastrointestinal and musculoskeletal effects in animals after chronic exposure to 
selenium or selenium compounds or to seleniferous grains might be helpful in determining the 
mechanisms of alkali disease whose symptoms have been observed in grazing livestock (Harr et al. 1967; 
Shamberger 1986).  Hepatic and renal lesions following chronic selenium exposure have been adequately 
characterized.  Investigations of systemic effects associated with chronic oral administration of selenium 
compounds, however, have been limited. 
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No studies were located regarding carcinogenic effects in animals after chronic inhalation exposure to 
selenium or selenium compounds.  No further investigation is needed since humans have not been shown 
to have an increased risk of malignancy from selenium exposure.  The majority of oral studies have 
provided information on the absence of carcinogenic effects in humans and animals (Beems 1986; Clark 
et al. 1996a, 1999; Coates et al. 1988; Duffield-Lillico et al. 2002; Harr et al. 1967; Menkes et al. 1986; 
Reid et al. 2002; Thompson and Becci 1979; Virtamo et al. 1987).  However, earlier and less complete 
studies had suggested that selenium was carcinogenic following oral exposure of animals (Nelson et al. 
1943; Schroeder and Mitchener 1971a; Volgarev and Tscherkes 1967).  Chronic oral exposure studies 
conducted in mice and rats by gavage administration of a mixture of selenium monosulfide and selenium 
disulfide produced liver tumors in rats and lung tumors in female mice (NTP 1980c).  The relative 
proportion of the two compounds was not clear, although physical evidence suggested that the dose 
solution was primarily selenium monosulfide.  Further studies utilizing selenium sulfides might be useful 
in determining possible effects in humans. 
Genotoxicity. Chromosomal aberrations and sister chromatid exchanges in lymphocytes were not 
increased in humans treated (oral or intramuscular injection) with sodium selenite (Norppa et al. 1980a).  
Compared to untreated controls, a significant increase in the number of micronuclei was observed in bone 
marrow cells of mice treated orally with selenite or selenate, and macaques treated orally with 
L-selenomethionine (Biswas et al. 1997, 1999a; Choy et al. 1989; Itoh and Shimada 1996; Rusov et al. 
1996). A significant increase in the number of micronuclei in bone marrow cells was not observed in the 
offspring of macaques treated with L-selenomethionine on gestation days 20–50 (Choy et al. 1993). 
Genotoxicity studies (Salmonella/microsome assays, sister chromatid exchange, and tests of unscheduled 
DNA synthesis and of chromosome aberrations in cultured mammalian cells) indicate that selenite, 
selenate, and selenide have both genotoxic and antigenotoxic effects (Biswas et al. 1997, 2000; Gairola 
and Chow 1982; Khalil 1994; Lu et al. 1995b; Schillaci et al. 1982; Ueda et al. 1997; van der Lelie et al. 
1997).  The underlying mechanisms responsible for the varying genotoxicity results remain to be 
elucidated. 
Reproductive Toxicity. One study that measured the concentration of selenium in sperm samples 
indicated no correlation between selenium concentrations and sperm count or motility (Roy et al. 1990).  
No significant increase in spontaneous abortions was reported among women chronically exposed to 
drinking water containing 7–9 µg/L selenium (Vinceti et al. 2000a).  This study is limited by a level of 
selenium in water that is not generally considered to be high, lack of data on selenium status, and 
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insufficient information on confounding variables.  No other human studies were located.  A few 
reproductive toxicity studies in animals (Chowdhury and Venkatakrishna-Bhatt 1983; Harr and Muth 
1972; NTP 1996; Schroeder and Mitchener 1971b; Wahlstrom and Olson 1959b) indicate that oral 
exposure to excess sodium selenite can reduce female fertility, although male fertility appears not to be 
affected.  Oral treatment of rats with sodium selenate or selenite has been shown to increase the number 
of abnormal sperm in males (El-Zarkouny et al. 1999; Kaur and Parshad 1994; NTP 1994), produce 
testicular hypertrophy (Turan et al. 1999a), and affect the estrous cycle (NTP 1994, 1996).  Fertility was 
not examined in these studies.  Selenium dioxide produced testicular degeneration following 
intraperitoneal administration to rats (Chowdhury and Venkatakrishna-Bhatt 1983).  Disturbances in the 
menstrual cycle (anovulation, short luteal and follicular phases) were observed in monkeys treated orally 
with L-selenomethionine (Cukierski et al. 1989) and mice treated orally with sodium selenite (Nobunaga 
et al. 1979). Studies of both male and female reproductive toxicity of selenium following oral and 
inhalation exposure in rats and other mammals to selenium dioxide and other forms of selenium, both 
organic and inorganic, would be useful.  Such studies could provide information regarding the 
reproductive effects of the various forms of selenium that might be encountered in occupational settings, 
at waste sites, and in the drinking water and food from highly seleniferous areas of the United States. 
Developmental Toxicity. No developmental studies were found regarding inhalation or dermal 
exposure in humans or animals.  Developmental studies using the oral route of administration indicate 
that excessive sodium selenate or sodium selenite intake can result in fetal toxicity and reduced growth in 
experimental mammals (Dinkel et al. 1963; Ferm et al. 1990; NTP 1996; Rosenfeld and Beath 1964; 
Wahlstrom and Olson 1959a), but generally only at doses that produce maternal toxicity.  Developmental 
effects were not observed in macaque fetuses from mothers given toxic oral doses of L-selenomethionine 
during gestation (Tarantal et al. 1991). Intravenous injection of sodium selenite in mice did not indicate 
that the compound is teratogenic in rodents (Yonemoto et al. 1984).  Intravenous injections of sodium 
selenate, D,L-selenomethionine, and D,L-selenocystine into neonatal rats indicated that some selenium 
compounds can contribute to the formation of one type of cataracts (Ostadalova and Babicky 1980).  
Cataracts were not observed in the offspring of macaques treated orally with L-selenomethionine during 
gestation (Tarantal et al. 1991). Additional developmental toxicity studies of selenium compounds in 
mammals do not seem to be necessary at this time. 
Immunotoxicity. No studies were located regarding adverse immunological effects in humans 
following inhalation or oral exposure.  One case report describes immunological effects following dermal 
exposure (Senff et al. 1988). Animal studies of possible adverse immunological effects from excessive 
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exposure to selenium compounds are limited (Dudley and Miller 1941; Glenn et al. 1964a; Hall et al. 
1951; Smyth et al. 1990). One study (Koller et al. 1986) included a battery of immunological tests, some 
of which indicated beneficial effects of sodium selenite administration and others that indicated adverse 
effects. Additional immunotoxicity tests, including challenges of the immune system, might characterize 
the significance of the different immunological effects that have been observed following selenium 
administration. 
Other than selenium sulfide, an ingredient in some antidandruff shampoos, selenium compounds have not 
been tested for sensitization. The potential for dermal contact by humans does exist, however, in 
occupational settings and to a lesser extent in soil at waste sites. 
Neurotoxicity. Data from an epidemiological study of humans and from studies in livestock indicate 
that the central nervous system is an end point of concern following oral exposure to selenium compounds 
(Baker et al. 1989; Boylan et al. 1990; Cukierski et al. 1989; Harrison et al. 1983; Panter et al. 1996; 
Rosenfeld and Beath 1964; Stowe et al. 1992; Tsunoda et al. 2000; Yang et al. 1983).  Chronic oral 
exposure studies of laboratory animals that focus on behavioral effects and histopathological changes in 
the central nervous system might provide useful dose-response information on central nervous system 
effects. 
Epidemiological and Human Dosimetry Studies. A few human epidemiological studies have 
identified blood selenium levels indicative of adequate selenium status and indicative of selenium 
toxicity.  However, there are large differences in selenium blood levels in populations from different parts 
of the world (e.g., China, New Zealand, and Finland) (Salonen et al. 1985; Yang et al. 1989a). For 
example, blood selenium levels in healthy New Zealand populations averaged 0.059 mg selenium/L (Rea 
et al. 1979), whereas blood selenium levels in healthy U.S. populations were much higher, averaging 
0.206 mg selenium/L (Allaway et al. 1968).  Extrapolation from the relationship between blood selenium 
levels and selenium toxicity in populations from one region of the world to populations in another region 
may not be appropriate.  Studies examining the particular forms of selenium and the contribution of diet 
in determining individual and population selenium status would be useful.  The selenium status of an 
individual will determine the magnitude of additional selenium intake that can be tolerated without 
resulting in adverse effects.  Evidence for adverse effects on the endocrine system has also been found 
following intermediate and chronic oral exposure to elevated levels of dietary selenium in humans and 
animals (Brätter and Negretti De Brätter 1996; Behne et al. 1992; Eder et al. 1995; Hawkes and Turek 
2001; Hotz et al. 1997).  Studies of humans with high dietary intakes of selenium that monitored thyroid 
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hormone levels and iodine intake would be useful.  Studies of humans taking selenium supplements 
would also help further identify the long-term effects of selenium status on human health. 
Biomarkers of Exposure and Effect. 
Exposure. Selenium exposure can be correlated with concentrations detected in human blood, blood 
components, urine, hair, and nails.  Selenium concentrations found in these biomarkers in the general 
population can be found in Table 3-7.  However, these markers vary greatly among different populations 
(Longnecker et al. 1991). Levels of plasma, erythrocyte and platelet GPX activity, as well as 
selenoprotein P may serve as better markers of selenium deficiency than selenium concentrations. 
Additional research into markers of selenium status in populations and how they may be used to estimate 
an additional selenium exposure that would be safe would be helpful. 
Effect. There currently are no good preclinical indicators of selenium toxicity.  Perhaps the earliest and 
most frequent symptoms of selenosis in humans are dry and brittle hair that breaks off, and brittle nails 
with white spots or streaks. Although these effects may not be specific to selenium, determination of 
selenium status could be useful if they are observed in a subject.  Additional biomarkers of negative 
effects that could be detected before clinical signs of selenium toxicity would be helpful in identifying 
and preventing selenium poisoning. 
Absorption, Distribution, Metabolism, and Excretion. The absorption of selenium has been 
investigated in humans following oral exposure and in animals following oral and inhalation exposures 
(Finley 1998; Glover 1970; Griffiths et al. 1976; Martin et al. 1989a; Medinsky et al. 1981a; Sánchez-
Ocampo et al. 1996; Thomson et al. 1977).  In humans, no quantitative data exist on either the extent or 
rate of absorption of selenium from the lung or the skin.  Information that selenium is absorbed following 
inhalation is limited to occupational case studies in which larger quantities of selenium have been 
measured in the urine of workers occupationally exposed to selenium.  In order to understand all possible 
routes for human overexposure to selenium, information concerning the dermal and inhalation absorption 
of selenium and its compounds in humans would be useful, even though potential exposures to selenium 
might be more likely to occur by the oral route for the general public. 
The oral absorption of different physical and chemical forms of selenium (e.g., selenite, selenate, and 
selenomethionine as solids or in aqueous solution) has been investigated in humans (Griffiths et al. 1976; 
Martin et al. 1989a; Moser-Veillon et al. 1992; Robinson et al. 1978; Swanson et al. 1991; Thomson 
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1974; Thomson and Stewart 1974; Thomson et al. 1977) and in animals (Finley 1998; Furchner et al. 
1975; Thomson and Stewart 1973; Vendeland et al. 1992; Whanger et al. 1976).  Oral absorption of 
naturally occurring selenium and the effects of dietary levels on the absorption of exogenous selenium 
have also been investigated (Young et al. 1982).  These studies have revealed that several selenium 
compounds appear to be readily absorbed from the gastrointestinal tract of humans and animals.  It also 
appears that the degree of absorption in humans is independent of the exposure level, but that in some 
cases, absorption is greater when a selenium deficiency exists. 
Distribution studies in humans and animals indicate that selenium is widely distributed in the body and is 
concentrated in the liver and kidney following oral, intravenous, or subcutaneous exposures (Cavalieri et 
al. 1966; Finley 1998; Heinrich and Kelsey 1955; Jereb et al. 1975; Kaneko et al. 1999; Mahan and Kim 
1996; Razagui and Haswell 1997; Shiobara et al. 1998; Thomson and Stewart 1973).  Studies of 
intravenous administration of selenomethionine have indicated that animals and humans concentrate this 
compound in the pancreas, but it is unlikely that this selenium compound will be encountered in large 
quantities in the environment except in animals and plants along with other organic selenium compounds.  
It would be useful to know if selenomethionine concentrates in the pancreas of humans following oral 
intake. Following oral exposure, the distribution of selenium across the placenta into the fetuses of rats, 
hamsters, dogs, and monkeys (Archimbaud et al. 1992; Choy et al. 1993; Hawkes et al. 1994; Mahan and 
Kim 1996; Parizek et al. 1971a; Willhite et al. 1990) and the transfer of selenium from milk to suckling 
offspring of rats, dogs, and monkeys (Archimbaud et al. 1992; Choy et al. 1993; Hawkes et al. 1944; 
Parizek et al. 1971a) have also been investigated.  Selenium levels have been measured in human milk 
(Brätter and Negretti De Brätter 1996; Brätter et al. 1991b; Li et al. 1999; Michalke and Schramel 1998; 
Moser-Veillon et al. 1992; Rodríguez Rodríguez et al. 1999; Viitak et al. 1995; Yang 1989b), and the 
concentration of selenium in human milk has been shown to correlate with dietary intake (Brätter et al. 
1991b). The uptake of selenium by erythrocytes and its subsequent metabolic alteration and ultimate 
binding to plasma proteins have been investigated (Sandholm 1973). 
The metabolism of selenium is now fairly well understood.  To become incorporated into selenium-
specific proteins (e.g., glutathione peroxidase, thioredoxin reductase, iodothyronine 5'-deiodinase) 
through a cotranslational mechanism requires that selenium be in the form of selenide (Sunde 1990).  All 
forms of selenium can be transformed to selenide, although the rates of transformation vary. For 
example, selenate is not converted to selenide as readily as selenite.  The formation of selenide from 
selenocysteine requires a specific enzyme, selenocysteine β-lyase, which catalyzes the decomposition of 
selenocysteine to alanine and hydrogen selenide.  Excess selenium can be methylated and exhaled or 
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excreted in the urine in both humans and animals.  Further research is required to determine which 
selenium metabolites or intermediates lead to toxicity. 
In humans and animals, intravenous and oral administration data indicate that the major route of selenium 
excretion is in the urine (Byard and Baumann 1967; Davidson-York et al. 1999; Finley 1998; Griffiths et 
al. 1976; Palmer et al. 1970; Patterson et al. 1989; Shiobara et al. 1998; Swanson et al. 1991).  Excretion 
of selenium in feces constitutes a minor pathway immediately following exposure, but the amount 
excreted can be equal to that excreted in urine depending on the chemical form of selenium administered, 
the size of the dose, and the length of time since dosing.  Both human and animal studies indicate that the 
extent of excretion by any one route is related to the administered dose and the frequency of 
administration (Finley 1998; Lathrop et al. 1972; McConnell and Roth 1966; Shiobara et al. 1998; 
Thomson and Stewart 1974).  The extent of excretion of selenium compounds in the expired air has been 
investigated in animals, but no quantitative studies in humans for this route exist; however, it is believed 
to be a minor pathway especially at lower doses (McConnell and Roth 1966; Olson et al. 1963). 
Comparative Toxicokinetics. The target organs and adverse health effects are generally similar 
across species.  However, the liver appears to be the primary target organ for the oral toxicity of selenium 
in animals following intermediate and chronic exposure (Baker et al. 1989; Biolac-Sage et al. 1992; 
Fitzhugh et al. 1944; Halverson et al. 1970; Harr et al. 1967; Hasegawa et al. 1994; Kolodziejczyk et al. 
2000; Nelson et al. 1943; Palmer and Olson 1974; Sayato et al. 1993; Schroeder and Mitchener 1972; 
Skowerski et al. 1997a; Turan et al. 1999a), whereas liver cirrhosis or dysfunction have not been found in 
reports of chronic selenosis in humans (Longnecker et al. 1991; Yang et al. 1989a).  Different metabolites 
may help explain the cataract formation observed in neonatal rats and the teratogenic activity of selenium 
seen in birds but not in humans or other mammals (Tarantal et al. 1991).  Toxicokinetic studies with some 
design similarities have been performed in humans and several animal species (Behne et al. 1991; Bopp et 
al. 1982; Cantor et al. 1975; Ganther 1979; Hawkes et al. 1992; Obermeyer et al. 1971; Palmer et al. 
1970; Willhite et al. 1990, 1992).  Comparative toxicokinetic studies, per se, have not been performed.  
PBPK models for selenium administered orally as selenite or selenomethionine have been developed for 
humans, but no animal models were located.  Animal models for the oral route would be useful in 
assessing toxicokinetic similarities and differences between species. 
Methods for Reducing Toxic Effects. Current methods for reducing toxic effects of selenium and 
selenium compounds after acute exposures are general supportive treatment methods based on those used 
for other toxic metals (HSDB 2001; Mack 1990).  Because there is no suitable way to treat either acute or 
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chronic selenium poisoning, additional research aimed at decreasing absorption, speeding excretion, and 
reducing the body burden of selenium would be valuable. 
Children’s Susceptibility.    Limited information is available on the toxicity of selenium in children, 
but the available information suggests that children may be less susceptible to toxic effects of selenium 
than adults and more susceptible to deficiency.  Most data comes from children living in areas of chronic 
high dietary selenium intake (Yang et al. 1989a, 1989b).  Additional research on age specific effects of 
selenium toxicity does not appear necessary at present. 
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: 
Exposures of Children. 
3.12.3 Ongoing Studies 
The American Health Foundation is involved in on-going research to develop new organoselenium 
chemopreventive agents for cancer having an increased therapeutic ratio compared with some of the 
historical selenium compounds, such as selenite.  Additional federally sponsored research that was 
reported in the CRIS/USDA (2002), CRISP (2002), and FEDRIP (2002) databases is shown in Table 3-8. 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
Alberts, DS University of Arizona Phase III trials of chemopreventive CRISP 2001 
agents on colon carcinogenesis 
Aposhian, HV Not Available Detoxification of metals – In vitro and CRISP 2002 
in vivo studies 
Bar-Noy, S and National Institutes of Mammalian thioredoxin reductase FEDRIP 2002 
Nhlbi, NIH Health 
Beck, MA University of North The influence of nutrition on influenza FEDRIP 2002 
Carolina virus infection 
Bell, J Not available Effects of selected metal salts on the CRISP 2002 
fidelity of DNA synthesis in vitro 
Bennish, ML National Institutes of Micronutrients and enteric infection in FEDRIP 2002 
Health African children 
Beran, M Vyzkumny Ustav Evaluation of combined CRIS/UDSA 2001 
Potravinarsky supplementation with selenium and 
iodine on levels of selenium-
dependent enzymes, thyroidal 
hormones and other biochemical 
parameters 
Berry, MJ Brigham and Women's Mechanism of selenoprotein CRISP 2001 
Hospital synthesis in eukaryotes 
Berry, MJ Brigham and Women's Selenoprotein P function and CRISP 2002 
Hospital regulation of expression 
Block, E Roswell Park Memorial Identify selenium compounds from CRISP 2001 
Institute high-selenium garlic 
Bosland, MC New York University Preclinical prostate cancer CRISP 2001 
School of Medicine chemoprevention studies 
Burk, RF Vanderbilt University Nutritional and metabolic significance FEDRIP 2002 
of selenium 
Burk, RF Vanderbilt University Selenium supplementation of patients CRISP 2001 
with cirrhosis 
Burk, RF Vanderbilt University Selenoprotein-P structure, function, CRISP 2001 
and activity 
Carlson, SG National Institutes of Antioxidant protection in age- FEDRIP 2002 
Health associated atherosclerosis 
Cassano, PA Cornell University Nutritional influences on lung disease CRIS/UDSA 2001 
Chirase, NK Texas A&M University Nutritional and environmental stress FEDRIP 2002 
and immune response of feeder cattle 
Chu, F-F National Institutes of Selenium-afforded protection against FEDRIP 2002 
Health atherosclerosis 
Clarke, LC University of Arizona Phase II chemoprevention trial of CRISP 2002 
selenium and prostate cancer 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
Clarke, LC and  University of Arizona Randomized, controlled CRISP 2002 
Marshall, JR chemoprevention trials in populations 
at very high risk for prostate cancer:  
Elevated prostate-specific antigen 
and high-grade prostatic 
intraepithelial neoplasia 
Cohen, HJ Stanford University Relationship of the synthesis and CRISP 2001 
secretion of an extracellular selenium 
dependent glutathione peroxidase to 
changes in renal function 
Cohen, HJ Stanford University Selenium nutrition—Effects on blood FEDRIP 2002 
cell function 
Coltman, CA CTRC Research Chemoprevention of prostate cancer CRISP 2001 
Foundation 
Combs, GF Cornell University Characterization of antioxidant status FEDRIP 2002 
of a large cohort of free-living 
Americans 
Combs, GF Cornell University Dietary selenium and maintenance of FEDRIP 2002 
colonic health 
Combs, GF Cornell University Metabolic events at extremes of CRIS/UDSA 2001 
selenium intake; characterization of 
antioxidant status of a large cohort of 
free-living Americans 
Combs, GF Cornell University Kinetics of organic and inorganic CRIS/UDSA 2001 
selenium during dietary supple­
mentation 
Costello, AJ University of Melbourne A randomized, controlled Costello 2001 
chemoprevention trial of selenium in 
familial prostate cancer:  Rationale, 
recruitment, and design issues 
Davis, CD Agricultural Research Role of selenium in cancer CRIS/UDSA 2001 
Service susceptibility 
Diamond, AM University of Illinois Mechanism by which selenium CRISP 2001 
protects against mutagenesis 
Diamond, AM University of Illinois Selenium, aminothiols, and radiation CRISP 2002 
Doolittle, JJ South Dakota University Bioavailability of nutrients and FEDRIP 2002 
contaminants in soil 
Driscoll, DM Cleveland Clinic Mechanism of selenoperoxidase CRISP 2001 
Foundation biosynthesis 
Driskell, JA University of Nebraska Nutrient bioavailability: A key to FEDRIP 2002 
human nutrition 
El-Bayoumy, KE American Health Chemoprevention of oral cancer: CRISP 2001 
Foundation model studies 
El-Bayoumy, KE American Health Chemoprevention of lung cancer by CRISP 2002 
Foundation organoselenium:  Model studies 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
El-Bayoumy, KE American Health Chemoprevention of mammary CRISP 2001 
Foundation cancer by organoselenium 
Fawzi, WW National Institutes of Trials of vitamins in HIV positive FEDRIP 2002 
Health progression and transmission 
Fiala, E American Health Organoselenium compounds as CRISP 2002 
Foundation modifiers of initiation/postinitiation 
carcinogenesis 
Finley, JW University of North Chemical forms of selenium in foods FEDRIP 2002 
Dakota 
Finley, JW Oregon State University Health benefits of high-selenium FEDRIP 2002 
foods to humans 
Funt, RC and Ohio State University Increasing the antioxidant level in FEDRIP 2002 
Clinton, S Ohio berries for potential prevention 
and intervention of certain cancers in 
humans 
Ganther, H Roswell Park Memorial Selenium metabolism and anti- CRISP 2001 
Institute carcinogenic action 
Ganther, H University of Wisconsin Organoselenium compounds 
biosynthesis and function 
Gesteland, RF University of Utah Genetic analysis of synthesis of CRISP 2001 
selenium containing proteins 
Gladyshev, VN University of Nebraska Biochemistry and molecular biology 
of selenium containing enzymes 
Gladyshev, VN University of Nebraska Identity of terminator and CRISP 2001 
selenocysteine UGA codons 
Glauert, HP University of Kentucky Effect of dietary antioxidants on 
hepatic NF-KB activation 
Gorbach, SL Tufts University Impact of micronutrients on FEDRIP 2002 
progression of SIV  
Gorbach, SL Harvard University Wasting, nutritional status, and FEDRIP 2002 
micronutrients 
Gottschall, EB National Jewish Medical Randomized, placebo-controlled, CRISP 2001 
and Research Center double blind trial of asbestos-exposed 
workers using high selenium yeast 
supplementation 
Gottschall, EB National Jewish Medical Selenium and lung cancer risk in CRISP 2002 
and Research Center asbestos workers 
Guttenplan, JB New York University Antimutagenesis by lycopene and CRISP 2001 
selenium in rodents 
Hakala TR Department of Veterans Select trial FEDRIP 2002 
Affairs 
Honn, KV Wayne State University Prostate cancer FEDRIP 2002 
Hurwitz. BE University of Miami Drug abuse, HIV, selenium FEDRIP 2002 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
Ip, C Roswell Park Memorial Mammary cancer prevention by novel CRISP 2002 
Institute selenium compounds 
James, LF Agricultural Research Livestock poisoning from Astragalus CRIS/UDSA 2001 
Service and Oxytropis species 
Johnson, JL University of Nebraska Interaction of trace minerals as FEDRIP 2002 
related to prenatal supplementation of 
the pregnant beef cow 
Kadlubar, F Not available Environmental and genetic CRISP 2002 
epidemiology of colorectal adenomas 
Karagas, M Not available Epidemiology of arsenic and other CRISP 2002 
toxic metals 
Kegley, EB and University of Arkansas Effect of trace mineral level and FEDRIP 2002 
Kellogg, DW source on immune function and 
performance of weaned beef cattle 
Kim, J University of Texas Feasibility study of L-seleno- CRISP 2001 
MD Anderson Cancer methionine in prevention of prostate 
Center cancer 
Kiremidjian- New York University, Dietary selenium and FEDRIP 2002 
Schumacher, L College of Dentistry immunocompetence in the elderly 
et al. 
Klein, EA Cleveland Clinic SELECT: The selenium and vitamin Klein et al. 2000 
Foundation E cancer prevention trial:  Rationale 
and design 
Kolonel, LN University of Hawaii at Biomarkers of prostate cancer risk in CRISP 2001 
Manoa a multi-ethnic cohort 
Kolonel, LN University of Hawaii at Epidemiologic studies of diet and CRISP 2001 
Manoa cancer in Hawaii 
Koutnik, V University of Brno Selenium in food chains and its CRIS/UDSA 2001 
impact on human health 
Lacourciere, G National Institutes of Utilization of selenocysteine in FEDRIP 2002 
and Nhlbi, NIH Health selenophosphate biosynthesis 
Lei, X Cornell University Antioxidative role of glutathione CRISP 2001 
peroxidase in transgenic mice 
Lei, XG et al. Cornell University Developing an organic selenium FEDRIP 2002 
supplement for animal nutrition and 
environmental protection 
Lei, XG et al. Cornell University Mineral nutrition in animal agriculture FEDRIP 2002 
and environmental protection 
Lemarchand, L University of Hawaii Phytochemicals and lung risk in a FEDRIP 2002 
multi ethic cohort 
Levander, OA Agricultural Research Role of vitamin E and selenium in CRIS/UDSA 2001 
Service human health promotion 
Levander, OA University of Maryland Kinetics of organic and inorganic CRIS/UDSA 2001 
selenium during dietary 
supplementation 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
Lewis, NS California Institute of Picosecond dynamic studies of FEDRIP 2002 
Technology electron transfer rates as III-V 
semiconductor/liquid interfaces 
Longnecker, M National Institutes of Validity of toenail element levels as a CRISP 2002 
Health surrogate measure of exposure 
Mahan, DC Ohio State University Mineral and vitamin nutrition of swine FEDRIP 2002 
Mark, S Not available Intervention trials and related studies CRISP 2002 
Marshall, JR University of Arizona Phase II chemprevention trial of CRISP 2002 
selenium and prostate cancer 
May, JM Vanderbilt University Antioxidant interactions of selenium CRISP 2001 
and vitamins C and E 
Medina, D Roswell Park Memorial Selenoproteins in rat mammary CRISP 2001 
Institute tumorigenesis 
Medina, D Roswell Park Memorial Selenium modified gene expression CRISP 2002 
Institute in the carcinogen treated mammary 
gland 
Morgan, DL National Institutes of Toxicity of chemicals used in the FEDRIP 2002 
Health semiconductor industry 
Nomura, AM Kuakini Medical Center Cancer epidemiology of migrant CRISP 2001 
Japanese in Hawaii 
Ogasawara, Y National Institutes of Properties of selenotrisulfides and FEDRIP 2002 
and Nhlbi, NIH Health perselenides  
Page, JG Not available Thirteen week oral toxicity study of CRISP 2002 
1,4-phenylenebis (methylene) 
selenocyanate 
Palmer, IS South Dakota University Biochemistry of selenium FEDRIP 2002 
Pence, BC Texas Technical Induction by selenium of the CRISP 2001 
University Health antioxidant and the prooxidant, 
Sciences Center apoptotic pathways in cultured cells 
Penland, JG Department of Mineral element nutrition, FEDRIP 2002 
Agriculture neuropsuchological function and 
behavior 
Powis, G University of Arizona Thioredoxin reductases and cancer CRISP 2001 
Prolla, TA University of Wisconsin Role of dietary selenium in intestinal CRISP 2001 
tumorigenesis 
Rao, L University of Wisconsin Genetic characterization of the CRISP 2001 
selenoenzyme phospholipids-
hydroperoxide glutathione peroxidase 
Reddy, BS American Health Chemoprevention of colon cancer by CRISP 2002 
Foundation organoselenium compounds 
Reddy, CC Pennsylvania State Antioxidant effects on prostaglandin CRIS/UDSA 2001 
University metabolism, lipid peroxidation, and 
immunologic defense 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
Repine, JE Department of Veterans Effect of NAC and/or selenium on FEDRIP 2002 
Affairs blood markers of oxidative stress and 
inflammation 
Roberts, JC University of Utah Advances in selenium CRISP 2002 
supplementation 
Roughead, ZK Department of Biomarkers for assessment of human FEDRIP 2002 
Agriculture mineral nutritional status and 
requirements 
Roy, M New York University Selenium supplementation and CRIS/UDSA 2001 
immunocompetence in the elderly 
Sampliner, RE Department of Veterans Phase III study of the effects of FEDRIP 2002 
Affairs celecoxib, selenium, or the 
combination on adenomatous polyp 
recurrence in adenomatous polyp 
patients 
Sevanian, A University of Southern Oxidant stress and atherogenicity of FEDRIP 2002 
California oxidized LDL 
Shearer, TR Oregon Health & Mechanism of selenium induced FEDRIP 2002 
Science University cataract 
Simoneau, AR Department of Veterans Selenium in prostate cancer FEDRIP 2002 
Affairs 
Smith, AM Ohio State University Influence of gender and life cycle on CRIS/UDSA 2001 
selenium requirements and 
metabolism 
Sordillo, LM Pennsylvania State Oxidant stress and endothelial cell FEDRIP 2002 
University metabolism 
Sordillo, LM Pennsylvania State Mechanisms of endothelia cell FEDRIP 2002 
University dysfunction during selenium 
deficiency 
Stadtman, TC National Institutes of Selenium biochemistry FEDRIP 2002 
and Nhbli, NIH Health 
Stampfer, MJ National Cancer Nutritional and biochemical markers FEDRIP 2002 
Institute of cancer 
Stampfer, MJ Harvard University Prospective study of diet and bladder FEDRIP 2002 
cancer 
Sunde, RA University of Missouri New essential roles for selenium; CRIS/UDSA 2001 
regulatory elements of selenium-
dependent peroxidases; regulatory 
elements of the rat glutathione 
peroxidase gene 
Sunde, RA University of Missouri Glutatione peroxidases:  Selenium FEDRIP 2002 
requirement and function 
Taylor, JR Department of Veterans Prevention of non-melanoma skin FEDRIP 2002 
Affairs cancer with a nutritional 
supplementation of selenium 
Taylor, EW University of Georgia Selenoproteins, NF-KB, and HIV CRISP 2001 
disease in drug users 
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Table 3-8. On-going Studies on Selenium Health Effects 
Investigator Institute Research area Reference 
Terris, MK Department of Veterans Blood and tissue sampling in prostate FEDRIP 2002 
Affairs ultrasound patients 
Terris, MK Department of Veterans Phase II study of the effect of FEDRIP 2002 
Affairs selenium supplementation on the 
progression of prostate cancer 
Thompson, I University of Texas Biomarkers of risk for prostate cancer CRISP 2001 
Health Science Center 
San Antonio 
Thompson, H Roswell Park Memorial Mechanisms of selenium anticancer CRISP 2001 
Institute and toxic activities 
Thompson, H Roswell Park Memorial Selenium and lung cancer risk CRISP 2002 
Institute 
Turnlund, JR et Department of Influence of dietary intervention on FEDRIP 2002 
al. Agriculture mineral homeostasis 
Turnlund, JR et Department of Trace element metabolism, status FEDRIP 2002 
al. Agriculture and requirements of humans 
Veillon, C Agricultural Research Metabolism, function, and interactions CRIS/UDSA 2001 
Service of selenium using stable isotopes 
Weiss, GR Department of Veterans Pilot study of 1-selenomethionine in FEDRIP 2002 
Affairs prostate cancer patients scheduled to 
undergo radical prostatectomy 
Weiss, SL University of Missouri Molecular basis for selenium CRIS/UDSA 2001 
regulation of glutathione peroxidase 
mRNA 
Whanger, PD Oregon State University Effect of selenium on selenoproteins FEDRIP 2002 
in human muscle and brain cells 
Whanger, PD Oregon State University Metabolic function of selenoprotein CRISP 2001 
Whanger, P Oregon State University Role of selenium and vitamin E in CRIS/UDSA 2001 
scour and immunity of newborn 
calves; influence of pregnancy on 
selenium metabolism in women of 
low selenium status; metabolic 
relationship between selenium and 
myopathy 
Yu, MC University of Southern Singapore cohort study of diet and CRISP 2001 
California cancer 
CRIS = Current Research Information System; CRISP = Computer Retrieval of Information on Science Projects; 
FEDRIP = Federal Research in Progress; NCI = National Cancer Institute; NIH = National Institutes of Health; 
USDA = US Department of Agriculture 
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4.1 CHEMICAL IDENTITY 
Information regarding the chemical identity of selenium and selenium compounds is presented in 
Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
Selenium is a non-metal element with atomic number 34 and an atomic mass of 78.96 (Lide 2000).  
Selenium belongs to Group 6 (Group VIA) of the periodic table, located between sulfur and tellurium, 
and resembles sulfur both in its various forms and in its compounds.  The six stable isotopes of selenium 
are 74Se, 76Se, 77Se, 78Se, 80Se, and 82Se. These isotopes occur naturally with approximate abundances of 
0.87, 9.02, 7.58, 23.52, 49.82, and 9.19%, respectively (Hoffmann and King 1997).  Artificial radioactive 
isotopes of selenium have also been created by neutron activation.  The gamma-emitting isotope 75Se has 
been used in diagnostic applications of medicine (Hoffmann and King 1997).  Selenium exists in several 
allotropic forms.  Three are generally recognized, but as many as six have been claimed (Lide 2000).  The 
stable form at ordinary room temperatures is the grey or hexagonal form with a melting point of 220.5 EC 
(Lide 2000). The other two important forms are red (monoclinic) with a melting point of 221 EC and 
amorphous selenium, which exists in black and red forms.  Black amorphous selenium is vitreous and is 
formed by the rapid cooling of liquid selenium.  Red amorphous selenium is colloidal and is formed in 
reduction reactions (Hoffmann and King 1997).  Important selenium oxidation states are -2, 0, +4, and +6. 
The chemical properties of selenium are similar to sulfur.  Selenium combines with metals and many 
nonmetals directly or in aqueous solution.  The selenides resemble sulfides in appearance, composition, 
and properties (Hoffmann and King 1997).  Selenium may form halides by reacting vigorously with 
fluorine and chlorine, but the reactions with bromine and iodide are not as rapid.  Selenium does not react 
directly with hydrogen fluoride or hydrogen chloride, but decomposes hydrogen iodide to liberate iodine 
and yield hydrogen selenide (Hoffmann and King 1997).  Selenium reacts with oxygen to form a number 
of oxides, the most stable of which is selenium dioxide.  
Information regarding the physical and chemical properties of selenium and selenium compounds is 
located in Table 4-2. 
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Table 4-1. Chemical Identity of Selenium and Selected Compoundsa 
Hydrogen Selenious 









selenium base; hydrogen dioxide; 
selenium dust; selenide [H2Se]; selenous 












Chemical formula Se H2Se H2SeO4  H2SeO3 




CAS 7782-49-2 7783-07-5 7783-08-6 7783-00-8 
 NIOSH RTECS VS7700000 MX1050000 VS6575000 VS7175000 









UN 1905; IMCO 8.0 
No data 
No data 
 shipping Hydrogen 
selenide; 
anhydrous 
HSDB 4493 548 675 6065 
NCI No data No data No data No data 
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Table 4-1. Chemical Identity of Selenium and Selected Compoundsa 
Potassium Sodium 
Characteristic Sodium selenate selenate Sodium selenide selenite 

















SS02 and SS-20c 
No data No data 
Chemical formula Na2SeO4 d  K2SeO4 Na2Seb Na2SeO3 d 




CAS 13410-01-0 7790-59-2 1313-85-5b 10102-18-8 
 NIOSH RTECS No data VS6600000 WE0350000b VS7350000 













HSDB No data No data No data 768 
NCI No data No data No data No data 
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Table 4-1. Chemical Identity of Selenium and Selected Compoundsa 
Selenium 
Characteristic Selenium dioxide trioxide Selenocystine Selenomethionine 
Synonyms 	 Selenious No data Selenium Methionine, selenob; 
anhydride; selenium cystineb; 2-amino-4­
oxide; selenium 3,3-diselenodi- (methylselenyl) 
oxide [SeO2]; DL-alanineb; butyric acid; 
selenous acid seleno-DL- 2-amino-4-(methylsel 
anhydride cystineb; DL- eno) 
selenocystineb 
Registered trade No data No data 
name(s) 





CAS 7446-08-04 13768-86-0f 1464-43-3b 1464-42-2 
 NIOSH RTECS VS8575000 No data AY6030000b ES100000 
 EPA hazardous V204c No data No data No data 
 waste 
 OHM/TADS 7800105 No data No data No data 
 DOT/UN/NA/IMCO No data No data No data No data 
 shipping 
HSDB 677 No data No data No data 
NCI No data No data No data No data 
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Table 4-1. Chemical Identity of Selenium and Selected Compoundsa 
Characteristic 	 Selenium sulfide Selenium disulfide 
Synonyms 	 Selenium monosulfide; Selenium disulphide; selenium 
selenium sulfide [SeS]; sulfideb; sulfur selenide 
selensulfid (German); sulfur 
selenide (SSe) 
Registered trade name(s) No data 	 Exsel; Selsun Blue; Selsumb; 
Seleen 
Chemical formula 	 SeS SeS2b 
Wisewesser line notation 	 SE S SE S2b 
Identification numbers: 
CAS 744-34-6 7488-56-4 
 NIOSH RTECS VTO525OOO VS8925000 
EPA hazard waste V205b V205 
 OHM/TADS 8400272 8400272 
 DOT/UN/NA/IMCO shipping No data UN 2657 
HSDB 679 No data 
NCI NCI-C50033 No data 
aAll information obtained from HSDB 2001, except where noted
bRTECS 2001 
cEPA 1980a, 1980b (40 CFR 261.33)
dBudavari et al. 1996 
eLide 2000 
fChemIDplus 3003 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances 
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Property Selenium selenide Selenic acid Selenious acid 
Molecular weight 78.96 80.98 144.97 128.97 






Physical state Solid Gas Solid Solid 
Melting point 221 EC(red); 
220.5 EC (grey); 
180 EC (black)b 
-65.73 EC 58 EC 70 EC 
(decomposes)b 
Boiling point 685 EC -41.3 EC 260 EC None, loses water 
upon heating 
Density (g/cm3) 4.39 (red); 4.81 
(grey); 4.28 (black)b 
2.12 (-42 EC) 2.9508 (15 EC) 3.004 (15 EC) 





 Water (mg/m3) No data No data No data No data 
Air No data No data No data No data 
Solubility: Insoluble 377 mL/100 mL at Very soluble in 90 parts dissolve 
 Water 4 EC; hot water in 100 parts of 
270 mL/100 mL at water at 0 EC; 400 
22.5 EC; parts in 100 parts 
0.73 mL/100 mL at 
20 ECc 
at 90 EC 
Organic solvent(s) Insoluble in alcohol, 
slightly soluble in 




Very soluble in 
alcohol 
carbon disulfide chloride 
(2 mg/100 mL, 
room temperature), 
soluble in ether 
Partion coefficients: 
 Log Kow No data No data No data No data 
 Log Koc No data No data No data No data 
Vapor pressure 1 mmHg at 356 EC 1,330 mmHg at ­ No data 2 mmHg at 15 EC; 
(grey) 30 EC; 3,420 mmHg 4.5 mmHg at 
at 0.2 EC; 9,120 33 EC; 7mmHg at 
mmHg at 30.8 EC 40.3 EC 
Henry’s Law Not applicable No data Not applicable Not applicable 
constant 
Autoignition No data No data No data No data 
temperature 
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Property Selenium selenide Selenic acid Selenious acid
 
Flashpoint No data	 Not applicable No data No data 
Flammability limits No data	 No data No data No data 
Conversion factors No data	 ppm selenium to mg No data No data 
Selenium/m3 in air 
(20 EC): ppm 
selenium x 3.23=mg 
selenium/m3 to ppm 
selenium in air 




Explosive limits Unknownd	 No data No data No data 
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Property Sodium selenate selenate selenide Sodium selenite 
Molecular weight	 188.94 221.15 124.94 172.94 
Color/form	 White crystals Colorless crystals or Crystalline; White tetragonal 
white powder	 turns red on crystalsb 
exposure to air 
and 
deliquesces 
Physical state	 Solid Solid Solid Solid 
Melting point	 No data No data >875 EC No data 
Boiling point	 No data No data No data No data 
Density (g/cm3)	 1.61b 3.07 2.625 (10 EC) No data 
Odor	 No data No data No data No data 
Odor threshold: 
 Water (mg/m3) No data No data No data No data 
Air No data No data No data No data 
Solubility: 
 Water Very soluble in Soluble in about 1 Decomposes in Freely soluble in 
water part of water water water 
Organic solvent(s) No data No data No data No data 
Partition coefficients: 
 Log Kow No data No data No data No data 
 Log Koc No data No data No data No data 
Vapor pressure 	 No data No data No data No data 
Henry’s Law 	 No data No data No data No data 
constant 
Autoignition No data No data Not flammablee Not flammablee 
temperature 
Flashpoint	 No data No data Not flammablee Not flammablee 
Flammability limits	 No data No data Not flammablee Not flammablee 
Conversion factors	 No data No data No data No data 
Explosive limits	 No data No data No data No data 
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Property Selenium dioxide trioxide Selenocystine Selenomethionine 
Molecular weight	 110.96 126.96b 334.12c 196.11 
Color/form	 Lustrous, White crystalsb No data Transparent, 
tetragonal needles; hexagonal sheets or 
yellowish-green plates; metallic luster 
vapor or crystals 
Physical state	 Solid Solid No data Solid 
Melting point 340 EC; sublimes at 118 ECb No data DL form: 265 EC 
315 ECb (decomposes); L 
form: 266–268 EC 
Boiling point Noneb Sublimesb No data Not applicable 
Density (g/cm3)	 3.954 (15 EC) 3.44 b No data No data 
Odor	 Pungent sour smell No data No data No data 
Odor threshold: 
 Water (mg/m3) 0.0002e No data No data No data 
Air No data No data No data No data 
Solubility: 
Water (g/100 mL) 38.4 at 14 EC; Soluble in water No data No data 
 Organic solvent(s) in methanol: 10.16 No data No data No data 
(parts/100 parts at 11.8 EC; in 93% 
solvent) ethanol: 6.67 at 
14 EC; in acetone: 
4.35 at 15.3 EC; in 
acetic acid: 1.11 at 
13.9 EC; soluble in 
benzene 
Partition coefficients: 
 Log Kow No data No data No data No data 
 Log Koc No data No data No data No data 
Vapor pressure 12.5 mm Hg at No data No data No data 
70 EC; 20.2 mm Hg No data No data 
at 94 EC; 39.0 mm 
Hg at 181 EC; 
760 mm Hg at 
315 EC; 848 mm 
Hg at 320 EC 
Henry’s Law Not applicable Not applicable No data No data 
constant 
Autoignition Not flammablee Not flammablee No data No data 
temperature 
Flashpoint Not flammablee Not flammablee No data No data 
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Property Selenium dioxide trioxide Selenocystine Selenomethionine 
Flammability limits	 Not flammablee Not flammablee No data No data 
Conversion factors	 ppm (v/v) to mg/m3 No data No data No data 
in air (20 EC): 
ppm (v/v) x 
4.53=mg/m3; 
mg/m3 to ppm (v/v) 
in air (20 EC): 
mg/m3 x 0.22=ppm 
(v/v) 
Explosive limits	 No data No data No data No data 
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Property Selenium sulfide Selenium disulfide 
Molecular weight 111.02f 143.08f 
Color/form Orange-yellow tablets or powderf Bright red-yellow 
powderf 
Physical state Solidf Solidf 
Melting point 118–119 EC (decomposes)f <100 ECf 
Boiling point No data No data 
Density (g/cm3) 3.056 (0 EC)f No data 
Odor No data No data 
Odor threshold: 
 Water (mg/m3) No data No data 
Air No data No data 
Solubility: 
 Water Insoluble Insoluble 
 Organic solvent(s) Insoluble in ether; decomposes in alcoholf No data 
Partition coefficients: 
 Log Kow Not applicable No data 
 Log Koc Not applicable No data 
Vapor pressure Not applicable Not applicable 
Henry’s Law constant Not applicable Not applicable 
Autoignition temperature No data No data 
Flashpoint No data No data 
Flammability limits No data No data 
Conversion factors No data No data 
Explosive limits No data No data 






Note: The gray metallic form is the most stable form of selenium (Budavari et al. 1996). 
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5.1 PRODUCTION 
Selenium is distributed widely in nature and is found in most rocks and soils at concentrations between 
0.1 and 2.0 ppm (Fishbein 1983).  However, elemental selenium is seldom found naturally, but it is 
obtained primarily as a byproduct of copper refining (Fishbein 1983).  Selenium is contained in the 
constituents of the copper anode that are not solubilized during the copper refining process and ultimately 
accumulate on the bottom of the electrorefining tank.  These constituents, usually referred to as slimes, 
contain roughly 5–25% selenium and 2–10% tellurium.  Selenium is commercially produced by either 
soda ash roasting or sulfuric acid roasting of the copper slimes. 
Soda Ash Roasting.  A soda ash binder is mixed with the slimes and water to form a stiff paste.  The 
paste is extruded or pelletized and allowed to dry and then roasted at 530–650 EC. The roasted product is 
then ground and leached into water.  The resultant hexavalent selenium dissolves as sodium selenate, 
Na2SeO4. The sodium selenate may be reduced by controlled heating to sodium selenide, which is 
leached with water to form a liver-red solution of sodium selenide that is readily oxidized to the elemental 
form by blowing air through the solution (Hoffmann and King 1997).  A second process for the reduction 
of hexavalent selenium involves the use of concentrated hydrochloric acid or ferrous iron salts catalyzed 
by chloride ions as the reductant (Hoffmann and King 1997). 
Sulfuric Acid Roasting.  In this method, the copper slimes are mixed with sulfuric acid and roasted at 
500–600 EC to produce selenium dioxide, which volatilizes readily at the roasting temperature.  The 
selenium dioxide is reduced to elemental selenium during the scrubbing process with sulfur dioxide and 
water. The resultant commercial-grade selenium can be purified to 99.5–99.7% (Hoffmann and 
King 1997). 
The U.S. production of selenium was 373 and 379 metric tons in 1995 and 1996, respectively (USGS 
2001, 2002).  No production data were reported for the years 1997–2001.  All of the primary selenium 
producers in the United States are electrolytic copper refiners.  Asarco Incorporated and Kennecott Utah 
Copper Corporation produce refined selenium in the United States (Hoffmann and King 1997; SRI 2000).  
Two other copper refiners, Phelps Dodge Corporation and Magma Copper Company, send selenium or 
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selenium-bearing copper slimes outside of the United States for final processing (Hoffmann and King 
1997). 
Tables 5-1 and 5-2 list facilities in each state that produce, process, or import selenium and selenium 
compounds, respectively, for commercial use.  The data do not include facilities such as electric power 
generating plants that release selenium unintentionally as a by-product.  The intended use and the range of 
maximum amounts of these substances that are stored on site are also included.  The data listed in these 
tables are derived from the Toxics Release Inventory (TRI00 2002).  Only certain types of facilities were 
required to report.  Therefore, this is not an exhaustive list. 
5.2 IMPORT/EXPORT 
The import volumes of selenium were 324, 428, 346, 339, 326, 452, and 500 metric tons for 1995, 1996, 
1997, 1998, 1999, 2000, and 2001, respectively (USGS 2001, 2002).  The U.S. exports of selenium were 
270, 322, 127, 151, 233, 89, and 75 metric tons for 1995, 1996, 1997, 1998, 1999, 2000, and 2001, 
respectively (USGS 2001, 2002). 
5.3 USE 
In electronics, selenium's semiconductor and photoelectric properties make it useful in "electric eyes," 
photographic exposure meters, and rectifiers for home entertainment equipment.  In addition, a large 
proportion of the available selenium is used to coat the metal cylinders from which a photographic image 
is transferred in xerography (Fishbein 1983).  Selenium is widely used in the glass industry to counter 
coloration that results from iron impurities.  It is also used in the production of both red and black glasses 
(Fishbein 1983).  Selenium is contained in pigments that are used in plastics, paints, enamels, inks, and 
rubber (Fishbein 1983).  Selenium is used as a catalyst in the preparation of pharmaceuticals including 
niacin and cortisone, as an ingredient in antidandruff shampoos (selenium sulfide), and as a constituent of 
fungicides (selenium sulfide) (IARC 1975a).  Radioactive selenium is used in diagnostic medicine and 
aids in the visualization of difficult-to-study malignant tumors (Fishbein 1983; Jereb et al. 1975).  
Selenium is contained in some dietary supplements at concentrations in the range of 10–25 µg/tablet 
(Goodman et al. 1990).  Selenium is also used as a nutritional feed additive for poultry and livestock, in 
pesticide formulations, and as an accelerator and vulcanizing agent in rubber production (Fishbein 1983; 
NAS 1976a).  Table 5-3 lists some specific uses of selected selenium compounds. 
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Table 5-1. Facilities that Produce, Process, or Use Selenium 
Number of Minimum amount Maximum amount on 
Statea facilities on site in poundsb site in poundsb Activities and usesc 
AZ 1 1,000 9,999 12 

CA 2 100 99,999 12 

IA 1 100 999 7 

IL 1 1,000 9,999 7 

IN 2 100,000 999,999 8 

LA 1 1,000 9,999 12 

MI 1 0 99 12 

OK 1 100 999 1, 5 

OR 1 100,000 999,999 12 

PA 2 10,000 99,999 6, 8 

SC 1 10,000 99,999 1, 3, 4, 5, 9, 12, 13 

WA 1 100 999 14 

WY 1 0 99 1, 13 

Source: TRI00 2002 

aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 11. Chemical Processing Aid 
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 
5. Byproduct 10. Repackaging 
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Table 5-2. Facilities that Produce, Process, or Use Selenium Compounds 
Number of Minimum amount Maximum amount 
Statea facilities on site in poundsb on site in poundsb Activities and usesc 
AL 4 100 99,999 1, 3, 4, 5, 8, 9, 12, 13 
AR 1 10,000 99,999 12 
AZ 2 10,000 999,999 1, 3, 4, 5, 9, 13, 14 
CA 1 10,000 99,999 8, 9 
FL 1 1,000 9,999 1, 5, 9, 12, 13, 14 
GA 5 1,000 99,999 1, 2, 3, 4, 5, 6, 9, 13 
IA 2 100 9,999 3, 4, 7, 8 
ID 1 100,000 999,999 1, 5 
IL 3 1,000 99,999 1, 5, 7, 12, 13 
IN 4 0 99,999 1, 5, 7, 9, 12, 13 
KY 5 100 99,999 1, 3, 4, 5, 9, 12, 13 
LA 1 10,000 99,999 1, 3, 4, 5, 6, 8 
MA 1 10,000 99,999 1, 5 
MD 2 1,000 99,999 1, 3, 4, 5, 6, 13 
MI 4 1,000 999,999 1, 2, 3, 4, 5, 8, 9, 12, 13 
MN 1 1,000 9,999 1, 2, 9, 13, 14 
MO 1 10,000 99,999 7 
MT 1 10,000 99,999 1, 5, 12, 14 
NC 3 10,000 99,999 1, 3, 4, 5, 9, 12, 13, 14 
NM 4 0 99,999 1, 3, 4, 5, 9, 12, 13 
NV 6 10,000 9,999,999 1, 5, 6, 10, 13, 14 
OH 8 1,000 9,999,999 1, 3, 4, 5, 7, 9, 12, 13, 14 
OK 1 1,000 9,999 8 
PA 8 0 999,999 1, 4, 5, 6, 9, 12, 13, 14 
SC 1 10,000 99,999 1, 3, 4, 5, 9, 12, 13 
TN 2 1,000 99,999 1, 5 
TX 10 10,000 999,999 1, 2, 3, 4, 5, 6, 8, 9, 12, 14 
UT 4 10,000 9,999,999 1, 3, 4, 5, 6, 9, 12, 13 
VA 1 10,000 99,999 1, 5 
WV 9 100 99,999 1, 3, 4, 5, 9, 12, 13, 14 
WY 2 0 99,999 1, 4, 5, 9, 12, 13 
Source: TRI00 2002 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 11. Chemical Processing Aid 
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 
5. Byproduct 10. Repackaging 
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Table 5-3. Some Selenium Compounds and Their Usesa 
Compound Use 
Elemental selenium In rectifiers, photoelectric cells, blasting caps, xerography, stainless 
steel; as a dehydrogenation-catalyst 
Sodium selenate As an insecticide; in glass manufacture; in medicinals to control animal 
(Na2SeO4) diseases 
Sodium selenite In glass manufacture; as a soil additive for selenium-deficient areas 
(Na2SeO3) 
Selenium diethyldithio- Fungicide; vulcanizing agent 
carbamate 
Selenium disulfide In veterinary medicine 
(SeS2) 
Selenium sulfide In anti-dandruff shampoos and in veterinary medicine 
(SeS) 
Selenium dioxide Catalyst for oxidation, hydrogenation, or dehydrogenation of organic 
(SeO2) compounds 
Selenium hexafluoride As a gaseous electric insulator 
(SeF6) 
Selenium oxychloride Solvent for sulfur, selenium, tellurium, rubber, bakelite, gums, resins, 
(SeOCl2) glue, asphalt, and other materials 
Aluminum selenide Preparation of hydrogen selenide for semi-conductors 
(Al2Se3) 
Ammonium selenite Manufacture of red glass 
[(NH4)2SeO3] 
Cadmium selenide Photoconductors, photoelectric cells, rectifiers 
Cupric selenate In coloring copper and copper alloys 
(CuSeO4) 
Tungsten diselenide In lubricants 
(WSe2) 
aAdapted from Fishbein 1983 
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The 2002 consumption patterns for selenium by industry were as follows: glass manufacturing, 35%; 
chemicals and pigments, 20%; electronics, 12%; and miscellaneous (including agriculture and 
metallurgy), 33% (USGS 2002). 
5.4 DISPOSAL 
Selenium was listed by EPA in 1973 as a nonradioactive hazardous element and, as such, is subject to 
many regulations (Dawson and Mercer 1986).  Selenium compounds should be stored in a dry area to 
avoid contamination of water with selenium and to decrease the hazards that may result from human 
exposure to selenium-contaminated water (ITII 1976). 
Disposal and waste treatment consist of treating an acidified solution of selenium with sodium sulfite to 
form the reducing agent sulfur dioxide.  The selenium solution is then heated to produce elemental 
selenium, which is less mobile in the environment and less bioavailable, and the solution is filtered and 
washed (ITII 1976). 
According to the TRI, in 2000, an estimated 76,248 pounds of elemental selenium and 1,782,654 pounds 
of selenium compounds were transferred off-site, presumably for disposal (TRI00 2002). 
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6.1 OVERVIEW 
Selenium has been identified in at least 508 of the 1,623 hazardous waste sites that have been proposed 
for inclusion on the EPA National Priorities List (NPL) (HazDat 2003).  However, the number of sites 
evaluated for selenium is not known.  The frequency of these sites can be seen in Figure 6-1. Of these 
sites, 502 are located within the United States, 4 are located in the Commonwealth of Puerto Rico, 1 is 
located in Guam, and 1 is located in the U.S. Virgin Islands (not shown). 
Selenium is ubiquitous in the environment, being released from both natural and anthropogenic sources.  
The principal releases of selenium into the environment as a consequence of human activities result from 
the combustion of coal.  Workers in the metals industry and health services, mechanics, and painters may 
be exposed to higher levels of selenium than the general population or persons employed in other trades.  
For the general population, the primary exposure pathways, in order of decreasing relative proportions, 
are food, water, and air. The relative proportions of these exposure pathways at hazardous waste sites are 
not known. Although selenium has been reported at hazardous waste sites, analysis on specific forms has 
not been performed.  In air, selenium dioxide, methyl selenide, and dimethyl selenide are the most 
prevalent forms found in the atmosphere.  Selenates and selenites are water soluble and, thus, can be 
found in water sources.  Salts of selenic and selenious acids are most likely to be found in surface water 
and water contained in soil.  Selenium sulfides would not be expected to be found at most hazardous 
waste sites, since they are usually manufactured for use in shampoos.  Natural sources of selenium 
include the weathering of selenium-containing rocks to soils and volcanic eruptions. 
The primary factor determining the fate of selenium in the environment is its oxidation state.  Selenium is 
stable in four valence states (-2, 0, +4, and +6) and forms chemical compounds similar to those of sulfur.  
The heavy metal selenides (-2) are insoluble in water, as is elemental selenium. The inorganic alkali 
selenites (+4) and selenates (+6) are soluble in water (Weast 1988) and are therefore more bioavailable. 
Conditions such as pH (negative log hydrogen ion concentration), Eh (oxidation-reduction potential), and 
the presence of metal oxides affect the partitioning of the various compounds of selenium in the 
environment.  In general, elemental selenium is stable in soils and is found at low levels in water because 







Freq u en cy  of
NPL Sites 
Derived from HazDat 2003 
SELENIUM 236 
6. POTENTIAL FOR HUMAN EXPOSURE 
Figure 6-1. Frequency of NPL Sites with Selenium Contamination 
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converted to organic compounds such as selenomethionine, selenocysteine, dimethyl selenide, and 
dimethyl diselenide.  Selenium is bioaccumulated by aquatic organisms and may also biomagnify in 
aquatic organisms. 
6.2 RELEASES TO THE ENVIRONMENT 
The greatest proportion of selenium released to the environment as a consequence of regulated human 
activities is in coal fly ash, resulting from coal combustion.  Anthropogenic emission sources of 
atmospheric selenium include coal and oil combustion facilities, selenium refining factories, base metal 
smelting and refining factories, mining and milling operations, and end-product manufacturers (e.g., some 
semiconductor manufacturers).  Natural atmospheric releases of selenium result from volatilization of 
selenium by plants and bacteria, and from volcanic activity.  Some selenium is released to water via 
sewage effluent, agricultural runoff, and industrial waste water.  Selenium is released to soil primarily by 
leaching and weathering of the parent bedrock material, although dry and wet deposition also contribute 
to soil selenium levels. 
According to the Superfund Amendments and Reauthorization Act (SARA), Section 313, Toxic Release 
Inventory (TRI00 2002), an estimated total of 264,267 pounds of elemental selenium was released to air, 
water, land, or injected underground from manufacturing and processing facilities in the United States in 
2000 (see Table 6-1). In addition, 7,870,609 pounds of selenium compounds were released to air, water, 
land, or injected underground in 2000 (see Table 6-2).  These data include all facilities that manufacture, 
import, and process selenium and selenium compounds as well as facilities (electric generating facilities, 
petroleum facilities, etc.) with unintentional releases to the environment.  The TRI data should be used 
with caution because only certain types of facilities are required to report.  This is not an exhaustive list. 
6.2.1 Air 
Combustion of coal and other fossil fuels is the primary source of airborne selenium compounds.  In air, 
elemental selenium burns to form selenium dioxide; however, during the combustion of fossil fuels, 
essentially all of the selenium dioxide produced should be reduced to elemental selenium by the sulfur 
dioxide that results from the combustion of these materials (NAS 1976a).  Estimates of the quantity of 
selenium released to the air from fossil fuel combustion vary.  Estimated annual selenium air emissions 
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Reported amounts released in pounds per yeara 
Number Under- Total on- Total off- Total on and 
Stateb 
of 









AZ 1 No data No data No data No data No data 71,747 71,747 
CA 2 1 0 No data 35,848 35,849 10 35,859 
IA 1 No data No data No data 27 27 339 366 
IL 3 109 19 No data 1 129 231 360 
IN 3 0 No data No data 2,260 2,260 2,056 4,316 
LA 2 No data No data 40,246 No data 40,246 No data 40,246 
MI 1 5 No data No data No data 5 5 10 
OK 1 No data 250 No data 250 500 No data 500 
OR 1 0 No data No data 112,600 112,600 1 112,601 
PA 2 61,437 750 No data No data 62,187 1,857 64,044 
SC 1 3,929 No data No data 6,533 10,462 No data 10,462 
WA 1 No data No data No data 2 2 2 4 
WY 1 No data No data No data No data No data 0 0 
Total 25 65,481 1,019 40,246 157,521 264,267 76,248 340,515 
Source: TRI00 2002 
aData in TRI are maximum amounts released by each facility.

bPost office state abbreviations are used. 

cThe sum of fugitive and stack releases are included in releases to air by a given facility.

dThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

eTotal amount of chemical transferred off-site, including to publicly owned treatment works (POTW).
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Reported amounts released in pounds per yeara 
Number Under- Total on- Total off- Total on and 
Stateb 
of 









AL 4 15,545 4,125 No data 33,253 52,923 1,069 53,992 
AR 1 546 No data No data No data 546 7,493 8,039 
AZ 2 505 0 No data 820,005 820,510 2,265 822,775 
CA 1 5 No data No data No data 5 No data 5 
FL 2 7,105 No data No data 362 7,467 3 7,470 
GA 6 72,273 1,037 No data 43,067 116,377 10 116,387 
IA 5 No data No data No data No data No data No data 0 
ID 1 1,849 No data No data 98,184 100,033 5 100,038 
IL 7 56 No data No data 0 56 81,940 81,996 
IN 5 4,427 1,871 No data 9,665 15,963 7,739 23,702 
KY 5 19,750 14,200 No data 41,051 75,001 No data 75,001 
LA 1 192 0 No data No data 192 45,241 45,433 
MA 1 234 100 No data 580 914 7,440 8,354 
MD 2 16,001 360 No data 720 17,081 1,262 18,343 
MI 4 16,408 2,417 No data 2,758,596 2,777,421 897,981 3,675,402 
MN 2 255 2,400 No data No data 2,655 265 2,920 
MO 2 250 No data No data No data 250 250 500 
MT 1 250 0 No data 13,000 13,250 250 13,500 
NC 4 56,017 1,092 No data 27,080 84,189 10 84,199 
NM 4 1,056 0 No data 91,282 92,338 24,300 116,638 
NV 6 2,400 40 0 1,174,514 1,176,954 0 1,176,954 
OH 9 71,941 16,635 No data 74,622 163,198 46,858 210,056 
OK 1 9,000 No data No data No data 9,000 50 9,050 
PA 8 39,509 2,093 No data 23,500 65,102 40,199 105,301 
SC 1 4,174 No data No data 11,605 15,779 No data 15,779 
TN 2 14,010 4,600 No data 21,550 40,160 5 40,165 
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Reported amounts released in pounds per yeara 
Number Under- Total on- Total off- Total on and 
Stateb 
of 









TX 12 131,637 22 27,699 197,164 356,522 609,353 965,875 
UT 4 4,122 1,000 No data 1,635,235 1,640,357 263 1,640,620 
VA 1 4,100 600 No data 14,000 18,700 No data 18,700 
WV 9 72,843 3,456 No data 93,928 170,227 8,403 178,630 
WY 2 10,469 No data No data 26,970 37,439 No data 37,439 
Total 119 576,929 56,048 27,699 7,209,933 7,870,609 1,782,654 9,653,263 
Source: TRI00 2002 
aData in TRI are maximum amounts released by each facility.

bPost office state abbreviations are used. 

cThe sum of fugitive and stack releases are included in releases to air by a given facility.

dThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

eTotal amount of chemical transferred off-site, including to publicly owned treatment works (POTW).
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from stationary sources in the United States for 1969–1971, 1978, and 1983 were 900, 1,240, and 
1,560 tons selenium/year, respectively (EPA 1974; Lee and Duffield 1979).  Dulka and Risby (1976) 
estimated yearly releases of selenium to the air from fossil fuel combustion to be 1,000 tons. Harr (1978) 
estimated that 1,500 tons were released annually, with additional air releases from industrial and 
municipal wastes totaling 2,700 tons and 360 tons, respectively.  Selenium releases to the air are likely to 
increase as more coal is burned in the future.  The estimated selenium emissions from Canadian non­
ferrous smelters (stack plus fugitive) were 3.02 tons in 1993 (Skeaff and Dubreuil 1997). 
Incineration of rubber tires, paper, and municipal waste is an additional source of atmospheric selenium.  
Hashimoto et al. (1970) reported selenium concentrations in rubber tires to be 1.3 mg/kg.  Seventy 
different kinds of paper have been found to contain selenium (West 1967).  Combustion of municipal 
solid waste results in stack emissions ranging from 0.00098 to 0.00216 pounds (0.44–0.98 g) of selenium 
per ton of refuse (Johnson 1970). 
The amount of selenium contributed to the air by other sources is not known.  Microbial action within the 
soil may also contribute selenium to the air (Fishbein 1983).  Selenium biomethylation volatilizes about 
3,000 tons of selenium per year into the atmosphere, which eventually returns to earth in rainfall (NAS 
1976a). Volcanic gas is suspected to be the major natural source of atmospheric selenium.  Certain plants 
metabolize inorganic selenium compounds to volatile selenium in the forms of dimethyl selenide (Lewis 
et al. 1971) and dimethyl diselenide (Evans et al. 1968).  Animals are also capable of volatilizing 
selenium and releasing dimethyl selenide in expired air (Schultz and Lewis 1940). 
Fly ash settling ponds (which contain high concentrations of selenium) and hazardous waste sites where 
selenium compounds were disposed of in the past are potential sources of atmospheric selenium through 
fugitive dust emissions.  Selenium emissions from these potential sources have not been quantified. 
According to TRI, an estimated total of at least 65,481 pounds of elemental selenium and 576,929 pounds 
of selenium compounds were discharged to the air from manufacturing and processing facilities in the 
United States in 2000 (TRI00 2002) (see Tables 6-1 and 6-2).  The data listed in the TRI tables should be 
used with caution since only certain types of facilities are required to report.  This is not an exhaustive 
list. 
Selenium has been identified in air at 13 of the 508 NPL hazardous waste sites where it was detected in 
some environmental media (HazDat 2003).  
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6.2.2 Water 
Surface waters can receive selenium from the atmosphere by dry and wet deposition, from adjoining 
waters that may contain selenium, from surface runoff, and from subsurface drainage.  Sewage treatment 
plants are another source of selenium releases to water.  Effluents from sewage treatment plants and oil 
refineries appear to be the major sources of selenium in the San Francisco estuarine system (Cutter 1989).  
In a study of direct discharges from oil refineries in San Francisco Bay, the average selenium 
concentration in the effluent was 0.067 mg/L with a range of 0.0066–0.156 mg/L (Barceloux 1999; Cutter 
1989).  Approximately 50–76% of the total selenium in the effluents was selenite.  This proportion of 
selenite is higher than that found in natural estuary sources in the San Francisco Bay (Cutter 1989).  
About 150,000–460,000 tons of selenium per year are deposited in coal fly ash (Andren and Klein 1975; 
Doran 1982).  Selenium from fly ash settling ponds and hazardous waste sites could reach surface water 
via runoff or could reach groundwater via leaching.  Concentrations of 0.10–0.25 mg/L in a settling basin 
effluent from coal fly ash in North Carolina were reported by Lemly (1985).  Overflow from the ash basin 
of a coal fired electric generating facility to Belews Lake resulted in surface water selenium 
concentrations of 0.005–0.020 mg/L in the lake basin.  These levels have been reduced considerably since 
1986 when the discharge of selenium laden waste water to the lake was discontinued.  The peak selenium 
concentration in 1996 was <0.001 mg/L (Lemly 1997).  Selenium concentrations as high as 0.28 mg/L 
have been reported for raw sewage, 0.045 mg/L for primary effluent, and 0.050 mg/L for secondary 
effluent (Baird et al. 1972).  Irrigation drainage from seleniferous soils can increase selenium 
concentrations in surface water and has resulted in levels that are toxic to wildfowl at Kesterson National 
Wildlife Refuge in California (Ohlendorf et al. 1986a, 1988).  Selenium was found to be released during 
coal mining because of the oxidation of selenium-bearing pyrite (Dreher and Finkelman 1992). 
According to the TRI, an estimated total of 1,019 pounds of elemental selenium and 56,048 pounds of 
selenium compounds were discharged to surface water from manufacturing and processing facilities in 
the United States in 2000 (see Tables 6-1 and 6-2).  The data listed in the TRI tables should be used with 
caution since only certain types of facilities are required to report.  This is not an exhaustive list. 
Selenium has been identified in groundwater at 271 sites and surface water at 106 sites of the 508 NPL 
hazardous waste sites where it was detected in some environmental media (HazDat 2003).  
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6.2.3 Soil 
The primary factor that controls selenium concentrations in soil is the selenium content of the parent 
bedrock materials that release selenium via weathering processes and leaching (NAS 1976a). Natural 
weathering processes are thought to release about 100,000–200,000 metric tons of selenium per year 
(Andren and Klein 1975). Atmospheric deposition of selenium also contributes to selenium in the soil.  
In the past, selenium was used in pesticide products, but because of its stability in soils and subsequent 
contamination of food crops, its use in pesticide products is now restricted.  The release of selenium to 
soil from fly ash settling ponds and hazardous waste sites has not been quantified. 
According to the TRI, an estimated total of 157,521 pounds of elemental selenium and 7,209,933 pounds 
of selenium compounds were discharged to land from manufacturing and processing facilities in the 
United States in 2000 (TRI00 2002).  In addition, 40,246 pounds of selenium and 27,699 pounds of 
selenium compounds were injected underground (see Table 6-2).  The data listed in the TRI tables should 
be used with caution since only certain types of facilities are required to report.  This is not an exhaustive 
list. 
Selenium has been identified in soil at 188 sites and sediment at 113 of the 508 NPL hazardous waste 
sites where it was detected in some environmental media (HazDat 2003). 
6.3 ENVIRONMENTAL FATE 
The behavior of selenium in the environment is influenced to a large degree by its oxidation state and the 
consequent differences in the behavior of its different chemical compounds (EPA 1979c; NAS 1976a).  
The oxidation state of selenium in the environment is dependent on ambient conditions, particularly on 
pH, pE, and biological activity (Maier et al. 1988). 
6.3.1 Transport and Partitioning 
The volatile selenium compounds that partition into the atmosphere include the inorganic compounds, 
selenium dioxide and hydrogen selenide, and the organic compounds, dimethyl selenide and dimethyl 
diselenide. Hydrogen selenide is highly reactive in air and is rapidly oxidized to elemental selenium and 
water (NAS 1976a), but the other compounds can persist in air. 
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Selenium compounds released to the atmosphere can be removed by dry or wet deposition to soils or to 
surface water.  The annual wet deposition rate of selenium at two rural/agricultural sites in Queenstown, 
Maryland and St. Mary’s, Maryland were 287 and 140 µg/m2-year, respectively (Scudlark et al. 1994).  
Selenium concentrations ranging from 0.04 to 1.4 µg/L have been detected in rain and snow (Hashimoto 
and Winchester 1967).  Kubota and coworkers (1975) reported selenium concentrations of 0.02– 
0.37 µg/L in rainwater at several locations in the United States and Denmark.  Selenium was detected at 
average concentrations of 5.60–7.86 µg/L during four rainfall events in Riyadh, Saudi Arabia 
(Alabdula’aly and Khan 2000). 
The forms of selenium expected to be found in surface water and the water contained in soils are the salts 
of selenic and selenious acids.  Selenic acid (H2SeO4) is a strong acid.  The soluble selenate salts of this 
acid are expected to occur in alkaline waters.  Sodium selenate is one of the most mobile selenium 
compounds in the environment because of its high solubility and inability to adsorb onto soil particles 
(NAS 1976a). Selenious acid (H2SeO3) is a weak acid, and the diselenite ion predominates in waters 
between pH 3.5 and 9. Most selenites are less soluble in water than the corresponding selenates (NAS 
1980b). 
Selenium in an aquatic environment is bioaccumulated by aquatic organisms (Chau and Riley 1965; 
Ohlendorf et al. 1986a; Rudd and Turner 1983a; Saiki and Lowe 1987).  Lemly (1985) has reported 
bioconcentration factors (BCFs) of 150–1,850 and bioaccumulation factors (BAFs) of 1,746–3,975 for 
selenium in freshwater.  In the Kesterson National Wildlife Refuge in the San Joaquin Valley of 
California, elevated levels of selenium have been measured (dry weight) in algae (average 35 mg/kg), 
midge larvae (139 mg/kg), dragonfly and damselfly nymphs (average 122 and 175 mg/kg, respectively), 
and mosquito fish (170 mg/kg) (Ohlendorf et al. 1986b).  For comparison, the mean concentrations of 
selenium found in fish throughout the United States in the 1976–1977, 1978–1979, and 1980–1981 
National Pesticide Monitoring Program were 0.56, 0.46, and 0.47 mg/kg wet weight, respectively (Lowe 
et al. 1985; May and McKinney 1981; Ohlendorf et al. 1986b).  Similarly, Lemly (1985) found elevated 
selenium concentrations in aquatic organisms living in a power plant cooling reservoir in North Carolina.  
The degree of bioaccumulation of selenium exhibited a stable pattern over several years, with selenium 
concentrations (wet weight) as follows: fish (6–35 mg/kg) > benthic insects (12–15 mg/kg) > annelids 
(10–12 mg/kg) > molluscs and crustaceans (5–9 mg/kg) > periphyton (4–6 mg/kg) (Ohlendorf et al. 
1986a). In fish, selenium was concentrated in visceral tissue (25–35 mg/kg wet weight) more than in 
skeletal muscle (6–11 mg/kg wet weight).  Adams (1976) reported BCFs of 62.1, 14.3, 6.3, 3.2, and 
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10.5 for selenium in the viscera, gill, head and tail, muscle, and whole trout, respectively.  The BCFs and 
BAFs for selenium in visceral tissue (i.e., heart, hepatopancreas, spleen, and gonads) of fish have been 
estimated to range from 35 to 1,850 and from 1,058 to 3,980, respectively (Lemly 1982, 1985).  Lemly 
(1985) also estimated BAFs for selenium in skeletal muscle of fish to range from 485 to 1,746, depending 
on the species. Maier et al. (1988) estimated selenium BAFs for algae to range from 100 to 2,600, and 
Besser et al. (1993) estimated BCFs of 16,000 for algae, 200,000 for daphnids, and 5,000 for bluegills 
from exposures to 1 µg/L selenomethionine.  Selenite was more concentrated than selenate for algae and 
daphnids, whereas bluegills concentrated both inorganic species about equally (Besser et al. 1993).  
Selenium accumulation from selenomethionine occurred more readily than from selenite or selenate 
(Besser et al. 1989). 
Some evidence indicates that selenium might biomagnify in aquatic organisms under natural conditions 
(Lemly 1985; Maier et al. 1988; NCDNR 1986; Sandholm et al. 1973).  Biomagnification is evidenced by 
progressively higher concentrations of an element or substance in organisms at successively higher 
trophic levels. More than 50% of the selenium contained in sediments in the ponds and the reservoir in 
the Kesterson National Wildlife Refuge in California occurs in organic forms (Maier et al. 1988), 
resulting from the synthesis and bioaccumulation of organic selenium before the plants die and decay on 
the bottom. 
In soils, pH and Eh are determining factors in the transport and partitioning of selenium.  Elemental 
selenium is essentially insoluble and may represent a major inert "sink" for selenium introduced into the 
environment under anaerobic conditions (NAS 1976b). Heavy metal selenides and selenium sulfides, 
which are also insoluble, predominate in acidic (low pH) soils and in soils with high amounts of organic 
matter. Selenium in this form is immobile and will remain in the soil.  The selenides of other metals such 
as copper and cadmium are of low solubility (NAS 1976b).  Sodium and potassium selenites dominate in 
neutral, well-drained mineral soils, where some soluble metal selenites may be found as well.  In alkaline 
(pH>7.5), well-oxidized soil environments, selenates are the major selenium species.  Because of their 
high solubility and low tendency to adsorb onto soil particles, the selenates are very mobile (Kabatas-
Pendias and Pendias 1984) and are readily taken up by biological systems (Klaassen et al. 1986) or 
leached through the soil. Gerritse et al. (1982) found selenium to be very mobile in sewage sludge 
leachate. They reported Kd values (distribution coefficient = [concentration of selenium sorbed on soil or 
rock]/[concentration of selenium in solution]) of 14.9 mL/g for sandy loam and 5.91 mL/g for sludge-
treated sandy soils.  Selenite forms stable ferric oxide-selenite adsorption complexes in acid or neutral 
soils (Geering et al. 1968). 
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When environments favor the soluble forms of selenium (alkaline and oxidizing conditions), these forms 
can be accumulated by plants.  In addition, although both selenite (Se4+) and selenate (Se6+) are soluble 
forms of selenium, selenate was found to be the preferred form of selenium taken up by plants (Baňuelos 
and Meek 1990). Preferential uptake of selenate may be caused by its tendency to be less strongly 
adsorbed to soil particles and organic matter than selenite (Baňuelos and Meek 1990). Selenium uptake 
by plants is influenced by many factors including soil type, pH, colloidal content, concentration of 
organic material, oxidation-reduction potentials in the root-soil environment, and total level of selenium 
in the soil (Fishbein 1983; Robberecht et al. 1982).  In acidic soils (pH 4.5–6.5) and under high moisture 
conditions, selenium is in the form of selenite and is bound to colloids as iron hydroxide selenium 
complexes.  These complexes are insoluble and generally not bioavailable to plants (Galgan and Frank 
1995).  In basic soils (pH 7.5–8.5), selenium is present as soluble selenate.  Soluble selenates (principally 
sodium selenate) appear to be responsible for most of the naturally occurring accumulation of high levels 
of selenium by plants, although much of the total selenium in soil may be present in other forms (NAS 
1976a). The use of lime and plant ash as fertilizers, which would raise the pH of the soil and favor the 
formation of selenate, has been implicated as a contributing factor in the accumulation of selenium in 
crops grown in high selenium soil found in certain regions of China (Yang et al. 1988). 
6.3.2 Transformation and Degradation 
6.3.2.1 Air 
Selenium dioxide released to the air from the combustion of fossil fuels should be largely reduced to 
elemental selenium by sulfur dioxide formed during the combustion (NAS 1976b).  During a 1991 study, 
Oehm et al. found that selenium dioxide reacting with atmospheric moisture generates selenious acid 
aerosols. Hydrogen selenide is unstable in air and is oxidized to elemental selenium and water (NAS 
1976a). Hazards from hydrogen selenide are expected, therefore, to be confined to occupational settings 
where the confined gas might build up to hazardous levels despite oxidative losses (NAS 1976a).   
Dimethyl selenide and methyl selenide are volatile organic compounds that can partition into and persist 
in the atmosphere.  Other selenium compounds released to the atmosphere as dust can be removed by wet 
deposition (in rain or snow) or by dry deposition. 
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6.3.2.2 Water 
In general, the more soluble and mobile forms of selenium (e.g., selenite and selenate) dominate under 
aerobic (high oxygen concentrations) and alkaline (high pH) conditions (NAS 1976a; Shamberger 1981).  
Selenates have been predicted thermodynamically to predominate under aerobic conditions, but a review 
of the literature indicates that both selenites and selenates are equally common in surface waters 
(Robberecht and Van Grieken 1982). For selenites in solution, equilibria will be set up between H2SeO3, 
HSeO3-, SeO3-, HSe2O5-, and Se2O52-. The relative concentrations of these species will be determined by 
the pH of the solution and the total concentration of the electrolytes.  Between pH 3.5 and 9, dissolved 
selenite would be expected to be present predominantly as the diselenite ion, whereas dissolved selenate 
would occur predominantly as SeO42 -. Sodium predominates as the counter ion of selenate and selenite in 
most surface waters. 
A study completed by Bender et al. (1991) using a simulated laboratory pond found that bacteria and 
cyanobacteria have two possible mechanisms for the uptake and transformation of selenate.  The uptake 
mechanism involves the reduction of selenate to elemental selenium that will be physically held within 
the biological mat.  The microorganisms were also found to cause the transformation of soluble selenium 
into volatile alkyl selenium compounds (Bender et al. 1991). 
In some deep aquifers, selenium transport in groundwater was found to be strongly retarded (White et al. 
1991).  This phenomena is thought to be caused by chemical reduction and precipitation mediated by 
microbial activity. 
Under acidic conditions, selenite can be rapidly reduced to elemental selenium by mild reducing agents 
such as ascorbic acid or sulfur dioxide (NAS 1980b).  Selenate can be converted to selenite or elemental 
selenium in aquatic systems, but this reaction is slow relative to other transformations.  Once formed, 
elemental selenium is stable over a wide range of pH values and a range of mildly oxidizing to reducing 
conditions. The formation of various metal selenides is favored by acidic and reducing conditions (NAS 
1976b), as found in organic-rich sediments. 
Aquatic organisms can convert selenium to both inert and soluble forms.  Duckweed, phytoplankton, 
bacteria, and fungi have been demonstrated to synthesize selenoamino acids from absorbed inorganic 
selenium compounds (Maier et al. 1988).  These selenoamino acids are not likely to be found at 
significant dissolved concentrations in water, however, because amino acids are rapidly catabolized by 
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bacteria. Benthic bacteria and fungi are capable of methylating elemental and inorganic selenium salts 
(Chau et al. 1976). Hydrogen selenide can be formed in a reducing environment (Cutter 1982; NAS 
1976a). Both hydrogen selenide and the methylated forms of selenium are unstable in water and would 
be expected to rapidly volatilize to the atmosphere (Fishbein 1983). 
6.3.2.3 Sediment and Soil 
In soils, elemental selenium and inorganic selenium compounds such as sodium selenite can be 
methylated by microorganisms and subsequently volatilized to the atmosphere (Doran 1982; Fishbein 
1983; Shamberger 1981).  Microorganisms such as Aeromonas, Flavobacterium, and Pseudomonas are 
suspected of methylating inorganic and organic selenium compounds to dimethyl selenide and dimethyl 
diselenide (Doran and Alexander 1976; Fishbein 1983; Reamer and Zoller 1980).  Microbes cultured 
from rhizosphere of bulrush (Scirpus robustus) plants were shown to biomethylate soluble selenate and 
selenite and substantially volatilize these compounds over a 15-day incubation period (Azaizeh et al. 
1997).  Temperature plays a significant role in the microorganism-mediated volatilization of selenium 
compounds; temperature reductions from 20 to 10 EC and from 20 to 4 EC resulted in 25 and 90% 
decreases, respectively, in the dimethyl selenide produced (Chau et al. 1976).  Reamer and Zoller (1980) 
examined microbial transformation of selenium in aerobic sewage contaminated with elemental selenium 
and selenite. They found dimethyl selenide to be the principal microbial product at low selenite 
concentrations (1–10 mg/kg), whereas dimethyl diselenide and dimethyl selenone were the principal 
products at higher selenite concentrations (100–1,000 mg/kg).  Dimethyl selenide was the only product 
recovered from sludge contaminated with elemental selenium (Reamer and Zoller 1980).  In general, 
microorganisms appear to methylate organic selenium compounds more readily than either selenite or 
selenate (Maier et al. 1988).  Elemental selenium is converted to methylated selenium compounds the 
least rapidly (Maier et al. 1988).  Selenium methylation and subsequent return from the atmosphere as 
selenite in rainwater is likely to be the major natural process by which selenium cycling occurs in the 
environment (Doran 1982). 
Demethylation of the trimethylselenonium ion can also occur in soil.  Microorganisms are evidently 
required for this reaction since it did not occur in autoclaved soil (Yamada et al. 1994).  Selenium added 
to the soil as trimethylselenonium was not recovered in the soil, suggesting that trimethylselenonium was 
demethylated to gaseous selenium compounds, for example, dimethylselenide. 
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Terrestrial plants take up soluble selenate and selenite and biosynthesize organic selenium compounds, 
predominantly selenomethionine and, to a lesser extent, selenocysteine.  Selenates tend to be taken up by 
plants from soils more readily than selenites, in part because selenites tend to adsorb more strongly to 
soils (Dimes et al. 1988; Zhang et al. 1988).  These compounds can be released to the soils once the plants 
die and decay. Water-soluble organic selenium compounds are also probably readily taken up by plants 
(Shamberger 1981; Shrift 1964). 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Selenium can be detected in most biological and nonbiological materials in the environment.  Selenium 
occurs in aquatic and terrestrial organisms as well as in water, air, and soil.  Among foods consumed by 
humans, meat products generally contain the highest concentration of selenium while vegetables and 
fruits contain the lowest.  Brazil nuts contain extremely high levels of selenium since they grow in the 
foothills of the Andes Mountains, where the soils are high in selenium (Secor and Lisk 1989).  Cereals 
contain intermediate levels of selenium. 
6.4.1 Air 
Background ambient air concentrations of selenium are generally in the ng/m3 range (Harrison et al. 1971; 
John et al. 1973; Peirson et al. 1973).  Dams et al. (1970) found concentrations of selenium in suspended 
air particulate matter of 2.5 ng/m3 in Niles, Michigan, and 3.8 ng/m3 in East Chicago, Indiana. During 
1968–1969, 18 air samples collected around Buffalo, New York, showed a range of 3.7–9.7 ng/m3 (Pillay 
et al. 1971). Based on these results, the National Academy of Sciences (NAS 1976a) has estimated that 
the average selenium concentration in the air is well below 10 ng/m3. A monitoring study to determine 
the seasonal variation of pollutants in the air of Alaska was conducted from 1984 to 1987 (Sturges and 
Shaw 1993). The average concentrations of selenium in Poker Flats, Alaska were 0.035 ng/m3 (June 1 
through January 31, 1984–1987) and 0.067 ng/m3 (February 1 through May 31, 1984–1987). The nearly 
2-fold increase in concentration during the spring months were attributed to local marine biogenic 
volatilization of selenium, and not a coal burning origin (Sturges and Shaw 1993).  Selenium was 
detected in the ambient atmosphere at seven sites in the United Kingdom at concentrations ranging from 
0.1 to 42.3 ng/m3 (Lee et al. 1994).  The lowest levels were observed in the rural areas of Chilton and 
Windermere with mean concentrations of 1.3 and 0.9 ng/m3, respectively.  The highest mean 
concentration of 16.7 ng/m3 was observed in the industrial area of Walsall. 
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6.4.2 Water 
Selenium has been detected in surface waters and groundwaters in the United States at generally low 
concentrations. Selenium has been detected in oceans at an average value of 9x10-5 mg/L (0.09 µg 
selenium/L) (Schutz and Turekiam 1965).  In a study of selenium concentrations in major watersheds of 
the United States, selenium was detected in only 2 of 535 samples (<0.5%) at a concentration greater than 
the lowest detection limit of 0.010 mg/L (Lakin and Davidson 1967).  Examination of the EPA STORET 
database for the state of North Carolina revealed that only 3.3% of 657 samples of surface water 
contained more than 0.001 mg/L, and the highest value was 0.012 mg/L (NCDNR 1986).  Watersheds 
that receive selenium-contaminated waste water have high levels of selenium in surface water samples.  
The selenium concentration in Lake Belews, North Carolina has dropped from a maximum value of about 
0.020 mg/L (pre -1986) to <0.001 mg/L in 1996, due to the discontinued release of selenium laden waste 
water from a local coal fired power plant (Lemly 1997).  The selenium concentration in portions of 
Pigeon River and Pigeon Lake, Michigan which receive waste water input from a coal fly ash disposal 
facility, were <0.001–0.0075 mg/L (Besser et al. 1996). 
High selenium levels are more likely to be found in irrigation return waters, seeps, springs, and shallow 
wells where seleniferous soils may contribute to the selenium content of the water.  Glover et al. (1979) 
found that under unusual geological conditions, selenium concentrations in groundwater may reach 
0.60 mg/L.  In another study conducted in a seleniferous area of South Dakota, 34 of 44 wells did not 
show any measurable selenium; however, the remaining 10 had concentrations ranging from 0.050 to 
0.339 mg/L (Smith and Westfall 1937).  Selenium concentrations determined in 107 irrigation and 
44 livestock well waters in the San Joaquin area of California exceeded 0.010 mg/L in 26 wells, but 
exceeded 0.020 mg/L in only 11 wells (Oster et al. 1988a).  The maximum concentration was 0.272 mg/L 
(Oster et al. 1988a). 
Selenium accumulation in agricultural drainage waters and basins has been documented in the western 
United States, particularly in California.  The problem was first discovered in the Kesterson Wildlife 
Refuge in the San Joaquin Valley of California.  In 1975, the U.S. Bureau of Reclamation finished 
construction of an 85-mile subsurface agricultural water drain that terminated in a series of evaporation 
ponds called Kesterson Reservoir.  By 1983, however, it was confirmed that the drain waters contained 
high concentrations of selenium (>1.35 mg/L in some areas) leached from the soil by application of 
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irrigation water (Maier et al. 1988). Because the high selenium levels produced death and deformities in 
fish and waterfowl, delivery of subsurface water to Kesterson was terminated in 1986 (Lewis 1988). 
Measurements of trace elements in the 27 other evaporation basins in the San Joaquin Valley have 
revealed only 3 basins with total selenium exceeding 0.10 mg/L and only 50 acres of evaporation basin 
cells with selenium concentrations in excess of 1.0 mg/L (CRWQCB 1988).   
6.4.3 Sediment and Soil 
Selenium is estimated to be the 69th most abundant element in the earth's crust, with an average 
concentration of 0.05–0.09 mg/kg (Glover et al. 1979).  Chemically, selenium closely resembles sulfur.  
Consequently, sulfides of bismuth, iron, mercury, silver, copper, lead, and zinc have been found to 
contain selenium (Shamberger 1981).  Selenium is concentrated in the sulfide minerals galena, 
chalcopyrite, arsenopyrite, sphalerite, pyrite, marcasite, and pyrrhotite (Coleman and Delevaux 1957).  
Jarosite and barite have also been found to contain selenium at low levels.  The sulfides containing the 
highest selenium concentrations are those associated with uranium ores in sandstone-type deposits in the 
western United States.  In the immediate vicinity of sandstone-type uranium deposits, selenium 
concentrations as high as 1,000 mg/kg have been found (Shamberger 1981).  Hydrothermal ore is also 
known to contain high concentrations of selenium.  The best known are epithermal gold, silver, antimony, 
and mercury deposits (Shamberger 1981).  Selenium has been found in volcanic rocks in the western 
United States at concentrations as high as 120 mg/kg (Glover et al. 1979). 
Various studies estimated selenium concentration of most soils to be between 0.01 and 0.2 mg/kg 
(Sindeeva 1964).  One study analyzed several thousand soil samples in the United States and found that 
most seleniferous soils contained <2 mg/kg, with a maximum concentration of <100 mg/kg (Rosenfeld 
and Beath 1964). The highest U.S. soil levels of selenium are found in areas of the West and Midwest. 
Atmospheric deposition of selenium from mining and smelting activities also appears to be a source to 
soils and plants (Glooschenko and Arafa 1988).  In this study, an indirect relationship between distance 
from smelters and selenium concentration was shown using Sphagnum fuscum as an indicator. Washout 
of atmospheric selenium by precipitation appeared to be the primary mechanism for accumulating 
selenium in soils and plants in the vicinity of smelters (Glooschenko and Arafa 1988).  
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Sandstone has been found to contain selenium in varying concentrations, but most probably contains 
<1 mg/kg (Rosenfeld and Beath 1964).  However, sandstone in Wyoming has been found to contain 
>100 mg/kg (Beath et al. 1946).  Generally, the selenium concentration of limestone is low; however, 
shales of the Niobrara formation in South Dakota have been found to contain over 40 mg/kg.  The range 
of selenium concentrations in phosphate rocks is <1–300 mg/kg (NAS 1976a).  Shales appear to contain 
consistently higher concentrations of selenium than limestone or sandstone.  Despite the fact that shales 
vary so widely in their selenium concentration, they are fairly reliable indicators of soils high in selenium 
(NAS 1976a). 
The disposal of selenium contaminated waste water has resulted in elevated selenium levels in sediments 
of Lake Belews, North Carolina. The concentration of selenium in sediments ranged from 4 to 12 µg/g 
(pre-1986), but has dropped to 1–4 µg/g (1996) due to the discontinued release of selenium laden waste 
water from a local coal fired power plant (Lemly 1997).  Selenium was measured in 445 surface soil 
samples from Florida with a concentration range of 0.01–4.62 µg/g and an arithmetic mean of 0.25 µg/g 
(Chen et al. 1999). Selenium was detected in soils and bed sediment from the South Platter River Basin 
at concentrations of 0.30–3.80 µg/g (Heiny and Tate 1997).  The highest levels were observed in areas 
consisting of a high degree of Precambrian rock formation.  
6.4.4 Other Environmental Media 
Coal and Oil.  Petroleum has been found to contain 500–950 mg/kg crude petroleum and 500– 
1,650 mg/kg heavy petroleum (Hashimoto et al. 1970).  An average of 2.8 mg/kg coal has been reported 
for 138 samples from U.S. deposits (Pillay et al. 1969). 
Plants. Several species of grasses and herbaceous plants accumulate selenium, and some of these are 
endemic to the western United States.  Primary accumulators are Astragalus, Oonopsis, Stanelya, 
Xylorhiza, and Machaeranthera. Secondary accumulators are Astor, Gatierreaia, Atriplex, Grindelia, 
Castillaja, and Comandra.  Primary accumulators can contain 100–100,000 mg/kg of plant tissue, 
whereas secondary accumulators contain 25–100 mg/kg of plant tissue (dry weight).  Nonaccumulator 
plants generally contain less than 25 mg of selenium/kg of plant tissue (dry weight) (Rosenfeld and Beath 
1964).  In some plants, including the leaves of beets and cabbage, and in garlic, as much as 40–50% of the 
selenium may be in the form of selenate (Cappon 1981). 
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A study by Arthur et al. (1992) showed an increased uptake of selenium by terrestrial plants growing on 
soil-capped fly ash landfill sites.  Selenium concentrations rarely exceeded 5 mg/kg, and there were no 
signs of selenium toxicity to plants.  A similar study by Shane et al. (1988) on greenhouse vegetables 
established that the uptake of selenium by these vegetables is proportional to the percentage of selenium 
in the growth medium.  Another greenhouse study showed that four floating aquatic plants, Azolla 
caroliniana, Eichjornia crassipes, Salvinia rotundifolia, and Lemna minor, absorbed selenium quickly 
upon exposure (Horne 1991). 
Animals. Aquatic animals accumulate selenium from lakes and rivers high in selenium content.  Fish in 
the Kesterson National Wildlife Refuge in California had selenium concentrations up to 96 mg/kg, and 
aquatic birds had levels up to 130 mg/kg (Barceloux 1999).  Selenium was detected in fish from three 
sites of the Pigeon River and Pigeon Lake in Michigan (Besser et al. 1996).  It was determined that 
selenium concentrations in fish at sites receiving seepage and effluents from a coal fly ash disposal 
facility were considerably higher than for fish upstream from the facility.  Mean concentrations of 
selenium in white sucker and northern pike ranged from 0.46 to 0.88 µg/g in an uncontaminated portion 
of the river, while concentrations in a contaminated portion of the river and lake were 1.1–2.4 µg/g 
(Besser et al. 1996).  The mean concentrations of selenium in the feathers of five species of birds at Clear 
Lake, California were 3.20 µg/g (osprey), 1.38 µg/g (western grebe), 2.51 µg/g (great blue heron), 
0.94 µg/g (turkey vulture), and 1.05 µg/g (mallard) (Cahill et al. 1998). Ospreys (which consume large 
mature fish) had the highest selenium levels, while turkey vultures (which rarely interact with the 
contaminated aquatic system) and mallards (which are semi-domesticated) had the lowest levels.  
Selenium was observed in 24 of 24 black-crowned night herons from the Delaware Bay at concentrations 
of 2.84–5.95 µg/g (Rattner et al. 2000).  The highest levels were observed in herons from Pea Patch 
Island, an island adjacent to a shipping channel for the petrochemical industry. Selenium was observed in 
the liver of 70 out of 70 redheads (Athya americana) in Louisiana and Texas at concentrations of  
1.56–5.86 µg/g (Michot et al. 1994).  The selenium concentration in moose liver from 12 areas of Sweden 
ranged from 0.0027 to 3.054 µg/g (Galgan and Frank 1995).  The highest levels were observed in areas 
with a high degree of selenium deposition from industrial sources. 
Food. In a review of the foods that contribute the highest proportion of the daily selenium intake of 
human populations in the United States, Schubert et al. (1987) estimated selenium concentrations in over 
100 food items on the basis of 65 articles published after 1960.  Table 6-3 presents the selenium 
concentrations for some of the food items analyzed.  The quality of the data was evaluated on the basis of 
sample size, analytic method, sample handling, sampling plan, and analytic quality control.  Schubert et 
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Table 6-3. Selenium Concentrations in Foods in the United Statesa 
(mg selenium/kg, wet weight) 
Number of 
Food item Average Minimum Maximum acceptable samples 
Fruits and vegetables
 Apples, raw 0.004 0.003 0.006 5 
 Carrots, raw 0.017 0.006 0.029 5 
 Oranges 0.015 0.013 0.018 3 
Potatoes 0.013 0.004 0.023 7 
Grains, nuts, and cereals 
 Bread, white 0.32 0.23 0.54 6 
 Bread, whole wheat 0.44 0.28 0.67 3 
 Corn flakes 0.063 0.026 0.12 4 
 Special K 0.063 0.35 0.94 4 
 Egg noodles, dry 0.66 0.43 1.35 7 
 Egg noodles, cooked 










 Whole milk 0.016 0.011 0.025 4 
 Swiss cheese 0.083 0.062 0.10 2 
 Cottage cheese 0.060 0.052 0.068 2 
Meat 
 Chicken, cooked 0.21 0.17 0.26 2 
 Beef, cooked 0.26 0.15 0.52 3 
 Pork/ham, fresh/cured 0.33 0.19 0.51 6 
Salami 0.20 0.13 0.33 2 
Seafoodc
 Salmon, canned 0.75 0.31 1.49 3 
 Shrimp, canned/cooked 0.64 0.21 1.61 4 
Swordfish 2.84 2.54 3.44 4 
Organ meats 
Beef liver, cooked 0.56 0.43 0.71 2 
Beef kidney, raw 1.70 1.45 2.32 4 
aFood is the normal source of selenium which is essential for human health.  Concentrations from Schubert et al.  

(1987), except where noted. 

bSecor and Lisk (1989) 

cBioavailability of selenium from some fish may be lower than from other foods.
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al. (1987) chose not to present standard deviations or standard errors of the samples because of the 
different sampling biases present in the studies. 
In general, fruits and vegetables were found to contain <0.01 mg/kg, whereas root vegetables contained 
higher concentrations of selenium (Table 6-3).  Beale et al. (1990) found milk and meat to have the same 
range of selenium concentrations as Schubert et al. (1987).  In another study, no apparent correlation 
existed between the selenium concentration of canned versus fresh fruits and vegetables (Morris and 
Levander 1970). 
Grain products varied greatly in their selenium concentration.  Wheat bread and flour were high in 
selenium, whereas white bread and white flour contained considerably less selenium.  Very low levels of 
selenium were found in certain processed cereals, such as corn flakes, but not in others, such as oat cereal 
(Morris and Levander 1970; Schubert et al. 1987). 
Dairy products contained variable concentrations of selenium as well, but, in general, contained lower 
levels than meat products.  Organ meats (e.g., liver and kidney) and seafoods contained higher levels of 
selenium than poultry or beef (Morris and Levander 1970; Schubert et al. 1987).  The U.S. Fish and 
Wildlife Service collected 315 whole fish samples from 109 stations nationwide and analyzed them for 
selenium.  Selenium concentrations were as follows (wet weight): geometric mean of 0.42 µg/g, 
maximum of 2.3 µg/g, and 85th percentile concentration of 0.73 µg/g (Schmitt and Brumbagh 1990).  
Consumption of the foods with higher selenium levels contributes to the daily intake of adequate amounts 
of selenium.  
Analysis of commercial baby foods indicated that processing may reduce selenium levels of the food 
(Morris and Levander 1970). 
A recent survey conducted by the U.S. Food and Drug Administration (FDA), which analyzed foods 
consumed in the United States during the period of 1991–1999, detected selenium in 3,654 out of 
6,679 food samples analyzed (FDA 2000).  The results of this survey are summarized in Table 6-4. 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 
























Overall: 6,671 3,025 1,206 0.07 0.12 0 1.8 0.017 
Whole milk, 
fluid 




2 25 6 14 0.022 0.015 0 0.056 0.025 
Chocolate 
milk, fluid 
3 25 5 15 0.021 0.014 0 0.054 0.023 
Skim milk, 
fluid 
4 25 5 14 0.024 0.016 0 0.058 0.025 
Plain yogurt, 
lowfat 




7 25 5 17 0.023 0.014 0 0.051 0.026 
Evaporated 
milk, canned 








11 25 2 4 0.083 0.039 0 0.178 0.08 
Cheddar 
cheese 




13 25 0 1 0.197 0.052 0.127 0.333 0.187 
Beef chuck 
roast, baked 




16 25 0 1 0.256 0.063 0.13 0.439 0.24 
Ham, baked 17 25 0 1 0.29 0.077 0.12 0.42 0.278 
Pork chop, 
pan-cooked 
18 25 0 0 0.46 0.16 0.245 0.808 0.448 





20 25 0 0 0.38 0.15 0.186 0.836 0.323 
Pork roast, 
baked 
21 25 0 1 0.34 0.11 0.13 0.692 0.333 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 
Lamb chop, 
pan-cooked 










26 25 0 0 0.34 0.14 0.095 0.583 0.329 
Liver, beef, 
fried 
27 25 0 0 0.65 0.25 0.089 1.22 0.67 
Frankfurters, 
beef, boiled 
28 25 2 3 0.098 0.037 0 0.155 0.102 
Bologna, 
sliced 
29 25 0 5 0.134 0.037 0.07 0.239 0.13 
Salami, 
sliced 
30 25 0 3 0.202 0.046 0.079 0.313 0.197 
Tuna, 
canned in oil 




34 26 0 1 0.168 0.035 0.076 0.257 0.171 
Eggs, 
scrambled 
35 26 0 1 0.217 0.073 0.076 0.405 0.206 
Eggs, fried 36 25 0 0 0.278 0.084 0.149 0.454 0.259 
Eggs, boiled 37 25 0 2 0.27 0.1 0.023 0.477 0.274 
Pinto beans, 
dry boiled 













46 25 18 5 0.007 0.013 0 0.044 0 





48 25 5 5 0.075 0.068 0 0.272 0.063 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 


















































56 25 18 7 0.005 0.008 0 0.029 0 
Popcorn, 
popped in oil 
57 26 5 7 0.083 0.071 0 0.267 0.073 
White bread 58 25 0 3 0.211 0.075 0.05 0.363 0.197 
White roll 59 25 0 0 0.265 0.076 0.144 0.41 0.266 
Cornbread, 
homemade 





61 24 0 3 0.127 0.038 0.073 0.22 0.119 
Whole 
wheat bread 
62 25 0 0 0.32 0.079 0.198 0.48 0.32 
Tortilla, flour 63 25 0 1 0.227 0.099 0.032 0.469 0.229 




65 25 0 3 0.113 0.04 0.065 0.246 0.108 
Saltine 
crackers 
66 26 1 5 0.098 0.036 0 0.197 0.1 
Corn chips 67 25 5 8 0.04 0.032 0 0.099 0.034 
Pancake 
from mix 
68 25 0 5 0.136 0.074 0.05 0.39 0.129 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 



























69 25 0 1 0.218 0.082 0.052 0.373 0.232 
Macaroni, 
boiled 
70 26 0 1 0.242 0.087 0.034 0.43 0.245 





72 25 0 5 0.075 0.026 0.031 0.14 0.079 
Shredded 
wheat cereal 
73 26 7 5 0.046 0.04 0 0.13 0.044 
Raisin bran 
cereal 
74 26 5 9 0.049 0.059 0 0.297 0.035 
Crisped rice 
cereal 
75 25 1 10 0.085 0.071 0 0.216 0.044 
Granola 
cereal 
76 26 0 2 0.144 0.053 0.066 0.244 0.14 
Oat ring 
cereal 
77 26 1 0 0.23 0.078 0 0.335 0.235 
Apple, red, 
raw 
78 26 25 1 0 0.002 0 0.011 0 
Orange, raw 79 26 24 2 0.001 0.003 0 0.012 0 
Banana, raw 80 26 16 8 0.009 0.014 0 0.054 0 
Watermelon, 
raw 
81 26 25 1 0 0.002 0 0.012 0 
Peach, raw 83 26 25 1 0 0.002 0 0.012 0 
Applesauce, 
bottled 
84 26 26 0 0 0 0 0 0 
Pear, raw 85 26 26 0 0 0 0 0 0 











88 26 26 0 0 0 0 0 0 
Cantaloupe, 
raw 
89 26 16 10 0.007 0.009 0 0.025 0 
Plums, raw 91 26 25 1 0 0.002 0 0.012 0 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 






























93 26 25 1 0.001 0.003 0 0.017 0 
Sweet 
cherries, raw 
94 20 20 0 0 0 0 0 0 
Raisins, 
dried 
95 25 24 1 0.001 0.003 0 0.014 0 
Prunes, 
dried 
96 25 25 0 0 0 0 0 0 
Avocado, 
raw 
















103 26 25 1 0 0.002 0 0.011 0 
Lemonade, 
from frozen 





107 25 18 7 0.003 0.005 0 0.015 0 
Collards, 
fresh/frozen 
108 25 17 7 0.005 0.009 0 0.041 0 
Iceberg 
lettuce, raw 
109 26 24 2 0.001 0.004 0 0.014 0 
Cabbage, 
fresh, boiled 





111 26 17 8 0.011 0.016 0 0.047 0 
Sauerkraut, 
canned 
112 26 14 11 0.009 0.015 0 0.071 0 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 



























113 26 16 8 0.011 0.027 0 0.134 0 








116 26 17 7 0.009 0.022 0 0.103 0 










121 26 23 3 0.001 0.004 0 0.013 0 
Cucumber, 
raw 





124 26 22 4 0.002 0.005 0 0.019 0 







126 26 24 2 0.001 0.003 0 0.012 0 
Onion, 
mature, raw 
128 26 18 8 0.006 0.01 0 0.039 0 




134 26 25 1 0.001 0.003 0 0.016 0 
Mashed 135 26 21 5 0.004 0.009 0 0.035 0 
potatoes, 
from flakes 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 








139 26 14 10 0.012 0.015 0 0.048 0 















Macaroni 146 26 0 2 0.195 0.055 0.076 0.339 0.189 
and cheese, 






147 26 0 2 0.177 0.046 0.091 0.3 0.173 
Meatloaf, 
homemade 
148 26 0 2 0.191 0.048 0.074 0.3 0.195 
Spaghetti 
with tomato 






151 26 0 4 0.147 0.032 0.093 0.213 0.147 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 


















157 26 11 15 0.01 0.01 0 0.026 0.013 
White 160 26 6 6 0.032 0.022 0 0.076 0.035 
sauce, 
homemade 














166 26 11 12 0.021 0.021 0 0.078 0.024 
Half & half 167 26 6 18 0.019 0.013 0 0.042 0.021 
cream 





169 26 26 0 0 0 0 0 0 
Pancake 170 26 26 0 0 0 0 0 0 
syrup 
Honey 172 26 26 0 0 0 0 0 0 
Tomato 173 26 22 4 0.002 0.005 0 0.016 0 
catsup 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 




Vanilla 177 24 6 10 0.026 0.016 0 0.046 0.03 
flavored light 
ice cream 












Sweet 182 26 0 5 0.128 0.04 0.043 0.22 0.123 
roll/Danish, 
commercial 
















186 26 6 11 0.033 0.021 0 0.076 0.037 




Caramel 188 26 10 15 0.017 0.015 0 0.05 0.022 
candy 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 
Cola 191 26 25 1 0.001 0.003 0 0.014 0 
carbonated 
beverage 
Fruit drink, 193 26 25 0 0.001 0.006 0 0.032 0 
from powder 








Tea, from 197 26 25 1 0.001 0.006 0 0.032 0 
tea bag 
Beer 198 26 21 5 0.002 0.005 0 0.015 0 
Dry table 199 26 24 2 0.002 0.008 0 0.04 0 
wine 
Whiskey 200 26 25 1 0 0.001 0 0.007 0 
Tap water 201 26 25 1 0 0 0 0.002 0 











Beef, 205 26 6 12 0.028 0.02 0 0.075 0.026 
strained/ 
junior 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 








208 2 0 2 0.064 0.004 0.061 0.066 0.064 


























213 26 7 18 0.016 0.012 0 0.041 0.018 














216 26 7 14 0.025 0.022 0 0.095 0.025 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 
Carrots, 218 26 25 1 0.001 0.005 0 0.026 0 
strained/ 
junior 
















Peas, 223 26 23 3 0.001 0.004 0 0.016 0 
strained/ 
junior 




Applesauce, 225 26 24 2 0.001 0.003 0 0.012 0 
strained/ 
junior 
Peaches, 226 26 26 0 0 0 0 0 0 
strained/ 
junior 
Pears, 227 25 24 1 0 0.002 0 0.012 0 
strained/ 
junior 
Apple juice, 230 25 25 0 0 0 0 0 0 
strained 
Orange 231 26 26 0 0 0 0 0 0 
juice, 
strained 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 










Swiss 236 26 0 5 0.18 0.054 0.109 0.368 0.174 
cheese 




238 26 0 1 0.165 0.045 0.098 0.354 0.162 
Ham 239 26 0 0 0.237 0.078 0.096 0.374 0.22 
luncheon 
meat, sliced 
Chicken 240 25 0 1 0.27 0.12 0.09 0.623 0.228 
breast, 
roasted 








242 25 0 1 0.218 0.065 0.131 0.353 0.21 
Haddock, 
pan-cooked 
243 19 0 0 0.397 0.076 0.256 0.503 0.4 
Shrimp, 
boiled 












247 25 1 0 0.53 0.39 0 1.8 0.44 
Cracked 248 26 0 0 0.285 0.065 0.209 0.448 0.269 
wheat bread 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 




























250 26 0 0 0.263 0.068 0.144 0.402 0.25 
Graham 
crackers 
251 26 4 3 0.055 0.03 0 0.1 0.057 
Butter-type 
crackers 
252 26 4 2 0.061 0.031 0 0.102 0.069 





















258 26 22 4 0.003 0.007 0 0.023 0 
Carrot, 
fresh, boiled 




260 26 24 2 0.001 0.003 0 0.014 0 
Tomato 
juice, bottled 




262 25 22 3 0.002 0.006 0 0.023 0 






264 26 2 3 0.108 0.054 0 0.227 0.095 
Eggplant, 
fresh, boiled 
265 26 26 0 0 0 0 0 0 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 








267 26 22 3 0.003 0.008 0 0.03 0 




Beef 269 26 0 0 0.191 0.043 0.121 0.311 0.183 
stroganoff, 
homemade 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 










Frankfurter 277 26 0 3 0.199 0.048 0.096 0.315 0.197 
on bun, fast-
food 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 
















Vanilla ice 286 26 6 19 0.019 0.012 0 0.043 0.021 
cream 




288 26 25 1 0.001 0.006 0 0.03 0 


















292 26 4 13 0.039 0.025 0 0.091 0.035 
Suckers, 
any flavor 




294 26 5 7 0.04 0.025 0 0.094 0.043 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 


































297 26 22 4 0.002 0.005 0 0.017 0 
Yellow 
mustard 
298 26 0 0 0.33 0.13 0.103 0.724 0.308 
Black olives 299 26 25 0 0.001 0.007 0 0.038 0 
Sour cream 300 26 4 20 0.027 0.022 0 0.1 0.022 











303 26 24 2 0.002 0.006 0 0.023 0 
Olive/ 
safflower oil 
304 26 25 1 0.001 0.003 0 0.014 0 
Coffee, from 
ground 





306 26 25 1 0.001 0.004 0 0.022 0 
Fruit drink, 
canned 
307 26 24 2 0.001 0.005 0 0.022 0 










310 12 0 0 0.293 0.026 0.253 0.33 0.292 
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Table 6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market 

Baskets 91-3 through 99-1 

Selenium—summary of results 
Number Standard 
TDS food TDS food Number of not Number Mean deviation Minimum Maximum Median 
description number of results detected of traces (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) 










Beets, 313 26 25 1 0 0.002 0 0.01 0 
strained/ 
junior 







Teething 316 26 8 18 0.015 0.011 0 0.038 0.017 
biscuits 
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6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Because selenium is ubiquitous in the environment and has been detected in so many media, exposure of 
the general population to selenium can occur in a variety of ways, including occupational exposure, 
inhalation, and ingestion of selenium via drinking water, foods, and selenium supplements.  For exposure 
via the food pathway, Schubert et al. (1987) estimated that beef, white bread, pork or ham, chicken, and 
eggs provide over 50% of the daily selenium intake in the U.S. population.  FDA (1982a) estimated that 
the greatest portion of daily selenium intake occurs from the ingestion of grains and cereals (51.8%).  
Meat, fish, and poultry were estimated to contribute 36.4% and dairy products were estimated to 
contribute 9.7% (FDA 1982a). 
Various estimates of the selenium intake for Americans have ranged from 0.071 to 0.152 mg/day (DHHS 
2002; FDA 1982a; Levander 1987; Pennington et al. 1989; Schrauzer and White 1978; Schubert et al. 
1987; Welsh et al. 1981). Schubert et al. (1987) estimated the intake of selenium for the U.S. population 
to be 0.071 mg/day.  They based their estimate on their review of selenium concentrations in different 
types of foods and the amount of each type of food eaten.  The amount of each food type eaten daily was 
estimated from the U.S. Department of Agriculture's 1977–1978 Nationwide Food Consumption Survey 
(NFCS). Welsh et al. (1981) estimated the mean daily selenium intake of a group of 22 Maryland 
residents to be 0.081 mg/day (the median was 0.074 mg/day).  In California, the mean daily selenium 
intake of eight individuals was estimated to be 0.127 mg/day (Schrauzer and White 1978).  FDA (1982a) 
estimated the average daily selenium intake of the U.S. population to be 0.1523 mg/day (152.3 µg/day).  
Pennington et al. (1989) estimated the daily dietary intake of selenium by age group and by sex between 
1982 and 1986, based on FDA's Total Diet Studies for those years, to be between 0.020 mg/day 
(20 µg/day) for infants and 0.120 mg/day (120 µg/day) for adult males between 25 and 30 years of age.  
Based on information collected from 1988-94 in the third National Health and Nutrition Examination 
Survey (NHANES III), the dietary intake of selenium was estimated by sex and age in the United States 
(see Table 6-5).  Based on data from this study, the average dietary intake for all ages and both sexes was 
estimated to be 0.114 mg/day (DHHS 2002).  These values are sufficient to meet the RDA for selenium of 
0.055 mg/day for men and women (NAS 2000). 
Both inorganic selenium and selenomethionine are found in selenium supplements.  The amounts in these 
supplements generally range from 10 to 25 µg/tablet (Goodman et al. 1990), although current products are 
SELENIUM 276 
6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-5. Selenium Dietary Intake (µg/day) by Sex and Age for the Total U.S. 

Population, 1988–1994 (DHHS 2002)a
 
Sex and age Sample size Mean SEM Median 
Both sexes 
All agesb 29,105 114 1.1 99 
Under 6 yearsb 6,871 66 0.8 62 
6–11 years 3,134 96 1.7 87 
12–19 years 3,121 117 2.4 102 
20–59 years 10,940 127 1.6 111 
60 years and over 5,039 100 1.3 89 
Male 
All agesb 13,923 134 1.6 118 
Under 6 yearsb 3,410 69 1.0 64 
6–11 years 1,581 102 2.8 92 
12–19 years 1,462 140 3.1 125 
20–59 years 5,019 153 2.1 137 
60 years and over 2,451 118 1.7 106 
Female 
All agesb 15,182 94 1.1 85 
Under 6 yearsb 3,461 63 0.9 59 
6–11 years 1,553 90 1.6 82 
12–19 years 1,659 93 2.4 87 
20–59 years 5,921 102 1.8 92 
60 years and over 2,588 87 1.6 78 
aBased on information collected in the third National Health and Nutrition Examination Survey (NHANES III). 
bExcludes nursing infants and children, includes data for poverty income ratio. 
SEM = Standard error of the mean 
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available in the 100–200 µg/tablet level.  A guide to vitamin and minerals recommends that not more than 
200 µg selenium/day should be taken in any form (Hendler 1990). 
The mean whole blood selenium concentration of residents from 19 U.S. cities ranged from 0.10 to 
0.34 mg/L with a mean value of 0.21 mg/L (Barceloux 1999).  A synopsis of selenium concentrations in 
human tissues has been summarized in Table 3-6.  Based on information collected from 1988 to 94 in 
NHANES III, the serum concentration of selenium was estimated by sex and age in the United States (see 
Table 6-6). Based on data from this study, the mean selenium serum concentration for all ages and both 
sexes was estimated to be 0.125 mg/L (DHHS 1997). 
The National Occupation Hazard Survey (NOHS), conducted by the National Institute for Occupational 
Safety and Health (NIOSH), estimated that 108,682 workers in 15,127 plants were potentially exposed to 
selenium in the workplace in 1970 (NOHS 1976).  These estimates were derived from observations of the 
actual use of selenium (1% of total estimate), the use of trade name products known to contain selenium 
(4%), and the use of generic products suspected of containing the selenium compounds (95%).  The 
largest numbers of exposed workers were heavy equipment mechanics, painters, mechanics in service 
stations, and special trade contractors.  Data from a second workplace survey, the National Occupational 
Exposure Survey (NOES), conducted by NIOSH from 1981 to 1983, indicated that 27,208 workers, 
including 9,632 women, in 1,102 plants were potentially exposed to selenium in the workplace (NIOSH 
1983). The majority of these workers were employed in the health services (e.g., nursing), as janitors and 
cleaners, as machine operators, in the metals industry, or in work involving food and kindred products.  
These estimates were derived from observations of the actual use of selenium (87% of the total estimate) 
and the use of trade name products known to contain the selenium compounds (13%) (NIOSH 1989). 
Neither the NOHS database nor the NOES database contain information on the frequency, level, or 
duration of the exposure of workers to any of the chemicals listed therein.  They are surveys that provide 
estimates of workers potentially exposed to the chemicals. 
The average selenium concentration in the blood of 20 workers employed in a rubber tire repair shop 
located in Mexico was 148 µg/L, while the average concentration in a control group of 18 healthy 
volunteers was 100 µg/L (Sánchez-Ocampo et al. 1996).  Selenium was measured in the blood of 222 coal 
miners at concentrations ranging from 34.9–99.5 µg/L (Orszczyn et al. 1996). Selenium content in the 
blood decreased with age and unexpectedly, smokers had slightly lower blood plasma concentrations than 
nonsmokers.  Furthermore, the most exposed miners (miners exposed to coal dust for more than 10 years) 
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Table 6-6. Serum Selenium Concentrations (µg/L) in U.S. Population from 
NHANES III (DHHS 1997)a 
Sex and age n Populationb Mean SEM GM GM SE 
Both sexes 
All ages 18,292 192,615,658 124.75 0.47 123.63 0.44 
<6 years old 0 0 — — — — 
6–11 years old 0 0 — — — — 
12–19 years old 2,968 25,412,279 121.09 0.49 120.03 0.46 
20–59 years old 10,519 129,562,302 125.25 0.49 124.17 0.45 
60 years and older 4,905 37,641,076 125.48 0.55 124.26 0.54 
Males 
All ages 8,561 92,798,087 126.16 0.53 125.10 0.50 
<6 years old 0 0 — — — — 
6–11 years old 0 0 — — — — 
12–19 years old 1,330 12,835,980 121.46 0.58 120.57 0.57 
20–59 years old 4,839 63,886,151 127.22 0.56 126.17 0.52 
60 years and older 2,392 16,075,956 125.72 0.61 124.54 0.59 
Females 
All ages 9,731 99,817,571 123.43 0.45 122.29 0.43 
<6 years old 0 0 — — — — 
6–11 years old 0 0 — — — — 
12–19 years old 1,538 12,576,300 120.71 0.68 119.47 0.63 
20–59 years old 5,680 65,676,151 123.34 0.45 122.26 0.42 
60 years and older 2,513 21,565,120 125.30 0.58 124.04 0.57 
aData source: Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 (DHHS 1997).  

Data analysis:  Syracuse Research Corporation, Syracuse, NY, using SUDAAN® and SAS®. 

bPortion of the United States represented by the sample
 
GM = geometric mean; GM SE = standard error of the geometric mean; SEM = Standard error of the mean 
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had lower selenium plasma levels than recently hired miners.  Although the precise mechanism 
explaining the decrease in selenium concentration with dust exposure and smoking is unknown, the 
authors speculated that the decreased selenium levels might reflect its use by the increased demand in 
antioxidant protection, involving glutathione-peroxidase.  Concentrations of selenium in the plasma and 
urine of copper refinery workers was studied (Rajotte et al. 1996).  The levels of selenium in the urine and 
plasma of the 20 workers were 34.02–189.95 and 113.93–173.57 µg/L, respectively.  The respective 
selenium levels in a control group that was not occupationally exposed were 26.71–118.39 µg/L and 
119.51–187.35 µg/L. 
6.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in 3.7 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Children are exposed to selenium by the same pathways as adults.  The primary route of exposure for 
children is through the ingestion of food sources.  Selenium has been identified in pasteurized milk and 
milk-based infant formulas in the United States at mean concentrations in the range of 0.011–0.070 mg/kg 
(Table 6-4). Children may also be exposed to selenium by breast feeding mothers.  Selenium was 
identified in the postpartum breast milk of women at different lactation stages at concentrations of  
6.1–53.4 µg/L (Li et al. 1999). Using these concentrations, the daily intake of selenium for fully breast 
fed infants was estimated to range from 5.2 to 17.9 µg/day.  Others have reported the estimated daily 
dietary intake of selenium for infants as 20 µg/day, while the daily intake for adult males was estimated as 
120 µg/day (Pennington 1989).  Selenium was detected in the umbilical blood of 350 subjects in the 
Czech Republic at concentrations of 4.0–82.6 µg/L (Černá et al. 1997). The concentration of selenium in 
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the blood of 388 children (196 males, 192 females) ranged from 5.0 to 98.2 µg/L (Černá et al. 1997).  
Selenium was detected in fetal tissues at a mean concentration of 2.8 µg/g (Robkin et al. 1973).  The 
concentration of selenium in various tissues of infants has been reported by Dickson and Tomlinson 
(1967) and is summarized in Table 3-6.  In areas containing low (0.42 mg/kg), medium (3.09 mg/kg), and 
high (9.54 mg/kg) seleniferous soils, the mean whole blood selenium levels of school children 
(7–14 years of age) were 0.13, 0.37, and 1.57 mg/L, respectively (Yang et al. 1989b).  Selenium was 
detected in postmortem liver, lung, and spleen samples of infants in Glasgow, Scotland at mean 
concentrations of 2.24, 0.76, and 0.099 ppm, respectively (Raie 1996).   
The tendency of young children to ingest soil, either intentionally through pica or unintentionally through 
hand-to-mouth activity, is well documented.  This potential route of exposure is most likely in areas that 
naturally have high selenium content in soil.  Since children often play in fields and soils, both dermal 
exposure and inhalation of dust particles from soil surfaces are possible.  The soluble forms of selenium 
such as the inorganic alkali selenites and selenates are more likely to be bioavailable in soils than the 
relatively insoluble selenides.  Children are not likely to be exposed to selenium from their parents’ work 
clothes, skin, hair, tools, or other objects removed from the workplace.  Selenium is contained in some 
household products such as shampoos and preparations to treat dandruff and eczema (IARC 1975a).  It is 
also contained in some dietary supplements (Goodman et al. 1990).  Since it is unlikely that children 
would use these products without adult supervision, the potential for overexposure to selenium from these 
products is low, except for the possibility of accidental poisoning. 
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
Because selenium is a naturally occurring element found in rocks, soils, plants, and animals, the general 
population is commonly exposed to selenium through diet and drinking water.  As a result of the uneven 
distribution of selenium in the earth's crust, populations living in certain areas of the United States are 
exposed to greater than average levels of selenium.  Areas of the United States with highly seleniferous 
soils and plants include South Dakota, Wyoming, Montana, North Dakota, Nebraska, Kansas, Colorado, 
Utah, Arizona, and New Mexico (Valentine et al. 1978).  Hawaii also has high levels of selenium in the 
soil, but not in plants (Smith et al. 1936; Valentine et al. 1978).  Human exposure to selenium occurs 
through the ingestion of food (including meat, milk, eggs, and vegetables) and drinking water from these 
areas (Smith et al. 1936).  Selenium was found at elevated levels in fish from rivers, creeks, and lakes in 
California, North Carolina, Texas, and Utah (RTI 1993).  Farmers and fishermen living in these regions 
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may be at higher risk of selenium exposure than people living in urban areas because farmers tend to 
consume a larger proportion of locally grown foods, and fishermen tend to consume seafood, whereas 
people in urban areas tend to consume foods grown over a wider geographic area.  In addition, people 
who irrigate their home gardens with groundwater containing high selenium levels may grow and 
consume plants that contain high levels of selenium because this element accumulates in some plants.  
Fishermen and hunters of waterfowl who regularly consume fish and game from waterways with elevated 
selenium levels may increase their selenium body burden, but no reports of selenosis attributable to this 
practice have appeared in the literature. 
People living in the vicinity of hazardous waste sites or coal burning plants may also be exposed to high 
levels of selenium.  Selenosis has been reported in residents of the Wudang Mountains, China where food 
was grown in highly seleniferous soil (Yang et al. 1989a, 1989b).  Selenium blood levels of five patients 
with long persisting, distinct clinical signs of selenosis ranged from 1.054 to 1.854 mg/L (Yang et al. 
1989b).  To attain selenium blood levels of this magnitude, it was estimated that the daily intake must be 
at least 910 µg/day.  The mean selenium concentration in hair samples obtained from residents of a highly 
seleniferous region of Glasgow, Scotland was 18.92 ppm (Raie 1996).  By comparison, the mean levels 
for adults from Iran and Iceland were only 5.72 and 1.81 ppm, respectively. 
6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of selenium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of selenium.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of elemental selenium 
and most of the common environmental forms of selenium have been characterized (Budavari et al. 1996; 
Lide 2000) and no further data are needed (see Chapter 4). 
Production, Import/Export, Use, Release, and Disposal. Knowledge of a chemical's production 
volume is important because it often correlates with possible environmental contamination and human 
exposure. Current data regarding the import (USGS 2002), export (USGS 2002), and use (Hoffmann and 
King 1997) of selenium are available.  No statistics regarding the U.S. production of selenium have been 
reported since 1996 (USGS 2002).  Current information on the U.S. production of selenium would assist 
in identifying potential exposures, particularly in regions of the country where environmental exposure to 
selenium through food and drinking water is already relatively high. 
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. 
Section 11023, industries are required to submit substance release and off-site transfer information to 
EPA. The Toxics Release Inventory (TRI), which contains this information for 2000, became available in 
May of 2002.  This database will be updated yearly and should provide a list of industrial production 
facilities and emissions. 
Environmental Fate. Information is available to permit assessment of the environmental fate and 
transport of selenium in air (NAS 1976a), water (Chau and Riley 1965; NAS 1980b; Ohlendorf et al. 
1986a; Rudd and Turner 1983a; Saiki and Lowe 1987), and soil (Kabatas-Pendias and Pendias 1984, 
NAS 1976b). Selenium released to the air will be removed by wet and dry deposition.  The forms of 
selenium expected to be found in surface water and the water contained in soils are the salts of selenic and 
selenious acids.  Selenic acid (H2SeO4) is a strong acid.  The soluble selenate salts of this acid are 
expected to occur in alkaline waters.  Sodium selenate is one of the most mobile selenium compounds in 
the environment because of its high solubility and inability to adsorb onto soil particles (NAS 1976a).  
Selenious acid (H2SeO3) is a weak acid, and the diselenite ion predominates in waters between pH 3.5 and 
9. Most selenites are less soluble in water than the corresponding selenates (NAS 1980b).   
It has been suggested that a biological cycle exists for selenium (Shrift 1964), but certain components of 
the cycle remain uncharacterized.  The biological transformation of selenide to elemental selenium has 
not been well described in the literature (see Maier et al. 1988).  Further research on the biological 
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selenium cycle might help to identify "hot spots" of selenium in the environment.  For example, further 
investigation of parameters that influence the tendency of selenium to move from one medium to another 
(e.g., from soil to water) would improve fate and transport modeling efforts. 
Bioavailability from Environmental Media. The available monitoring data indicate that selenium 
is present in samples of air (Dams et al. 1970; Harrison et al. 1971; John et al. 1973; Peirson et al. 1973; 
Pillay et al. 1971), water (Besser et al. 1996; CRWQCB 1988; Cutter 1989; Glover et al. 1979; Lakin and 
Davidson 1967; Lewis 1988; Maier et al. 1988; NCDNR 1986; Oster et al. 1988a; Schutz and Turekiam 
1965; Smith and Westfall 1937), soil/sediment (Glover et al. 1979; Lemly 1997; Sindeeva 1964), human 
tissues (Li et al. 1999; Orszczyn et al. 1996; Yang et al. 1989a, 1989b), fish (Besser et al. 1996; Lowe et 
al. 1985; May and McKinney 1981; Ohlendorf et al. 1986b), and food (Beale et al. 1990; FDA 2000; 
Schubert et al.1987).  Thus, it can be concluded that selenium is bioavailable from the environmental 
media. 
Food Chain Bioaccumulation. Selenium in food contributed to the highest proportion of the daily 
selenium intake for human populations in the United States.  Fruits, vegetables, milk, meat, and grains 
contain very low levels of selenium.  However, selenium is bioaccumulated by aquatic organisms (Chau 
and Riley 1965; Ohlendorf et al. 1986a; Rudd and Turner 1983a).  Based on reported BCFs and BAFs 
(Lemly 1982, 1985), selenium is expected to bioaccumulate in fish.  Some evidence indicates that under 
natural conditions, selenium might also biomagnify in aquatic organisms (Lemly 1985; Maier et al. 1988; 
NCDNR 1986; Sandholm et al. 1973). 
Exposure Levels in Environmental Media. Selenium has been detected in air (Dams et al. 1970; 
Harrison et al. 1971; John et al. 1973; Peirson et al. 1973; Pillay et al. 1971), water (CRWQCB 1988; 
Cutter 1989; Glover et al. 1979; Lakin and Davidson 1967; Lewis 1988; Maier et al. 1988; NCDNR 1986; 
Oster et al. 1988a; Schutz and Turekiam 1965; Smith and Westfall 1937), soil and sediment (Beath et al. 
1946; Coleman and Delevaux 1957; Glooschenko and Arafat 1988; Glover et al. 1979; Lemly 1997; NAS 
1976a; Rosenfeld and Beath 1964; Shamberger 1981; Sindeeva 1964), coal and oil (Hashimoto et al.  
1970; Pillay et al. 1969), plants (Arthur et al. 1992; Cappon 1981; Horne 1991; Rosenfeld and Beath 
1964; Shane et al. 1988), and food (Beale et al. 1990; FDA 2000; Schubert et al. 1987).  Continued 
monitoring data of selenium levels in the environment are necessary to understand current exposure 
levels. 
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Reliable monitoring data for the levels of selenium and selenium compounds in contaminated media at 
hazardous waste sites are needed.  This information can be used in combination with the known body 
burden of selenium and selenium compounds to assess the potential risk of adverse health effects in 
populations living in the vicinity of hazardous waste sites. 
Exposure Levels in Humans. Selenium has been detected in the blood (Barceloux 1999; Orszczyn 
et al. 1996), urine (Gromadzinska et al. 1996), hair (Raie 1996; Yang et al. 1989a, 1989b), and nails 
(Yang et al. 1989a, 1989b) of exposed individuals.  Various estimates of selenium intake for the U.S. 
populations have been reported (FDA 1982a; Levander 1987; Pennington et al. 1989; Schrauzer and 
White 1978; Schubert et al. 1987; Welsh et al. 1981).  The largest numbers of exposed workers were 
heavy equipment mechanics, painters, mechanics, and special trade contractors (NOHS 1976).  
Preliminary data from another workplace study indicate that workplace exposure decreased from 1976 to 
1984 (NIOSH 1989).  Continued monitoring data are necessary to understand and evaluate human 
exposures to selenium in both occupational and nonoccupational settings. 
Exposures of Children. Data are available regarding the exposure and body burdens of children to 
selenium.  Children, like adults, are primarily exposed to selenium through the diet.  In areas containing 
low (0.42 mg/kg), medium (3.09 mg/kg), and high (9.54 mg/kg) seleniferous soils, the mean whole blood 
selenium levels of school children (7–14 years of age) were 0.13, 0.37, and 1.57 mg/L, respectively (Yang 
et al. 1989b).  Selenium was detected in postmortem liver, lung, and spleen samples of infants in 
Glasgow, Scotland at mean concentrations of 2.24, 0.76, and 0.099 ppm, respectively (Raie 1996).  
Children can be exposed to selenium from breast feeding mothers.  Selenium was identified in the 
postpartum breast milk of women at different lactation stages at concentrations of 6.1–53.4 µg/L (Li et al. 
1999). Using these concentrations, the daily intake of selenium for fully breast fed infants was estimated 
to range from 5.2 to 17.9 µg/day.  Others have reported the estimated daily dietary intake of selenium for 
infants as 20 µg/day, while the daily intake for adult males was estimated as 120 µg/day (Pennington 
1989). Since selenium is found in soil surfaces and children ingest soil either intentionally through pica 
or unintentionally through hand-to-mouth activity, pica is a unique exposure pathway for children.  While 
selenium is found in some home products like shampoos (IARC 1975a) and dietary supplements 
(Goodman et al. 1990), this exposure route should be low and will not disproportionally affect children.  
Continued monitoring data are necessary to understand potentially dangerous routes of childhood 
exposure. 
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Child health data needs relating to susceptibility are discussed in 3.12.2 Identification of Data Needs: 
Children’s Susceptibility. 
Exposure Registries. No exposure registries for selenium or selenium compounds were located.  
This substance is not currently one of the compounds for which a subregistry has been established in the 
National Exposure Registry. The substance will be considered in the future when chemical selection is 
made for subregistries to be established. The information that is amassed in the National Exposure 
Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be 
related to exposure to this substance. 
The development of a registry of exposures would provide a useful reference tool in assessing exposure 
levels and frequencies. In addition, a registry developed on the basis of exposure sources would allow an 
assessment of the variations in exposure levels from one source to another and of the effect of 
geographical, seasonal, or regulatory actions on the level of exposure from a certain source.  These 
assessments, in turn, would provide a better understanding of the needs for research or data acquisition 
based on the current exposure levels. 
6.8.2 Ongoing Studies 
A summary of some pertinent ongoing research related to selenium is reported.  Federally sponsored 
research reported in the Federal Research in Progress (FEDRIP 2002) databases is shown in Table 6-7. 
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Table 6-7. Ongoing Studies on the Environmental Effects of Seleniuma 















Dudley LM et al. 
Logan TJ, 
Traina, SJ 
University of North Dakota 
(Grand Forks, North Dakota) 
University of California 
(Riverside, California) 
Virginia Polytechnical 
Institute and State University, 
(Blacksburg, Virginia) 




University of California, 
(Berkeley, California) 
University of California, 
(Berkeley, California) 
Oklahoma State University 
(Stillwater, OK) 
University of California 
(Riverside, California) 
University of California, 
(Berkeley, California) 
Utah State University (Logan, 
Utah) 
Ohio State University 
(Columbus, Ohio) 
Chemical forms of selenium in foods 
Selenium and arsenic speciation and 
mobilization in irrigated soils and 
drainage waters 
Trace elements, chemistry, and plant 
uptake from soil applied coal by­
products/organic amendments 
Biogeochemistry and management of 
salts and potentially toxic trace 
elements in arid-zone soils, 
sediments and waters 
Trace elements in broiler littered soils: 
fate and effects on nitrogen 
transformation 
Factors controlling the distribution of 
trace elements in the solid-phase of 
terrestrial ecosystems 
Use of constructed wetlands in the 
bioremediation of selenium 
contaminated waters 
Chemistry and bioavailability of waste 
constituents in soils 
Biogeochemistry and management of 
salts and possible toxic trace 
elements in arid soils, sediments and 
waters 
Biogeochemistry and management of 
salts and potentially toxic trace 
elements in arid-zone soils, 
sediments and waters 
Biogeochemistry and Management of 
salts and potentially toxic elements in 
arid-zone soils sediments and water 
Chemistry and bioavailability of waste 















aSource: FEDRIP 2002 
NRI = National Research Institute; USDA = United Stated Department of Agriculture 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring selenium, its metabolites, and other biomarkers of exposure and effect to 
selenium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
The analytical methods used to quantify selenium in biological and environmental samples are 
summarized below.  Table 7-1 lists the applicable analytical methods used for determining selenium and 
selenium compounds in biological fluids and tissues, and Table 7-2 lists the methods used for determining 
selenium in environmental samples. 
7.1 BIOLOGICAL MATERIALS 
Sampling of biological material for determination of total selenium concentrations does not usually pose a 
problem unless specific selenium compounds are to be identified (Bem 1981).  One exception is the 
collection and storage of urine samples without loss of volatile selenium compounds (Bem 1981).  Unless 
special precautions are taken, most analyses of biological materials probably underestimate the 
concentration of these compounds.  Ideally, selenium should be measured in 24-hour urine samples that 
have been stored in polyethylene containers in acid medium (Sanz Alaejos and Diaz Romero 1993).  
Blood samples should be separated into plasma or serum and cell fractions prior to freezing if the 
selenium levels in these components are to be measured separately.  Freezing of biological samples 
immediately following collection is recommended to reduce enzymatic formation of volatile selenium 
compounds. 
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Table 7-1. Analytical Methods for Determining Selenium in Biological Materials 
Sample 
Sample 	 Analytical detection Percent 
matrix	 Preparation method method limit recovery Reference 
Air (breath)	 Calibrate personal 
sampling pump; sample at 
a known flow rate for a 
total sample size of  
5–2,000 L; analyze at 
190.6 nm 
Blood Mineralize using HNO3­
HClO4 mixture, generate 
hydride, and atomize 
Digest blood sample with a 
nitric/perchloric acid 
mixture; fume mixture at 
200 EC and measure 
2,3-diaminonaphthalene 
Blood, 	 Digest with Mg(NO3)2 or 
plasma, or 	 HNO3 at a solution 
tissue 	 temperature of 100 EC for 
homogenate	 60–90 minutes; add HCl; 
and add hydroxylamine 
sulfate, EDTA, and urea 
Serum	 Dilute sample with matrix 
modifier containing 
Mg(NO3)2 and Ni(NO3)2 to 
thermally stabilize Se; 
heat, dry, atomize; use 
Zeeman background 
correction 
Dilute sample with matrix 
modifier containing NiCl2; 
heat, dry, and atomize 
Nitric-perchloric acid 




On-line acid ashing of 
sample followed by 
hydrive generation 
ICP/AES 21 ng/mL 
HGAAS 1x10-8 g/g 
Fluorometric 1.2x10-9 g/g 
GC/ECD 1x10-8 g/g 
ZAAS No data 
GFAAS No data 
HGAAS No data 





No data 	 Clinton 1977 
98%	 Rongpu et al. 
1986 
95–105%	 McCarthy et 
al. 1981 




84–116% 	 Oster and 
Prellwitz 
1982 




et al. 1993 
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Table 7-1. Analytical Methods for Determining Selenium in Biological Materials 
Sample 








Urine 24-hour samples analyzed 
to measure CT and 
Folin-Wu 
method for CT 
No data No data Hojo 1981b, 
1982 






Digest sample with HNO3 
and HClO4 
Fluorometric No data 100±22% Koh and 
Benson 1983 
EAAS No data 4–8% Saeed 1986 







Digest with 25% 
tetramethylammonium 
hydroxide in methanol 





Decompose sample with 
nitric acid; use 1,2-dibro­
mobenzene as a reagent 
to measure piazselenol 
GC/ECD 1x10-9 g/g No data Shimoishi 
1977 
Spike sample with 82Se; 
digest; acidify with HCl; 
react with 






irradiate the sample; 
digest with HNO3, HClO4, 
and the carrier source; 
Radiochemical 
NAA 
2.2x10-10 g/g No data Lievens et al. 
1977 
distill sample, and use 
distillate for analysis 
Protein 
(human liver) 
INAA and gel 
filtration 
No data No data Norheim and 
Steinnes 
1975 
CT = creatinine; EAAS = electrothermal atomic absorption spectroscopy; EDTA = ethylenediaminetetraacetic acid; 
GC/ECD = gas chromatography/electron capture detection; GFAAS = graphite furnace atomic absorption spectroscopy; 
HCI = hydrochloric acid; HClO4 = perchloric acid; HGAAS = hydride generation atomic absorption spectroscopy; 
HNO3 = nitric acid; ICP/AES = inductively coupled plasma/atomic emission spectroscopy; IDGC/MS = isotope dilution 
gas chromatography/mass spectrometry; INAA = instrumental neutron activation analysis; Mg(NO3)2 = magnesium 
nitrate; NAA = neutron activation analysis; NiCl2 = nickel chloride; Se = selenium; ZAAS = graphite furnace atomic 
absorption spectroscopy with Zeeman background correction 
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Reduce selenium in 
sample from SeVI to 
SeIV; add zinc to the 
acidified sample; pass 
gaseous selenium 



















acidify with HNO3 
Acidify sample with 
HCl, degas solution 













Zhou and Liu 
(1997) 
Vien and Fry 
1988 
Reduce selenium to 




ICP/AES 0.06 µg/L 100% selenite; 
88% selenate 
Adkins et al. 
1995 























subject to acid 
digestion 




measure at 196 mm 
ICP and 
GFAAS 
7.5x10-8 g/mL 94–112% EPA 1986c 
(methods 
3050, 6010) 
Acid digestion with 
HNO3/sulfuric acid; 





2x10-9 g/mL 100% EPA 1997a 
(method 
7741a) 
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Sample Analytical detection Percent 
matrix Preparation method method limit recovery Reference 
Wastes/soil/ Nitric acid digestion or AA, furnace 3x10-9 g/mL 100.5 % EPA 1997b 
groundwater nitric/peroxide/hydrochl (method 
oric acid digestion 7742) 
Organic Oxidize organic Cathodic 5x10-9 g/mL No data DOE 1987 
waste samples, absorb stripping 
combustion products in 
NaOH; separate on an 
ion exchange column 
Digest aqueous 
sample with HNO3 and 
perchloric acid 
Marine Decompose tissue HGAAS 2x10-7 g/g No data Welz and 
biological sample with HNO3 Melcher 1985 
tissues under pressure; add 
sulfuric and perchloric 
acids; heat at 310 EC 
to evaporate excess 
acid; add HCl 
Marine Digest sample with HGAES-ICP 5x10-9 g/mL No data DOE 1987 
samples concentrated HNO3 at 
room temperature; add 
HNO3, perchloric, and 
sulfuric acids to 
complete digestion; 
evaporate extra acids; 
dissolve residue in HCl 
Avian eggs Digest sample with GFAAS 4x10-7 g/g No data Krynitsky 
and liver HNO3; and hydrogen 1987 
peroxide to increase 
solubility 
Fat materials Melt butter under an HGAAS 10 ppb No data Narasaski 
(butter) infrared lamp; digest 1985 
with HNO3, sulfuric, 
and perchloric acids 
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2x10-6 g/g No data AOAC 1984 
(method 
3.101) 
Grind air-dried or fresh 
samples; acid digest 
with HNO3 and HCl 
Fluorometric 
method 
<4x10-6 g/g No data AOAC 1984 
(method 
3.102 to 
add EDTA; neutralize 
with NH4OH; add HCl; 
3.107) 
shake with decalin; 
centrifuge decalin 
layer; read decalin 
solution with 
fluorometer at 525 nm 
within 5 minutes 
Food Digest sample with 
HNO3, perchloric, and 
sulfuric acids; heat; 
Titrimetric 
method 
No data No data AOAC 1984 
(methods 
25.154 and 
add H2O2; mix with 
EDTA, NH4OH, and 
25.158) 
DAN; boil; add 
cyclohexane and 
shake; read 





matter from air; 
irradiate and count 
NAA, non­
destructive 
1x10-10 g/m3 No data Dams et al. 
1984 
sample 
Air Calibrate sampling 
pump; sample at a 
known flow rate for a 
total sample size of 
13–2,000 L; analyze at 
190.6 nm 
ICP/AES 21 ng/mL 97–105% NIOSH 1994a 
(method 
7300) 
AA = atomic absorption; AES = atomic emission spectrometry; CFAAS = graphite furnace atomic absorption 

spectroscopy; DAN = 2,3-diaminonaphthalene; EDTA = ethylenediamine tetraacetate; HCl = hydrochloric acid; 

HGAAS = hydride generation atomic absorption spectroscopy; HGAES = hydride generation atomic emission 

spectroscopy; HGGC = hydride generation gas chromatography; HNO3 = nitric acid; ICP = inductively coupled plasma; 

KBr = potassium bromide; N2 = nitrogen; NAA = neutron activation analysis; NaOH = sodium hydroxide; 

NH4OH = ammonium hydroxide
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A variety of analytical methods can be used to determine trace concentrations (ng/g) of selenium in 
biological tissues. These include fluorometry, neutron activation analysis (NAA), atomic absorption 
spectroscopy (AAS), inductively coupled plasma-atomic emission spectroscopy (ICP-AES), inductively 
coupled plasma-mass spectrometry (ICP-MS), gas chromatography (GC), spectrophotometry, x-ray 
fluorescence analysis, and others. 
Classical flame AAS techniques do not have sufficiently low detection limits for selenium to be useful for 
determining its presence in biological samples (Koirtyohann and Morris 1986).  Hydride generation 
atomic absorption spectroscopy (HGAAS) has been used instead for determination of selenium in 
biological samples such as blood and blood constituents and meat, fruits, and vegetables (Bem 1981). 
Graphite furnace atomic absorption spectroscopy (GFAAS) offers high sensitivity (5x10-11 g selenium/g 
sample), but interference from the matrix can cause significant difficulties (Lewis 1988). GFAAS 
methods rely on the fact that numerous metal compounds react with selenium compounds to form 
relatively refractory metal selenides (Oster and Prellwitz 1982).  Nickel, molybdenum, and platinum are 
commonly added to the sample to thermally stabilize the selenium.  Organic materials are then destroyed 
by high temperature in the furnace prior to atomization of the sample at very high temperatures (e.g., 
2,700 EC) (Oster and Prellwitz 1982). One advantage of GFAAS techniques is that the material in the 
graphite sample cell can be chemically treated in situ to reduce chemical interference.  GFAAS 
techniques require correction for background absorption.  Correction techniques include the deuterium 
continuum light source method (Hoenig and Van Hoeyweghen 1986) and the Zeeman splitting of the 
absorption line (Koirtyohann and Morris 1986).  A Zeeman-effect system, which applies a magnetic field 
to the atomizer, allows the background correction to be performed at the exact analyte wavelength 
without the use of auxiliary light sources (Fernandez and Giddings 1982).  The Zeeman-effect 
background correction is necessary for the determination of selenium in blood and blood products when 
GFAAS is used because a spectral interference from iron occurs at the selenium wavelength that cannot 
be corrected by a deuterium continuum source.  
A modification of the GFAAS method for determining selenium levels in human urine was described by 
Saeed (1986). In this electrothermal atomic absorption spectrometry (EAAS) method, nitric acid, nickel, 
and platinum are added to the graphite cell.  The addition of nickel helps to mask the spectral interference 
from phosphates in urine.  EAAS has been used to determine selenium levels in human spermatozoa 
(Suistomaa et al. 1987).  For human blood plasma and serum, the detection limit of the EAAS method  
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was 0.8 µg/L (2 ng absolute), with recoveries of 87–96% for plasma and 94–104% for serum (Harrison et 
al. 1996). 
HGAAS offers reduced chemical interference but requires larger sample volumes than GFAAS 
techniques (Koirtyohann and Morris 1986).  HGAAS techniques have been used to measure selenium 
concentrations in food (Fiorino et al. 1976). These techniques use wet-sample digestion (e.g., nitric-
perchloric acid) to destroy organic matter.  Sample reduction to convert Se(VI) (+6 valence state) to 
Se(IV) (+4 valence state) is necessary prior to using sodium borohydride to reduce all selenium present to 
selenium hydride (Macpherson et al. 1988).  The selenium hydride is thermally decomposed and atomized 
in the sample beam of the atomic absorption spectrophotometer.  Nitric-perchloric acid is commonly used 
for the digestion step.  Because perchloric acid is potentially explosive, use of phosphoric acid instead is 
also common.  Following the International Union of Pure and Applied Chemists (IUPAC) interlaboratory 
trial for the determination of selenium in human body fluids, Welz and Verlinden (1986) reported that it 
was important to use a temperature of at least 200 ºC for sample decomposition when using HGAAS.  
They attributed the severe imprecision and systematic errors in measuring selenium in multiple samples to 
improper sample decomposition.  Norheim and Haugen (1986) demonstrated that a combined system of a 
wet digestion and an automated hydride generator could analyze approximately 80 samples per day.   
ICP-AES with hydride vapor generation has been used to determine total selenium in biological samples 
(Tracy and Moller 1990).  This technique is especially suited to the analysis of small samples.  Samples 
are wet ashed with nitric, sulfuric, and perchloric acids at temperatures up to 310 ºC. After treatment with 
hydrochloric acid, selenium is reduced by sodium borohydride to hydrogen selenide in a simplified 
continuous flow manifold.  A standard pneumatic nebulizer affects the gas-liquid separation of H2Se, 
which is quantified by ICP-AES at 196.090 nm.  The instrument detection limit for this method has been 
determined to be 0.4 µg/L 
Hydride generation atomic fluorescence spectrometry (HGAFS) has been used to measure selenium 
concentrations in urine (Sabé et al. 2001).  Samples were completely mineralized using a focused 
microwave oven with a mixture of nitric acid and sulfuric acid for 14 minutes.  Complete recovery was 
achieved from selenocystine (SeCys), selenomethionine (SeMet), and trimethyl selenium (TMeSe) 
species. The detection and limit of quantization for this method were 57 and 190 pg selenium/L. 
Application of gas-liquid chromatography (GLC) to determine selenium in biological samples allows for 
the elimination of interference from the biological matrix.  GLC requires prior decomposition of organic 
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matter with nitric acid.  GLC techniques are based on measurement of the amount of piazselenol formed 
by the reaction of selenium (IV) with appropriate reagents in acidic media (Bem 1981).  For gas 
chromatographic determination of selenium with an electron capture detector, 1,2-diaminoarenes can be 
used as reagents to produce piazselenols (McCarthy et al. 1981; Poole et al. 1977; Shimoishi 1977; 
Young and Christian 1973).  Using 1,2-diamino-3,5-dibromobenzene as a reagent, Shimoishi (1977) 
obtained a detection limit of 1x10-9 g selenium per gram of sample. 
Isotope dilution gas chromatography/mass spectrometry (IDGC/MS) is a highly accurate technique that is 
more accessible than NAA techniques.  IDGC/MS has been used to determine selenium in foods, plasma 
and serum, red blood cells, feces, urine, and human breast milk (Lewis 1988).  The minimum sample size 
per determination is 0.5–10 g (0.5–10 mL).  In the IDGC/MS method, a stable selenium isotope is added 
to the sample prior to digestion.  This procedure eliminates the need for quantitative sample preparation 
and external standardization (Lewis 1988).  However, a disadvantage of this technique is that enriched 
isotopic standards are expensive. 
NAA techniques provide lower detection limits for selenium (between 10-8 and 10-9 g selenium per gram 
of sample), but there are few reactors at which NAA facilities and expertise are available (Koirtyohann 
and Morris 1986). The most common NAA procedure for selenium determination is to produce the long-
lived 75Se radionuclide (half-life of 119 days) and count the samples after a 50–100-hour irradiation 
period and a 2–10-week cooling period.  A faster NAA technique utilizes metastable 77mSe, which has a 
much shorter half-life (17.4 seconds), so that counting can be initiated after an irradiation and cooling 
period of <1 minute (Koirtyohann and Morris 1986).  The most common standard reference sample for 
NAA techniques is bovine liver tissue (Bem 1981).  Biological tissues that can be analyzed for selenium 
using the NAA technique include bone, hair, liver, kidney, lung, serum, blood, feces, urine, brain, 
stomach, skin, aorta, heart, testis, pituitary gland, tooth enamel, tongue, muscle, spleen, and thyroid 
(Yukawa et al. 1980). For many NAA techniques, destructive sample pretreatment (involving 
radiochemical separation) is required to avoid interference from the biological matrix (Koirtyohann and 
Morris 1986).  The advantages of NAA are its low detection limits and multielement capability (Molokhia 
et al. 1979). Because facilities at which NAA can be performed are extremely limited, NAA's most 
useful application is as a reference method against which other less expensive and more common methods 
can be compared for accuracy. 
Spectrophotometric, fluorometric, voltammetric, and x-ray fluorescence analysis methods have also been 
successfully employed to determine selenium levels in blood, tissue, and human hair.  Of these, 
SELENIUM 296 
7. ANALYTICAL METHODS 
fluorometric methods are most commonly used (Koh and Benson 1983).  The reaction of selenium(VI) 
with 2,3-diaminonaphthalene (DAN) or with 3,3-diaminobenzidine (DAB) to form a fluorescent Se-DAN 
or Se-DAB heterocyclic compound is the basis of the fluorometric method of selenium determination 
(Allaway and Cary 1964; Chen et al. 1982; Lewis 1988).  The piazselenol formed with DAN as the 
reagent has greater fluorescence sensitivity than the piazselenol formed with DAB as the reagent and is 
also extractable into organic solvents from acid solution (Chen et al. 1982).  Fluorometric techniques 
require sample digestion to destroy organic matter and sample reduction to convert the selenium to the 
selenium(IV) oxidation state (Macpherson et al. 1988).  Loss of volatile selenium compounds is possible 
during sample digestion and manipulation because several steps are required.  Chen et al. (1982), 
Hasunuma et al. (1982), and Koh and Benson (1983) developed modifications of the digestion and 
treatment steps for selenium determination by fluorometric methods.  Their methods allow small sample 
sizes, can be performed in a single flask, and measure submicrogram amounts of selenium. 
Some of the methods for determining selenium in biological materials have been compared within the 
same laboratory for accuracy and precision.  Macpherson et al. (1988) compared the accuracy of three 
methods for the determination of selenium in biological fluid samples from biological materials with 
certified selenium levels.  Acid decomposition fluorometry, HGAAS, and EAAS gave equally accurate 
results. Lewis et al. (1986) compared the graphite furnace atomic absorption spectrometry with the 
Zeeman-effect background correction (ZAAS) to isotope dilution mass spectrometry (IDMS) for 
determination of selenium in plasma and concluded that the ZAAS method compared favorably 
(correlation coefficient 0.987), but was half as precise as the IDMS method.  Oster and Prellwitz (1982) 
compared HGAAS and GFAAS for the determination of selenium in serum.  They concluded that the two 
techniques exhibited approximately equal detection limits in their laboratory. 
In three studies that compared analytical methods for the detection of selenium in biological samples, all 
found that fluorometry gave both accurate and reliable results (Burguera et al. 1990; Heydorn and 
Griepink 1990; Macpherson et al. 1988). Burguera et al. (1990) indicated the acceptance of HGAAS as 
yielding reliable results, whereas Heydorn and Griepink (1990) reported HGAAS had a high relative 
standard deviation of 11.4%. 
Decomposition procedures have been improved and analytical methods have been modified in recent 
years to increase the accuracy and speed of determination of selenium concentrations in plasma, serum, 
and urine. Reamer and Veillon (1983) used phosphoric acid along with nitric acid and hydrogen peroxide 
in digestion of biological fluids instead of perchloric acid to prepare samples for fluorometry.  They 
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concluded that phosphoric acid digestion increases the safety and convenience of the determination.  
Krynitsky (1987) used a modified wet digestion method for the determination of selenium in biological 
samples such as eggs and liver of avian species.  This method uses hydrogen peroxide to enhance the 
solubility of the sample.  Digestion with HNO3 and HClO4 is essential for accurate analysis of the total 
selenium in urine to ensure complete oxidation of the trimethylselenonium ion (Koh and Benson 1983). 
7.2 ENVIRONMENTAL SAMPLES 
Many of the basic analytical methods used for determining selenium in biological media are also used for 
determining selenium levels in soil, water, and air.  Precautions in the collection and storage of 
environmental samples, however, are necessary to prevent loss of the volatile selenium compounds to the 
air. The destruction of organic matter before selenium measurement is also often necessary. 
Acidification of water samples to a pH of 1.5 is recommended to preserve selenium compounds (MuZoz 
Olivas et al. 1994). Nitric acid can be used, although it interferes with the hydride generation method of 
analysis.  The best storage method for selenium compounds in water is in glass containers at 4 EC 
(Wiedmeyer and May 1993). 
The analytic methods generally fall into two groups: (1) those that do not require the destruction of 
organic materials in the sample and (2) those that require the elimination of interfering matter before the 
selenium content can be measured.  X-ray fluorescence and some of the neutron activation analysis 
techniques do not require sample destruction, whereas spectrophotometry, GC, atomic absorption 
spectrometry, polarography, titration, spark source, MS, fluorometry, and other neutron activation 
analysis techniques require some degree of sample destruction.  Fluorometry, atomic absorption 
spectrometry, and neutron activation analysis are the most frequently used methods. 
Inductively coupled plasma (ICP) emission techniques can be used to measure selenium concentrations.  
ICP techniques offer multielement capabilities, but instrumentation is costly and background interference 
can be a problem (Koirtyohann and Morris 1986).  The NIOSH-recommended method for determining 
selenium in air is inductively coupled argon plasma atomic emission spectroscopy (NIOSH 1994a).  
Selenium may be measured in water following NIOSH Method 7300.  The limit of detection for this 
method is 21 ng/mL using a selenium emission line at 190.6 nm (NIOSH 2001).  ICP-MS has been used 
to determine the concentration of selenium in cloud water at detection limits of 100 and 25 pg/mL using 
pneumatic and ultrasonic nebulization, respectively (Richter et al. 1998). 
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AAS techniques are commonly used for the determination of selenium in environmental samples.  
Hydride generation AAS is more sensitive than flame or graphite furnace AAS for the determination of 
selenium in materials of variable composition.  Water samples, including freshwater, river water, sea 
water, and surface waters, and industrial wastes, muds, sediments, and soil samples have been analyzed 
by AAS techniques to detect selenium at parts-per-trillion levels (Bem 1981).  Selenium(VI) and 
selenium(IV) can be distinguished in water samples with GFAAS by selective extraction procedures.  
HGAAS can also be used to distinguish between selenium(VI) and selenium(IV) in environmental 
samples because selenium(VI) does not readily form the hydride without reduction (Koirtyohann and 
Morris 1986).  Selenium(VI) is calculated on the basis of the total selenium minus selenium(IV) (Bem 
1981). 
NAA has been used to determine selenium levels in environmental samples.  Dams et al. (1970) reported 
a detection limit of 1x10-10 g/m3 selenium using nondestructive NAA for determining selenium in air 
particulate matter.  For determining selenium levels in soil, radiochemical variants of NAA have been 
commonly employed (Bem 1981).  Instrumental neutron activation analysis (INAA) is frequently used to 
determine selenium concentrations in water and can also be used to distinguish between selenium(IV) and 
selenium(VI) oxidation states (Bem 1981).  INAA is also used to determine selenium concentrations in air 
(Bem 1981). 
Gas liquid chromatography allows for elimination of interference from the matrix when analyzing 
environmental samples.  When analyzing biological samples, a variety of reagents can be used to convert 
selenium to piazselenols for measurement with an electron capture detector.  Spectrophotometric 
determinations of selenium are performed using organic reagents, whereas fluorometric analysis relies on 
piazselenol fluorescence to measure submicrogram levels of the element.   
The hydride generation GC with photoionization detection (HGGC-PD) method for selenium 
determination was developed by Vien and Fry (1988). The combined usage of a photoionization detector 
and a cold trap provided at least two orders of magnitude improvement in detectability over the existing 
GC systems.  The detection limit for the HGGC-PD method was 1x10-12 g selenium/mL (0.001 ppb) for 
28 mL samples.  An advantage of the HGGC-PD technique is the ability to perform simultaneous 
determinations of at least four different hydride-forming elements (Vien and Fry 1988). 
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EPA's Contract Laboratory Program (EPA 1984b) requires the participating laboratories to meet the 
Contract Required Detection Level (CRDL) for selenium of 5x10-9 g selenium/mL (5 µg selenium/L) 
using proven instruments and approved analytical techniques, including ICP and atomic absorption 
methods. 
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of selenium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of selenium.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. 
Exposure. Methods that distinguish among the various selenium compounds are not commonly used to 
estimate human exposure to selenium, but have been used in specialized metabolic studies.  Analytical 
methods currently used to measure concentrations of selenium in biological fluids or human tissue 
samples as an indication of human exposure are described in Table 7-1.  Attempts to use measures of 
whole blood GPX activity levels as indicators of human exposure to selenium have not been successful.  
Errors can result if the selenium-dependent GPX activity is not distinguished from the nonselenium­
dependent GPX activity (Edwards and Blackburn 1986).  In addition, whole blood selenium 
concentrations and GPX activity appear to correlate with one another only at low blood selenium levels 
(<0.100 mg selenium/L) (Allaway et al. 1968; Valentine et al. 1980).  GPX activity levels measured in 
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platelets have provided an indication of selenium exposure levels at low blood selenium levels (NPve et 
al. 1988).  Whether platelet GPX activity levels would provide an indication of selenium status in 
populations with plasma selenium levels above 0.012 mg selenium/L is not known.  There is great 
variability in the exposure data available for humans.  Therefore, until larger databases of selenium 
concentrations in biological materials from affected and unaffected populations are available, no 
recommendations for analytical methods can be made. 
Effect. There are no known sensitive and specific biomarkers of effect for selenium.  Therefore, no 
analytical methods recommendations can be made for biomarkers of effect for selenium, at the present 
time. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Numerous analytical methods are available for the determination of selenium levels in 
environmental media (AOAC 1984; Bem 1981; Dams et al. 1970; DOE 1987; EPA 1984b, 1986c; 
Koirtyohann and Morris 1986; NIOSH 1994a; Vien and Fry 1988).  However, most of these do not 
distinguish among the various selenium compounds.  Many of the available methods can be used to detect 
selenium at subnanogram levels.  For the determination of selenium only, fluorometry, chromatography, 
or spectrometry are the preferred techniques.  When conducting a multielemental analysis or when 
analyzing a complex matrix, more sophisticated methods are required. 
It is possible to detect selenium levels as low as 1 ng/m3 of air using neutron activation analysis.  
Standardized methods for selenium determination in different environmental samples such as water, soil, 
sludge, and industrial waste are available in the above-mentioned literature. 
There are fewer methods available for distinguishing among the inorganic forms of selenium in the 
environment.  HGAAS, INAA, and GFAAS with selective extraction procedures can be used to 
distinguish between selenium(VI) and selenium(IV) in samples of soil and water.  Methods for 
determining selenium sulfide levels in the environment are lacking, but would be useful for the 
identification and measurement of this potentially carcinogenic selenium compound. 
Very limited information is available regarding the sensitivity, reliability, and specificity of the existing 
methods. Further studies to determine these factors would be useful. 
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7.3.2 Ongoing Studies 
N.J. Miller-Ihli and coworkers at the Agricultural Research Service (Beltsville, Maryland) are conducting 
studies to develop single and multielement methods for the determination of trace elements of nutritional 
and health concern (e.g., selenium).  Some techniques proposed in their studies include:  GFAAS and 
electrothermal vaporization inductively coupled plasma-mass spectrometry (ICP-MS); inductively 
coupled plasma-atomic emission spectrometry (ICP-AES); electrothermal vaporization ICP-MS (USS­




8. REGULATIONS AND ADVISORIES 

Because of its potential to cause adverse health effects in exposed people, a number of regulations and 
guidelines have been established for selenium by various national and state agencies.  These values are 
summarized in Table 8-1. 
The current Recommended Dietary Allowances (RDAs) for selenium, established by the Food and 
Nutrition Board of the National Research Council (National Academy of Sciences) (NAS 2000), are listed 
below. The recommended Tolerable Upper Intake Level (UL) for selenium in adults is 0.4 mg/day (NAS 
2000).  The UL is defined as the highest level of daily nutrient intake that is likely to pose no risk of 





Pregnant women: 0.060 mg/day
 
Lactating women: 0.070 mg/day
 
Infants (0–6 months):  0.015 mg/day
 
Infants (7–12 months):  0.020 mg/day
 
Children (1–3 years):  0.020 mg/day
 
Children (4–8 years):  0.030 mg/day
 
Children (9–18 years):  0.040 mg/day
 
A chronic oral MRL of 0.005 mg/kg/day was derived for selenium based on a NOAEL of 
0.015 mg/kg/day for disappearance of symptoms of selenosis in recovering individuals (Yang and Zhou 
1994), as discussed in Section 2.3. The NOAEL was divided by an uncertainty factor of three to account 
for sensitive individuals. The EPA used the same human NOAEL for clinical selenosis 
(0.015 mg/kg/day) (Yang et al. 1989a, 1989b) and an uncertainty factor of three to derive a chronic oral 
reference dose (RfD) of 0.005 mg/kg/day for selenium (EPA 2003). 
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Agency 
Table 8-1. Regulations and Guidelines Applicable to Selenium 
Description Information References 
INTERNATIONAL 
Guidelines:  
IARC Carcinogenicity classification 
WHO Guideline for drinking water 






ACGIH TLV (8-hour TWA) 
Selenium and compounds 
 Selenium hexafluoride 
EPA 	 Hazard rank under Section 112(g) of 
the Clean Air Act Amendments 
Reference air concentration 
NIOSH REL (TWA) 
Selenium and compounds,  
except selenium hexafluoride 
IDLH 
Selenium and compounds 
OSHA General industry PEL (TWA) 

Selenium and compounds 

 Selenium hexafluoride 

 Hydrogen selenide 

Construction industry PEL (TWA) 
Selenium and compounds 






Groundwater monitoring (PQL) 
 Groundwater monitoring— 
concentration limits 
Group 3a	 IARC 2001 
0.01 mg/L 	 WHO 2001 





42 out of 1–100, with EPA 2001a 
100 being the most 
toxic 







0.2 mg/m3	 29CFR1910.1000, 





0.05 mg/L 	 EPA 2001c 
40CFR141.51 
0.05 mg/L 	 EPA 2001d 
40CFR141.62 
0.2 mg/L 	 EPA 2000 
0.05 mg/L 
750 µg/L EPA 2001e 
40CFR264, 
Appendix IX 
0.01 mg/L 	 EPA 2001f 
40CFR264.94 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description Information 
NATIONAL (cont.) 
References 
EPA Water quality standards EPA 2001g 
 Freshwater 40CFR131.36 








FDA Approved use of selenium as a food ≤0.3 ppm FDA 2001a 
additive in animal feeds—added to 
feed for chickens, swine, turkeys, 
21CFR573.920 
sheep, cattle, and ducks 
Bottled water—allowable level 0.05 mg/L FDA 2001b 
21CFR165.110 
 RDA (mg/day) NAS 2000 
Men 0.055 
 Women 0.055 
 Pregnant women 0.060 
 Lactating women 0.070 
 Infants (0–6 months) 0.015 
 Infants (7–12 months) 0.020 
 Children (1–3 years) 0.020 
 Children (4–8 years) 0.030 
 Children (9–18 years) 
d. Other 
0.040 
EPA Carcinogenicity classification IRIS 2001 
Selenium and compounds 
 Selenium sulfide 
Group Db 
Group B2c 
Designation of hazardous  EPA 2001h 
substances
 Selenium oxide 
40CFR116.4 
 Sodium selenite 
Determination of reportable EPA 2001i 
quantities 40CFR117.3 
 Selenium oxide 10 pounds 
 Sodium selenite 100 pounds 
Extremely hazardous substance EPA 2001j 
40CFR355, 
Reportable quantity Appendix B 
 Hydrogen selenide 10 pounds 
 Selenious acid 10 pounds 
 Selenium oxychloride 500 pounds 
Threshold planning quantity 
 Hydrogen selenide 10 pounds 
 Selenious acid 1,000/10,000 pounds 
 Selenium oxychloride 500 pounds 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description 	 Information References 
NATIONAL (cont.) 
EPA Identification and listing of 
hazardous waste 
Selenium 
Selenium and compounds 
 Selenium dioxide 
 Selenium sulfide 
Selenium tetrakis, (dimethyl- 
 dithiocarbamate) 
 Selenious acid 
 Selenourea 
 Thallium selenite 
Protection standards at inactive 
uranium processing sites—listed 
constituents 
Selenium and compounds 
 Selenium dioxide 
 Selenium sulfide 
Recommended daily allowances 




 Reportable quantity 
Selenium and compounds 
 Selenium dioxide 
 Selenium sulfide 
 Selenious acid 
 Selenourea 
 Sodium selenite 

 Thallium selenite 

 Reportable quantity 

 Selenium oxide 
Sewer sludge—disposal or use 
standards
 Ceiling concentration 
Cumulative pollutant loading 
rate 
 Pollutant concentrationd 
Annual pollutant loading rate 
Toxic chemical release reporting; 






 Hawaii HAP 
 EPA 2001k 
40CFR261, 
Appendix VIII 








1 pound 40CFR302.4, 













5.0 kg/hectare per 
365-day period 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description 	 Information References 
STATE (cont.)
 
Illinois Toxic air contaminant BNA 2001 

 Kansas HAP BNA 2001 

Kentucky HAP BNA 2001 

Maryland Toxic air pollutant BNA 2001 

 Selenium sulfide 

Minnesota HAP threshold—de minimis level BNA 2001 

 Selenium compounds 0.1 ton/year 

 Selenium sulfide 0.1 ton/year 

Nebraska HAP—effective date  12/15/98 BNA 2001 

New Hampshire Regulated toxic air pollutant BNA 2001 





 Emissions 0.0133 mg/m3
 




 Selenium compounds 1 µg/m3
 
Rhode Island HAP BNA 2001 

South Carolina Toxic air emissions—maximum BNA 2001 

Vermont Hazardous ambient air standards BNA 2001 

 Annual average 4.80 µg/m3
 
 Action level 0.40 pounds/8-hours 

 Washington HAP—threshold levels BNA 2001 

Selenium and compounds 0.5 tons/year 

 Selenium hexafluoride 0.5 tons/year 









Acute 20 µg/L 





Acute 300 µg/L 

Chronic 71 µg/L 

MCL 0.05 mg/L BNA 2001 

Primary drinking water standard 0.01 mg/L BNA 2001 

Alaska 	 Groundwater cleanup level 0.05 mg/L BNA 2001 

MCL 0.05 mg/L BNA 2001 

Arizona 	 Aquifer water quality standards 0.05 mg/L BNA 2001 

Drinking water guideline 45 µg/L HSDB 2001 

MCL 0.05 mg/L BNA 2001 

Water quality standards EPA 2001r 

 Conversion factore for 40CFR131.38 
 saltwater—acute criteria 0.998 
 Conversion factore for 
 saltwater—chronic criteria 0.998 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description 	 Information References 
STATE (cont.) 
Colorado 	 Groundwater protection—MCL 0.01 mg/L BNA 2001 

MCL 0.05 mg/L BNA 2001 

Primary drinking water standard 0.01 mg/L BNA 2001 

Connecticut MCL 0.05 mg/L BNA 2001 

Delaware Groundwater protection—MCL 0.01 mg/L BNA 2001 

Primary drinking water standard 0.01 mg/L BNA 2001 

Florida MCL 0.05 mg/L BNA 2001 

Georgia MCL 0.05 mg/L BNA 2001 

Hawaii MCL 0.05 mg/L BNA 2001 






Acute 20 µg/L 
Chronic 5.0 µg/L 
Saltwater 
Acute 300 µg/L 
Chronic 71 µg/L 




MCL 0.05 mg/L 

Groundwater quality standard 0.01 mg/L BNA 2001 

MCL 0.05 mg/L BNA 2001 

Indiana MCLG 0.05 mg/L BNA 2001 

Iowa MCL 0.05 mg/L BNA 2001 

Kansas Surface water quality standard BNA 2001 

 Aquatic life 
Acute 20 µg/L 
Chronic 5.0 µg/L 
Agriculture 
Livestock 50 µg/L 
Irrigation 20 µg/L 
Public health food 
Procurement 6,800 µg/L 
Domestic water supply 50 µg/L 
Kentucky 	 Domestic water supply use— 0.05 mg/L BNA 2001 











 Chronic 20 µg/L 

 Maximum groundwater contaminant 0.01 mg/L BNA 2001 

Kentucky Primary drinking water standard 0.01 mg/L BNA 2001 





8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description Information References 
STATE (cont.) 
Louisiana Groundwater protection—MCL 0.01 mg/L BNA 2001 
Maine Drinking water guideline 10 µg/L HSDB 2001 















MCL 0.05 mg/L BNA 2001 
Primary drinking water standard 0.01 mg/L BNA 2001 












Groundwater protection—MCL 0.01 mg/L BNA 2001 
MCL 0.05 mg/L BNA 2001 





Minnesota Drinking water guideline 30 µg/L HSDB 2001 
Mississippi Groundwater standard 50 ppb BNA 2001 
Water quality criteria— 
concentration shall not exceed 
0.01 mg/L BNA 2001 
Montana MCL 0.05 mg/L BNA 2001 
North Carolina Fresh surface water quality standard 
for Class C waters 
5.0 ug/L BNA 2001 
Groundwater quality standard 0.05 mg/L BNA 2001 






Water supply 0.05 mg/L BNA 2001 
MCL 0.05 mg/L BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description Information References 
STATE (cont.) 
New Hampshire Water quality criteria BNA 2001 
Protection of aquatic life 
 Fresh 
acute 5.0 µg/L 
chronic 290µg/L 
Marine 
acute 71 µg/L 
chronic 170 µg/L 
Protection of human health 
Water and fish ingestion 11,000 µg/L 
New Mexico MCL 0.05 mg/L BNA 2001 
 Nevada Domestic water supply BNA 2001 
 Dissolved selenium 0.05 mg/L 
New York MCL 0.05 mg/L BNA 2001 
North Dakota MCL 0.05 mg/L BNA 2001 
Ohio Groundwater concentration limit 0.01 mg/L BNA 2001 
Oklahoma Public and private water supplies 0.01 mg/L BNA 2001 
Fish and wildlife propagation BNA 2001 
Acute 20 µg/L 
 Chronic 5.0 µg/L 
Rhode Island Groundwater quality standard 0.05 mg/L BNA 2001 
Preventive action limit 0.025 mg/L 
South Carolina MCL 0.05 mgL BNA 2001 
South Dakota Groundwater maximum allowable 0.05 mg/L BNA 2001 
concentration 
Aquatic life value BNA 2001 
Acute 20 µg/L 
 Chronic 5.0 µg/L 
Tennessee Groundwater criteria concentration 0.05 mg/L BNA 2001 
MCL 0.05 mg/L BNA 2001 
Texas MCL 0.05 mg/L BNA 2001 
Utah MCL 0.05 mg/L BNA 2001 
 Water quality BNA 2001 
 Domestic 0.01 mg/L 
Agriculture 0.05 mg/L 
Vermont Groundwater quality standards BNA 2001 
 Enforcement standard 50 µg/L 
Preventive action level 25 µg/L 
MCLG 0.05 mg/L BNA 2001 
MCL 0.05 mg/L 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description Information References 
STATE (cont.) 
Vermont Water quality criteria for protection 
of aquatic organisms 




Average allowable  
 concentration 
20 µg/L 
Chronic 5.0 µg/L 
Virginia Groundwater protection levels 
 Protection level 




MCL 0.01 mg/L BNA 2001 









 Human health 
300 µg/L 
71 µg/L 
Public water supplies 
All other surface waters 
170 µg/L 
11,000 µg/L 
Washington MCL 0.05 mg/L BNA 2001 
Wisconsin Groundwater quality standards
 Enforcement standard 




MCL 0.05 mg/L BNA 2001 
Wyoming Water quality 
 Aquatic life 
Acute 
Chronic 






New York Bottled water sampling 
requirements—MCL 
0.01 mg/L BNA 2001 
d. Other 
Alabama Identification and listing of 
hazardous waste 
 BNA 2001 





California Hazardous waste injection 
restrictions—waste specific 
prohibitions 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description Information References 
STATE (cont.) 
California Known to cause cancer or BNA 2001 
reproductive toxicity—initial 
appearance of chemical on list 
 Selenium sulfide 10/01/89 
Total threshold limit concentration 10,000 mg/kg BNA 2001 
Delaware Regulated toxic substance— 
sufficient quantity 
 Selenium hexafluoride 900 pounds/hour 
BNA 2001 
Florida Toxic substance in the workplace 
 Hydrogen selenium 
Selenium 
 BNA 2001 
 Selenium hexafluoride 
 Selenium oxychloride 
 Selenium sulfide 
Hawaii Restricted use pesticides 
 Selenium compounds All concentrations 
BNA 2001 
Kentucky Threshold planning quantity 
 Hydrogen selenide 
 Selenious acid 





Massachusetts Oil and hazardous material  BNA 2001 
 Selenious acid 
Selenium and compounds 
 Selenium dioxide 
 Selenium disulfide 
 Selenium oxide 
 Selenium oxychloride 
 Selenium sulfide 
 Selenourea 
 Minnesota RfD 




New Hampshire Restricted use pesticide All concentrations BNA 2001 
New Jersey Extraordinary hazardous 
substance—threshold quantity 
 Selenium hexafluoride 700 pounds 
BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Selenium 
Agency Description Information References 
STATE (cont.) 
Oregon Toxic substance—de minimis 1.0 percent BNA 2001 
concentration 
Vermont Restricted use pesticide All concentrations BNA 2001 
Selenium and compounds 
aGroup 3: not classifiable as to its carcinogenicity to humans
bGroup D: not classifiable as to its carcinogenicity to humans 
cGroup B2: probable human carcinogen 
dMonthly average concentrations 
eConversion factors are based on a hardness of 100 mg/L as calcium carbonate 
ACGIH = American Conference of Governmental Industrial Hygienists; BNA = Bureau of National Affairs; 
CFR = Code of Federal Regulations; DWEL = drinking water equivalent level; EPA = Environmental Protection 
Agency; FDA = Food and Drug Administration; HAP = hazardous air pollutant; IARC = International Agency for 
Research on Cancer; IDLH = immediately dangerous to life and health; IRIS = Integrated Risk Information System; 
MCL = maximum contaminant level; MCLG = maximum contaminant level goal; NIOSH = National Institute for 
Occupational Safety and Health; OEL = occupational exposure limit; OSHA = Occupational Safety and Health 
Administration; PEL = permissible exposure limit; PQL = practical quantitation limit; RDA = recommended daily 
allowance; REL = recommended exposure limit; RfD = reference dose; TLV = threshold limit value; TWA = time-
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research but are not actual research studies. 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 




Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air which has been 
reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a minimal risk 
level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
Organophosphate or Organophosphorus Compound—A phosphorus containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism.  Utilizing computational techniques, it provides the means of studying the 
absorption, distribution, metabolism and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereby the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 




Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical information 
such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also called 
biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL-from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 24­
hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
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Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic, that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value - Time Weighted Average (TLV-TWA) may 
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The study of the absorption, distribution and elimination of toxic compounds in the 
living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of one can be used; 
however a reduced UF of three may be used on a case-by-case basis, three being the approximate 
logarithmic average of 10 and 1. 
Xenobiotic—Any chemical that is foreign to the biological system. 
SELENIUM A-1 
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as a hundredfold below levels 
that have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 




MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Selenium 
CAS Number: 7782-49-2 (elemental) 
Date:   June 5, 2003 
Profile Status: Post Public Comments, Draft 3 
Route: [ ] Inhalation [X] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key:  101 
Species: Human 
Minimal Risk Level: 0.005 [X] mg/kg/day  [ ] ppm 
Reference: Yang G, Zhou R.  1994.  Further observations on the human maximum safe dietary selenium 
intake in a seleniferous area of China. J Trace Elem Electrolytes Health Dis 8:159-165. 
Experimental design: This study was an examination of a group of five individuals who were recovering 
from selenosis, and who had been drawn from a larger population studied by the same authors (Yang et 
al. 1989a, 1989b).  Yang et al. (1989a, 1989b) examined a population in an area of China where selenosis 
occurred. Data were collected on selenium levels in the diet, blood, nails, hair, urine, and milk of 
residents, and the incidence of clinical symptoms of selenosis (morphological changes in fingernails) was 
compared with dietary intake of selenium and selenium levels in blood.  Selenium levels in blood 
corresponded to the dietary intake of selenium, and symptoms of selenosis occurred at or above a 
selenium intake level of 910 µg/day (0.016 mg/kg/day) (Yang et al 1989a).  In 1992, Yang and Zhou 
(1994) reexamined five individuals from the high selenium site who had been suffering from symptoms 
of selenosis (loss of fingernails and hair), but were recovering (nails were regrowing).  Since their earlier 
report, the living conditions of the population had improved; they had been cautioned against consuming 
high selenium foods and parts of their locally produced corn had been replaced with rice or cereals.  Yang 
and Zhou (1994) found that the mean concentration of selenium in the blood of these selenosis patients 
had fallen from 1,346 µg/L (measured in 1986) to 968 µg/L (measured in 1992). Using a regression 
equation derived from the data in their earlier report (Yang et al. 1989b) and average body weights of 
55 kg, Yang and Zhou (1994) calculated that the mean dietary intake of selenium associated with 
selenosis in these individuals was 1,270 µg/day (LOAEL of 0.023 mg/kg/day), while a mean intake of 
819 µg selenium/day (NOAEL of 0.015 mg/kg/day) was associated with recovery. 
Effects noted in study and corresponding doses: A NOAEL of 0.015 mg/kg/day for nail disease based on 
recovery from symptoms of selenosis, and a LOAEL of 0.023 mg/kg/day based on nail damage were 
calculated from selenium concentrations in blood using average body weights of 55 kg and the regression 
equation: Yblood-Se (mg/L) = 8230 x 10-4 Xse-intake (µg) + 0.176 derived in Yang et al. (1989b). 
Dose and end point used for MRL derivation: 0.015 mg/kg/day; nail disease (selenosis) 
[X] NOAEL [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[ ]  10 for use of a LOAEL 
[ ]  10 for extrapolation from animals to humans 
[X]  3 for human variability 
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A factor of 3 was considered appropriate because the individuals in this report were sensitive individuals 
drawn from the larger population in the Yang et al. (1989a, 1989b) studies and because of the supporting 
studies described below. 
Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
If so, explain: 
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
NA 
Other additional studies or pertinent information which lend support to this MRL: 
Yang et al. (1989a, 1989b) examined a population of 349 individuals in an area of China where selenosis 
occurred. They collected data on selenium levels in the diet, blood, nails, hair, urine, and milk of 
residents at three sites with low, medium, and high selenium, and compared the incidence of clinical 
symptoms of selenosis (morphological changes in finger nails) with dietary intake of selenium and 
selenium levels in blood.  They found that selenium levels in blood corresponded to the dietary intake of 
selenium, and that symptoms of selenosis were found at or above a selenium intake level of 910 µg/day 
(0.016 mg/kg/day) (Yang et al 1989a). The population included adult men and women, teenagers, 
children, and infants.  High selenium levels were found in individuals of all ages, but symptoms of 
selenosis were generally confined to adults (97% of cases) and were never observed in children younger 
than 12 years of age (Yang et al. 1989b).  The manifestation of symptoms of selenosis was not solely 
dependent on selenium intake, but was subject to individual variability, as individuals who exhibited 
selenosis did not necessarily have the highest blood selenium levels. 
Longnecker et al. (1991) examined two groups of adults (142 individuals) in areas of Wyoming and South 
Dakota with elevated selenium intake.  The average daily intake of selenium in this population was 
239 µg/day (0.003 mg/kg/day) and some individuals consumed as much as 724 µg/day (0.01 mg/kg/day).  
The highest blood concentration of selenium noted in this population was 0.67 mg/kg, a concentration 
lower than the 1.05 mg/L concentration associated with effects in China.  No symptoms of selenosis or 
any other significant health effects associated with selenium exposure were reported for individuals in this 
study.  This study suggests that the estimates of dietary intake of selenium produced by the regression 
equation in Yang et al. (1989b) may be conservative.  Longnecker et al. (1991) reported doses of  
68–724 µg/day associated with blood concentrations of 0.18–0.67 mg/kg.  If the doses from the 
Longnecker et al. (1991) study are placed in the regression equation from Yang et al. (1989b), blood 
concentrations of 0.14 and 0.88 mg/L are calculated.  If it is assumed that a liter of blood weighs 
approximately 1 kg, then this regression equation overpredicts blood levels of selenium at the higher 
doses in the population from North Dakota.  This provides support for additional exposure (e.g., 
inhalation exposure) in the Chinese population that was not accounted for in the regression equation.  
Selenium is a component of all three members of the deiodinase enzyme family, the enzymes responsible 
for deiodination of the thyroid hormones (St. Germain and Galton 1997).  Two human studies were 
located that describe significant decreases in triiodothyronine levels in response to elevated selenium; 
however, the hormone levels observed in these studies were subclinical within the normal human range 
and the biological significance of the effect is not clear.  In the first study, Brätter and Negretti De Brätter 
(1996) examined a Venezuelan population with high selenium intake.  Serum, erythrocyte, toenail, and 
breast milk selenium concentrations were determined for 65 women living in three seleniferous regions of 
Venezuela. Selenium dietary intakes were determined from the selenium concentration of breast milk by 
regression (Bratter et al. 1991), and free thyroxine (T4), free triiodothyronine (T3), and human thyroid 
stimulating hormone (TSH) levels were measured.  Selenium intake ranged from 170 to 980 µg/day.  
There was a significant inverse correlation between free T3 and selenium levels in serum (Spearman R 
SELENIUM A-5 
APPENDIX A 
test), but free T3, free T4, and TSH levels were found to be within normal ranges.  No symptoms of 
selenosis were found in the women included in this study. 
In the second human study, serum hormone, semen, immunological, and hematological status was 
evaluated in a 120-day double blind study of healthy men (20–45 years old) who consumed a controlled 
diet of foods naturally low or high in selenium (Hawkes and Turek 2001; Hawkes et al. 2001).  Eleven 
subjects were fed a diet that provided 47 µg Se/day (0.0006 mg/kg/day) for the first 21 days of the study. 
For the following 99 days, six of the subjects were fed a diet providing 13 µg Se/day (0.0002 mg/kg/day), 
and five of the remaining subjects were fed a diet providing 297 µg/day (0.004 mg/kg/day).  
Comprehensive evaluations were performed at weeks 3 (baseline), 17 (ending value), and several interim 
time points on end points that included selenium levels (in blood plasma, erythrocytes, seminal plasma, 
and sperm); thyroid hormone levels (serum T3 and TSH); reproductive hormone levels (serum 
testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone); 
semen quality (sperm concentration, semen volume, sperm total number, fraction motile sperm, percent 
progressive sperm, mean forward velocity, and various sperm morphology parameters); immunological 
indices (complete blood counts, lymphocyte phenotypes, serum immunoglobulins (IgA, IgG, IgM); 
complement fractions; peripheral blood mononuclear cell (PBMNC) in vitro proliferative responses to 
mitogenic stimulation with phytohemagglutinin (PHA), concanavalin A (ConA), and pokeweed; natural-
killer cell (NKC) activity; delayed-type hypersensitivity (DHS) skin responses to recall antigens 
(tuberculin purified-protein derivative, mumps, tetanus toxoid, candida, trichophyton, streptokinase 
strepase, and coccidioidin); antibody responses to diptheria-tetanus and influenza vaccines); and 
hematological indices (complete blood counts, white blood cells, lymphocytes, granulocytes, platelets, 
erythrocytes, hematocrit, and hemoglobin concentration).  For measurements repeated more than twice, 
the baseline value was subtracted from the value at each time point to calcuate within-subject changes, 
and two-way repeated measures analysis of variance was used to test for significant effects of dietary 
selenium and time.  When the selenium main effect or the selenium x time interaction was significant, the 
Student-Newman-Keuls comparison test was used to identify significant differences between the low-
selenium and high-selenium groups at individual time points.  For measurements obtained only twice 
(during baseline and at end of study), within-subject changes were compared between groups with a two-
tailed ttest. Measurements obtained only at the end of the study were compared between groups with a 
two-tailed t-test without any correction.  A probability of ≤0.05 was considered significant in all tests. 
Selenium levels in blood plasma began to change within 3 days of starting the low- and high-selenium 
diets and progressively continued throughout the study (Hawkes and Turek 2001).  By week 17, mean 
plasma selenium concentrations had increased by 109% in the high-selenium group and decreased by 
38.5% in the low-selenium group.  Group mean serum T3 concentrations (averages of within-subject 
changes from baseline) were significantly different in the low-selenium subjects and high-selenium 
subjects at all time points, but the magnitudes of the changes are insufficient to be considered biologically 
significant in either group.  In the low-selenium group, serum T3 levels increased an average of 14 and 
8% from baseline during weeks 8 and 17, respectively.  In the high-selenium group, serum T3 levels 
decreased an average of 23 and 11% from baseline during weeks 8 and 17, respectively.  Analysis of 
variance (ANOVA) indicated a significant effect of dietary selenium on serum T3 concentrations and that 
the magnitude of the effect was modified by the duration of exposure (i.e., the group changes in T3 levels 
decreased over time).  Although the decreases in serum T3 in the high selenium group and increases in 
serum T3 in the low selenium group lessened in magnitude during the study, all group mean values appear 
to have remained within the normal range (only week 17 values were actually reported).  The respective 
baseline and week 17 serum T3 values (mean±SD) were 1.82±0.36 and 1.57±0.07 nmol/L in the high-
selenium group and 1.57±0.25 and 1.64±0.16 nmol/L in the low-selenium group, compared to a normal 
human range of 1.1–2.7 nM/L for total T3, indicating that the changes were subclinical and not 
biologically significant.  Serum TSH concentrations increased significantly by 32% over its baseline 
concentration in the high-selenium group but did not change significantly in the low-selenium group.  
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Baseline and ending TSH values in the high-selenium group were 2.25±0.81 and 2.96±1.05 mU/L, 
respectively, both of which are in the normal range of 0.3–4.0 mU/L (Stockigt 2000).  There were no 
significant changes in the serum levels, nor any significant differences between groups in free or total 
testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, or progesterone. 
The pattern of changes in seminal plasma selenium levels was similar to that observed for blood 
selenium, although selenium levels in sperm did not change significantly in either group (Hawkes and 
Turek 2001).  Mean sperm motility (average of within-subject changes from baseline in fraction of motile 
sperm) was significantly different in the low-selenium subjects and high-selenium subjects at week 13, 
but not at weeks 8 or 17. The fraction of motile sperm increased an average of 10% in the low-selenium 
group at week 13, and was essentially the same as baseline at week 17.  Sperm motility decreased an 
average of 32% in the high-selenium group at week 13, and ended 17% lower than the baseline value at 
week 17. The ANOVA indicated a significant effect of dietary selenium on sperm motility and that the 
effect of selenium was modified by duration of exposure (the groups diverged over time).  Baseline and 
ending motile sperm fractions in the high-selenium group were 0.588±0.161 and 0.488±0.193, 
respectively; >50% motility is considered normal (FDA 1993).  The decrease in sperm motility in the 
high-selenium group cannot be clearly attributed to exposure because the effect was not related to 
duration of treatment, and is unlikely to be adverse because the effect is at the low end of the normal 
range and not accompanied by any significant significant effects of high- or low-selenium treatment on 
sperm progression, concentration, total number, or morphology.  Additionally, there were no effects of 
selenium on serum levels of the reproductive hormones, and changes in the thyroid hormones, which 
could also affect sperm function, were not outside normal ranges. 
The immunological assessment showed that the high-selenium diet was not immunotoxic and had some 
mild and transient immune-enhancing properties (Hawkes et al. 2001).  There is an indication that 
selenium supplementation increased the secondary immune response to diphtheria vaccine when 
rechallenged at the end of the study.  The mean within-subject ratio of diphtheria antibody titers 14 days 
after reinoculation (day 116) to titers 14 days after the initial challenge at baseline (day 19) was 
significantly greater in the high-selenium group than in the low-selenium group (2.7±1.8-fold vs. 
0.9±0.6-fold, p=0.03).  Lymphocyte counts were significantly increased in the high-selenium group on 
day 45, but not at the end of the study, and there were no clear effects of selenium on numbers of 
activated or cytotoxic T-cells.  The proliferative response of peripheral lymphocytes to stimulation with 
pokeweed mitogen (a B-cell mitogen) was significantly higher in the high-selenium group than in the 
low-selenium group on days 45 and 72, although not at the end of the study.  There was no selenium-
induced lymphocyte proliferation in response to the T-cell mitogens (phytohemagglutinin or concanavalin 
A) or changes in any of the other immunological end points.  The hematological assessment (Hawkes et 
al. 2001) found minor mean within-subject changes from baseline in white blood cell counts that were 
significantly different in the low- and high-selenium groups at the last two time points (days 70 and 99); 
WBCs were decreased by 5% in the high-selenium group and increased by 10% in the low-selenium 
group at the end of the study.  The changes in WBC counts were due mainly to changes in granulocytes.  
Lymphocyte counts were significantly increased in the high-selenium group on day 45, but not at the end 
of the study. 
Chemical Manager: John Risher, Ph.D. 
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Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around 
hazardous waste sites? 
The chapter covers end points in the same order they appear within the Discussion of Health Effects by 
Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect.  Human data are 
presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  In vitro 
data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered 
in this chapter. If data are located in the scientific literature, a table of genotoxicity information is 
included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal risk levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
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Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic).  These 
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure 
levels at which adverse health effects are not expected to occur in humans. 
They should help physicians and public health officials determine the safety of a community living near a 
chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest NOAEL that does not 
exceed any adverse effect levels.  When a NOAEL is not available, a lowest-observed-adverse-effect 
level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed.  
Additional uncertainty factors of 10 must be used both for human variability to protect sensitive 
subpopulations (people who are most susceptible to the health effects caused by the substance) and for 
interspecies variability (extrapolation from animals to humans).  In deriving an MRL, these individual 
uncertainty factors are multiplied together.  The product is then divided into the inhalation concentration 
or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL 
are provided in the footnotes of the LSE Tables. 
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (3-1, 3-2, and 3-3) and figures (3-1 and 3-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects.  These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels 
(MRLs) to humans for noncancer end points, and EPA's estimated range associated with an upper- bound 
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a 
quick review of the health effects and to locate data for a specific exposure scenario.  The LSE tables and 
figures should always be used in conjunction with the text.  All entries in these tables and figures 
represent studies that provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels 
(NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
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The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 3-1 
(1) 	 Route of Exposure One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  When 
sufficient data exists, three LSE tables and two LSE figures are presented in the document.  The 
three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and 
dermal (LSE Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not therefore have all five of the tables and figures. 
(2) 	 Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15–364 days), 
and chronic (365 days or more) are presented within each relevant route of exposure.  In this 
example, an inhalation study of intermediate exposure duration is reported.  For quick reference 
to health effects occurring from a known length of exposure, locate the applicable exposure 
period within the LSE table and figure. 
(3) 	 Health Effect The major categories of health effects included in LSE tables and figures are death, 
systemic, immunological, neurological, developmental, reproductive, and cancer.  NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer.  Systemic effects are 
further defined in the "System" column of the LSE table (see key number 18). 
(4) 	 Key to Figure Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the 2 "18r" data points in Figure 3-1). 
(5) 	 Species The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane via 
inhalation for 6 hours per day, 5 days per week, for 3 weeks.  For a more complete review of the 
dosing regimen refer to the appropriate sections of the text or the original reference paper, i.e., 
Nitschke et al. 1981. 
(7) 	 System This column further defines the systemic effects.  These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 




(8) 	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which 
no harmful effects were seen in the organ system studied.  Key number 18 reports a NOAEL of 
3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation 
MRL of 0.005 ppm (see footnote "b"). 
(9) 	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 
that caused a harmful health effect.  LOAELs have been classified into "Less Serious" and 
"Serious" effects. These distinctions help readers identify the levels of exposure at which adverse 
health effects first appear and the gradation of effects with increasing dose.  A brief description of 
the specific end point used to quantify the adverse effect accompanies the LOAEL.  The 
respiratory effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm.  
MRLs are not derived from Serious LOAELs. 
(10) 	 Reference The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in 
the footnotes.  Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to derive 
an MRL of 0.005 ppm. 
LEGEND 
See Figure 3-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures 
help the reader quickly compare health effects according to exposure concentrations for particular 
exposure periods. 
(13)	 Exposure Period The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the intermediate and chronic exposure periods are illustrated. 
(14) 	 Health Effect These are the categories of health effects for which reliable quantitative data exists.  
The same health effects appear in the LSE table. 
(15)	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16)	 NOAEL In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
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(17)	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived.  The 
diamond symbol refers to a Cancer Effect Level for the test species-mouse.  The number 38 
corresponds to the entry in the LSE table. 
(18)	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 









1 → TABLE 3-1. Levels of Significant Exposure to [Chemical x] - Inhalation  
Exposure LOAEL (effect) 
Key to frequency/ NOAEL 
figurea Species duration System (ppm) Less serious (ppm) Serious (ppm) Reference 
2 → INTERMEDIATE EXPOSURE  
5 6 7 8 9 10













3b 18 Rat 13 wk 10 (hyperplasia) Nitschke et al. Resp 






38 Rat 18 mo 20 (CEL, multiple organs) Wong et al. 1982 
5 d/wk 
7 hr/d 
39 Rat 89-104 wk 10 (CEL, lung tumors, nasal NTP 1982 
5 d/wk tumors) 
6 hr/d 
40 Mouse 79-103 wk 10 (CEL, lung tumors, NTP 1982 
5 d/wk hemangiosarcomas) 
6 hr/d 
a 12 → The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5 x 10-3 ppm; dose adjusted for intermittent exposure and divided  





































APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACOEM American College of Occupational and Environmental Medicine 
ACGIH American Conference of Governmental Industrial Hygienists 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AOEC Association of Occupational and Environmental Clinics 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
ANOVA analysis of variance 
AOAC Association of Official Analytical Chemists 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotranferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
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DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
GPX glutathione peroxidase 
GSH glutathione 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LCLo lethal concentration, low 
LC50 lethal concentration, 50% kill 
LDLo lethal dose, low 
LD50 lethal dose, 50% kill 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LT50 lethal time, 50% kill 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
m meter 
MA trans,trans-muconic acid 




MCL maximum contaminant level 
MCLG maximum contaminant level goal 




mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
NHANES National Health and Nutrition Examination Survey 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
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PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg pictogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
RDA Recommended Daily Allowance 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RR relative risk 
RTECS Registry of Toxic Effects of Chemical Substances 
RQ reportable quantity 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
T3 triiodothyronine 
T4 thyroxine 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TSH thyroid stimulating hormone 
TWA time-weighted average 
UF uncertainty factor 
UL Tolerable Upper Intake Level 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
























white blood cell 
World Health Organization 
greater than 
greater than or equal to 
equal to 
less than 








cancer slope factor 
negative 
positive 
weakly positive result 
weakly negative result 
